<SEC-DOCUMENT>0001213900-21-006573.txt : 20210322
<SEC-HEADER>0001213900-21-006573.hdr.sgml : 20210322
<ACCEPTANCE-DATETIME>20210203192329
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-21-006573
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		31
FILED AS OF DATE:		20210204
<PUBLIC-REL-DATE>20210322
DATE AS OF CHANGE:		20210203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Regencell Bioscience Holdings Ltd
		CENTRAL INDEX KEY:			0001829667
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03785
		FILM NUMBER:		21588116

	BUSINESS ADDRESS:	
		STREET 1:		11/F FIRST COMMERCIAL BUILDING
		STREET 2:		33-35 LEIGHTON ROAD, CAUSEWAY BAY
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999077
		BUSINESS PHONE:		852 2155 0823

	MAIL ADDRESS:	
		STREET 1:		11/F FIRST COMMERCIAL BUILDING
		STREET 2:		33-35 LEIGHTON ROAD, CAUSEWAY BAY
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999077
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>As confidentially submitted to the
Securities and Exchange Commission on February 3, 2021<BR>
pursuant to the Jumpstart our Business Startups Act</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> <B></B> <B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>AMENDMENT NO. 1 TO<BR>
FORM F-1</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman
    Islands</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2833</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction of<BR>
    incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary
    Standard Industrial<BR>
    Classification Code Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<BR>
    Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">11/F First Commercial Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">33-35 Leighton Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Causeway Bay, Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">+ 852 2155 0823</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Puglisi &amp; Associates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">850 Library Avenue, Suite 204</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Newark, Delaware 19711</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">302-738-6680</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and
telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>With a Copy to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Joan
                                         Wu, Esq. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Arila Zhou, Esq. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Hunter Taubman Fischer &amp;
        Li LLC </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> 800 Third Avenue, Suite 2800 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> New York, NY 10022 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Tel: 212.530.2208 </P></TD>
    <TD STYLE="vertical-align: bottom; width: 20%"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Mitchell
                                         Nussbaum, Esq. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Angela M. Dowd, Esq. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Loeb &amp; Loeb LLP </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> 345 Park Avenue </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> New York, NY 10154 </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Tel: 212.407.4000 </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Approximate date of commencement of proposed sale to the
public:</B> Promptly after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this Form are
to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Title of Each Class of Securities to Be Registered</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount to&nbsp;Be Registered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed Maximum offering price
    per share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed
    Maximum<BR> Aggregate Offering<BR> Price<SUP>(1)(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    of<BR> Registration<BR> Fee<SUP>(6)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares, par value US$0.01 per share<SUP>(1) (3)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter&rsquo;s
    warrants<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares, par value US$0.01 &nbsp;per share, underlying Underwriter&rsquo;s warrants<SUP>(5)</SUP></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for purposes of calculating
    the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. Includes the offering price of ordinary
    shares that the Underwriters have the option to purchase to cover over-allotments, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Rule 416(a), the Registrant
    is also registering an indeterminate number of additional Ordinary Shares that shall be issuable pursuant to Rule 416 to prevent
    dilution resulting from share splits, share dividends or similar transactions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely for the purpose of determining
    the amount of registration fee in accordance with Rule 457(o) under the Securities Act.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No separate fee is required pursuant to Rule
    457(i) of the Securities Act. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant will issue to the Underwriter
    warrants to purchase a number of Ordinary Shares equal to an aggregate of 2.5% of the total number of &nbsp;Ordinary Shares
    (the &ldquo;Underwriter Warrants&rdquo;) sold in the offering (exclusive of any Ordinary Shares that may be issued upon exercise
    by the Underwriter of the over-allotment option). The Underwriter Warrants will have an exercise price of 110% of the public
    offering price per Ordinary Shares sold in the offering. The Underwriter Warrants are exercisable commencing six (6) months
    immediately following the closing of this offering for a period of five (5) years after the closing of this offering, at any
    time, and from time to time, in whole or in part. As estimated solely for the purpose of calculating the registration fee
    pursuant to Rule 457(g) under the Securities Act. Resales of Ordinary Shares issuable upon exercise of the Underwriter Warrants
    on a delayed or continuous basis pursuant to Rule 415 under the Securities Act are also registered hereby.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be paid upon first non-confidential filing
    of registration statement with the Securities and Exchange Commission.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities
and Exchange Commission, acting pursuant to such Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Red"><B>The information in this prospectus
is not complete and may be changed. We may not sell the securities until the registration statement filed with the Securities
and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting
any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B>SUBJECT TO
COMPLETION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <FONT STYLE="color: Red"><B>PRELIMINARY
PROSPECTUS DATED [&nbsp;&nbsp;], 2021</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[&#9679;] <B><I>Ordinary Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> This is an initial public offering of
our ordinary shares. We are offering on a firm commitment basis, [&#9679;] ordinary shares, US$0.01 par value per share (&ldquo;Ordinary
Shares&rdquo;). The estimated initial public offering price per Ordinary Share is between $____ and $______. We have applied to
list our Ordinary Shares on the Nasdaq Capital Market under the symbol &ldquo;RGCB.&rdquo; There can be no assurance that we will
be successful in listing our Ordinary Shares on the Nasdaq Capital Market; however, we will not complete this offering unless
we receive approval for listing on Nasdaq Capital Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B>Investing in our Ordinary Shares
involves a high degree of risk, including the risk of losing your entire investment. See &ldquo;Risk Factors&rdquo; beginning
on page&nbsp;14 to read about factors you should consider before buying our Ordinary Shares.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an &ldquo;emerging growth company&rdquo;
as defined under the federal securities laws and will be subject to reduced public company reporting requirements. Please read
the disclosures beginning on page&nbsp;iii of this prospectus for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Yat-Gai Au, our founder, director,
and Chief Executive Officer (the &ldquo;CEO&rdquo;), currently own approximately __% of our Ordinary Shares. Upon the closing
of this offering, Mr. Yat-Cai Au will continue to own a controlling interest in us and we will meet the definition of a &ldquo;controlled
company&rdquo; under the corporate governance standards for Nasdaq listed companies and we will be eligible to utilize certain
exemptions from the corporate governance requirements of the Nasdaq Stock Market. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriter discount (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds to us, before expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                         have agreed to reimburse the underwriters for certain expenses. See the section titled
                                         &ldquo;Underwriting&rdquo; beginning on page 101 of this prospectus for additional disclosure
                                         regarding underwriter compensation and offering expenses.</FONT> </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have granted the representative of the
underwriters an option to purchase from us, at the public offering price, up to additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary
Shares, less the underwriting discounts and commissions, within&nbsp;45 days from the date of this prospectus to cover over-allotments,
if any. If the representative of the underwriters exercises the option in full, the total underwriting discounts and commissions
payable will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The underwriters expect to deliver the
shares to purchasers in the offering on or about ______, 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Maxim Group LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> The date of this prospectus dated [&#9679;],
2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 92%; padding-left: 9pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCLOSURE
    REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> iii </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS
    SUMMARY</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 1 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
    OFFERING</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 12 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
    FACTORS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 14 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENFORCEABILITY
    OF CIVIL LIABILITY</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 35 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE
    OF PROCEEDS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 36 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIVIDEND
    POLICY</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 37 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAPITALIZATION</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 38 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 39 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 40 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDUSTRY
    OVERVIEW</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 45 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OUR
    BUSINESS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 49 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGULATIONS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 70 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 75 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE
    COMPENSATION</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 79 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL
    SHAREHOLDERS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 81 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED
    PARTY TRANSACTIONS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 82 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
    OF SHARE CAPITAL</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 83 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARES
    ELIGIBLE FOR FUTURE SALE</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 96 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAXATION</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 97 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 101 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
    MATTERS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 109 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 109 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 109 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTEREST
    OF NAMED EXPERTS AND COUNSEL</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 109 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCLOSURE
    OF COMMISSION POSITION ON INDEMNIFICATION</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 109 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE
    YOU CAN FIND MORE INFORMATION</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 109 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_028"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXPENSES
    RELATING TO THIS OFFERING</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> 110 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"> <A HREF="#RB_DRS_029"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
    TO FINANCIAL STATEMENTS</B></FONT></A> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> F-1 </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>About this Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We and the underwriter have not authorized
anyone to provide any information or to make any representations other than those contained in this prospectus or in any free
writing prospectuses prepared by us or on our behalf or to which we have referred you. We take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to
sell only the Ordinary Shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We
are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or where the person
making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make such offer or sale. The
information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial
condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Other Pertinent Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise indicated or the context
requires otherwise, references in this prospectus to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;China&rdquo;
    or the &ldquo;PRC&rdquo; are to the People&rsquo;s Republic of China, excluding Taiwan and the special administrative regions
    of Hong Kong and Macau for the purposes of this prospectus only;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Hong Kong&rdquo; is to the Hong Kong
    Special Administrative Region of the People&rsquo;s Republic of China for the purposes of this prospectus only;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HKD&rdquo; or &ldquo;HK$&rdquo;
    refers to the legal currency of Hong Kong;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell Bioscience Holdings&rdquo;
    is to Regencell Bioscience Holdings Limited, a Cayman Islands exempted company incorporated under the laws of Cayman Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell Bioscience Ltd.&rdquo; is to
    Regencell Bioscience Limited, a Hong Kong limited liability company organized under the laws of Hong Kong and a wholly-owned
    subsidiary of Regencell Bioscience Holdings Limited;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell (BVI) Ltd.&rdquo; is to Regencell
    (BVI) Limited, a British Virgin Islands business company organized under the laws of British Virgin Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Regencell Ltd.&rdquo; is to Regencell
    Limited, a Hong Kong limited liability company organized under the laws of Hong Kong and a wholly-owned subsidiary of Regencell
    Bioscience Holdings Limited;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"> &nbsp; </TD>
    <TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Shares&rdquo;, &ldquo;shares&rdquo;
    or &ldquo;Ordinary Shares&rdquo; are to the Ordinary Shares of Regencell Bioscience Holdings Limited, par value $0.01 per
    share; </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;TCM&rdquo; refers to Traditional Chinese
    Medicine; </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The TCM Practitioner&rdquo; or &ldquo;our
    TCM Practitioner&rdquo; refers to our strategic TCM research partner, Mr. Sik-Kee Au, father of our Chief Executive Officer
    and director; and</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We&rdquo;, &ldquo;us&rdquo;, &ldquo;RGCB&rdquo;,
    the &ldquo;Company&rdquo; or the &ldquo;Group&rdquo; are to one or more of Regencell Bioscience Holdings and its affiliated
    entities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our business is conducted in Hong Kong
through our Hong Kong subsidiary Regencell Bioscience Ltd. since our inception, using Hong Kong dollars, the currency of Hong
Kong. In October 2020, we opened our California office where we will conduct preliminary market research on TCM. Currently, we
are not actively developing the U.S. market and will conduct preliminary market research on TCM once our TCM products achieve
success in Hong Kong. Our consolidated financial statements are presented in United States dollars. In this prospectus, we refer
to assets, obligations, commitments and liabilities in our consolidated financial statements in United States dollars. These dollar
references are based on the exchange rate of Hong Kong dollars to United States dollars, determined as of a specific date or for
a specific period. Changes in the exchange rate will affect the amount of our obligations and the value of our assets in terms
of United States dollars which may result in an increase or decrease in the amount of our obligations (expressed in dollars) and
the value of our assets, including accounts receivable (expressed in dollars). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_001"></A><B>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have made statements in this prospectus,
including under &ldquo;Prospectus Summary,&rdquo; &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations,&rdquo; &ldquo;Our Business&rdquo; and elsewhere that constitute forward-looking
statements. Forward-looking statements involve risks and uncertainties, such as statements about our plans, objectives, expectations,
assumptions or future events. In some cases, you can identify forward-looking statements by terminology such as &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;continuing,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;expect,&rdquo;
&ldquo;we believe,&rdquo; &ldquo;we intend,&rdquo; &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;could&rdquo;
and similar expressions denoting uncertainty or an action that may, will or is expected to occur in the future. These statements
involve estimates, assumptions, known and unknown risks, uncertainties and other factors that could cause actual results to differ
materially from any future results, performances or achievements expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Examples of forward-looking statements
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of the development of future services;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">projections of revenue, earnings, capital structure
    and other financial items;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development of future company-owned branches;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements regarding the capabilities of our
    business operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements of expected future economic performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">statements regarding competition in our market;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assumptions underlying statements regarding
    us or our business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ultimate correctness of these forward-looking
statements depends upon a number of known and unknown risks and events. We discuss our known material risks under the heading
&ldquo;Risk Factors&rdquo; below. Many factors could cause our actual results to differ materially from those expressed or implied
in our forward-looking statements. Consequently, you should not place undue reliance on these forward-looking statements. The
forward-looking statements speak only as of the date on which they are made, and, except as required by law, we undertake no obligation
to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to
reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the
extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
    <DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_002"></A><B>PROSPECTUS
                                         SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following summary is qualified in
its entirety by, and should be read in conjunction with, the more detailed information and financial statements included elsewhere
in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of
investing in our Ordinary Shares, discussed under &ldquo;Risk Factors,&rdquo; before deciding whether to buy our Ordinary Shares.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are an early-stage bioscience company
that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration,
specifically Attention Deficit Hyperactivity Disorder (&ldquo;ADHD&rdquo;) and Autism Spectrum Disorder (&ldquo;ASD&rdquo;). Our
goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment
of ADHD and ASD globally. We started in Hong Kong in 2014 with main operation and assets in Hong Kong. We aim to launch three
liquid-based standardized TCM formulae candidates for mild, moderate, and severe ADHD and ASD patients in Hong Kong first and
subsequently to other markets as we deem appropriate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We strategically partner with Mr. Sik-Kee
Au, our TCM Practitioner, the father of our CEO and director. As of the date hereof, the TCM Practitioner has standardized the
adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a result, we have three standardized
TCM formulae candidates under development targeting mild, moderate, and severe ADHD and ASD patients, each consisting of a standard
base formula and a fixed adjusted formula. We plan to commence our second research study using those three standardized TCM formulae
candidates in the second quarter of 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our three liquid-based standardized
TCM formulae candidates are derived from a TCM base formula developed by our TCM Practitioner based on his TCM brain theory, known
as &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo;, and has demonstrated some improvement in patients&rsquo; condition in our
first research study. The activity and specificity of the TCM base formula have been optimized by the TCM Practitioner in his
prior ADHD and ASD treatment. The TCM brain theory is not recognized in general literature of TCM or elsewhere. However, the TCM
Practitioner has prescribed the TCM base formula based on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological
disorders and obtained satisfactory clinical treatment results. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have been headquartered in Hong Kong
since our inception. In October 2020, we opened our California office where we conduct preliminary market research on TCM. Currently,
we are not actively developing the U.S. market and will conduct preliminary market research on TCM once our TCM-based products
obtain regulatory approvals and achieve success in Hong Kong. We have been keeping books and records in Hong Kong since our inception.
Our research study and supplement of TCM raw materials are in Hong Kong. As we are still at the stage of conducting TCM research,
we have not applied for regulatory approvals; we have no sales, marketing or distribution capabilities or experience, and no granted
patents or pending patent applications; and we have not generated revenues since inception. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Business Plan and Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our goal is to improve the lives of
ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally.
The TCM Practitioner has been treating ADHD and ASD patients for over 30 years and we intend to commercialize the TCM formulae
utilized in his treatment first in Hong Kong and subsequently globalize the use of such TCM formulae in order to address the unmet
medical needs of the growing ADHD and ASD patient population in other countries such as the U.S. We are committed to: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">showing in a quantifiable
    and systematic way, the TCM formulae utilized in the TCM Practitioner&rsquo;s treatment is effective for the treatment of
    ADHD and ASD;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">filing patent applications
    in Hong Kong and abroad; </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">standardizing the
    TCM Practitioner&rsquo;s formulae in our second research study; </FONT> </TD></TR>
</TABLE>

<P STYLE="margin: 0"> &nbsp; </P>

</DIV>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="margin: 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting up of centralized
    production facilities to support our application for the approval and registration of our proprietary Chinese medicine (&ldquo;pCm&rdquo;);
    </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">branding and commercializing
    our standardized TCM formulae candidates; </FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing markets
    in other locations globally; and</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conducting further
    research and development on TCM base formula for other applications. </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <IMG SRC="image_002.jpg" ALT="" STYLE="height: 297px; width: 624px"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date hereof, we have completed
our first research study with the TCM Practitioner and have three standardized TCM formulae candidates under development targeting
mild, moderate, and severe ADHD and ASD patients, each consisting of a standard base formula and a fixed adjusted formula. We
plan to commence our second research study using those three standardized TCM formulae candidates in the second quarter of 2021.
We intend to conduct further investigation and research on the application of the TCM base formula for other neurological illnesses.
We will also commercialize our standardized TCM formulae candidates by building our own specialized sales and marketing organization
initially in Hong Kong after obtaining necessary approvals from Hong Kong regulatory agencies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>TCM Industry in Hong Kong</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We conduct our research and operation
in Hong Kong and plan to commercialize our standardized TCM formulae candidates for ADHD and ASD patients in the Hong Kong market
first. Whilst Hong Kong is part of the People&rsquo;s Republic of China (&ldquo;PRC&rdquo;), the TCM industry and regulations
in the PRC are inapplicable to us in Hong Kong because Hong Kong and the PRC are regarded as two separate markets and jurisdictions
in law. Under the &ldquo;One Country, Two Systems&rdquo;, Hong Kong retains its own systems and way of life after the handover
of sovereignty to the PRC in 1997. The Legislative Council of Hong Kong, Chinese Medicine Council, Chinese Medicines Board, and
Chinese Medicine Regulatory Office of Department of Health of Hong Kong are independent and separate entities from the PRC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Hong Kong Basic Law (the &ldquo;Basic
Law&rdquo;), being Hong Kong&rsquo;s constitutional document, gives legal effect to the &ldquo;One Country, Two Systems&rdquo;
policy. Pursuant to the Basic Law, the laws previously in force in Hong Kong, that is, the common law, rules of equity, ordinances,
subordinate legislation and customary law shall be maintained, except for any that contravene the Basic Law, and subject to any
amendment by the Legislative Council of Hong Kong. The socialist system and policies shall not be practiced in Hong Kong, and
the previous capitalist system and way of life shall remain unchanged for 50 years. Hence, within Hong Kong&rsquo;s legal system,
the laws and regulations of the PRC do not apply. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

</DIV>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>TCM Industry</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> TCM has a long history in Hong Kong.
The TCM industry in Hong Kong is regulated by the Hong Kong Chinese Medicine Ordinance (&ldquo;HKCMO&rdquo;), which was passed
by the Legislative Council of Hong Kong in July 1999. <FONT STYLE="background-color: white">The Chinese Medicine Council of Hong
Kong, or the Council, is a statutory body established in September 1999 under the Hong Kong Chinese Medicine Ordinance. The Council
is responsible for implementing regulatory measures for Chinese medicine. </FONT>The Council implemented the licensing system
of TCM traders and the registration system of proprietary Chinese medicine (&ldquo;pCm&rdquo;) by phases. The role of TCM is now
well established and the dispensation, storage, and labeling of Chinese herbal medicines have been regulated since 2003. The safety,
efficacy and quality of pCm will be assessed by the Hong Kong Chinese Medicines Board before the products being allowed to be
registered. The dispensation, storage and labeling of TCM will also be regulated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of June 2020, there were over 10,000
TCM practitioners in Hong Kong, compared with 14,600 doctors of western medicine. These TCM practitioners have an important role
to contribute to Hong Kong&rsquo;s health care system. Since the supportive initiatives were launched by the Hong Kong government
in 1997, the TCM industry has grown into one of the main industries in the healthcare sector. According to the list on the website
of the Council, as of December 2020, there are over 6,000 TCM stores, wholesalers, and other distribution channels in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Hong Kong Government is committed
to promoting TCM, and has implemented measures including creation of a network of institutions of high standing for research and
development work, development of new drugs for enhancement of the competitiveness of the Chinese medicine industry, and setting
up of research funds for the support of research in Chinese medicine. Under the Hong Kong Government&rsquo;s policy direction
to promote the development of &ldquo;evidence-based&rdquo; TCM and out-patient TCM services in the public sector, as well as to
provide training placements for local TCM degree program graduates, the Hong Kong Hospital Authority was tasked to establish a
total of 18 Chinese Medicine Centers for Training and Research (&ldquo;CMCTRs&rdquo;) in each of the 18 districts of Hong Kong
since 2003. In 2018, the total number of attendances at the 18 CMCTRs was about 1.2 million. In the 2018-19 Hong Kong Government
Budget, a Chinese Medicine Development Fund of HK$500 million was set up to facilitate applied research and Chinese medicine specialization.
Part of the fund is dedicated to promoting public awareness and nurturing talents for Chinese medicine hospital. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Key Differences between Regulated Pharmaceutical Industry
and TCM Industry in Hong Kong </I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Currently in Hong Kong, there are several
U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) and Hong Kong Pharmacy and Poisons Board approved drugs available to treat
ADHD and ASD symptoms that are manufactured by global pharmaceutical companies. However, we are a TCM bioscience company focusing
on TCM holistic treatments and do not compete directly with those pharmaceutical companies. There are several key differences
between the regulated pharmaceutical drug industry and the TCM industry in Hong Kong. For example, pharmaceutical drugs are regulated
under the Pharmacy and Poisons Ordinance (&ldquo;PPO&rdquo;), while TCM is regulated under the HKCMO. Apart from the PPO, the
Import and Export Ordinance, the Undesirable Medical Advertisements Ordinance, the Antibiotics Ordinance and the Dangerous Drugs
Ordinance also provide regulations in the control of pharmaceutical drugs in Hong Kong, while TCM is not regulated by such ordinances
and only adheres to the HKCMO. Furthermore, all pharmaceutical manufacturers with manufacturing capability in Hong Kong must comply
with the Hong Kong Good Manufacturing Practices (&ldquo;GMP&rdquo;), whereas TCM manufacturers are not required to have GMP certifications.
In terms of registration, pharmaceutical drugs sold in the Hong Kong market must be registered with the Hong Kong Pharmacy and
Poisons Board, while pCm formulae products are registered with the Hong Kong Chinese Medicines Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> TCM is a holistic treatment that provides
progressive improvement over time while pharmaceutical drugs target to short term symptomatic relief. Based on research provided
by Persistence Market Research, no large TCM companies are providing similar ADHD and ASD products in the Hong Kong market. As
such, the TCM ADHD and ASD markets are highly fragmented and there is no large TCM competitor in our target market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

</DIV>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Research and Competitive Strengths </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM Practitioner</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We strategically partner with the TCM
Practitioner, the father of Mr. Yat-Gai Au, our CEO and director. Pursuant to the strategic partnership agreement and the supplemental
agreement (collectively, the &ldquo;Partnership Agreements&rdquo;) we have with the TCM Practitioner, we have exclusive rights
and ownership of (1) all his TCM formulae for patients suffering from ADHD and ASD disorders and (2) the intellectual property
rights of the TCM formulae, including research and development, trademark, copyright, patent, and any other intellectual property
rights in relation to the TCM formulae that the TCM Practitioner develops. Pursuant to the Partnership Agreements, the TCM Practitioner
is responsible for research and development of TCM formulae for ADHD and ASD patients, however, any inventions, TCM formulae,
utilities, improvements, research, discoveries, designs, processes, methods of manufacture, and products conceived or made by
the TCM Practitioner in relation to his TCM research shall be the sole and exclusive property of us. To support the TCM Practitioner&rsquo;s
continued research on ADHD and ASD under his TCM theory, we undertake to pay for all reasonable costs and expenses incurred by
the TCM Practitioner in conducting research, testing, attending meetings/seminars, compiling records, or performing any similar
acts in relation to the development of the TCM formulae. In furtherance of our research, development, and commercialization of
TCM formulae candidates, we have direct supervision and control over the TCM Practitioner&rsquo;s TCM formulae research pursuant
to the Partnership Agreements. We have full discretion to assign, refine, update, or redesign the TCM Practitioner&rsquo;s research
tasks from time-to-time pursuant to the Partnership Agreements. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;&nbsp;&nbsp;&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The TCM Practitioner has been practicing
TCM under the guidance of the HKCMO in his clinic in Hong Kong since 1999 and has accumulated in-depth experience of TCM research
and clinical practice. For over 30 years the TCM Practitioner has focused his TCM study on TCM thesis of his father, who was a
renowned TCM doctor in Hong Kong in the 1950s, and other traditional treatises of TCM. He is experienced in treating patients
suffering from a wide range of neurocognitive disorders and degeneration. In particular, the TCM Practitioner has treated over
100 children afflicted with ADHD and ASD during his practice. He has always been passionate about treating patients and donating
back to society with his skills and knowledge. He decided to dedicate all his efforts to treat people afflicted with incurable
diseases, illnesses, and disorders. Prior to starting his TCM clinical practice, the TCM Practitioner founded a successful technology
and property business in California. The TCM Practitioner graduated from the University of California, Berkeley with a Bachelor&rsquo;s
and Master&rsquo;s Degrees in Electrical Engineering in Circuit Design and Network Theory. He was the pioneer who invented the
prototype high-density recording drive on flexible media while working at IBM, which later became known as Iomega Corporation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>TCM Research Studies and Standardized TCM Formulae
Candidates</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>TCM Research Study</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Seven (7) of the TCM Practitioner&rsquo;s
patients in Hong Kong, who were clinically diagnosed with ADHD or ASD by their healthcare professionals at different levels of
severity, voluntarily consented through their parents or guardians to participate in our first research study in November 2018
and March 2019. In the first research study, the TCM Practitioner treated the enrolled patients with the use of the personalized
TCM formulae. The personalized TCM formulae were comprised of two formula components, a base formula and an adjustable formula
targeting different severity of symptoms. The base TCM formula is the product of &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo;,
which is used to treat ADHD and ASD by the TCM Practitioner over his 30 years of practice. The adjustable formula is &ldquo;personalized&rdquo;
to each patient for different severity of symptoms. The enrolled patients&rsquo; ages ranged from five to twelve years old. Six
of the enrolled patients completed a three-month treatment and one completed a two-month treatment. Under the treatment by the
TCM Practitioner, the enrolled patients consumed liquid-based TCM twice a day, which was prepared based on personalized TCM formulae
by our TCM Practitioner, and temporarily stopped consuming any other medicines. All the enrolled patients and their parents were
required to meet with the TCM Practitioner in his clinic weekly and provide regular reports to update the patients&rsquo; symptoms
and conditions by phone. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We used globally accepted assessment
tools such as Autism Treatment Evaluation Checklist (&ldquo;ATEC&rdquo;) and Vanderbilt ADHD Diagnostic Parent Rating Scale (&ldquo;VADRS&rdquo;),
together with additional assessments, written observations, photos, videos, and parent testimonials to track the enrolled patients&rsquo;
progress. Within three months of using our TCM formulae, our research showed that the enrolled patients had gained improvements
in their speech, communication, sociability, cognition, and behavior. The enrolled patients using the personalized TCM formulae
prescribed by the TCM Practitioner experienced better bowel movement, sweating, and temporary fatigue as part of the improvement
process. Please see the &ldquo;Research and Development&rdquo; section for more details. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

</DIV>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>Standardized TCM Formulae Candidates and Second Research
Study</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of the date
hereof, the TCM Practitioner has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions.
As a result, we have three standardized TCM formulae candidates under development targeting mild, moderate, and severe ADHD and
ASD patients, each consisting of a standard base formula and a fixed adjusted formula. We plan to commence our second research
study using those three standardized TCM formulae candidates in the second quarter of 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The standardized TCM formulae candidates
were developed on the premise of &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo;, which explains why a healthy brain is essential
in restoring the body&rsquo;s systems to normal from disorders and illnesses such as ADHD and ASD. The TCM brain theory is not
recognized in general literature of TCM or elsewhere. However, the TCM Practitioner has prescribed the TCM base formulae based
on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological disorders and obtained satisfactory clinical
treatment results. According to the TCM brain theory, the blockage of or reduced blood flow, and damage of the interconnecting
central nervous system, endocrine system and blood circulatory system disrupt the production of hormones and transmission of neurotransmitters,
such as melatonin, dopamine, and norepinephrine, leading to a defective encoding and decoding of functions, and resulting in deficient
or abnormal social behaviors that are the hallmarks of ADHD and ASD. Our standardized TCM formulae candidates aim to address the
fundamental cause of the disorders to achieve an optimal outcome compared to available stimulant and non-stimulant medications
currently available in the market. TCM takes a holistic approach, using natural ingredients to treat different elements within
the body. The fundamental properties and treatment process of TCM are different from the mainstream stimulant and non-stimulant
medications. TCM takes a holistic approach, using natural ingredients to treat different elements within the body. Every bodily
function is taken into consideration when preparing the TCM formulae for the patients so that the optimal results of the treatment
could be reached. This explains the improvements in both their symptoms and overall health. As provided in the Partnership Agreements,
we continue to work closely with the TCM Practitioner to include those treatments in our future development. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We seek to protect our standardized
TCM formulae candidates, including TCM base formula and the fixed adjusted TCM formulae, and technology that we consider commercially
important by filing patent applications in Hong Kong and abroad. In addition, we also rely on trade secrets or TCM related regulatory
protection to protect our intellectual property. Our trade secrets and confidential information include unpatented know-how, technology
and other proprietary information, to maintain our competitive position and to protect our TCM formulae candidates. We seek to
protect these trade secrets and confidential information, in part, by entering into non-disclosure and confidentiality agreements
with parties that have access to them. Further, we also rely on or intend to rely on our trademarks, trade names and brand names
to distinguish our products from the products of our competitors, and have registered or will apply to register a number of these
trademarks. We have received trademark certificates for &ldquo;&#33126;&#36996;&#21407;<SUP>&reg;</SUP>&rdquo; (directly translates
as &ldquo;brain restoration&rdquo;) and &ldquo;RGC Regencell<SUP>&reg;</SUP>&rdquo; from the Hong Kong Registrar of Trade Marks
in July 2020. We also filed a trademark application for &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo; in January 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Regulatory Approvals Prior to Commercialization in Hong
Kong</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the outcome of further research
and development, if we commercialize our TCM formulae candidates in Hong Kong, the Company will need to receive include a manufacturer license
issued by the Hong Kong Chinese Medicines Board, which was established in 1999 under HKCMO. Once we receive the license and complete
pCm registrations for our standardized TCM formulae candidates, our standardized pCm formulae products can be manufactured and sold over
the counter without the supervision and prescription of a TCM practitioner in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

</DIV>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> When applying for registration of
pCm in Hong Kong, we will be required to provide sufficient documents to show the safety, stability, quality and efficacy of
our pCm formulae products to the Hong Kong Chinese Medicines Board. To show the efficacy of our pCm formulae products,
documents required include reference materials in which the claimed therapeutic functions are supported by research studies,
interpretation and principle of formulating a prescription and a summary report on all the product efficacy documents. To
prove the safety, stability and quality of our pCm formulae products, we will work with accredited laboratories, a list of
which is provided by the Hong Kong Chinese Medicines Board, to conduct all the necessary tests, such as heavy metals and
toxic element test and pesticide residues test. As for the application of manufacturer license, the major documents required
are a brief floor plan of the premise and a list of manufacturing equipment. GMP certification is not required for the
manufacturing of pCm in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our current primary roles include recruiting
and arranging patients to be treated by the TCM Practitioner, collecting research data from patients, conducting analysis over
research data, and planning for commercialization of our standardized TCM formulae candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Time and Cost Estimate Prior to the Commercialization
of Our Standardized TCM Formulae Candidates in Hong Kong</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We estimate that it will take us approximately
four years to commercialize our standardized TCM formulae candidates in Hong Kong, including as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to complete our second research study, including enrollment of qualified patients
                                         for treatment by qualified TCM practitioner(s) with the use of our standardized TCM formulae
                                         candidates, assessment and analysis;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to develop an efficient centralized production process to manufacture our liquid-based
                                         standardized TCM formulae candidates, in which six months to set up our centralized production facility
                                         after our second research study;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to prepare for efficacy documents and conduct tests, including safety, quality
                                         and stability tests upon completion of our second research study, during which time we
                                         will also apply for manufacturer license for our pCm formulae products with the Hong Kong Chinese
                                         Medicines Board; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year or more for review process of our pCm registration application after submission
                                         of our application to the Hong Kong Chinese Medicines Board.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our estimated costs prior to the commercialization
of our pCm formulae products in Hong Kong aggregate to a total amount of approximately US$19.3 million including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second research study
    &ndash; US$2.3 million;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff salaries &ndash;
    US$11.0 million;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product and intellectual
    properties registration and legal expenses &ndash; US$0.7 million; </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facilities rental,
    renovations and equipment &ndash; US$4.2 million; </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and conferences
    &ndash; US$0.4 million; and</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous &ndash;
    US$0.7 million.</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




</DIV>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Risks and Challenges</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our prospects should be considered in
light of the risks, uncertainties, expenses and difficulties frequently encountered by similar companies. Below please find a
summary of the principal risks we face, organized under relevant headings. These risks are discussed more carefully in the section
titled &ldquo;Risk Factors.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Risks Related to Our Business</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                         are an early stage TCM bioscience company with a limited operating history and have not
                                         generated revenue or applied for any regulatory approvals, nor have distribution capabilities
                                         or experienced or any granted patents or pending patent applications, and may never be
                                         profitable;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                         have limited sources of working capital and will need substantial additional financing;</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Risks Related to Our Product Development, Regulatory
Approval, Manufacturing and Commercialization</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">If
                                         we are unable to obtain regulatory approval and ultimately commercialize our standardized
                                         TCM formulae candidates or experiences significant delays in doing so, our business,
                                         financial condition, results of operations, and prospects will be materially and adversely
                                         affected;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         assessment tools used in our research study have inherent biases, and our reliance on
                                         data collected from these standard assessment tools, if inaccurate, may cause us to direct
                                         our resources inefficiently;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">If
                                         we encounter difficulties enrolling patients in our research studies, our TCM formulae
                                         development could be delayed or otherwise adversely affected;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                         TCM formulae candidates may cause undesirable side effects that could delay or prevent
                                         their regulatory approval, limit the commercial profile of an approved label, or result
                                         in significant negative consequences following regulatory approval, if any;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                         success depends on our ability to obtain and protect our intellectual property; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Adverse
                                         publicity associated with our standardized TCM formulae candidates, ingredients or network marketing
                                         program, or those of similar companies, could harm our financial condition and operating
                                         results.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>General Company Related Risks</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;&nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is uncertainty
    regarding our ability to continue as a going concern, indicating the possibility that we may be required to curtail or discontinue
    our operations in the future. If we discontinue our operations, you may lose all of your investment;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our future operating
    results are difficult to predict and may vary significantly from quarter to quarter, which may adversely affect the price
    of our ordinary shares;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain agreements
    that we entered into with our lenders contain, and future debt agreements may contain, restrictions that may limit our flexibility
    in operating our business;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are wholly dependent
    on certain key personnel and Mr. Sik-Kee Au, our TCM Practitioner and the father of our founder, director, and CEO, and loss
    of these individuals could have a material adverse effect on our business, financial condition and results of operations;
    and </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have identified
    material weaknesses in our internal control over financial reporting. If we fail to develop and maintain an effective system
    of internal control over financial reporting, we may be unable to accurately report our financial results or prevent fraud.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Risks Related to the Offering and Our Ordinary Shares</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">As
                                         a foreign private issuer, we are not subject to certain U.S. securities law disclosure
                                         requirements that apply to a domestic U.S. issuer, which may limit the information publicly
                                         available to our shareholders;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                         may lose our foreign private issuer status in the future, which could result in significant
                                         additional costs and expenses;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                         have broad discretion in the use of the net proceeds from our initial public offering
                                         and may not use them effectively;</FONT> </TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

</DIV>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">If
                                         you purchase ordinary shares in this offering, you will experience immediate and substantial
                                         dilution;</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                         founder and CEO will continue to own a significant percentage of our Ordinary Shares
                                         and will be able to exert significant control over matters subject to shareholder approval;
                                         and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">As
                                         a &ldquo;controlled company&rdquo; under the rules of the Nasdaq Capital Market, we may
                                         choose to exempt our company from certain corporate governance requirements that could
                                         have an adverse effect on our public shareholders.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Risks Related to Doing Business in Hong Kong</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Because
                                         our business is conducted in Hong Kong dollars and the price of our Ordinary Shares is
                                         quoted in United States dollars, changes in currency conversion rates may affect the
                                         value of your investments; and</FONT> </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Certain
                                         political risks exist associated with conducting business in Hong Kong.</FONT> </TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we face other risks and uncertainties
that may materially affect our business prospect, financial condition, and operations. You should consider the risks discussed
in &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus before investing in our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our authorized share capital consists of
US$1,000,000 divided into 100,000,000 shares, par value US$0.01 per share. Holders of Ordinary Shares are entitled to one vote
per share. [Upon adoption of the amended Memorandum and Articles of Association, the authorized capital will consist of [*] Ordinary
Shares, and [*] preference shares.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located
at 11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong, and our phone number is +852 2155 0823. We maintain
a corporate website at http://www.regencellbioscience.com/. The information contained in, or accessible from, our website or any
other website does not constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Corporate History and Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are a holding company incorporated
in the Cayman Islands on October 30, 2014. We have no substantive operations other than holding all of the issued and outstanding
shares of Regencell Bioscience Ltd. and Regencell Ltd. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Ltd. owns
100% equity interest of Regencell Bioscience Ltd., which was incorporated in Hong Kong on May 12, 2015. Currently, we conduct
research and development activities in the TCM industry through Regencell Bioscience Ltd., which has entered Partnership Agreements
with the TCM Practitioner. In October 2020, Regencell Bioscience Ltd. entered into a leasing agreement with Regus in California, </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Ltd. owns
100% equity interest of Regencell Ltd., which was incorporated in Hong Kong on November 20, 2014. Currently, Regencell Ltd. has
no operation and is reserved for future expansion use. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our CEO and director, Mr. Yat-Gai Au,
beneficially owns 100% of Regencell Bioscience Holdings Ltd. through Regencell (BVI) Ltd. Regencell (BVI) Ltd. was incorporated pursuant to the BVI Business Companies Act, 2004, on May 25, 2017, and has no operation
since its inception. Mr. Yat-Gai Au has been the sole shareholder of Regencell (BVI) Ltd. since its inception. On September 28,
2020, Regencell (BVI) Ltd. acquired all equity interest of Regencell Bioscience Holdings Ltd. from Mr. Yat-Gai Au. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following diagram illustrates our corporate
structure as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 222px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our consolidated financial statements
as of and for the years ended June 30, 2020 and 2019 were prepared assuming that we will continue as a going concern and do not
include any adjustments that might be necessary if we are unable to continue as a going concern. There were substantial doubts
about our ability to continue as a going concern at the audit report date of our consolidated financial statement as of and for
the years ended June 30, 2020 and 2019. Our independent registered public accounting firm, Friedman LLP, has issued their opinion
with an explanatory paragraph in connection with the consolidated financial statements for the years ended June 30, 2020 and 2019
included in our annual report that expresses substantial doubt about our ability to continue as a going concern. As of June 30,
2020, and 2019, we have outstanding shareholder loans amounting to approximately $3.07 million and $2.08 million, respectively,
from Mr. Yat-Gai Au, the founder and CEO. On November 10, 2020, we entered into a loan agreement with Mr. Yat-Gai Au to evidence
the existing loan and document our oral agreements of the terms and conditions of such existing loan when such loan was initially
generated. The loan agreement also sets forth that the Mr. Yat-Gai Au will continue to make loan to the us for daily operation
and research activities. The use of loan shall be agreed and determined by both parties before granting the loan. All loans shall
bear 0% interest per annual. The maturity date of such loans is June 30, 2021, subject to indefinite extension if agreed by the
parties in writing. On February 2, 2021, a loan extension agreement was entered by Mr. Yat-Gai Au and us, pursuant to which Mr.
Yat-Gai Au agreed to provide up to US$3 million in the form of loan or make payments on behalf of us during the period from January
1, 2021 to June 30, 2022 to support our operations and research activities for the period from January 1, 2021 to June 30, 2022
and further extend the maturity of the existing loans from June 30, 2021 to December 31, 2022. We acknowledge that uncertainty
remains over our ability to meet our liabilities as they fall due. If we cannot secure the financing needed to continue as a viable
business, our shareholders may lose some or all of their investment in us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Our Being an &ldquo;Emerging Growth Company&rdquo;
and &ldquo;Foreign Private Issuer&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a company with less than $1.07 billion
in revenue during our last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act. An &ldquo;emerging growth company&rdquo; may take advantage of reduced reporting
requirements that are otherwise generally applicable to public companies. In particular, as an emerging growth company, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may present only two years of audited financial statements and only two years of related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations, or MD&amp;A;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives, which is commonly referred to as &ldquo;compensation discussion and analysis&rdquo;;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to obtain an attestation and report from our auditors on our management&rsquo;s assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required to obtain a non-binding advisory vote from our shareholders on executive compensation or golden parachute arrangements (commonly referred to as the &ldquo;say-on-pay,&rdquo; &ldquo;say-on frequency&rdquo; and &ldquo;say-on-golden-parachute&rdquo; votes);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under &sect;107 of the JOBS Act; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will not be required to conduct an evaluation of our internal control over financial reporting for two years.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to take advantage of all of these
reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption of new or revised financial
accounting standards under &sect;107 of the JOBS Act. Our election to use the phase-in periods may make it difficult to compare
our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the
phase-in periods under &sect;107 of the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain of these reduced reporting requirements
and exemptions were already available to us due to the fact that we also qualify as a &ldquo;smaller reporting company&rdquo; under
SEC rules. For instance, smaller reporting companies are not required to obtain an auditor attestation and report regarding management&rsquo;s
assessment of internal control over financial reporting, are not required to provide a compensation discussion and analysis, are
not required to provide a pay-for-performance graph or CEO pay ratio disclosure, and may present only two years of audited financial
statements and related MD&amp;A disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a foreign private issuer within the
meaning of the rules under the Exchange Act, and as such we are exempt from certain provisions of the securities rules and regulations
in the United States that are applicable to U.S. domestic issuers. Moreover, the information we are required to file with or furnish
to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers.
In addition, as a company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation
to corporate governance matters that differ significantly from the Nasdaq listing standards. As such, we may rely on home country
practice to be exempted from the corporate governance requirements that we have a majority of independent directors on our board
of directors and the audit committee of our board of directors has a minimum of three members. These practices may afford less
protection to shareholders than they would enjoy if we complied fully with the Nasdaq listing standards. However, following this
offering, we will voluntarily have a majority of independent directors and our audit committee will consist of three independent
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
</DIV>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Controlled Company</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the completion of this offering, we
will be a &ldquo;controlled company&rdquo; as defined under the Nasdaq Stock Market Rules because Mr. Yat-Gai Au, our founder,
director and CEO, will beneficially own [ ]% of our Ordinary Shares and will be able to exercise [ ]% of the total voting power
of our issued and outstanding shares, assuming the full exercise of the over-allotment option by the underwriter and the exercise
of the warrants.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the completion of this offering, our
directors, executive officers and principal shareholders will continue to have substantial control over our company. Our affiliates
will be able to exercise [ ]% of the total voting power of our issued and outstanding shares, assuming the full exercise of the
over-allotment option by the underwriter and the exercise of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As long as our officers and directors, either
individually or in the aggregate, own at least 50% of the voting power of our Company, we are a &ldquo;controlled company&rdquo;
as defined under Nasdaq Marketplace Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For so as we are a controlled company under
that definition, we are permitted to elect to rely, and may rely, on certain exemptions from corporate governance rules, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that a majority of our board of directors must be independent directors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that the compensation
    of our CEO must be determined or recommended solely by independent directors; and</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that our director nominees must be selected or recommended solely by independent directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result, you will not have the same
protection afforded to shareholders of companies that are subject to these corporate governance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we do not intend to rely on the
&ldquo;controlled company&rdquo; exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future.
If we elect to rely on the &ldquo;controlled company&rdquo; exemption, a majority of the members of our board of directors might
not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely
of independent directors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
</DIV>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_003"></A><B>THE
                                         OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares offered by us</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 71%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] Ordinary Shares (excluding the over-allotment discussed below).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price per Ordinary Share</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[&#9679;] per Ordinary Share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriters have an option for a period of 45 days to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional Ordinary Shares solely to cover over-allotments, if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares outstanding prior to completion of this offering</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] Ordinary Shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ordinary Shares outstanding immediately after this offering</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] Ordinary Shares, assuming no exercise of the underwriters&rsquo; over-allotment option.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Shares to be subscribed by independent directors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;] Ordinary Shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to use the proceeds from this offering
    for research and development of our TCM formulae and products, human resources development, clinical and regulatory development
    approval, intellectual property applications, and for working capital and general corporate purposes. See &ldquo;Use of Proceeds&rdquo;
    on page 36 for more information.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Nasdaq Capital Market Trading
    Symbol and Listing</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have applied to list our Ordinary Shares
    on the Nasdaq Capital Market under the symbol &ldquo;RGCB.&rdquo; No assurance can be given that such listing will be approved
    or that a liquid trading market will develop for our Ordinary Shares; however, we will not complete this offering unless we
    receive approval for listing on Nasdaq Capital Market.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We and our directors, officers any other holder(s) of three percent (3.0%) or more of our outstanding ordinary share have agreed with the representative not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our Ordinary Shares or securities convertible into Ordinary Shares for a period of 180-days commencing on the effective date of this prospectus. See &ldquo;Underwriting.&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer Agent</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vstock Transfer, LLC</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Ordinary Shares offered hereby involve a high degree of risk. You should read &ldquo;Risk Factors,&rdquo; beginning on page 14 for a discussion of factors to consider before deciding to invest in our Ordinary Shares.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of Ordinary Shares that are and will be outstanding
immediately before and after this offering as shown above is based on [____] shares outstanding as of January___, 2021, which,
as used throughout this prospectus, unless otherwise indicated, excludes the Ordinary Shares issuable upon the exercise of the
warrants to be issued to the representative of the underwriter, and assuming no exercise of over-allotment option by the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</DIV>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="width: 98%; padding: 4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY
                                         CONSOLIDATED FINANCIAL DATA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the table below, we provide you with
historical selected financial data for the years ended June 30, 2020 and 2019. This information is derived from our consolidated
financial statements included elsewhere in this prospectus. Historical results are not necessarily indicative of the results that
may be expected for any future period. When you read this historical selected financial data, it is important that you read it
along with the historical financial statements and related notes and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; included elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For
                                         the Years Ended <BR>
                                         June 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Consolidated Statements of Operations and Comprehensive Loss:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Operating Expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">812,371</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">390,990</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Loss from Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">812,371</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">390,990</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Earnings per share, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(81.24</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(39.10</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Weighted average number of ordinary shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Consolidated Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Current assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">386,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">243,307</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">514,018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">243,307</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,164,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,081,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,164,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,081,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Shareholder&rsquo;s deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,650,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,838,521</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Working capital (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,777,931</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,838,521</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
</DIV>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Investment in our securities involves
a high degree of risk. You should carefully consider the risks described below together with all of the other information included
in this prospectus before making an investment decision. The risks and uncertainties described below represent our known material
risks to our business. If any of the following risks actually occurs, our business, financial condition or results of operations
could suffer. In that case, you may lose all or part of your investment. You should not invest in this offering unless you can
afford to lose your entire investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks related to Our Financial Position and Need for Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are an early stage TCM bioscience company with a limited
operating history. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an early stage TCM bioscience company
with a limited operating history that focuses on research, development, and commercialization of TCM for children afflicted by
ADHD and ASD and we have not generated any revenue. We have incurred operating losses since our formation. We incurred total net
losses of US$0.81 million and US$0.39 million, respectively, for the fiscal years ended June 30, 2020 and 2019. The likelihood
of success of our business plan and growth strategy must be considered in light of the problems, substantial expenses, difficulties,
complications and delays frequently encountered in connection with developing and expanding early-stage businesses and the regulatory
and competitive environment in which we operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, you should consider our prospectus
in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development,
especially early stage bioscience research companies such as ours. Potential investors should carefully consider the risks and
uncertainties that a company with a limited operating history will face. In particular, potential investors should consider that
we cannot assure you that we will be able to, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">successfully
                                         implement or execute our current business plan, and we cannot assure you that our business
                                         plan is sound;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully manufacture
    and commercialize our standardized liquid-based TCM formulae treatment for mild, moderate, and severe ADHD and ASD patients
    after our second research studies;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully complete the research studies to obtain regulatory approval for the marketing of our TCM formulae candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">obtain,
                                         secure, maintain and, as necessary, defend our intellectual property rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">attract
                                         and retain an experienced management and research team;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">launch
                                         commercial sales of our standardized liquid-based TCM formulae candidates, whether alone
                                         or in collaboration with others;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">raise
                                         sufficient funds in the capital markets or otherwise to effectuate our business plan;
                                         and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">utilize
                                         the funds that we do have and/or raise in this offering or in the future to efficiently
                                         execute our business strategy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we cannot successfully execute any one
of the foregoing, our business may fail and your investment will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>We have not generated revenue from any TCM formulae
candidates or applied for any regulatory approvals, nor have distribution capabilities or experienced or any granted patents or
pending patent applications, and may never be profitable.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our ability to become profitable depends
upon our ability to generate revenue. As the date hereof, we have not applied any regulatory approvals, no granted or pending
patent applications and we have no distribution capabilities or experience, and we have not generated any revenue from our development
stage TCM formulae candidates and we do not know when, or if, we will generate any such revenue. We do not expect to generate
significant revenue unless and until we obtain marketing approval of our standardized TCM formulae candidates, produce and commercialize
products based on such TCM formulae. Our ability to generate future revenue from sales of products based on our TCM formulae depends
heavily on our success in many areas, including but not limited to: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining favorable results from and progress
    the research studies of our TCM formulae candidates;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and obtaining regulatory approval
    for registration for our TCM formulae candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, assessing and/or developing potential
    new TCM formulae candidates for ADHD and ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately identifying demand for our product
    candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued consumer interest in treatments to
    the symptoms of ADHD and ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining market acceptance of our liquid-based
    TCM formulae treatment, if approved for marketing, as viable treatment options for ADHD and ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating favorable terms in any collaboration,
    licensing or other arrangements into which we may enter; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting, hiring and retaining qualified personnel.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have limited sources of working capital and will need
substantial additional financing </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The working capital required to implement
our business plan will most likely be provided by funds obtained through offerings of our equity, debt, debt-linked securities,
and/or equity-linked securities, and, in the future, revenues generated by us. No assurance can be given that we will have revenues
sufficient to sustain our operations or that we would be able to obtain equity/debt financing in the current economic environment.
If we do not have sufficient working capital or raise additional funds, we may delay the completion of or significantly reduce
the scope of our current business plan; delay some of our research and development; postpone the hiring of new personnel; or,
under certain dire financial circumstances, substantially curtail or cease our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our inability to obtain sufficient additional
financing would have a material adverse effect on our ability to implement our business plan and, as a result, could require us
to significantly curtail or potentially cease our operations. Our ability to complete additional financings is dependent on, among
other things, the state of the capital markets at the time of any proposed offering, market reception of the Company and the likelihood
of the success of our business model and offering terms. There is no assurance that we will be able to obtain any such additional
capital through asset sales, equity or debt financing, or any combination thereof, on satisfactory terms or at all. Additionally,
no assurance can be given that any such financing, if obtained, will be adequate to meet our capital needs and to support our
operations. If we do not obtain adequate capital on a timely basis and on satisfactory terms, our revenues and operations and
the value of our Ordinary Shares and Ordinary Share equivalents would be materially negatively impacted and we may cease our operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Product Development, Regulatory Approval,
Manufacturing and Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Our standardized TCM formulae candidates for mild,
moderate, and severe ADHD and ASD patients are still in development. If we are unable to obtain regulatory approval and ultimately
commercialize our standardized TCM formulae and/or products based on our TCM formulae or experiences significant delays in doing
so, our business, financial condition, results of operations, and prospects will be materially and adversely affected.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Currently, three standardized TCM formulae
candidates for mild, moderate, and severe ADHD and ASD patients are under research and development. None current formulae candidate
is currently in the process of the regulatory approval and commercialization. Our ability to generate revenues from our standardized
TCM formulae candidates are dependent on the completion of our research and development, receipt of regulatory approval and successfully
commercializing products based on such formulae, which may never occur. Each of our TCM formulae candidates will require additional
research and development, regulatory approval in Hong Kong and other jurisdictions where we plan to sell, development of manufacturing
supply and capacity, substantial investment, and significant marketing efforts before we generate any revenue from product sales.
The success of our three standardized TCM formulae candidates for mild, moderate, and severe patients will depend on several factors,
including the following: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful enrollment in, and completion of,
    research studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt of regulatory approvals from applicable
    regulatory authorities for planned research studies, future research studies, or drug registrations, manufacturing, and commercialization;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful completion
    of all safety studies required to obtain regulatory approval in Hong Kong and other jurisdictions in which our standardized
    TCM formulae candidates intend to sell;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing commercial manufacturing capabilities to the specifications for our candidates for clinical supply and commercial manufacturing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making and maintaining arrangements with third-party TCM raw material suppliers or manufacturers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and maintaining patent, trade secret,
    and other intellectual property protection and/or regulatory exclusivity for our standardized TCM formula candidates;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching commercial sales of our standardized liquid-based TCM formulae treatment, if and when approved, whether alone or in collaboration with others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance of the standardized liquid-based TCM formulae treatment, if and when approved, by patients and the medical community;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively competing with other therapies and alternative drugs, particularly those for ADHD and ASD;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully enforcing and defending intellectual property rights and claims; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining a continued acceptable safety
    profile of the standardized TCM formulae candidates following regulatory approval.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The success of our business is highly
dependent upon our ability to develop and commercialize our standardized TCM formulae candidates for ADHD and ASD, of which has
research studies currently on-going. As a result, our business is substantially dependent on our ability to complete the research
and development of, obtain regulatory approval for, and successfully commercialize our standardized liquid-based TCM formulae
treatment and other TCM formulae candidates for ADHD and ASD patients in a timely manner. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We cannot commercialize standardized
TCM formulae candidates in Hong Kong, where we intend to launch our first standardized TCM formulae and products, without first
obtaining regulatory approval from authorities concerned in Hong Kong. Similarly, we cannot commercialize standardized TCM formulae
candidates in the U.S. or globally without receipt of regulatory approvals from applicable regulatory authorities for our TCM
formulae or, alternatively, compliance with regulatory requirements applicable to non-drug products, as applicable. The process
to develop, obtain regulatory approval for, and commercialize standardized TCM formulae candidates is long, complex, and costly
and approval may not be granted. Obtaining regulatory approval in one jurisdiction does not mean that regulatory approval will
be obtained in any other jurisdiction. Approval processes vary among countries and can involve additional product testing and
validation and additional administrative review periods. No assurance can be given that we can obtain regulatory approval in Hong
Kong, even if our TCM formulae candidates, which to be proved its efficiency, were to successfully obtain approval from the Hong
Kong Chinese Medicines Board, we would still need to seek approval in other jurisdictions where we plan to market the product.
Any safety issues, product recalls, or other incidents related to products approved and marketed in one jurisdiction may impact
approval of those products by another jurisdiction. If we are unable to obtain regulatory approval for our standardized TCM formulae
candidates in one or more jurisdictions, or any approval contains significant limitations imposed on certain standardized TCM
formulae candidates, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development
of our TCM formulae candidates or any other TCM formulae candidates that we may acquire or develop in the future. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our research and development of TCM formulae candidates
is at an early stage of development and all of our TCM formulae candidates may require significant interactions with regulatory
authorities and investments before their respective commercial launches. If we are unable to advance our TCM formulae candidates
to final development, meet regulatory requirements, including obtaining regulatory approval, where applicable, or ultimately commercialize
our product candidates or experience significant delays in doing so, our business will be materially harmed.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our research and development of TCM
formulae is at an early stage and will require significant investment and regulatory approvals prior to commercialization. Each
of our TCM formulae candidates will require additional research and development, obtaining regulatory approval, such as obtaining
manufacturing supply, substantial investment, and significant marketing efforts before it generates any revenue from product sales.
We are not permitted to market or promote any of our standardized TCM formulae candidates before our receipt of regulatory approval
from the Hong Kong Chinese Medicines Board, or comparable regulatory authorities, and we may never receive such regulatory approval
for any such standardized TCM formulae candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The success of our product candidates will
depend on several factors, including but not limited to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">receipt
                                         of regulatory approvals from applicable regulatory authorities for drug product candidates
                                         or, alternatively, compliance with regulatory requirements applicable to non-drug products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing current
    GMP-compliant supply and commercial manufacturing operations or deciding with GMP-compliant third-party manufacturers for
    supply and commercial manufacturing;</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">obtaining
                                         and maintaining patent and trade secret protection or regulatory exclusivity for our
                                         product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">launching
                                         commercial sales of our product candidates, if and when approved or allowed for marketing,
                                         whether alone or in collaboration with others; and </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">maintaining
                                         a continued acceptable safety profile of the product candidates following approval or
                                         commercialization.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot be certain that research and
development of any of our TCM formulae candidates will be successful or that we will obtain regulatory approval or be able to
successfully commercialize any product based on our TCM formulae and generate revenue. Success in our research studies does not
ensure that application of regulatory approval will be successful. Our research studies may fail to demonstrate that our TCM formulae
candidates are safe and effective for their proposed uses. Any such failure could cause us to abandon further development of any
one or more of our TCM formulae candidates and may delay development of other TCM formulae candidates. Any delay in, or termination
of, our development will delay and possibly preclude the filing with regulatory authorities and, ultimately, our ability to commercialize
the TCM formulae candidates and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>The assessment tools used in our research study have
inherent biases, and our reliance on data collected from these standard assessment tools, if inaccurate, may cause us to direct
our resources inefficiently.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The assessment tools we used in our
research study include Autism Treatment Evaluation Checklist (ATEC), Gilliam Autism Rating Scale (GARS), Vanderbilt ADHD Diagnostic
Parent Rating Scale (VADRS), and Swanson, Nolan, and Pelham (SNAP)-IV 26-item Parent Rating Scale (SNAP-IV-26). These assessment
tools are globally recognized and accepted methods of scoring severity levels of ADHD and ASD patients. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We believe that these assessment tools
serve a useful purpose in helping us to evaluate whether our TCM formulae candidates are having their intended effects, and that
they may thus enable us to identify more promising TCM formulae candidates, to direct our resources efficiently, and to provide
data support for our future application of pCm registrations with the Hong Kong Chinese Medicine Council. We also believe that
these assessment tools may eventually allow us to monitor patient compliance with study protocols. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> However, these assessment tools have
some inherent biases, such as parental expectations, social desirability and recall bias. If our understanding and use of these
assessment tools is inaccurate or flawed, or if the parents of enrolled ADHD and ASD patients fail to observe and record accurately,
then we will not only fail to realize any benefits from using these assessment tools, but may also be led to invest time and financial
resources inefficiently in attempting to develop inappropriate TCM formulae candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we encounter difficulties enrolling patients in our
research studies, our TCM formulae development could be delayed or otherwise adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We conduct research studies involving TCM
formulae candidates whose activity and specificity have been optimized by our TCM Practitioner in his prior ADHD and ASD treatment.
Timely completion of research studies in accordance with the protocols depends, among other things, on our ability to enroll a
sufficient number of patients who meet the research study criteria and remain in the study until the conclusion. We may experience
difficulties enrolling and retaining appropriate patients in its research study for a variety of reasons, including but not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size and nature of the patient population;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient eligibility criteria defined in the
    research study protocol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of study population required for statistical
    analysis of the study&rsquo;s primary endpoints;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the design of the study and changes to the design
    of the study;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit personnel with the appropriate
    competencies and experience;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing research studies for similar therapies
    or other new therapeutics, which will reduce the number and types of patients available;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients&rsquo; perceptions as to the potential
    advantages and side effects of the TCM formulae being studied in relation to other available therapies, including any new
    drug candidates or treatments that may be approved for the indications we are investigating;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain patient consents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients enrolled in research study that may
    not complete a research study; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of approved therapies that
    are similar to our TCM formulae candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even if we are able to enroll a sufficient
number of patients in our research study, delays in patient enrollment may result in increased costs or may affect the timing
or outcome of the planned research studies, which could prevent completion of these studies and adversely affect our ability to
advance the development of our TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Results of our earlier studies on personalized TCM
formulae may not be predictive of future research study results. Failure can occur at any stage of research and development.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The results of research studies of our
personalized TCM formulae may not be predictive of the results of standardized TCM formulae candidates. Standardized TCM formulae
candidates may fail to show the desired safety and efficacy despite positive results of personalized TCM formulae. Based upon
negative or inconclusive results, we, along with our TCM Practitioner or any potential future collaborator may decide, or regulators
may require us, to conduct additional research studies. In addition, data obtained from research studies are susceptible to varying
interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit, or prevent regulatory
approval. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we do not know whether future
research studies will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule,
if at all. Research studies can be delayed or aborted for a variety of reasons, including delay or failure to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruit suitable patients to participate in
    research studies and have such patients complete the research studies or return for post-treatment follow-up;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any patient safety concerns that arise
    during the course of a research study;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure that patients comply with and complete
    research study protocol;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate or add a sufficient number of research
    study sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture sufficient quantities of TCM formulae
    candidate for use in research studies and ensure research study material is provided to research study sites in a timely manner;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain the statistical analysis plan to be used
    to evaluate the research study data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Qualified patient enrollment is a significant
factor in our research studies and is affected by many factors, including the size and nature of the patient population, the eligibility
criteria for the studies, the design of the research study, competing research studies and patients&rsquo; perceptions as to the
potential advantages of the TCM formulae being studied in relation to other available therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we experience delays in the start or
completion of, or termination of, any research studies of our TCM formulae candidates, the commercial prospects of our TCM formulae
candidates may be affected, and our ability to generate product revenues will be delayed. In addition, any delays in completing
our research studies will increase our costs, slow down our TCM formulae candidates&rsquo; development and approval process and
jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may negatively harm our business,
financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion
of research studies may also ultimately lead to the denial of regulatory approval of our TCM formulae candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM formulae candidates may cause undesirable side
effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in
significant negative consequences following regulatory approval, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Potential undesirable side effects caused
by our TCM formulae candidates may cause it to interrupt, delay, or halt research studies or could cause regulatory authorities
to interrupt, delay, or halt our research studies or could result in a more restrictive label or the delay or denial of regulatory
approval by the Hong Kong Chinese Medicines Board, or other regulatory authorities. We may observe some potential side effects
in future research studies that could affect patient recruitment or the ability of enrolled patients to complete the study or
result in potential product liability claims. Any of these occurrences may harm our business, financial condition, and prospects
significantly. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our research studies assessed a sample of
the potential patient population. With a limited number of patients and duration of exposure, rare and severe side effects of our
TCM formulae candidates may only be uncovered with a large number of patients exposed to the TCM formulae treatment. If our TCM
formulae candidates receive regulatory approval and we, our partners, or others identify undesirable side effects caused by such
standardized liquid-based TCM formulae treatment after such approval, a number of potentially significant negative consequences
could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Hong Kong Chinese
    Medicines Board or other comparable regulatory authorities may withdraw or limit their approval of such standardized TCM formulae
    candidates;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be required to change the way such
    standardized TCM formulae candidates are distributed or administered, conduct additional research studies, or change the labeling
    of our TCM formulae treatment;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Hong Kong Chinese Medicines Board or
    other comparable regulatory authorities may require a risk evaluation and mitigation strategy, plan to mitigate risks, which
    could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution
    methods, patient registries, and other risk minimization tools;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be subject to regulatory investigations and government enforcement actions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may decide to remove such TCM formulae treatment from the marketplace;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we could be sued and held liable for injury caused to individuals exposed to or taking our TCM formulae treatment; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of these events could prevent us from
achieving or maintaining market acceptance of the affected TCM formulae treatment and could substantially increase the costs of
commercializing our TCM formulae treatment, if approved, and significantly impact our ability to successfully commercialize our
TCM formulae candidates and generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If any of our TCM formulae candidates are approved for
marketing and commercialization and we are unable to develop manufacture, sales, marketing and distribution capabilities on our
own or enter into agreements with third parties to produce and sell our products on acceptable terms, we will be unable to successfully
commercialize any such future therapeutics.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We currently have no sales and marketing,
or distribution capabilities or experience. In order to commercialize our standardized TCM formulae candidates, if approved, we
must build marketing and sales capabilities or decide to make arrangements with third parties to produce and sell products, and
we may not be successful in doing so. Building the requisite sales, marketing or distribution capabilities will be expensive and
time-consuming and will require significant attention of our leadership team to manage. Any failure or delay in the development
of our sales, marketing or distribution capabilities would adversely impact the commercialization of our products. The competition
for talented individuals experienced in selling and marketing TCM products is intense, and we cannot assure you that we can assemble
an effective team. Additionally, we may choose to collaborate with third parties on the commercialization of our standardized
TCM formulae candidates. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to
successfully commercialize our standardized TCM formulae candidates if and when we receive regulatory approval or any such commercialization
may experience delays or limitations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may be subject to additional risks related
to operating in foreign countries either ourselves or through a third-party, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing regulatory requirements in foreign
    countries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected changes in tariffs, trade barriers,
    price and exchange controls and other regulatory requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic weakness, including inflation or political
    instability in particular foreign economies and markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with tax, employment, immigration
    and labor laws for employees living or traveling abroad;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign taxes, including withholding of payroll
    taxes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign currency fluctuations, which could result
    in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties staffing and managing foreign operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce uncertainty in countries where labor
    unrest is more common than in the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential liability under the Foreign Corrupt
    Practices Act of 1977 or comparable foreign regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges enforcing our contractual and intellectual
    property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the
    same extent as the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production shortages resulting from any events
    affecting raw material supply or manufacturing capabilities abroad; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business interruptions resulting from geopolitical
    actions, including war and terrorism.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to increase our brand recognition, we may
face difficulty in obtaining new customers or patients.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that developing, maintaining
and enhancing our brand recognition in a cost-effective manner outside of that market is critical to achieving widespread acceptance
of our future products and is an important element in our effort to build our customer or patient base. Successful promotion of
our brand and products in the TCM and medical industry will depend largely on our ability to maintain a sizeable and active customer
or patient base, our marketing efforts and ability to provide reliable and useful products and treatments at competitive prices.
Brand promotion activities may not yield increased revenue in the near future, and even if they do, any increased revenue may not
offset the expenses we will incur in building our brand. If we fail to successfully promote and maintain our brand during our commercialization
period, or if we incur substantial expenses in an unsuccessful attempt to promote and maintain our brand, we may fail to attract
enough customers or patients to the extent necessary to realize a sufficient return on our brand-building efforts, in which case
our business, operating results and financial condition, would be materially adversely affected.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our success depends on our ability to obtain and protect
our intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The TCM formulae are the core of our
business operation and TCM research and development. We seek to protect the TCM formulae candidates and technology that we consider
commercially important by filing patent applications in Hong Kong and abroad or rely on our trade secrets. Although we intend
to file for patent applications with the authorities concerned in Hong Kong, there is no assurance that they will be granted,
or that, if granted, any of our future patents will be held valid and enforceable against third-party infringement, or that our
formulae will not infringe any third-party patent or intellectual property. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any patents relating to our formulae, if
granted, may not be sufficiently broad to protect them. In addition, our patents, if granted, may be challenged, potentially invalidated
or potentially circumvented. Our patents, if granted, may not afford us protection against competitors with similar formulae or
permit the commercialization of our products without infringing third-party patents or other intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Further, we also rely on or intend to
rely on our trademarks, trade names and brand names to distinguish our products from the products of our competitors, and have
registered or will apply to register a number of these trademarks. We have received trademark certificates for &ldquo;&#33126;&#36996;&#21407;<SUP>&reg;</SUP>&rdquo;
(directly translates as &ldquo;brain restoration&rdquo;) and &ldquo;RGC Regencell<SUP>&reg;</SUP>&rdquo; from the Hong Kong Registrar
of Trade Marks in July 2020. We also filed a trademark application for &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo; in January
2021. While we also intend to seek to protect the trademarks in the U.S. and in other countries, we may be unsuccessful in obtaining
registrations and/or otherwise protecting these trademarks out of Hong Kong. However, third parties may oppose our trademark applications
or otherwise challenge our use of the trademarks. Further, our competitors may infringe our trademarks, or we may not have adequate
resources to enforce our trademarks. Effective trademark protection may not be available or may not be sought in every country
in which our products are made available in the future. In the event that our trademarks or applications are successfully challenged,
we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources
to advertising and marketing these new brands. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Third parties
may make claims challenging the inventorship or ownership of our TCM formulae. In addition, we may face claims by third parties
that our agreements with employees, contractors or consultants obligating them to&nbsp;assign&nbsp;intellectual&nbsp;property&nbsp;to
us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership
disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial
value of such intellectual property. Litigation may be necessary to resolve an ownership dispute, and if we are not successful,
we may be precluded from using certain intellectual property or may lose our exclusive rights in that intellectual property. Either
outcome could harm our business and competitive position. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We also rely on trade secrets, including
unpatented know-how, technology and TCM related regulatory protection, to maintain our competitive position in our TCM research.
While our current employment agreements with our employees contain provisions protecting our confidential information, including
the knowledge of proprietary Chinese medicine, prescriptions, techniques, and skills, we may seek to protect, in part, by entering
into separate confidentiality agreements with licensees, suppliers, employees and consultants in the future. These agreements
may be breached and there may not be adequate remedies in the event of a breach. Disputes may arise concerning the ownership of
intellectual property or the applicability of confidentiality agreements. Moreover, our trade secrets and proprietary technology
may otherwise become known or be independently developed by our competitors. If patents are not issued with respect to products
arising from research, we may not be able to maintain the confidentiality of information relating to these products. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Adverse publicity associated with our TCM formulae candidates,
ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The results of our operations may be significantly
affected by the public&rsquo;s perception of our TCM formulae candidates and the overall TCM treatment industry. This perception
is dependent upon opinions concerning:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.65pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and quality of our TCM formulae and
    ingredients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.65pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the safety and quality of similar products and
    ingredients distributed by other TCM companies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.65pt; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our sales force.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Adverse publicity concerning any actual
or purported failure to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing
practices, or other aspects of our business, whether or not resulting in enforcement actions or the imposition of penalties, could
have an adverse effect on our goodwill and could negatively affect our sales and ability to generate revenue. In addition, our
consumers&rsquo; perception of the safety and quality of products and ingredients as well as similar products and ingredients
distributed by other companies can be significantly influenced by media attention, publicized scientific research or findings,
widespread product liability claims and other publicity concerning our TCM formulae candidates or ingredients or similar products
and ingredients distributed by other companies. Adverse publicity, whether or not accurate or resulting from consumers&rsquo;
use or misuse of our TCM formulae treatment, that associates consumption of our TCM formulae treatment or ingredients or any similar
products or ingredients with illness or other adverse effects, questions the benefits of our or similar products or claims that
any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact
our reputation or the market demand for our TCM formulae treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Any disruption in the supply chain of raw materials and
our products could adversely impact our ability to produce and deliver products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As to the products we intend to manufacture,
we must manage our supply chain for raw materials and delivery of our products. Our raw material used in research study is currently
sourced by the TCM Practitioner from a Hong Kong vendor under the Hong Kong Chinese Medicine Regulatory Office guideline. Local
administrative bodies and physical infrastructure built to protect local interests pose transportation challenges for raw material
transportation as well as product delivery in Hong Kong. In addition, profitability and volume could be negatively impacted by
limitations inherent within the supply chain, including competitive, governmental, legal, natural disasters, and other events
that could impact both supply and price. Any of these occurrences could cause significant disruptions to our supply chain, manufacturing
capability and distribution system that could adversely impact our ability to produce and deliver some of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our raw materials are not sourced from
endangered species of animals or plants. All of our raw materials are readily available in over 6,000 TCM stores, wholesalers,
and other distribution channels in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B><I>&nbsp;</I></B>&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Third parties may assert that
our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We employ individuals
who previously worked with other companies, including our competitors or potential competitors. Although we try to ensure that
our employees, contractors, or consultants do not use the proprietary information or&nbsp;know-how&nbsp;of others in their work
for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise
used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other
third party. Litigation may be necessary to defend against these claims. If we fail in defending any such claims or settling those
claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights or personnel.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We face risks related to health epidemics and outbreaks,
including the SARS-Cov-2 (or COVID-19) pandemic, which could significantly disrupt our ongoing research studies, and therefore
our receipt of necessary regulatory approvals could be delayed or prevented.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We face risks
related to health epidemics or outbreaks of communicable diseases. For example, the recent outbreak around the world, including
in Hong Kong, the U.S., the European Union members, China and many other countries, of the highly transmissible and pathogenic
COVID-19. The outbreak of such communicable diseases could result in a widespread health crisis that could adversely affect general
commercial activity and the economies and financial markets of many countries, which in the case of COVID-19 has occurred. In
addition, the COVID-19 pandemic may have a severe effect on our ongoing and future research studies of many TCM formulae candidates.
The extent to which the COVID-19 pandemic may impact our research studies will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, such as the duration and geographic reach of the outbreak, the severity of
COVID-19, and the effectiveness of actions to contain and treat COVID-19 in Hong Kong. The continued spread of COVID-19 globally
could adversely impact our research study operations, including our ability to recruit and retain patients if an outbreak outlasts
in Hong Kong. Disruptions or restrictions on our ability to travel to monitor data from our enrolled patients, or to conduct research
studies, or the ability of patients enrolled in our studies to travel, as well as temporary closures of our facilities would negatively
impact our research study activities. As a result, the expected timeline for data readouts of our research studies on enrolled
patients and certain regulatory filings may be negatively impacted, which would adversely affect our ability to obtain regulatory
approval for and to commercialize our product candidates, increase our operating expenses and have a material adverse effect on
our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Company Related Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have a very limited operating history, which may make
it difficult for you to evaluate the success of our business to date and to assess our future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> We commenced
our operations in Hong Kong through our wholly-owned subsidiary Regencell Bioscience Ltd. in 2015. Our operations to date have
been limited to organizing and staffing the company, partnering with the TCM Practitioner to conduct research studies, identifying
potential partnerships and TCM formulae candidates, acquiring TCM raw materials, and conducting research and development activities
for our TCM formulae candidates. We have not yet demonstrated the ability to successfully complete large-scale, pivotal research
studies. We have also not yet applied for or obtained regulatory approval for, or demonstrated an ability to manufacture or commercialize,
any of our TCM formulae candidates. Consequently, any predictions about our future success, performance, or viability may not
be as accurate as they could be if it had a longer operating history or approved products on the market. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our limited operating
history, particularly in light of the evolving TCM formulae research and development industry in which we operate, may make it
difficult to evaluate our current business and prospects for future performance. Our short history makes any assessment of our
future performance or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced
by early-stage companies in evolving fields as we seek to transition to a company capable of supporting commercial activities.
In addition, as a new business, we may be more likely to encounter unforeseen expenses, difficulties, complications, and delays
due to limited experience. If we do not address these risks and difficulties successfully, our business will suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is uncertainty regarding our ability to continue
as a going concern, indicating the possibility that we may be required to curtail or discontinue our operations in the future.
If we discontinue our operations, you may lose all of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We incurred total
net losses of US$0.81 million and US$0.39 million, respectively, for the fiscal years ended June 30, 2020 and 2019, and have completed
only the preliminary stages of our business plan. We anticipate incurring additional losses before realizing any revenues. We
may need additional financing in order to meet our continuing obligations and ultimately, to attain profitability. The financial
statements do not include any adjustments that might result from the uncertainty about our ability to continue our business. If
we are unable to obtain enough financing from outside sources before we produce enough revenues, we may be forced to sell our
assets, or curtail or discontinue our operations. If this happens, you could lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <B><I>Our future operating results
are difficult to predict and may vary significantly from quarter to quarter, which may adversely affect the price of our ordinary
shares.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Our limited
research progress of our standardized TCM formulae candidates, together with our history of losses, make prediction of future
operating results difficult. You should not rely on our past performance as any indication of future growth rates or operating
results. Our valuation and the price of our securities likely will fall in the event our operating results do not meet the expectations
of analysts and investors. Comparisons of our quarterly operating results are an unreliable indication of our future performance
because they are likely to vary significantly based on many factors, including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to enroll enough mild-to-moderate ADHD and ASD patients into our second research studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of our standardized TCM formulae candidates to treat individuals with ADHD or ASD, and the possible future introduction of new products and treatments for ADHD or ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the successful completion of future research
    studies, and the possibility that the results of any future study may be adverse to our product and services, or reveal some
    heretofore unknown risk to patients from treatment in the personalized TCM formulae; the failure by us to make professional
    presentation and publication of positive outcomes data from these research studies;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to commercialize the standardized
    TCM formulae candidates in Hong Kong once we obtain permission from the Hong Kong Chinese Medicines Board;</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expansion and rate of success of our marketing and advertising efforts to ADHD and ASD patients, and the rate of success of our direct sales force in Hong Kong;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure of third-party contract manufacturers to deliver products or provide services in a cost effective and timely manner;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our failure to compete with other treatment for ADHD and ASD;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions relating to ongoing Chinese Medicine
    Ordinance of Hong Kong compliance;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated delays in the development and
    introduction of our future products and/or our inability to control costs;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effects of global or local pandemics or
    epidemics and governmental responses, such as COVID-19; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic conditions as well as those
    specific to our customers and markets.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Therefore, you
should expect that our results of operations will be difficult to predict, which will make an investment in our company uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Future debt agreements may contain, restrictions that
may limit our flexibility in operating our business.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Documents governing
our future indebtedness, or in connection with additional capital raises, if any, may contain, numerous financial and operating
covenants that limit the discretion of management with respect to certain business matters. Restrictive covenants included in
the above-mentioned credit facility include restrictions on, among others, our ability to&nbsp;incur or permit additional indebtedness
and change the nature of our business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Our ability
to comply with these and other provisions of the existing loan agreement is dependent on our future performance, which will be
subject to many factors, some of which are beyond our control. The breach of any negative covenants in our current or future agreements
could result in an event of default, as may be defined in such agreements, thereby leading to a potential default interest rate
or immediate repayment of any borrowed amounts. These restrictive covenants which may be in place from time to time and a lack
of compliance by us could limit our flexibility in operating our business. We currently entered into a loan agreement with Mr.
Yat-Gai Au, our CEO and director, which is subject to written amendment by both parties to extend the term of loans. We cannot
guarantee you that we can extend the loans with him in the future without being requested to accept additional restrictions in
connection with our future business operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>We are wholly dependent on certain key personnel and
our strategic partner, Mr. Sik-Kee Au, the father of our founder, director, and CEO, and loss of these individuals could have
a material adverse effect on our business, financial condition and results of operations.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our success is, to a certain extent,
attributable to the management, and research and development expertise and potential sales and marketing of key personnel. We
are dependent on the services of Mr. Yat-Gai Au, our founder, director, and CEO, and Dr. Yi-Chung Chao, our Chief Medical Officer
(&ldquo;CMO&rdquo;) and director, for the continued growth and operation of our Company, and critical to our overall management,
as well as the continued development of our strategic direction, due to their experience, personal and business contacts in Hong
Kong and the US. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our success of developing standardized
TCM formulae candidates is wholly dependent upon our strategic partnership with Mr. Sik-Kee Au, the TCM Practitioner, the father
of Mr. Yat-Gai Au, our director and CEO, for the continued research and development of the formulae candidates for the Company.
The whole basis of our TCM research is the TCM formulae transferred by the TCM Practitioner, which was developed by TCM Practitioner&rsquo;s
brain theory. We may not be able to retain our partnership with the TCM Practitioner for any given period of time. We are reliant
upon TCM Practitioner to provide these research services and have little control over his availability or expertise, except our
Partnership Agreements with the TCM Practitioner. Although we have no reason to believe that he will terminate the partnership
relationship with us, the interruption or loss of his services would adversely affect our ability to effectively run our business
and pursue our research on standardized TCM formulae candidates as well as our results of operations. We also highly rely upon
Dr. Yi-Chung Chao&rsquo;s collection and analysis over the research data of our research study. The loss of any of these individuals
could have a material adverse effect upon our business, financial condition, and results of operations. We do not carry key man
life insurance for any of our key personnel, nor do we foresee purchasing such insurance to protect against the loss of key personnel. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to hire and retain qualified personnel
to support our growth and if we are unable to retain or hire these personnel in the future, our ability to improve our products
and implement our business objectives could be adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We must attract, recruit and retain a sizeable
workforce of technically competent employees. Competition for senior management and personnel in Hong Kong is intense and the
pool of qualified candidates in Hong Kong is very limited. We may not be able to retain the services of our senior executives
or personnel, or attract and retain high-quality senior executives or personnel in the future. This failure could materially and
adversely affect our future growth and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have identified material weaknesses in our internal
control over financial reporting. If we fail to develop and maintain an effective system of internal control over financial reporting,
we may be unable to accurately report our financial results or prevent fraud.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">In connection with audits of our financial statements for the
fiscal years ended June 30, 2020 and 2019, our management identified material weaknesses in the design and operation of our internal
controls because:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our lack of sufficient skilled staff with U.S.
    GAAP knowledge and the SEC reporting knowledge for the purpose of financial reporting as well as the lack in formal accounting
    policies and procedures manual to ensure proper financial reporting in accordance with U.S. GAAP and SEC reporting requirements;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our lack of an audit committee and internal
    audit function to establish formal risk assessment process and internal control framework.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As defined under standards established
by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;), a material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of the Company&rsquo;s annual or interim consolidated financial statements will not be prevented or detected on a timely basis. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, in order to address the
material weakness in internal control over financial reporting of the Company, we have: (a) continued our efforts to set up the
internal audit department, and enhance the effectiveness of the internal control system; and (b) continued our efforts to implement
necessary review and controls at related levels and all important documents and contracts will be submitted to the office of its
CEO for retention. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All internal control systems, no matter
how well designed, have inherent limitations including the possibility of human error and the circumvention or overriding of controls.
Further, because of changes in conditions, the effectiveness of internal controls may vary over time. Projections of any evaluation
of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate. Accordingly, even those systems determined to
be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We cannot be certain that these measures
will successfully remediate the material weakness or that other material weaknesses will not be discovered in the future. If our
efforts are not successful or other material weaknesses or control deficiencies occur in the future, we may be unable to report
our financial results accurately on a timely basis or help prevent fraud, which could cause our reported financial results to
be materially misstated and result in the loss of investor confidence or delisting and cause the market price of our ordinary
shares to decline. In addition, it could in turn limit our access to capital markets, harm our results of operations, and lead
to a decline in the trading price of our securities. Additionally, ineffective internal control over financial reporting could
expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange
on which we list, regulatory investigations and civil or criminal sanctions. We may also be required to restate our financial
statements from prior periods. Because of our status as an emerging growth company, you will not be able to depend on any attestation
from our independent registered public accountants as to our internal control over financial reporting for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not be able to compete effectively against our
competitors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are at the early stage of the development
of our liquid-based TCM formulae treatment and have not sold any products successfully. We expect to face competition in the future
that may result in revenue reductions for the liquid-based TCM formulae treatment that we plan to deliver. We will be at a competitive
disadvantage in obtaining the facilities, employees, financing and other resources required to provide services demanded by prospective
customers. Our opportunity to obtain customers may be limited by our financial resources and other assets. We expect to be less
able than our larger competitors, such as international pharmaceutical companies, to cope with generally increasing costs and
expenses of doing business. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our business model may not be sufficient to ensure our
success in our intended market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our survival is currently dependent upon
the success of our efforts to gain ADHD and ASD patients&rsquo; acceptance of liquid-based TCM formulae treatment that will ultimately
represent a very small segment in our targeted industry when it is completed. Should our target market not be as responsive to
our products as we anticipate, we may not have in place alternate products or services that we can offer to ensure our survival.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our TCM formulae treatment may not be a
desired for purchase by patients, or potential competitors may develop services that imitate or compete with ours or prospective
offers and take our targeted revenue stream away from us or reduce our ability to command profitable revenue streams for our products.
If our competitors, such as those international pharmaceutical companies, develop more successful products to cure ADHD or ASD
or offer competitive products at lower price, our revenue, margins, and profitability will not suffer.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our TCM business is subject to inherent risks relating
to product liability and personal injury claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> TCM companies, similar to pharmaceutical
companies, are exposed to risks inherent in the manufacturing and distribution of TCM products, such as with respect to improper
filling of prescriptions, labeling of prescriptions, inadequacy of warnings, and unintentional distribution of counterfeit products.
In addition, product liability claims may be asserted against us with respect to any of the products we sell and as a distributor,
we are required to pay for damages for any successful product liability claim against us, although we may have the right under
applicable Hong Kong laws, rules and regulations to recover from the relevant manufacturer for compensation we paid to our customers
in connection with a product liability claim. We may also be obligated to recall affected products. If we are found liable for
product liability claims, we could be required to pay substantial monetary damages. Furthermore, even if we successfully defend
ourselves against this type of claim, we could be required to spend significant management, financial and other resources, which
could disrupt our business, and our reputation as well as our brand name may also suffer. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to the Offering and Our Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>The initial public offering
price of our Ordinary Shares may not be indicative of the market price of our Ordinary Shares after this offering. In addition,
an active, liquid and orderly trading market for our Ordinary Shares may not develop or be maintained, and our stock price may
be volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to this offering, our Ordinary Shares
were not traded on any market. An active, liquid and orderly trading market for our Ordinary Shares may not develop or be maintained
after this offering. Active, liquid and orderly trading markets usually result in less price volatility and more efficiency in
carrying out investors&rsquo; purchase and sale orders. The market price of our Ordinary Shares could vary significantly as a
result of a number of factors, some of which are beyond our control. In the event of a drop in the market price of our Ordinary
Shares, you could lose a substantial part or all of your investment in our Ordinary Shares. The initial public offering price
will be determined by us, based on numerous factors and may not be indicative of the market price of our Ordinary Shares after
this offering. Consequently, you may not be able to sell shares of our Ordinary Shares at prices equal to or greater than the
price paid by you in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following factors could affect our
share price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our operating and financial performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quarterly variations in the rate of growth of
    our financial indicators, such as net income per share, net income and revenues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the public reaction to our press releases, our
    other public announcements and our filings with the SEC;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">strategic actions by our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in revenue or earnings estimates, or
    changes in recommendations or withdrawal of research coverage, by equity research analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation in the press or investment community;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of research analysts to cover our
    Ordinary Shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our Ordinary Shares by us or other
    shareholders, or the perception that such sales may occur;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting principles, policies,
    guidance, interpretations or standards;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key management personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions by our shareholders;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">domestic and international economic, legal and
    regulatory factors unrelated to our performance; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the realization of any risks described under
    this &ldquo;Risk Factors&rdquo; section.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The stock markets in general have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations
may adversely affect the trading price of our Ordinary Shares. Securities class action litigation has often been instituted against
companies following periods of volatility in the overall market and in the market price of a company&rsquo;s securities. Such
litigation, if instituted against us, could result in very substantial costs, divert our management&rsquo;s attention and resources
and harm our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are a passive foreign investment company for United
States federal income tax purposes for any taxable year, United States holders of our Ordinary Shares could be subject to adverse
United States federal income tax consequences.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A non-United States corporation will be
a passive foreign investment company, or PFIC, for United States federal income tax purposes for any taxable year if either (i)
at least 75% of its gross income for such taxable year is passive income or (ii) at least 50% of the value of its assets (based
on an average of the quarterly values of the assets) during such year is attributable to assets that produce or are held for the
production of passive income. Based on the current and anticipated value of our assets and the composition of our income and assets,
we do not expect to be a PFIC for United States federal income tax purposes for our current taxable year ending June 2021 or in
the foreseeable future. However, the determination of whether or not we are a PFIC according to the PFIC rules is made on an annual
basis and will depend on the composition of our income and assets and the value of our assets from time to time. Therefore, changes
in the composition of our income or assets or the value of our assets may cause us to become a PFIC. The determination of the
value of our assets (including goodwill not reflected on our balance sheet) may be based, in part, on the quarterly market value
of our Ordinary Shares, which is subject to change and may be volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The classification of certain of our income
as active or passive, and certain of our assets as producing active or passive income, and hence whether we are or will become
a PFIC, depends on the interpretation of certain United States Treasury Regulations as well as certain IRS guidance relating to
the classification of assets as producing active or passive income. Such regulations and guidance are potentially subject to different
interpretations. If due to different interpretations of such regulations and guidance the percentage of our passive income or
the percentage of our assets treated as producing passive income increases, we may be a PFIC in one or more taxable years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are a PFIC for any taxable year during
which a United States person holds Ordinary Shares, certain adverse United States federal income tax consequences could apply
to such United States person. See &ldquo;Taxation&mdash;Passive Foreign Investment Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX
ADVISERS ABOUT THE PFIC RULES, THE POTENTIAL APPLICABILITY OF THESE RULES TO THE COMPANY CURRENTLY AND IN THE FUTURE, AND THEIR
FILING OBLIGATIONS IF THE COMPANY IS A PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>For as long as we are an emerging growth company, we
will not be required to comply with certain reporting requirements, including those relating to accounting standards and disclosure
about our executive compensation, that apply to other public companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April 2012, President Obama signed into
law the JOBS Act. We are classified as an &ldquo;emerging growth company&rdquo; under the JOBS Act. For as long as we are an emerging
growth company, which may be up to five full fiscal years, unlike other public companies, we will not be required to, among other
things, (i) provide an auditor&rsquo;s attestation report on management&rsquo;s assessment of the effectiveness of our system
of internal control over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act, (ii) comply with any new requirements
adopted by the PCAOB requiring mandatory audit firm rotation or a supplement to the auditor&rsquo;s report in which the auditor
would be required to provide additional information about the audit and the financial statements of the issuer, (iii) provide
certain disclosure regarding executive compensation required of larger public companies or (iv) hold nonbinding advisory votes
on executive compensation. We will remain an emerging growth company for up to five years, although we will lose that status sooner
if we have more than $1.07 billion of revenues in a fiscal year, have more than $700 million in market value of our Ordinary Shares
held by non-affiliates, or issue more than $1.0 billion of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent that we rely on any of the
exemptions available to emerging growth companies, you will receive less information about our executive compensation and internal
control over financial reporting than issuers that are not emerging growth companies. If some investors find our Ordinary Shares
to be less attractive as a result, there may be a less active trading market for our Ordinary Shares and our stock price may be
more volatile.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we fail to establish and maintain proper internal
financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations could
be impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to this offering, we were a private
company with limited accounting personnel and other resources with which to address our internal controls and procedures. Our
management has not completed an assessment of the effectiveness of our internal control over financial reporting, and our independent
registered public accounting firm has not conducted an audit of our internal control over financial reporting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In the course of auditing our consolidated
financial statements as of and for the years ended June 30, 2020, and 2019, we and our independent registered public accounting
firm identified two material weaknesses in our internal control over financial reporting as well as other control deficiencies.
As defined in standards established by the PCAOB, a &ldquo;material weakness&rdquo; is a deficiency, or a combination of deficiencies,
in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our
annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses identified
relate to (1) our lack of sufficient skilled staff with U.S. GAAP knowledge and the SEC reporting knowledge for the purpose of
financial reporting as well as the lack in formal accounting policies and procedures manual to ensure proper financial reporting
in accordance with U.S. GAAP and SEC reporting requirements; and (2) our lack of an audit committee and internal audit function
to establish formal risk assessment process and internal control framework. As a result, we have taken the following actions to
strengthen our U.S. GAAP financial reporting capabilities and our internal audit function: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (1) </TD><TD> On December 3, 2021 the board of directors passed a resolution
                                         to appoint three independent directors and form an audit committee comprising three independent
                                         directors upon effectiveness of this registration statement; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (2) </TD><TD> On January 18, 2021, we hired an experienced CFO with
                                         listed companies&rsquo; financial reporting and internal control experience; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (3) </TD><TD> On January 26, 2021, we hired an experienced U.S. GAAP
                                         accountant to manage the company&rsquo;s U.S. GAAP financial reporting process; and </TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> (4) </TD><TD> The Company has begun searching for an internal control
                                         service provider for the audit committee to consider. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon completion of this offering, we will
become a public company in the United States subject to the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act
of 2002 will require that we include a report of management on our internal control over financial reporting in our annual report
on Form 20-F beginning with our first required annual report for the prior fiscal year after completion of this offering. In addition,
once we cease to be an &ldquo;emerging growth company&rdquo; as such term is defined under the JOBS Act, our independent registered
public accounting firm must attest to and report on the effectiveness of our internal control over financial reporting. Our management
may conclude that our internal control over financial reporting is not effective. Moreover, even if our management concludes that
our internal control over financial reporting is effective, our independent registered public accounting firm, after conducting
its own independent testing, may issue a report that is qualified if it is not satisfied with our internal controls or the level
at which our controls are documented, designed, operated or reviewed, or if it interprets the relevant requirements differently
from us. In addition, after we become a public company, our reporting obligations may place a significant strain on our management,
operational and financial resources and systems for the foreseeable future. We may be unable to timely complete our evaluation
testing and any required remediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the course of documenting and testing
our internal control procedures, in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, we may
identify other weaknesses and deficiencies in our internal control over financial reporting. In addition, if we fail to maintain
the adequacy of our internal control over financial reporting, as these standards are modified, supplemented or amended from time
to time, we may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting in
accordance with Section 404 of the Sarbanes-Oxley Act of 2002. Generally, if we fail to achieve and maintain an effective internal
control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations,
which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access
to capital markets, and harm our results of operations. Additionally, ineffective internal control over financial reporting could
expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange
on which we list, regulatory investigations and civil or criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The obligation to disclose information publicly may put
us at a disadvantage to competitors that are private companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon completion of this offering, we will
be a publicly listed company in the United States. As a publicly listed company, we will be required to file periodic reports
with the SEC upon the occurrence of matters that are material to our company and shareholders. In some cases, we will need to
disclose material agreements or results of financial operations that we would not be required to disclose if we were a private
company. Our competitors may have access to this information, which would otherwise be confidential. This may give them advantages
in competing with our company. Similarly, as a U.S.-listed public company, we will be governed by U.S. laws that our non-publicly
traded competitors are not required to follow. To the extent compliance with U.S. laws increases our expenses or decreases our
competitiveness against such companies, our public listing could affect our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>As a foreign private issuer, we are not subject to certain
U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the information publicly available
to our shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a foreign private issuer, we are not
required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and therefore there
may be less publicly available information about us than if we were a U.S. domestic issuer. For example, we are not subject to
the proxy rules in the United States and disclosure with respect to our annual general meetings will be governed by Cayman Islands
law requirements. In addition, our officers, directors and principal shareholders are exempt from the reporting and &ldquo;short-swing&rdquo;
profit recovery provisions of Section 16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not know
on a timely basis when our officers, directors and principal shareholders purchase or sell our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may lose our foreign private issuer status in the
future, which could result in significant additional costs and expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As discussed above, we are a foreign private
issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of
the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer&rsquo;s
most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50%
of our Ordinary Shares are directly or indirectly held by residents of the U.S. and we fail to meet additional requirements necessary
to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required
to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive
than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements,
and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions
of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance
requirements under the Nasdaq Stock Market listing rules. As a U.S. listed public company that is not a foreign private issuer,
we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer,
and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Recent joint statement by the SEC and PCAOB, proposed
rule changes submitted by Nasdaq, and an act signed into law all call for additional and more stringent criteria to be applied
to emerging market companies upon assessing the qualification of their auditors. These developments could add uncertainties to
our offering.</I></B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 21, 2020, SEC Chairman Jay Clayton
and PCAOB Chairman William D. Duhnke III, along with other senior SEC staff, released a joint statement highlighting the risks
associated with investing in companies based in or have substantial operations in emerging markets. The joint statement emphasized
the risks associated with lack of access for the PCAOB to inspect auditors and audit work papers in China and higher risks of
fraud in emerging markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May 18, 2020, Nasdaq filed three proposals
with the SEC to (i) apply minimum offering size requirement for companies primarily operating in &ldquo;Restrictive Market&rdquo;,
(ii) adopt a new requirement relating to the qualification of management or board of director for &ldquo;Restrictive Market&rdquo;
companies, and (iii) apply additional and more stringent criteria to an applicant or listed company based on the qualifications
of the company&rsquo;s auditors. The proposed definition of &ldquo;Restrictive Market&rdquo; means a jurisdiction that Nasdaq
determines to have secrecy laws, blocking statutes, national security laws or other laws or regulations restricting access to
information by regulators of U.S.-listed companies in such jurisdictions. Nasdaq may consider the geographic locations of the
company&rsquo;s principal business segments, operations or assets; board and shareholders&rsquo; meetings; headquarters or principal
executive offices; senior management and employees; and books and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As part of a continued regulatory focus
in the United States on access to audit and other information currently protected by national law, in particular China&rsquo;s,
U.S. President Donald J. Trump signed into law on December 18, 2020 the Holding Foreign Companies Accountable Act, which will
require the SEC to propose rules within 90 days after its enactment to prohibit securities of any registrant from being listed
on any of the U.S. securities exchanges or traded &ldquo;over the counter&rdquo; if the auditor of the registrant&rsquo;s financial
statements is not subject to PCAOB inspection for three consecutive years after the law becomes effective. We could be delisted
if we are unable to cure the situation to meet the PCAOB inspection requirement in time. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The lack of access to the PCAOB inspection
in China prevents the PCAOB from fully evaluating audits and quality control procedures of the auditors based in China. As a result,
investors may be deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors
in China makes it more difficult to evaluate the effectiveness of these accounting firms&rsquo; audit procedures or quality control
procedures as compared to auditors outside of China that are subject to the PCAOB inspections, which could cause existing and
potential investors in our stock to lose confidence in our audit procedures and reported financial information and the quality
of our financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Enactment of the Holding Foreign Companies
Accountable Act or other efforts to increase U.S. regulatory access to audit information could cause investor uncertainty for
affected issuers, including us, and the market price of the ordinary shares could be adversely affected. In addition, enactment
of the Holding Foreign Companies Accountable Act will result in prohibitions on the trading of the ordinary shares on The Nasdaq
Capital Market or other U.S. exchange if our auditor fails to be inspected by the PCAOB for three consecutive years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We believe that we are not subject to
the proposed Nasdaq rules or the Holding Foreign Companies Accountable Act because our business is conducted exclusively in Hong
Kong, through our Hong Kong subsidiary Regencell Bioscience Ltd., using Hong Kong dollars. Our senior management and employees
are citizens of Hong Kong and the U.S. and our books and records are managed in Hong Kong. Hong Kong is a special administrative
region of the PRC and the basic policies of the PRC regarding Hong Kong are reflected in the Basic Law, namely, Hong Kong&rsquo;s
constitutional document, which provides Hong Kong with a high degree of autonomy and executive, legislative and independent judicial
powers, including that of final adjudication under the principle of &ldquo;one country, two systems&rdquo;. However, there is
no assurance that there will not be any changes in the economic, political and legal environment in Hong Kong in the future. Since
our operation is based in Hong Kong, any change of such political arrangements may pose immediate threat to the stability of the
economy in Hong Kong, thereby directly and adversely affecting our results of operations and financial positions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our auditor, Friedman LLP, the independent
registered public accounting firm that issues the audit report included elsewhere in this prospectus, as an auditor of companies
that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant
to which the PCAOB conducts regular inspections to assess our auditor&rsquo;s compliance with the applicable professional standards.
Our auditor is headquartered in Manhattan, New York, and has been inspected by the PCAOB on a regular basis with the last inspection
in June 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, the recent developments would
add uncertainties to our offering and we cannot assure you whether Nasdaq or regulatory authorities would apply additional and
more stringent criteria to us after considering our business operation and the effectiveness of our auditor&rsquo;s audit procedures
and quality control procedures, sufficiency of resources, geographic reach or experience as it relates to the audit of our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The requirements of being a public company may strain
our resources and divert management&rsquo;s attention.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a public company, we will be subject
to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act,
the Dodd-Frank Act, the listing requirements of the securities exchange on which we list, and other applicable securities rules
and regulations. Compliance with these rules and regulations will nonetheless increase our legal, accounting, and financial compliance
costs and investor relations and public relations costs, make some activities more difficult, time-consuming or costly and increase
demand on our systems and resources, particularly after we are no longer an &ldquo;emerging growth company.&rdquo; As a foreign
private issuer, the Exchange Act requires, among other things, that we file annual and current reports with respect to our business
and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of disclosure of information
in this prospectus and in filings required of a public company, our business and financial condition will become more visible,
which we believe may result in threatened or actual litigation, including by competitors and other third parties. If such claims
are successful, our business and operating results could be harmed, and even if the claims do not result in litigation or are
resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management
and adversely affect our business, brand and reputation and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also expect that being a public company
and these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and
we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also
make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our
audit committee and compensation committee, and qualified executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have broad discretion in the use of the net proceeds
from our initial public offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent (i) we raise more money than
required for the purposes explained in the section titled &ldquo;Use of Proceeds&rdquo; or (ii) we determine that the proposed
uses set forth in that section are no longer in the best interests of our Company, we cannot specify with any certainty the particular
uses of such net proceeds that we will receive from our initial public offering. Our management will have broad discretion in
the application of such net proceeds, including working capital, possible acquisitions, and other general corporate purposes,
and we may spend or invest these proceeds in a way with which our shareholders disagree. The failure by our management to apply
these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from
our initial public offering in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not intend to pay dividends for the foreseeable
future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently intend to retain any future
earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable
future. As a result, you may only receive a return on your investment in our Ordinary Shares if we are successfully listed and
the market price of our Ordinary Shares increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The price of the Ordinary Shares and other terms of this
offering have been determined by us along with our underwriter.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you purchase our Ordinary Shares in
this offering, you will pay a price that was not established in a competitive market. Rather, you will pay a price that was determined
by us along with our Underwriter. The offering price for our Ordinary Shares may bear no relationship to our assets, book value,
historical results of operations or any other established criterion of value. The trading price, if any, of the Ordinary Shares
that may prevail in any market that may develop in the future, for which there can be no assurance, may be higher or lower than
the price you paid for our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Shares eligible for future sale may adversely affect
the market price of our Ordinary Shares if the shares are successfully listed on Nasdaq or other stock markets, as the future
sale of a substantial number of outstanding shares of Ordinary Shares in the public marketplace could reduce the price of our
Ordinary Shares.</I></B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market price of our shares could decline
as a result of sales of substantial amounts of our shares in the public market, or the perception that these sales could occur.
In addition, these factors could make it more difficult for us to raise funds through future offerings of our Ordinary Shares.
An aggregate of [&#9679;] shares will be issued and outstanding before the consummation of this offering all of which, except
those held by management, are or will be freely tradable immediately upon effectiveness of this registration statement. All of
the shares sold in the offering will be freely transferable without restriction or further registration under the Securities Act.
The remaining shares will be &ldquo;restricted securities&rdquo; as defined in Rule 144. These shares may be sold without registration
under the Securities Act to the extent permitted by Rule 144 or other exemptions under the Securities Act. See &ldquo;Shares Eligible
for Future Sale.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If you purchase ordinary shares in this offering, you
will experience immediate and substantial dilution.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The initial public offering price of our
shares is substantially higher than the net tangible book value per share of our Ordinary Shares. Assuming the completion of the
minimum offering, if you purchase shares in this offering, you will incur immediate dilution of approximately $[&#9679;] per share
or approximately [&#9679;]% from the assumed offering price of $[&#9679;] per share and after deducting estimated underwriter fees
and commissions and estimated offering expenses payable by us. Assuming the completion of the maximum offering, if you purchase
shares in this offering, you will incur immediate dilution of approximately $[&#9679;] or approximately [&#9679;]% from the assumed
offering price of $[&#9679;] per share. Accordingly, if you purchase shares in this offering, you will incur immediate and substantial
dilution of your investment. See &ldquo;Dilution.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>A sale or perceived sale of a substantial number of shares
of our Ordinary Shares may cause the price of our Ordinary Shares to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our shareholders sell substantial amounts
of our Ordinary Shares in the public market, the market price of our Ordinary Shares could fall. Moreover, the perceived risk
of this potential dilution could cause shareholders to attempt to sell their shares and investors to short our ordinary shares.
These sales also may make it more difficult for us to sell equity or equity-related securities in the future at a time and price
that we deem reasonable or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The market price for our Ordinary Shares may be volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The initial public offering price for our
Ordinary Shares may vary from the market price of our Ordinary Shares following our initial public offering. If you purchase our
Ordinary Shares in our initial public offering, you may not be able to resell those shares at or above the initial public offering
price. We cannot assure you that the initial public offering price of our Ordinary Shares, or the market price following our initial
public offering, will equal or exceed prices in privately negotiated transactions of our shares that have occurred from time to
time prior to our initial public offering. The market price for our Ordinary Shares may be volatile and subject to wide fluctuations
due to factors such as:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the financial projections we may provide to
    the public, any changes in these projections or our failure to meet these projections;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated fluctuations in our quarterly
    operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in financial estimates by securities
    research analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative publicity, studies or reports;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our capability to catch up with the technology
    innovations in the industry;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of acquisitions,
    strategic partnerships, joint ventures or capital commitments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">addition or departure of key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations of exchange rates between Hong
    Kong dollar and the U.S. dollar; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic or political conditions in
    Hong Kong.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the securities market has
from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular
companies. These market fluctuations may also materially and adversely affect the market price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our founder and CEO will continue to own a significant
percentage of our Ordinary Shares and will be able to exert significant control over matters subject to shareholder approval.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr. Yat-Gai Au, our founder and CEO, currently
beneficially owns 100% of the Company through Regencell (BVI) Ltd., and after this offering is completed the Company will continue
to be controlled by him. Upon the closing of this offering, he will beneficially own approximately [&nbsp;&nbsp;&nbsp;]% of the
voting power of our outstanding ordinary shares, or approximately [ ] if the underwriters exercise their option to purchase additional
Ordinary Shares from us in full. Therefore, even after this offering, he will have the ability to substantially influence us through
this ownership position. For example, he may be able to control elections of directors, amendments of our organizational documents,
or approval of any merger, sale of assets, or other major corporate transaction. His interests may not always coincide with our
corporate interests or the interests of other shareholders, and he may act in a manner with which you may not agree or that may
not be in the best interests of our other shareholders. So long as he continues to own a significant amount of our equity, he will
continue to be able to strongly influence or effectively control our decisions.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>As a &ldquo;controlled company&rdquo; under the rules
of the Nasdaq Capital Market, we may choose to exempt our company from certain corporate governance requirements that could have
an adverse effect on our public shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the completion of this offering, we
will be a &ldquo;controlled company&rdquo; as defined under the Nasdaq Stock Market Rules because Mr. Yat-Gai Au, our founder,
director and CEO, will beneficially own [ ]% of our Ordinary Shares and will be able to exercise [ ]% of the total voting power
of our issued and outstanding shares, assuming the full exercise of the over-allotment option by the underwriter and the exercise
of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the completion of this offering, our
directors, executive officers and principal shareholders will continue to have substantial control over our company. Our affiliates
will be able to exercise [ ]% of the total voting power of our issued and outstanding shares, assuming the full exercise of the
over-allotment option by the underwriter and the exercise of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As long as our officers and directors,
either individually or in the aggregate, own at least 50% of the voting power of our Company, we are a &ldquo;controlled company&rdquo;
as defined under Nasdaq Market place Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For so long as we are a controlled company
under that definition, we are permitted to elect to rely, and may rely, on certain exemptions from corporate governance rules,
including: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that a majority of
    our board of directors must be independent directors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from
    the rule that the compensation of our CEO must be determined or recommended solely by independent directors; and</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the rule that our director nominees must be selected or recommended solely by independent directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result, you will not have the same
protection afforded to shareholders of companies that are subject to these corporate governance requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">Cayman
Islands law does not impose any fiduciary or other duties on a majority (or controlling) shareholder in respect of the company
or any minority shareholders. For more discussion regarding differences of fiduciary duties under Cayman Islands law and U.S.
corporate law, see &ldquo;&mdash; Description of Share Capital </FONT><FONT STYLE="background-color: white">&mdash;</FONT> <FONT STYLE="font-size: 10pt">Differences
in Corporate Law.&rdquo;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we do not intend to rely on the
&ldquo;controlled company&rdquo; exemption under the Nasdaq listing rules, we could elect to rely on this exemption in the future.
If we elect to rely on the &ldquo;controlled company&rdquo; exemption, a majority of the members of our board of directors might
not be independent directors and our nominating and corporate governance and compensation committees might not consist entirely
of independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts do not publish research
or reports about our business, or if they issue an adverse or misleading opinion regarding our shares, the price and trading volume
of our Ordinary Shares could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The trading market for our Ordinary Shares
will be influenced by the research and reports that industry or securities analysts publish about us or our business. If no or
few securities or industry analysts commence coverage of us, the trading price for our securities would be negatively impacted.
In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading
opinion regarding us, our business model, our intellectual property or our stock performance, or if our operating results fail
to meet the expectations of analysts, the price of our securities would likely decline. If one or more of these analysts cease
coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could
cause the price or trading volume of our Ordinary Shares to decline<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Doing Business in Hong Kong </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Political risks associated with conducting business in
Hong Kong.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our operations are based in Hong Kong.
Accordingly, our business operation and financial conditions will be affected by the political and legal developments in Hong
Kong. During the period covered by the financial information incorporated by reference into and included in this prospectus, we
maintain substantially all of our operations in Hong Kong and, specifically, from Regencell Bioscience Ltd. Any adverse economic,
social and/or political conditions, material social unrest, strike, riot, civil disturbance or disobedience, as well as significant
natural disasters, may affect the market may adversely affect the business operations of Regencell Bioscience Ltd. Hong Kong is
a special administrative region of the PRC and the basic policies of the PRC regarding Hong Kong are reflected in the Basic Law,
namely, Hong Kong&rsquo;s constitutional document, which provides Hong Kong with a high degree of autonomy and executive, legislative
and independent judicial powers, including that of final adjudication under the principle of &ldquo;one country, two systems&rdquo;.
However, there is no assurance that there will not be any changes in the economic, political and legal environment in Hong Kong
in the future. Since our operation is based in Hong Kong, any change of such political arrangements may pose immediate threat
to the stability of the economy in Hong Kong, thereby directly and adversely affecting our results of operations and financial
positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Basic Law of the Hong Kong Special
Administrative Region of the People&rsquo;s Republic of China, Hong Kong is exclusively in charge of its internal affairs and
external relations, while the government of the PRC is responsible for its foreign affairs and defense. As a separate customs
territory, Hong Kong maintains and develops relations with foreign states and regions. Based on certain recent development including
the Law of the People&rsquo;s Republic of China on Safeguarding National Security in the Hong Kong Special Administrative Region
issued by the Standing Committee of the PRC National People&rsquo;s Congress in June 2020, the U.S. State Department has indicated
that the United States no longer considers Hong Kong to have significant autonomy from China and President Trump signed an executive
order and Hong Kong Autonomy Act, or HKAA, to remove Hong Kong&rsquo;s preferential trade status and to authorize the U.S. administration
to impose blocking sanctions against individuals and entities who are determined to have materially contributed to the erosion
of Hong Kong&rsquo;s autonomy. The United States may impose the same tariffs and other trade restrictions on exports from Hong
Kong that it places on goods from mainland China. These and other recent actions may represent an escalation in political and
trade tensions involving the U.S, China and Hong Kong, which could potentially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given the relatively small geographical
size of Hong Kong, any of such incidents may have a widespread effect on our business operations, which could in turn adversely
and materially affect our business, results of operations and financial condition. It is difficult to predict the full impact
of the HKAA on Hong Kong and companies with operations in Hong Kong like us. Furthermore, legislative or administrative actions
in respect of China-U.S. relations could cause investor uncertainty for affected issuers, including us, and the market price of
our ordinary shares could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Because our business is conducted in Hong Kong dollars
and the price of our Ordinary Shares is quoted in United States dollars, changes in currency conversion rates may affect the value
of your investments.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is conducted in Hong Kong,
our books and records are maintained in Hong Kong dollars, which is the currency of Hong Kong, and the financial statements that
we file with the SEC and provide to our shareholders are presented in United States dollars. Changes in the exchange rate between
the Hong Kong dollar and U.S. dollar affect the value of our assets and the results of our operations in United States dollars.
The value of the Hong Kong dollar against the United States dollar and other currencies may fluctuate and is affected by, among
other things, changes in the Hong Kong&rsquo;s political and economic conditions and perceived changes in the economy of Hong
Kong and the United States. Any significant revaluation of the Hong Kong dollar may materially and adversely affect our cash flows,
revenue and financial condition. Further, our Ordinary Shares offered by this prospectus are denominated in United States dollars,
we will need to convert the net proceeds we receive into Hong Kong dollar in order to use the funds for our business. Changes
in the conversion rate between the United States dollar and the Hong Kong dollar will affect that amount of proceeds we will have
available for our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Volatility in our Ordinary Shares price may subject us
to securities litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market for our Ordinary Shares may
have, when compared to seasoned issuers, significant price volatility and we expect that our share price may continue to be more
volatile than that of a seasoned issuer for the indefinite future. In the past, plaintiffs have often initiated securities class
action litigation against a company following periods of volatility in the market price of its securities. We may, in the future,
be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert
management&rsquo;s attention and resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_005"></A><B>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are incorporated under the laws of the
Cayman Islands as an exempted company with liability limited by shares. We are incorporated in the Cayman Islands because of certain
benefits associated with being a Cayman Islands corporation, such as political and economic stability, an effective judicial system,
a favorable tax system, the absence of exchange control or currency restrictions and the availability of professional and support
services. However, the Cayman Islands has a less developed body of securities laws as compared to the United States and provides
protections for investors to a lesser extent. In addition, Cayman Islands companies may not have standing to sue before the federal
courts of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Substantially all of our assets are located
outside the United States. As a result, it may be difficult for investors to effect service of process within the United States
upon us or such persons or to enforce against them or against us, judgments obtained in United States courts, including judgments
predicated upon the civil liability provisions of the securities laws of the United States or any state thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have appointed Puglisi &amp; Associates
as our agent to receive service of process with respect to any action brought against us in the United States District Court for
the Southern District of New York under the federal securities laws of the United States or of any state in the United States
or any action brought against us in the Supreme Court of the State of New York in the County of New York under the securities
laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ogier, our counsel to the laws of the Cayman
Islands, and Fairbairn Catley Low &amp; Kong, our counsel to Hong Kong law, have advised us that there is uncertainty as to whether
the courts of the Cayman Islands or Hong Kong would (i) recognize or enforce judgments of United States courts obtained against
us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States or
any state in the United States or (ii) entertain original actions brought in the Cayman Islands or the Hong Kong against us or
our directors or officers predicated upon the securities laws of the United States or any state in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Ogier has further advised us that there
is currently no statutory enforcement or treaty between the United States and the Cayman Islands providing for enforcement of
judgments. A judgment obtained in the United States, however, may be recognized and enforced in the courts of the Cayman Islands
at common law, without any re-examination on the merits of the underlying dispute, by an action commenced on the foreign judgment
debt in the Grand Court of the Cayman Islands, provided such judgment: (i) is given by a foreign court of competent jurisdiction;
(ii) is final; (iii) is not in respect of taxes, a fine or a penalty; and (iv) was not obtained in a manner and is not of a kind
the enforcement of which is contrary to natural justice or public policy of the Cayman Islands. Furthermore, it is uncertain that
Cayman Islands courts would enforce: (1) judgments of U.S. courts obtained in actions against us or other persons that are predicated
upon the civil liability provisions of the U.S. federal securities laws; or (2) original actions brought against us or other persons
predicated upon the Securities Act. Ogier has informed us that there is uncertainty with regard to Cayman Islands law relating
to whether a judgment obtained from the U.S. courts under civil liability provisions of the securities laws will be determined
by the courts of the Cayman Islands as penal or punitive in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A judgment of a court in the United States
predicated upon U.S. federal or state securities laws may be enforced in Hong Kong at common law by bringing an action in a Hong
Kong court on that judgment for the amount due thereunder, and then seeking summary judgment on the strength of the foreign judgment,
provided that the foreign judgment, among other things, is (1) for a debt or a definite sum of money (not being taxes or similar
charges to a foreign government taxing authority or a fine or other penalty) and (2) final and conclusive on the merits of the
claim, but not otherwise. Such a judgment may not, in any event, be so enforced in Hong Kong if (a) it was obtained by fraud;
(b) the proceedings in which the judgment was obtained were opposed to natural justice; (c) its enforcement or recognition would
be contrary to the public policy of Hong Kong; (d) the court of the United States was not jurisdictionally competent; or (e) the
judgment was in conflict with a prior Hong Kong judgment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fairbairn Catley Low &amp; Kong has further
advised us that Hong Kong has no arrangement for the reciprocal enforcement of judgments with the United States. As a result,
there is uncertainty as to the enforceability in Hong Kong, in original actions or in actions for enforcement, of judgments of
United States courts of civil liabilities predicated solely upon the federal securities laws of the United States or the securities
laws of any State or territory within the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_006"></A><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that we will receive net proceeds
from this offering, after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable
by us and based upon an assumed initial public offering price of US$ ___ per Ordinary Share, of approximately $_____ (or approximately
$____ if the underwriters exercise their over-allotment option in full).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to use the net proceeds we receive
from this offering for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 75%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development
    of TCM formulae and products</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 23%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human resources development</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory approvals, IP applications, and
    working capital related</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately US$</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The foregoing represents our current
intentions based upon our present plans and business conditions to use and allocate the net proceeds of this offering. Based on
our current projection, we expect the net proceeds of the offering will provide funds to use for the purposes specified above
until end of the fiscal year ending June 30, 2024, at which time we may seek additional financing. However, we cannot guarantee
that if due to the process of our development, the net proceeds of the offering will be progressed sooner than we expected, or
if any additional financing will be available to us in the terms satisfactory to us, or if any at all. Our management, however,
will have significant flexibility and discretion to apply the net proceeds of this offering. If an unforeseen event occurs or
business conditions change, we may use the proceeds of this offering differently than as described in this prospectus. To the
extent that the net proceeds we receive from this offering are not immediately used for the above purposes, we intend to invest
our net proceeds in short-term, interest-bearing bank deposits or debt instruments. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_007"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to keep any future earnings to
finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Cayman Islands law, a Cayman
Islands exempted company may pay a dividend on its shares out of either distributable profits or amounts standing to the
credit of the share premium amount account, provided that in no circumstances may a dividend be paid if this would result in
the company being unable to pay its debts due in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we determine to pay dividends on any
of our Ordinary Shares in the future, as a holding company, we will be dependent on receipt of funds from our HK subsidiary, Regencell
Bioscience Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="RB_DRS_008"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth our capitalization
as of June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an as adjusted basis to reflect the issuance
    and sale of the Ordinary Shares by us in this offering at the initial public offering price of US$ [ ] per Ordinary Share,
    after deducting the estimated commissions to the Underwriter and the estimated offering expenses payable by us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should read this capitalization table
in conjunction with &ldquo;Use of Proceeds,&rdquo; &ldquo;Selected Consolidated Financial and Operating Data,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the consolidated financial statements and
the related notes appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As adjusted<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: -9pt; padding-left: 9pt">Ordinary shares, $0.01 par value, 100,000,000 shares authorized, and 10,000 shares issued and outstanding as of June 30, 2020, and 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated deficits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,651,248</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Total shareholders&rsquo; deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2,650,892</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">Reflects the sale of Ordinary Shares in this offering, excluding
the Ordinary Shares issuable upon the exercise of the warrants to be issued to the representative of the underwriter, at an assumed
initial public offering price of $[&#9679;] per share, and after deducting the estimated underwriting discounts, non-accountable
expense allowance, and estimated offering expenses payable by us. The as adjusted information is illustrative only, and we will
adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing,
and assuming no exercise of over-allotment option by the underwriter. Additional paid-in capital reflects the net proceeds we expect
to receive, after deducting the underwriting discounts, non-accountable expense allowance, and estimated offering expenses payable
by us. We estimate that such net proceeds will be approximately $[&#9679;].</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A US$1.00 increase (decrease) in the assumed initial public
offering price of US$[&#9679;] per Ordinary Share would increase (decrease) each of additional paid-in capital, total shareholders&rsquo;
equity and total capitalization by US$[&#9679;] million, assuming the number of Ordinary Shares offered by us, as set forth on
the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and
estimated expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_009"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you invest in our Ordinary Shares, your
interest will be diluted for each Ordinary Share you purchase to the extent of the difference between the initial public offering
price per Ordinary Share and our net tangible book value per Ordinary Share after this offering. Dilution results from the fact
that the initial public offering price per Ordinary Share is substantially in excess of the net tangible book value per Ordinary
Share attributable to the existing shareholders for our presently outstanding Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our net tangible book value as of June
30, 2020 was US$(2,650,892) or US$(265) per share based upon 10,000 outstanding shares. Net tangible book value per share represents
the amount of our total tangible assets, less the amount of our total liabilities, divided by the total number of shares outstanding.
Dilution is determined by subtracting the as adjusted net tangible book value per Ordinary Share from the initial public offering
price per Ordinary Share and after deducting the estimated commissions to the underwriters and the estimated offering expenses
payable by us. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After giving effect to our issuance and
sale of [&#9679;] shares in this Offering, excluding the Ordinary Shares issuable upon the exercise of the warrants to be issued
to the representative of the underwriter, at an offering price of $[&#9679;] per share, assuming no exercise of overallotment and
after deducting the estimated underwriting discounts and offering expenses payable by us, the as adjusted net tangible book value
as of June 30, 2020, would have been $[&#9679;] or $[&#9679;] per share. This represents an immediate increase in net tangible
book value to existing shareholders of $[&#9679;] per share. Accordingly, new investors who purchase shares in this Offering will
suffer an immediate dilution of their investment of $[&#9679;] per share. The following table illustrates this per share dilution
to the new investors purchasing shares in this Offering:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed offering price per ordinary share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per ordinary share as of June 30, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible book value per Ordinary Share attributable to payments by new investors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per Ordinary Share immediately after this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount of dilution in net tangible book value per Ordinary Share to new investors in the offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">The following tables summarize, on as adjusted basis as of
June 30, 2020, the differences between existing shareholders and the new investors with respect to the number of Ordinary Shares
purchased from us, the total consideration paid and the average price per Ordinary Share before deducting the estimated underwriting
discounts, non-accountable expense allowance, and the estimated offering expenses payable by us, and assuming no exercise of over-allotment
option by the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares<BR> purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<BR> price per<BR> Ordinary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Existing shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">New investors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The as adjusted information as discussed
above is illustrative only. Our net tangible book value following the completion of this offering is subject to adjustment based
on the actual initial public offering price of our Ordinary Shares and other terms of this offering determined at the pricing.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_010"></A><B>MANAGEMENT DISCUSSION AND ANALYSIS OF&nbsp;<BR>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with our consolidated financial statements
and related notes that appear in this prospectus. In addition to historical consolidated financial information, the following
discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ
materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences
include those discussed below and elsewhere in this prospectus, particularly in &ldquo;Risk Factors&rdquo;. All amounts included
herein with respect to the fiscal years ended June 30, 2020 and 2019 are derived from our audited consolidated financial statements
included elsewhere in this prospectus. The audited consolidated financial statements for the fiscal years ended 2020 and 2019
have been prepared in accordance with U.S. Generally Accepted Accounting Principles, or US GAAP.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are a holding company incorporated
on October 30, 2014, under the laws of the Cayman Islands, and conduct our business in Hong Kong through our wholly-owned subsidiary,
Regencell Bioscience Ltd., a company incorporated in Hong Kong on May 12, 2015, and Regencell Ltd., a company incorporated in
Hong Kong on November 20, 2014. We are an early stage bioscience company that focuses on research, development, and commercialization
of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Our goal is to improve the lives
of ADHD and ASD patients, their families and caregivers and become a market leader for the best treatment of ADHD and ASD globally.
Our TCM formulae candidates are developed based on our TCM Practitioner&rsquo;s TCM brain theory, and has demonstrated improvement
in patients&rsquo; condition in our first research study. The TCM brain theory is not recognized in general literature of TCM
or elsewhere. However, the TCM Practitioner has prescribed the formulae based on his TCM brain theory for over 30 years to treat
ADHD, ASD and many neurological disorders and obtained satisfactory clinical treatment results. We aim to launch three standardized
liquid-based TCM formulae candidate for mild, moderate, and severe ADHD and ASD patients in Hong Kong first and subsequently to
other markets as we deem appropriate. We have been headquartered in Hong Kong since inception. In October 2020, we opened our
California office where we will conduct preliminary market research on TCM. Currently, we are not actively developing the U.S.
market and will conduct preliminary market research on TCM once our TCM products achieve success in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Corporate History and Structure</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holding Ltd. is
a holding company incorporated in the Cayman Islands, which has no substantive operations other than holding all of the issued
and outstanding shares of Regencell Bioscience Ltd. and Regencell Ltd. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Ltd. owns
100% equity interest of Regencell Bioscience Ltd., which was incorporated in Hong Kong on May 12, 2015. Currently, we conduct
research and development activities in the TCM industry through Regencell Bioscience Ltd., which has entered Partnership Agreements
with the TCM Practitioner. In October 2020, Regencell Bioscience Ltd. entered into a leasing agreement with Regus in California. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Ltd. owns
100% equity interest of Regencell Ltd., which was incorporated in Hong Kong on November 20, 2014. Currently, Regencell Ltd. has
no operation and is reserved for future expansion needs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our CEO and director, Mr. Yat-Gai Au,
beneficially owns 100% of Regencell Bioscience Holdings Ltd. through Regencell (BVI) Ltd., which was incorporated pursuant
to the BVI Business Companies Act, 2004 on May 25, 2017. Mr. Yat-Gai Au has been the sole shareholder of Regencell (BVI) Ltd.
since its inception. On September 28, 2020, Regencell (BVI) Ltd. acquired all equity interest of Regencell Bioscience Holdings
Ltd. from Mr. Yat-Gai Au. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Strategic Partnership Agreement with TCM Practitioner</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January 2018, Regencell Bioscience
Ltd. entered into a Deed of Rights Transfer, Strategic Partnership and Undertaking (the &ldquo;Strategic Partnership Agreement&rdquo;)
with the TCM Practitioner, the father of our CEO and director. Pursuant to the Strategic Partnership Agreement we have with TCM
Practitioner, we have exclusive rights and ownership of (1) all his TCM formulae for patients suffering from ADHD and ASD disorders
and (2) the intellectual property rights of the TCM formulae, including research and development, trademark, copyright, patent,
and any other intellectual property rights in relation to the TCM formulae that the TCM Practitioner develops. Pursuant to Strategic
Partnership Agreement, the TCM Practitioner is responsible for research and development of TCM formulae, while, any inventions,
TCM formulae, utilities, improvements, research, discoveries, designs, processes, methods of manufacture, and products conceived
or made by the TCM Practitioner in relation to TCM shall be the sole and exclusive property of us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the Strategic Partnership
Agreement, in exchange for the rights, we are required to donate three percent (3.0%) of net revenue that Regencell Bioscience
Ltd. generates in association with the use and/or commercialization of the TCM formulae treatment to any of charitable institutions
and/or trusts of a public character anywhere in the world at the sole and absolute choice of the TCM Practitioner, or his assignee,
and in such proportion at the sole and absolute discretion of the TCM Practitioner on a yearly basis. We also undertake to pay
for all reasonable costs and expenses incurred by the TCM Practitioner in conducting research, testing, attending meetings/seminars,
compiling records, or performing any similar acts in relation to the development of the TCM formulae and TCM inventions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On November 10, 2020, Regencell Bioscience
Ltd. entered into a Supplemental Agreement of the Partnership Agreement (the &ldquo;Supplemental Agreement&rdquo; collectively
with the Strategic Partnership Agreement, the &ldquo;Partnership Agreements&rdquo;) with the TCM Practitioner. Under the Supplemental
Agreement, the TCM Practitioner shall provide his research by using his best endeavors on his TCM formulae and TCM inventions
under our direction and supervision. We have authorized the TCM Practitioner, his agents, subcontractors, development team, and
affiliates to use TCM formulae and TCM Inventions to conduct research. However, they shall not directly or indirectly publish,
disseminate or otherwise disclose, deliver or make available to any third party any confidential information, without prior written
notice given by the Company. The TCM Practitioner also shall not be directly or indirectly concerned with or engaged or interested
in any other business which is in any respect in competition with or similar to the TCM business conducted by the Company for
two years after the expiration or termination of the Supplemental Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We shall pay the TCM Practitioner for
his expenses on his TCM research within 30 days upon the receipt of invoice. The Supplemental Agreement shall remain effective
until the Strategic Partnership Agreement is expired or terminated. We can terminate the Supplemental Agreement without cause
without any indemnity or damages being due to TCM Practitioner with 30 days prior written notice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Operations Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impact of COVID-19 on Our Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The worldwide COVID-19 pandemic may affect
our ability to initiate and complete research studies, delay the initiation of our future research studies, disrupt regulatory
activities or have other adverse effects on our business, results of operations, financial condition and prospects. In addition,
the pandemic has caused substantial disruption in the financial markets and may adversely impact economies worldwide, both of which
could adversely affect our business, operations and ability to raise funds to support our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have not experienced material
business disruptions or impairments of any of our assets as a result of the pandemic. We are following, and plan to continue to
follow, recommendations from local governments regarding workplace policies, practices and procedures. We expect to continue to
monitor the situation and take actions as may be required or recommended by government authorities or as we determine are in the
best interests of our employees and other business partners. We are continuing to monitor the potential impact of the pandemic,
but we cannot be certain what the overall impact will be on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have not generated any revenue from
the sale of any products, and we do not expect to generate any revenue until we commercialize our standardized TCM formulae products
for ADHD and ASD patients in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Since our inception, our operations
have primarily been limited to the research studies of the proprietary TCM formulae. Our research and development expenses to
date consist of marketing and employee salaries and related benefits. Expenses in marketing were mainly for the sponsorship of
seminars and events with Non-governmental Organizations (&ldquo;NGOs&rdquo;) and institutions that have a large database of families
with ADHD and ASD children, who are our potential target patients and qualified patients to be enrolled in our research study
in the future. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the closing of this offering,
we expect to significantly increase our research and development efforts as we will initiate our second research study. Research
and development expenses will include employee-related expenses, such as salaries, share-based compensation, benefits and travel
expense for the research and development personnel that we plan to hire and treatment costs in connection with conducting research
studies. Research and development activities will continue to be central to our business model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and Administrative Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses consist
primarily of salaries, compensation, legal and accounting fees, as well as office rental, computer equipment and software and utilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We anticipate that our general and administrative
expenses will increase in the future to support our continued research and development activities and increased costs of operating
as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees
to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated
with being a public company including expenses related to services associated with maintaining compliance with Nasdaq rules and
SEC requirements, insurance, and investor relations costs. There is no assurance that our ADHD and ASD TCM formulae can obtain
regulatory approval for marketing, and even if regulatory approval for marketing is obtained, we expect that we would incur expenses
associated with hiring a sales and marketing team. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations for the years ended June 30, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth our results of operations for
the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Change</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Change</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0.125in">Selling and marketing</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">114,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,638</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">110,569</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,039</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,934</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,805</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386,230</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">228,223</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">158,007</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">69</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">812,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">421,381</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">108</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Selling and marketing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Selling and marketing expenses were
$0.11 million and $0.03 million for the years ended June 30, 2020 and June 30, 2019, respectively. The expenses were primarily
attributable to employee salaries and related benefits, and incurred by marketing efforts for qualified patients&rsquo; recruitment
for our research study during those periods. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Expenses in marketing were mainly for
the sponsorship of seminars and events with NGOs and institutions that have a large database of families with ADHD and ASD children,
who are our potential target patients and qualified patients to be enrolled in our research study in the future. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and Administrative Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses were
$0.31 million and $0.16 million for the years ended June 30, 2020 and June 30, 2019, respectively, and were primarily attributable
to employee salaries and related benefits, depreciation, legal, professional fees and consulting services associated with the formation
of our company, corporate matters and certain direct and indirect costs associated with services obtained by the Company. Moreover,
we moved to a new office space and the renovation cost incurred attributed to the increased depreciation in 2020 compared with
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expense</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Research and development expenses were
$0.39 million and $0.23 million for the years ended June 30, 2020 and 2019, respectively and were primarily attributable to employee
salaries and related benefits, depreciation, and other third-party services associated with research studies. Our CMO joined in
November 2019, which attributed to the increased spending in 2020 compared with 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with Accounting Standards
Update (&ldquo;ASU&rdquo;) 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern
(Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about the Company&rsquo;s ability to continue as a going concern within one year after the date that the consolidated financial
statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have incurred recurring negative
cash flows since inception and has funded our operations primarily from shareholder loans. We had an accumulated deficit of approximately
$2.65 million and $1.84 million as of June 30, 2020 and 2019, respectively. We had net losses of approximately $0.81 million and
$0.39 million for the years ended June 30, 2020 and 2019. We have received funding in the form of shareholder loans to support
our capital needs, which was provided by our CEO. The Company has received additional funding subsequent to June 30, 2020 in the
form of additional shareholder loans of $465,947. We acknowledge that uncertainty remains over our ability to meet our liabilities
as they fall due. If we cannot secure the financing needed to continue as a viable business, our shareholders may lose some or
all of their investment in us. On November 10, 2020, we entered into a loan agreement with Mr. Yat-Gai Au to evidence the existing
loan and document our oral agreements of the terms and conditions of such existing loan when such loan was initially generated.
The loan agreement also sets forth that the Mr. Yat-Gai Au will continue to make loan to the us for daily operation and research
activities. The maturity date of such loans is June 30, 2021, subject to indefinite extension if agreed by the parties in writing.
On February 2, 2021, a loan extension agreement was entered by and between Mr. Yat-Gai Au and us, pursuant to which Mr. Yat-Gai
Au agreed to provide up to US$3 million in the form of loan or make payments on behalf of us during the period from January 1,
2021 to June 30, 2022 to support our operations and research activities for the period from January 1, 2021 to June 30, 2022 and
further extend the maturity of the existing loans from June 30, 2021 to December 31, 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> During the years
ended June 30, 2020 and 2019, the we have an office rental agreement with Ace United International Limited, which is a company
wholly owned by the our CEO. We have paid a monthly rent of $4,103 and the terms of the agreement are renewed on an annual basis
from the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December each year. The rental payment is expensed as incurred. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to pursue a public offering of
our ordinary shares to fund future operations. If we are unable to complete a public offering for a sufficient amount in a timely
manner, it would need to pursue other financing alternatives such as private financing of debt or equity or collaboration agreements.
There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available
on terms acceptable to us, or at all. If we are unable to obtain sufficient funding, it could be required to delay our development
efforts, limit activities and reduce research and development costs, which could adversely affect our business prospects.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated
financial statements have been prepared on a basis that assumes we will continue as a going concern and which contemplates the
realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. The following summarizes
the key components of our cash flows for the years ended June 30, 2020 and 2019.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended <BR>
    June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(726,573</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(390,990</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(117,837</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net cash provided by financing
    activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">988,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">480,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net change in cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">143,672</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">90,004</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Flow in Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the years ended June 30, 2020 and
2019, net cash used in operating activities were $0.73 million and $0.39 million, respectively. Net cash used in operating activities
was primarily attributable to a new office lease, the hiring of our executive staff, research and development, ramped up marketing
efforts and general and administrative. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Flow in Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended June 30, 2020, net
cash used in investing activities were $0.12 million, which was primarily attributable to purchase of property and equipment.
There was no cash used in investing activities for the year ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cash Flow in Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the years ended June 30, 2020 and
2019, net cash from financing activities were $0.99 million and $0.48 million, respectively. Net cash from financing activities
was primarily attributable to shareholder loans.. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes our contractual
obligations as of June 30, 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments due by period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Contractual obligations</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Less
                                         than 1</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>year</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">1 &ndash; 3 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">3 &ndash; 5 years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>More
                                         than 5</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>years</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1.5pt">Operating lease obligations</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">483,206</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">136,923</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">224,616</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">121,667</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">483,206</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">136,923</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">224,616</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">121,667</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capital Expenditures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended June 30, 2020 and 2019,
we have capital expenditures of $117,837 and nil in relation to our property and equipment. Subsequent to June 30, 2020 and as
of the date of this prospectus, we did not purchase any material equipment for operational use. We do not have any other material
commitments to capital expenditures as of June 30, 2020 or as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have no material off-balance sheet
arrangements including arrangements that would affect our liquidity, capital resources, market risk support and credit risk support
or other benefits. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our financial statements and accompanying
notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements and accompanying notes requires
us to make estimates and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosure of
contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed
to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of
assets and liabilities that are not readily apparent from other sources. We have identified certain accounting policies that are
significant to the preparation of our financial statements. These accounting policies are important for an understanding of our
financial condition and results of operation. Critical accounting policies are those that are most important to the portrayal
of our financial conditions and results of operations and require management&rsquo;s difficult, subjective, or complex judgment,
often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent
periods. Certain accounting estimates are particularly sensitive because of their significance to financial statements and because
of the possibility that future events affecting the estimate may differ significantly from management&rsquo;s current judgments.
While our significant accounting policies are more fully described in Note 3 to the consolidated financial statements included
elsewhere in this prospectus, we believe the following critical accounting policies involve the most significant estimates and
judgments used in the preparation of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an &ldquo;emerging growth company&rdquo;
as defined under the federal securities laws and, as such, will be subject to reduced public company reporting requirements. Section
107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised
accounting standards. We have elected to take advantage of the extended transition period for complying with new or revised accounting
standards and acknowledge such election is irrevocable pursuant to Section 107 of the JOBS Act. As a result of our election, our
financial statements may not be comparable to those of companies that comply with public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Use of Estimates and assumptions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in
our consolidated financial statements required to be made by management include, but are not limited to, the useful lives of property
and equipment, impairment of long-lived assets and uncertain tax position. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Fair value measurement </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ASC 825-10 requires certain disclosures
regarding the fair value of financial instruments. Fair value is defined as the price that would be received to sell an asset
or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair
value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable
inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &mdash; inputs to the valuation methodology
    are quoted prices (unadjusted) for identical assets or liabilities in active markets.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &mdash; inputs to the valuation methodology
    include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar
    assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated
    by observable market data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &mdash; inputs to the valuation methodology
    are unobservable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise disclosed, the fair value of our financial
instruments including cash and shareholder&rsquo;s loans approximates their recorded values due to their short-term maturities.
The fair value of the long-term deposit approximates their carrying amounts because the deposit was paid in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Related Parties </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Parties, which can be a corporation or
individual, are considered to be related if we have the ability, directly or indirectly, to control the other party or exercise
significant influence over the other party in making financial and operational decisions. Companies are also considered to be
related if they are subject to common control or common significant influence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_011"></A><B>INDUSTRY OVERVIEW</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ADHD Overview and Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Attention Deficit and Hyperactivity Disorder (ADHD)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the Centers for Disease Control
and Protection (CDC), ADHD is one of the most common neurodevelopmental&nbsp;disorders of childhood. It is usually first
diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive
behaviors, or be overly active. Normal symptoms of ADHD include: having short attention span, easily distracted, constantly fidgeting,
excessive physical movement, little or no sense of danger. Some children may also have signs of anxiety, oppositional defiant
and conduct disorder, depression, and sleep problems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A meta-analysis of 175 research studies
worldwide on ADHD prevalence in children aged 18 and under found an overall pooled estimate of 7.2% (Thomas et al. 2015). Furthermore,
based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) screening of 11,422 adults for ADHD in
10 countries in the Americas, Europe and the Middle East, the estimates of worldwide adult ADHD prevalence averaged 3.4% (Fayyad
et al. 2007).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Hong Kong</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The reported prevalence of ADHD is estimated
to be 6.4% in children and adolescents in Hong Kong, according to Li Ka Shing Faculty of Medicine of The University of Hong Kong
(LKS Faculty of Medicine) published in 2018. The estimate of Hong Kong&rsquo;s population of children and adolescents was 1.2 million
in mid-2020, based on a population estimate by the Census and Statistics Department of the Hong Kong Government, which means approximately
76,800 children and adolescents are afflicted with ADHD. Although ADHD is often perceived as a disorder of childhood and adolescence,
an increasing number of evidences suggest that symptoms and impairments of ADHD may persist into adulthood for up to 65% of children
with ADHD, and that ADHD is present in approximately 2.5% of adults in Hong Kong. With a population of about 6.3 million adults
in Hong Kong in 2020 according to the Census and Statistics Department of the Hong Kong Government, approximately 157,500 adults
are living with ADHD in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>United States</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the U.S., the National Survey of Children&rsquo;s
Health (NSCH) reported that 6.1 million children and adolescents have been diagnosed with ADHD in 2016. According to Fortune Business
Insight, 5.9% of the 328 million U.S. population has ADHD in 2019, representing approximately 19.3 million ADHD cases in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>ADHD Market Drivers </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">An increase in
awareness about mental health among the general population and governments is expected to propel the ADHD market. We believe that
products launched across the globe, approval of new drugs, and increased research and development activities are also likely to
drive the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The rising number
of people suffering from a host of mental health disorders, including ADHD, has caught the attention of governments around the
world, forcing them to take necessary steps to address this condition. In 2016, the U.S. Department of Health &amp; Human Services
awarded up to US$54 million to the Substance Abuse and Mental Health Services Administration (SAMHSA) to address the needs of
individuals with serious mental illnesses. Similarly, National Health Service (NHS) England set up a five-year plan for mental
health in 2016. The government is committed to implementing this plan by 2020&ndash;2021, investing US$1.27 billion into the project.
According to the latest data of the NHS Mental Health Dashboard, mental health spending makes up 14.0% of local health spend in
2019/20, compared with 13.8% in 2018/19, 13.7% in 2017/18 and 13.1% in 2015/16. Mental health funding has gone up from US$14.2
billion in 2015/16 to US$17.2 billion in 2019/20. Therefore, government support, along with growing awareness among various parties,
is anticipated to boost the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ADHD-Economic Impact beyond Drug Cost</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ADHD has made a substantial economic impact
in the U.S., according to a study published in the&nbsp;<I>Journal of the American Academy of Child and Adolescent Psychiatry</I>,
&ldquo;Economic Impact of Childhood and Adult Attention-Deficit/Hyperactivity Disorder in the United States.&rdquo;&nbsp;Overall
national annual incremental costs of ADHD ranged from US$143 billion to US$266 billion in the U.S. spillover costs borne by the
family members of individuals with ADHD were also substantial (US$33 billion to US$43billion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ADHD Market Leaders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to Market Research Future (MRFR),
the global ADHD therapeutics market comprises a host of key players. This list includes Eli Lilly and Company, Concordia International
Corp., NEOS Therapeutics Inc., Highland Therapeutics Inc., Pfizer Inc., Novartis AG, Noven Pharmaceuticals Inc., Janssen Global
Services LLC, Shire, Teva Pharmaceutical and others. However, we do not compete with these players directly since they mainly
focus on prescription or over the counter drugs while we focus on TCM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ADHD Current Treatment Landscape and Therapy Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The global ADHD
drug market size was valued at US$17.9 billion in 2019 and is estimated to exhibit a compound annual group rate (CAGR) of 4.79%,
reaching a value of US$29.8 billion in 2030, based on a research done by Persistence Market Research. In Hong Kong, the ADHD drug
market size was valued at US$16.8 million in 2019 and is estimated to exhibit a CAGR of 7.8% to reach a value of US$38.5 million
in 2029. In the U.S., the ADHD drug market size was valued at US$9.7 billion in 2019 and is estimated to reach a value of US$15.7
billion in 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the ADHD Parents Medication
Guide of the American Psychiatric Association, medication does not cure ADHD but can alleviate the symptoms of ADHD when it is
taken as prescribed. Ongoing care and treatment monitoring are important since those symptoms may come back once medication is
halted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">Two main types
of medication for ADHD approved by the US Food and Drug Administration (FDA) are: stimulants and non-stimulants. Stimulants include
methylphenidate and amphetamines. Non-stimulants which include atomoxetine and guanfacine, are alternatives for those who do not
respond well to stimulants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">However, these
two types of medication for ADHD have multiple side effects. Common side effects of stimulants include: feeling restless and jittery,
difficulty sleeping, loss of appetite, headaches, upset stomach, irritability, mood swings, depression, dizziness, racing heartbeat
and tics. According to Help Guide, these stimulant medications may also cause personality changes, such as becoming withdrawn,
listless, rigid, or less spontaneous and talkative, others may develop obsessive-compulsive symptoms. Beyond the potential side
effects, that there are a number of safety concerns associated with the use of stimulant medications such as the effect on developing
brain, heart-related problem, psychiatric problem and potential abuse, indicated by experts. Non-stimulants also have side effects
including decreased appetite, nausea, vomiting, fatigue, indigestion, dizziness, and mood swings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ASD Overview and Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Autism Spectrum Disorder (ASD)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to the CDC, ASD is a&nbsp;developmental
disability&nbsp;characterized by repetitive and characteristic patterns of behavior and difficulties with social communications
and interaction. The learning, thinking, and problem-solving abilities of people with ASD can range from gifted to severely challenged.
These symptoms are present from early childhood and typically last a lifetime, affect daily functioning. The Diagnostic and Statistical
Manual of Mental Disorders 5<SUP>th</SUP> Edition (or DSM-5), published in 2013 includes Asperger syndrome, childhood disintegrative
disorder, and pervasive developmental disorders not otherwise specified (or PDD-NOS) as part of ASD rather than as separate disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ASD occurs in every racial and ethnical
group, and in both males and females. The World Health Organization (WHO) estimates that 1 in 160 children worldwide has ASD.
A Medscape article estimates the global prevalence of ASD at 7.6 cases per 100 which was estimated on review of epidemiological
studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Hong Kong</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hong Kong has the highest rate of ASD prevalence,
1 in 27, among children, according to World Population Review rankings. Based on an approximate children population of about 1.2
million, management estimates approximately 44,000 children with ASD. Fortune Business Insights estimates that 3.7% of the total
population in Hong Kong has ASD, or about 277,000 based on a total population of 7.5 million in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>United States</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">One in 54
children have been identified with ASD according to the estimates from the CDC Autism and Developmental Disabilities Monitoring
(ADDM) Network. National and state estimates of adults with ASD as published in </FONT>Journal of Autism and Developmental Disorders<FONT STYLE="font-size: 10pt">&nbsp;(2020)
state that more than 5.4 million people in the U.S., or 1 in 45, over age 18 are on the spectrum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ASD Market Drivers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to Fortune Business Insights,
growing prevalence of ASD globally, rising awareness about the condition and the available options for the treatment are the key
factors which are expected to drive the autism disorder and treatment market. Improved diagnosis rate is also a critical factor
for the growth of ASD drug market. To date, only two drugs are approved by the FDA which are specific to the treatment of ASD,
aripiprazole and risperidone. In January 2018, FDA granted Swiss drug maker Roche breakthrough therapy designation for Balovaptan,
which may improve social interaction and communication in people with ASD, to treat ASD, potentially accelerating the development
and approval of ASD drugs. Other antipsychotic drugs are prescribed as off label therapy across the globe for management of symptoms
associated with the disease. Growing investments by many key players in the research domain for the development of effective drugs
for the treatment of ASD is expected to fuel the ASD therapeutics market growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ASD-Economic Impact beyond Drug Cost</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Autism will cost the U.S. $268 billion
in 2020, roughly 1.5% of the country&rsquo;s gross domestic product. By 2025, the price tag could balloon to $461 billion. These
estimates, published in July in the Journal of Autism and Developmental Disorders, are the first to forecast the costs of autism
a decade into the future. They assume an autism prevalence of 1.1% in U.S. and that 40% of people with autism have intellectual
disability, one indicator of autism severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ASD Market Leaders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to Fortune Business Insights,
players engaged in ASD drug therapy in the global market include AstraZeneca, Eli Lilly and Company, Fusion Autism Center, Pfizer
Inc., Otsuka Holdings Co. Ltd., and other prominent players. However, we do not compete with these players directly since they
mainly focus on prescription or over the counter drugs while we focus on TCM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>ASD Current Treatment Landscape and Therapy Limitations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Based on a research
by Persistence Market Research, the global ASD drug market size was valued at US$2.8 billion in 2019 and is estimated to exhibit
a CAGR of 5.7% to reach a value of US$5.3 billion in 2030. In Hong Kong, the ASD drug market size was valued at US$2.1 million
in 2019 and is estimated to exhibit a CAGR of 4.9% to reach a value of US$3.5 million in 2030. In the U.S., ASD drug market size
was valued at US$1.5 billion in 2019 and is estimated to reach a value of US$2.8 billion in 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no medications that can cure ASD
or treat the core symptoms, according to the CDC. However, there are medications that can help ASD patients with related symptoms
like&nbsp;depression,&nbsp;anxiety, aggression, irritability, seizures, insomnia, and trouble focusing and help them function better.
Medicines for treating the three core symptoms of ASD, communication difficulties, social challenges and repetitive behavior, have
long represented a huge area of unmet need. However, few drugs on the market today effectively relieve these symptoms and individual
reaction to most commonly prescribed medicines can vary materially. Although the FDA has approved two antipsychotic drugs for treating
irritability and aggression associated with the autism (risperidone and aripiprazole), the prevalent behavioral problems associated
with ASD have not been able to be improved by these medications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Today, most
medicines prescribed to ease autism&rsquo;s disabling symptoms are used &ldquo;off-label,&rdquo; meaning the medication is being
used in a manner not specified in the FDA&rsquo;s approved packaging label, or insert. Such off-label use is common in virtually all
areas of medicine and is usually done to relieve significant suffering in the absence of sufficiently large and targeted studies. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Antidepressants
are among the world&rsquo;s most widely prescribed medications for ASD patients, such as selective serotonin reuptake inhibitors
(SSRIs), according to an article in Harvard Health Publishing. The range of their uses has expanded from depression to anxiety,
obsessive-compulsive disorder, eating disorders, and many other psychiatric conditions. Side effects include insomnia, skin rashes,
headaches, joint and muscle pain, stomach upset, nausea, or diarrhea. Anticonvulsants are most commonly prescribed when the patient
also suffers from epilepsy, as about one-third of autism patients do, however, common side effects include confusion, fever, hair
loss, paranoia, impairs judgement and memory, anxiety and depression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Traditional Chinese Medicine (TCM) Treatment for ADHD and
ASD Patients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our standardized TCM formulae candidates
aim to address the fundamental cause of the disorders to achieve an optimal outcome compared to available stimulant and non-stimulant
medications currently available in the market. The fundamental properties and treatment process of TCM are different from the
mainstream stimulant and non-stimulant medications. TCM takes a holistic approach, using natural ingredients to treat different
elements within the body. Every bodily function is taken into consideration when preparing the TCM formulae for the patients so
that the optimal results of the treatment could be reached. This explains the improvements of both their symptoms and overall
health. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several attempts have been made to reduce
the harmful side effects and increase the efficacy of current drugs used to treat ADHD. Some articles have studied medicinal herbs
as an effective supplement in treating ADHD. Thus far, TCM research related to ADHD has been mainly composed of research based
on original literature, systematic review based on search treatises, and experimental research testing the treatment effect of
herbs on ADHD. However, such research was limited to only listing herbal medicines that frequently appeared in text. On the other
hand, experimental research had difficulty in selecting the right herbal medicines to test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The volume of research into herbal medicines,
with fewer adverse effects, has increased for the treatment of children with ASD. According to <I>Herbal Medicine Treatment for
Children with Autism Spectrum Disorder: A Systematic Review,</I> Lee, Cho, et al., 2017, &ldquo;a review of herbal medicines reported
that 32 kinds of Chinese herbal medicine have pharmacological effects, which mainly resulted in immune system improvement, memory
enhancement, gastrointestinal tract improvement, and calming of the nerves. However, the study did not provide enough evidence
on the efficacy of the treatment of children with ASD. There is a lack of evidence on the efficacy of herbal medicines in the
treatment of autistic children.&rdquo; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Global acceptance and recognition of TCM</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More and more people are inclined to treat
chronic diseases using natural medicine due to the obvious side effects of chemical drugs, and TCM is aligned with this development
tendency. Moreover, many national governments have gradually accepted and attached importance to TCM and natural herbal medicine
because of, among other concerns, the high bio-pharmaceutical research and development costs relating to chemical drugs. Average
cost from research and development to commercialization for a new medicine is nearly US$4 billion, and can sometimes exceed US$10
billion. It is our belief that the international community continues to accept natural medicine, and market demand will continue
to grow. More than 90 countries and regions are introducing laws and regulations for the registration of TCM. (Ref: SWOT analysis
and revelation in traditional Chinese medicine Internationalization, Haitao Tang <I>et al.</I>, 2018)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">TCM is prevalent in 183 countries and regions
around the world. According to the WHO, 103-member states have approved the practice of acupuncture and moxibustion, 29-member
states have enacted special statutes on traditional medicine, and 18 have included acupuncture and moxibustion treatment in their
medical insurance provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Hong Kong&rsquo;s support of
the TCM development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Highlighted in the 2018 Policy Address,
Hong Kong&rsquo;s first Chinese medicine hospital will be a &ldquo;flagship institution&rdquo; for the sector. The government
will subsidize certain in-patient and out-patient services. A 400-bed hospital is expected to come into operation by phrases from
late 2024. As announced in the 2018-19 Budget, a Chinese Medicine Development Fund of HK$500 million is set up to facilitate applied
research and Chinese medicine specialization. Part of the fund is dedicated to promoting public awareness and nurturing talents
for Chinese medicine hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The collaboration between Chinese and Western
medicine has been in practice for some years. Under the Hong Kong government&rsquo;s policy direction to promote the development
of &ldquo;evidence-based&rdquo; Chinese medicine (CM) and out-patient CM services in the public sector, as well as to provide
training placements for local CM degree program graduates, the Hong Kong Hospital Authority (HA) was tasked to establish a total
of 18 Chinese Medicine Centers for Training and Research (CMCTRs) in each of the 18 districts of Hong Kong since 2003. In 2018,
the total number of attendances at the 18 CMCTRs was about 1.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>TCM for ADHD and ASD</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on research by Persistence Market
Research, key disorders treated with TCM are neurological (insomnia, ADHD, ASD), pain, skin and hair disorders, mild infections
and cancer treatment. Market size of TCM for ADHD was valued at US$3.6 billion globally in 2019 and is estimated to exhibit a
CAGR of 5.65% to reach a value of US$6.6 billion in 2030. Market size of TCM for ASD was valued at US$0.6 billion globally in
2019 and is estimated to exhibit a CAGR of 6.65% to reach a value of US$1.2 billion in 2030. In the US, market size of TCM for
ADHD was valued at US$1.8 billion in 2019 and is estimated to reach a value of US$3.0 billion in 2030. Market size of TCM for
ASD was valued at US$0.3 billion in 2019 and is estimated to reach a value of US$0.5 billion in 2030.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A number of global players have entered
into agreements and collaborations to strengthen their sales footprint and product portfolio in TCM market as supplemental offerings
strategy. Increase profitability and sustainable market share are driving the recent strategic developments from leading Chinese
and global pharmaceutical players as they face stiff competition. North America represents the most lucrative market, followed
by Asia Pacific and Europe. The global TCM ADHD and ASD market is expected to record prominent growth in East Asia and emerging
countries such as China, Australia and other South Asian countries. Manufacturers are focusing on the development of customized
products for end-use industries on the back of policy initiatives such as Belt and Road Initiative and overseas TCM centers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The global TCM therapy market has been
witnessing rising demand due to an increase in the pediatric illnesses, chronic behavioral diseases, growing awareness about mental
well-being and rising incidences of lifestyle diseases and disorders, such as ADHD and ASD. This has been driving the demand for and production
of alternative and off-the-shelf drugs due to added risk with mainstream drugs. Herbal medicines are commonly used in the treatment
of children with ADHD and ASD in conjunction with conventional therapy to improve the Childhood Autism Rating Scale (CARS) score.
Furthermore, continued prioritization of unmet medical needs in herbal extract-based drugs is expected to drive demand for TCM
formulations in the forthcoming years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_012"></A><B>OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are an early-stage bioscience company
that focuses on research, development, and commercialization of traditional Chinese medicine for the treatment of neurocognitive
disorders and degeneration, specifically ADHD and ASD. Our goal is to improve the lives of ADHD and ASD patients, their families
and caregivers and become a market leader for the best treatment of ADHD and ASD globally. We started in Hong Kong in 2014 with
main operation and assets in Hong Kong. We aim to launch three liquid-based standardized TCM formulae candidates for mild, moderate,
and severe ADHD and ASD patients in Hong Kong first and subsequently to other markets as we deem appropriate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We strategically partner with Mr. Sik-Kee
Au, our TCM Practitioner, the father of our CEO and director. As of the date hereof, the TCM Practitioner has standardized the
adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a result, we have three standardized
TCM formulae candidates under development targeting mild, moderate, and severe ADHD and ASD patients, each consisting of a standard
base formula and a fixed adjusted formula. We plan to commence our second research study using those three standardized TCM formulae
candidates in the second quarter of 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our three liquid-based standardized
TCM formulae candidates are derived from a TCM base formula developed by our TCM Practitioner based on his TCM brain theory, known
as &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo;, and have demonstrated some improvement in patients&rsquo; condition in our
first research study. The activity and specificity of the TCM base formula have been optimized by the TCM Practitioner in his
prior ADHD and ASD treatment. The TCM brain theory is not recognized in general literature of TCM or elsewhere. However, the TCM
Practitioner has prescribed the TCM base formula based on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological
disorders and obtained satisfactory clinical treatment results. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have been headquartered in Hong Kong
since our inception. In October 2020, we opened our California office where we conduct preliminary market research on TCM. Currently,
we are not actively developing the U.S. market and will conduct preliminary market research on TCM once our TCM-based products
obtain regulatory approvals and achieve success in Hong Kong. We have been keeping books and records in Hong Kong since our inception.
Our research study and supplement of TCM raw materials are in Hong Kong. As we are still at the stage of TCM treatment research,
we have not applied for regulatory approvals; we have no sales, marketing or distribution capabilities or experience, and no granted
patents or pending patent applications; and we have not generated revenues since inception. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Our TCM Practitioner </I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The TCM Practitioner has been practicing
TCM under the guidance of the Chinese Medicine Ordinance in his clinic in Hong Kong since 1999 and has accumulated in-depth experience
of TCM research and clinical practice. For over 30 years, the TCM Practitioner has focused his TCM study on TCM thesis of his
father, who was a renowned TCM doctor in Hong Kong in the 1950s, and other traditional treatises of TCM. He is experienced in
treating patients suffering from a wide range of neurocognitive disorders and degeneration. In particular, he has treated over
100 children afflicted with ADHD and ASD. He decided to dedicate all his efforts to treat people afflicted with incurable diseases,
illnesses, and disorders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Prior to starting his TCM clinical practice,
the TCM Practitioner founded a successful technology and property business in California. The TCM Practitioner graduated from
the University of California, Berkeley with a Bachelor&rsquo;s and Master&rsquo;s Degrees in Electrical Engineering in Circuit
Design and Network Theory. He was the pioneer who invented the first prototype high-density recording drive on flexible media
while working at IBM, which later became known as Iomega Corporation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Our TCM formulae and Sik-Kee Au TCM Brain Theory&trade;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM formulae were developed by the
TCM Practitioner and consist solely of natural ingredients without any synthetic components. We have exclusive ownership over
such TCM formulae and have conducted our first research study based on the personalized TCM formulae in November 2018 and March
2019. As of the date hereof, the TCM Practitioner has standardized the adjustable formula into three fixed formulae for mild,
moderate and severe conditions. As a result, we have three liquid-based standardized TCM formulae candidates under development
targeting mild, moderate, and severe ADHD and ASD patients, each consisting of a standard base formula and a fixed adjusted formula.
We plan to commence our second research study using those three standardized TCM formulae candidates in the second quarter of
2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The three liquid-based standardized
TCM formulae candidates are derived from the TCM base formula developed by TCM Practitioner based on his TCM brain theory, known
as &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo;. The TCM brain theory is not recognized in general literature of TCM or elsewhere.
However, the TCM Practitioner has prescribed his TCM formulae based on his TCM brain theory for over 30 years to treat ADHD, ASD
and many neurological disorders and obtained satisfactory clinical treatment results. The TCM brain theory explains why a healthy
brain is essential in restoring the body&rsquo;s systems to normal from disorders and illnesses such as ADHD and ASD. According
to the TCM brain theory, the blockage of or reduced blood flow, and damage of the interconnecting central nervous system, endocrine
system and blood circulatory system disrupt the production of hormones and transmission of neurotransmitters, such as melatonin,
dopamine, and norepinephrine, leading to a defective encoding and decoding of functions, and resulting in deficient or abnormal
social behaviors that are the hallmarks of ADHD and ASD. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Also, there are articles that explain
and describe the bases of what the TCM Practitioner&rsquo;s TCM brain theory has connected and put forward, that blockages in
the brain is connected to the disruption of neurotransmitters, which causes neurological disorders such as ADHD and ASD. In the
article &ldquo;Blood Flow May Be Key Player in Neural Processing&rdquo;, published in Scientific America. It says that <FONT STYLE="background-color: white">Christopher
Moore, an assistant neuroscience professor at the Massachusetts Institute of Technology&rsquo;s McGovern Institute for Brain Research
&lsquo;suggests blood&rsquo;s role in the cortex (a key brain processing center), specifically, is more than just bringing nutrients
to the cell, it can also alter the activity of local neuronal circuits. For instance, in experiments in his lab, Moore has seen
that there is more blood flow arriving in an area that processes information from a presented stimulus to a certain sense (e.g.
touch, visual, auditory) prior to the appearance of the stimulus, implying that the flow can prime a circuit for activity, as
well.&rsquo;</FONT> Also in the article &ldquo;Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins
and Progress in Developing Therapeutic Agents&rdquo;, published by The National Center for Biotechnology Information (NCBI), states
that &lsquo;a<FONT STYLE="background-color: white">utism spectrum disorder is associated with multiple neurotransmitter abnormalities,
most notably abnormalities in monoamine (i.e., dopamine, norepinephrine and serotonin) and amino acid (i.e., glutamate and GABA)
neurotransmitters.&rsquo;</FONT> In the publication &ldquo;ADHD Neuroscience 101&rdquo; posted in ADDitude digital magazine by
Larry Silver, M.D., &lsquo;b<FONT STYLE="background-color: white">rain scientists have found that deficiencies in specific neurotransmitters
underlie many common disorders, including anxiety, mood disorders and anger-control problems. ADHD was the first disorder found
to be the result of a deficiency of a specific neurotransmitter&rsquo;.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We believe that patients under treatments
utilizing our TCM formulae candidates provides progressive holistic improvements over time because it aims to correct the fundamental
cause of illnesses and disorders. According to the assessment of our first research study, patients have better eye contact, appetite,
daily excretion, longer sleep duration, communication, sociability, cognition, awareness and attentiveness, complexion, mood and
temper, which are substantial improvements over common symptoms associated with ADHD and ASD namely poor appetite, constipation
and sleep problems. However, there is no assurance that we can expect similar outcome in our second research study. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Corporate History and Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are a holding company incorporated
in the Cayman Islands on October 30, 2014. We have no substantive operations other than holding all of the issued and outstanding
shares of Regencell Bioscience Ltd. and Regencell Ltd. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holding Ltd. is
a holding company incorporated in the Cayman Islands, which has no substantive operations other than holding all of the issued
and outstanding shares of Regencell Bioscience Ltd. and Regencell Ltd. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Ltd. owns
100% equity interest of Regencell Bioscience Ltd., which was incorporated in Hong Kong on May 12, 2015. Currently, we conduct
research and development activities in the TCM industry through Regencell Bioscience Ltd., which has entered Partnership Agreements
with the TCM Practitioner. In October 2020, Regencell Bioscience Ltd. entered into a leasing agreement with Regus in California, </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Holdings Ltd. owns
100% equity interest of Regencell Ltd., which was incorporated in Hong Kong on November 20, 2014. Currently, Regencell Ltd. has
no operation and is reserved for future expansion needs. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our CEO and director, Mr. Yat-Gai Au,
beneficially owns 100% of Regencell Bioscience Holdings Ltd. through Regencell (BVI) Ltd. Regencell (BVI) Ltd. was incorporated
pursuant to the BVI Business Companies Act, 2004 on May 25, 2017, and has no operation since its inception. Mr. Yat-Gai Au has
been the sole shareholder of Regencell (BVI) Ltd. since its inception. On September 28, 2020, Regencell (BVI) Ltd. acquired all
equity interest of Regencell Bioscience Holdings Ltd. from Mr. Yat-Gai Au. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Regencell Bioscience Ltd. strategically
partners with the TCM Practitioner, the father of Mr. Yat-Gai Au, our CEO and director. Pursuant to the Partnership Agreements,
we have exclusive rights and ownership of all his TCM formulae and TCM inventions. Under our direction, the TCM Practitioner is
authorized to conduct research studies on these transferred TCM formulae and TCM inventions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following diagram illustrates our corporate
structure as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Our Business Plan and Growth Strategy</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are still a start-up company at early
stage and are committed to design standardized TCM formulae candidates for ADHD and ASD patients. The growth of our business highly
depends on our research and commercialization of our three liquid-based standardized TCM formulae candidates. Currently, we aim
to conduct research in the effectiveness and safety of our three standardized TCM formulae candidates for mild, moderate, and
severe ADHD and ASD patients and commercialize these three liquid-based standardized TCM formulae candidates for ADHD and ASD
patients in Hong Kong. After obtaining success of commercialization in the Hong Kong market, we may start to offer our pCm formulae
products to other markets. In October 2020, we opened our California office where we will conduct preliminary market research
on TCM. Currently, we are not actively developing the U.S. market and will conduct preliminary market research on TCM once our
TCM products achieve success in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Demonstrate effectiveness of the TCM Practitioner&rsquo;s
treatment for ADHD and ASD</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have completed our first
research study in 2019 with our TCM Practitioner and the result showed that each of the participants in our study has
demonstrated improvements in their ADHD and ASD symptoms with our personalized TCM formulae, which we believe are
significant. Please refer to the &lsquo;Research and Development&rsquo; section for more detail. Each of the participants of
our first research study was treated by the TCM Practitioner with a personalized TCM formula. Each personalized TCM formulae
is comprised of the TCM base formula, which remains the same among all participants, and an adjustable formula. As of the
date hereof, the TCM Practitioner has standardized the adjustable formula into three fixed formulae for mild, moderate and
severe ADHD and ASD conditions. As a result, we have three standardized TCM formulae candidates under development targeting
mild, moderate, and severe ADHD and ASD patients, each consisting of a standard base formula and a fixed adjusted formula. We
plan to commence our second research study using those three standardized TCM formulae candidates in the second quarter of
2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Filing patent applications in Hong Kong and abroad</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In order to protect our intellectual
properties, we will file for patent application for our TCM formulae, including the TCM base formula and the three standardized
TCM formulae candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Conducting second research study on standardized TCM
formulae candidates</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date hereof, the TCM Practitioner
has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a result, we have
three liquid-based standardized TCM formulae candidates under development targeting mild, moderate, and severe ADHD and ASD patients,
each consisting of a standard base formula and a fixed adjusted formula. We plan to commence our second research study using those
three standardized TCM formulae candidates in the second quarter of 2021 in Hong Kong. We plan to arrange one hundred patients
to be treated by TCM practitioner(s) with the use of our standardized TCM formulae candidates for a period of at least three months
and up to twelve months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Setting up of centralized production facilities </I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> To further lower the cost of manufacture
of our standardized TCM formulae candidates together with the anticipated increase in demand after we receive regulatory approvals
from the Hong Kong Chinese Medicines Board, we will setup a centralized production facility for mass production of our standardized
TCM formulae candidates. We will procure an industrial space, purchase new automated equipment and production lines and ensure
quality control of our products, once we obtain regulatory approvals from the Hong Kong Chinese Medicines Board approves the manufacturer
licenses. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Branding and commercializing our standardized TCM
formulae candidates</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> After the first year of our second research
study, we will improve, refine and automate the production process to improve efficiency to scale up our production. We will also
design new packaging and labelling, not only to comply with regulatory requirements but also for branding purpose. We will ensure
that the improved production and packaging process will not compromise the effectiveness of our pCm formulae products. We will then begin
to apply for necessary permits from Hong Kong regulatory agencies. We intend to expand our marketing efforts locally and globally
to gain brand recognition and favorable perception by our consumers in our target markets. Specifically, we will build a marketing
team to develop a strong image that we are a TCM company specializing in the treatment of ADHD and ASD. We plan to market to those
who are afflicted by these disorders, through advertisements in television, live radio stations, newspapers/magazine, online social
media and banner advertising, and in-person marketing in various healthcare events and seminars. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B><I>&nbsp;&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Developing markets in other locations globally</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We will also consider expanding our
market penetration to other countries. Our plan is to market our pCm formulae products in the U.S. and abroad upon our standardized
TCM formulae candidates receive regulatory approval and achieve commercial success in Hong Kong. Although we opened our California
office in October 2020 where we will conduct preliminary market research, we are not currently actively developing the U.S. market. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Conducting further R&amp;D on TCM base formula for
other application</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As the TCM base formula is developed
based on the TCM Practitioner&rsquo;s TCM brain theory, we believe that his TCM base formula potentially has a wider application.
We intend to conduct further investigation and research on the application of the TCM base formula for other applications for
other neurological disorders and illnesses. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Product Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mainstream drugs and treatments available
currently in the markets for ADHD and ASD aim to suppress or alleviate symptoms, whereas our TCM formulae aim to treat the fundamental
cause of neurocognitive disorders. Our TCM formulae contain solely of natural ingredients without any synthetic components. The
liquid-based and orally administered TCM formulae are currently personalized for each individual patient at different severities
and symptoms of ADHD and ASD. According to our TCM Practitioner&rsquo;s TCM brain theory, when our TCM formulae, with their nutrients
and medicinal properties, are absorbed and circulated throughout the body, the TCM formulae can perform the mechanism of removing
deposits, clots and toxins that have been built up in the body over time and provide better blood circulation to bring sufficient
blood supply to the brain. According to the TCM brain theory, with sufficient blood supply and circulation, the brain and organs
will regenerate and as a result brain activities and organ functions are normalized, metabolism boosted and endocrine system regulated,
thereby correcting the neurocognitive disorders and related symptoms such as attention deficit, hyperactivity, cognitive and social
impairment. The TCM brain theory is not recognized in general literature of TCM or elsewhere. However, the TCM Practitioner has
prescribed the formulae based on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological disorders and
obtained satisfactory clinical treatment results. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM Practitioner prescribes the
TCM formulae under the guidance of TCM fundamental principles in conjunction with his TCM brain theory. Although each herb can
be identified by its function in TCM terms, such as blood circulation, tonifying and qi-regulating herbs, the combination of herbs
in each formula also demands our TCM Practitioner to skillfully apply TCM fundamental principles of compatibility to ensure the
roles of each individual herb do not counteract with each other or become collectively harmful. The resulting combination creates
synergetic pharmacological properties to treat neurological disorders that disrupted the normal neurological functions in ADHD
and ASD patients. According to the assessment of our first research study, patients have better eye contact, daily excretion,
appetite, longer sleep duration, communication, sociability, cognition, awareness and attentiveness, complexion, mood and temper. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ingredients which our TCM Practitioner
uses are all listed in the Pharmacopoeia of the People&rsquo;s Republic of China, tracing back to Compendium of Materia Medical,
or Ben Cao Gang Mu (&ldquo;&#26412;&#33609;&#32177;&#30446;&rdquo;), more than 400 years ago. All raw materials are sourced under
the Hong Kong Chinese Medicine Regulatory Office guideline, and our TCM Practitioner carefully selects credible TCM herb vendors
that have passed high standard TCM herb inspection. Some of the herbs include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Blood circulation herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#26691;&#20161;
                                         Taoren (Persicae Semen)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#32005;&#33457;
                                         Honghua (Carthami Flos)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#20083;&#39321;
                                         Ruxiang (Olibanum)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#27794;&#34277;
                                         Moyao (Myrrha)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Tonifying herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#40643;&#33450; Huangqi (Astragali Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#22320;&#40643;
                                         Dihuang (Rehmanniae Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#23665;&#33585;&#33848;
                                         Shanzhuyu (Corni Fructus)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Qi regulating, heat and wind removing herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#33610;&#33445;
                                         Jingjie (Schizonepetae Herba)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#38450;&#39080;
                                         Fangfeng (Saposhnikoviae Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#39321;&#38468;
                                         Xiangfu (Cyperi Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Detoxication herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#28023;&#34299; Haizao, Algae (Sargassum)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#33970;&#20844;&#33521;
                                         Pugongying (Taraxaci Herba)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#40643;&#33449;
                                         Huangqin (Scutellariae Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Blood clot removing herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#19977;&#19971;
                                         Sanqi (Notoginseng Radix et Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#30070;&#27512;
                                         Danggui (Angelicae Sinensis Radix)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#24029;&#33422;
                                         Chuanxiong (Chuanxiong Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">o</TD><TD>Digestion herbs:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#30333;&#26414;
                                         Baizhu (Atractylodis Macrocephalae Rhizoma)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#23665;&#26946;
                                         Shanzha (Crataegi Fructus)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">&#9632;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#38622;&#20839;&#37329;
                                         Jineijin (Galli Gigerii Endothelium Coreneum)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our First Research Study in ADHD and ASD </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have conducted the first research
study, commenced in November 2018 and March 2019, to evaluate the efficacy of our personalized TCM formulae on seven patients,
who were between five and eleven years old and were clinically diagnosed with ADHD or ASD by their healthcare professionals at
different levels of severity, by arranging them to be treated by the TCM Practitioner with the use of our personalized TCM formulae
for up to three months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Patient Voluntary Participation in the First Research
Study</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Seven of the TCM Practitioner&rsquo;s
patients who were already diagnosed by a doctor or hospital with ADHD and/or ASD and be three to twelve years old, voluntarily
consented to provide their treatment data to us through their parents or guardians to participate in the first research study
of the TCM Practitioner. Moreover, to isolate the treatment&rsquo;s effectiveness, the parents or primary caretakers must agree
that the children patients would stop all other medical treatments, including both mainstream and Chinese medicine for the duration
of the treatment process, which was expected to last for three months. Children who failed to meet all of the above conditions
were not included in our research study. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The seven enrolled patients consumed
liquid-based TCM twice a day, which were prepared based on the personalized TCM formulae by our TCM Practitioner, and temporarily
stopped consuming any other medicine. Six of the enrolled patients completed a three-month treatment and one completed a two-month
treatment. All the patients and their parents were required to meet with the TCM Practitioner in his clinic weekly and provide
regular reports to update the patients&rsquo; symptoms and conditions by phone. Quantitative assessments were also conducted using
globally accepted assessment tools, described in the following, together with additional qualitative assessments, written observations,
photos, videos and parent testimonials to document their progress. Within three months of receiving treatment using our personalized
TCM formulae, our research showed that patients had gained pronounced improvements in their speech, communication, sociability,
cognition and behavior. Their overall health had also improved, except for experience of better bowel movement, sweating and temporary
fatigue, which were expected as part of the improvement process. However, there is no assurance that the second research study
will show the similar improvements in patients&rsquo; symptoms. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Assessment Methodology</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Each enrolled patient stopped all his
or her existing medical treatment for ADHD or ASD and was treated with a personalized TCM formulae for a period up to three months.
Efficacy and improvement in patient&rsquo;s symptoms were assessed through parent interviews and using the globally accepted assessment
tools, which were provided below. The parent&rsquo;s qualitative and quantitative assessment scores on the patient&rsquo;s behavior
were compared before, during, and after three months of treatment. The assessment tools used were the questionnaires filled in
by the parents, which included the Autism Treatment Evaluation Checklist (&ldquo;ATEC&rdquo;), the Gilliam Autism Rating Scale
(&ldquo;GARS&rdquo;), and the Vanderbilt ADHD Diagnostic Parent Rating Scale (&ldquo;VADRS&rdquo;) questionnaire. Based on the
results of the VADRS questionnaire, we also used the Swanson, Nolan, and Pelham (SNAP)-IV 26-item scale (SNAP-IV-26), which covered
the first 26 items of the VADRS, for further analysis. The individual assessment method is explained in detail below. The assessment
tools used in our research are globally recognized and accepted methods of scoring severity levels of ADHD and ASD patients. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> To minimize the impacts of patients&rsquo;
existing treatments to our assessment, four of the seven patients had stopped their other medications for more than a year before
they started receiving treatment using our personalized TCM formulae, and the other three stopped about a week before they started
receiving treatment using our personalized TCM formulae treatment in our study. Moreover, parents of the three patients who stopped
their medication only a week before our study had indicated that they had given those medication to their child only intermittently
as needed, such as when attending class, because of the adverse side effects the child was experiencing. Parents also noted that
the effect of the medication wore off after a few hours they have taken the medication and their condition would be the same as
before they took the medication until they took another dose again. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The first research study was only a
first phase of our research studies. Our first research study was designed with a small sample size to allow us to collect preliminary
data, monitor the treatment progress, observe the effect of the treatment and note any adverse side effects in a cost effective
and systematic way. It has helped us better prepare for our second research study we intend to begin in 2021, with a much larger
sample size of at least 100 candidates and for a longer duration, between 3 and 12 months. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We intend to register our pCm formulae
products with the Hong Kong Chinese Medicines Board, upon successful completion of our second research study, under group II of
the non-established medicines category, a category of pCm that does not contain any newly discovered Chinese herb, new medicinal
part(s) of Chinese herb, active group extracted from Chinese herb or set of active groups extracted from compound prescription.
As indicated in &ldquo;Our Products&rdquo; section, ingredients which our TCM Practitioner uses are all natural herbs tracing
back to Compendium of Materia Medical, or Ben Cao Gang Mu (&ldquo;&#26412;&#33609;&#32177;&#30446;&rdquo;), more than 400 years
ago. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> However, these assessment tools have
some inherent biases, such as parental expectations, social desirability and recall bias. If our understanding and use of these
assessment tools is inaccurate or flawed, or if the parents of enrolled ADHD and ASD patients fail to observe and record accurately,
then we will not only fail to realize any benefits from using these assessment tools, but may also be led to invest time and financial
resources inefficiently in attempting to develop inappropriate TCM formulae candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Autism Treatment Evaluation Checklist (ATEC) </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ATEC is specially designed to measure changes
in autistic severity, making it useful in monitoring behaviors over time as well as tracking the efficacy of a treatment. ATEC
comprises of four subscales: (1) Speech/Language/Communication, (2) Sociability, (3) Sensory/Cognitive Awareness, and (4) Health/Physical/Behavior.
ATEC is a caregiver-administered questionnaire designed to measure changes in the severity of autism in response to treatment.
The scores from each subscale are combined in order to calculate a Total Score. A lower score indicates a lower severity of autism
symptoms and a higher score correlates with more severe symptoms of autism.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Gilliam Autism Rating Scale (GARS)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">GARS is one of the most widely used instruments
for the assessment of ASD in the world. It is a 42-item norm-referenced screening instrument used for the assessment of individuals
ages 3-22 who have severe behavioral problems that may be indicative of autism. It gathers information about specific characteristics
typically noted in children with ASD in three areas: stereotyped behaviors, communication, and social interaction. It also contains
a Developmental Disturbances section. As the questions included in the developmental disturbances section of GARS refer to the
condition of the patient during the patient&rsquo;s first 36 months of age, the total score is calculated by adding the sum of
the raw scores of the three subscales of stereotyped behaviors, communications, and social interaction, but excluding the scores
of developmental disturbances.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS) </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">VADRS is a psychological assessment tool
for parents of children aged 6 to 12 designed to measure the severity of ADHD symptoms. Developed by Mark Wolraich at the Oklahoma
Health Sciences Center, this rating scale also includes items related to other disorders which are frequently comorbid with ADHD.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Swanson, Nolan, and Pelham (SNAP)-IV 26-item Parent Rating
Scale (SNAP-IV-26)</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> SNAP-IV-26, which is an abbreviated
version of the SNAP Questionnaire (Swanson, 1992; Swanson et al., 1983) and the same as the first 26 items of the VADRS, was
also used. Items from the <I>DSM-IV </I>criteria for ADHD are included in the two subsets of symptoms: Inattentive (items 1
&ndash; 9) (score range from 0 &ndash; 27) and Hyperactivity/Impulsivity (items 10 &ndash; 18) (score range from 0 &ndash;
27). Also, items from the <I>DSM-IV </I>criteria for the oppositional defiant disorder (ODD) are included (items 19
&ndash; 26) (score range from 0 &ndash; 24) because ODD is often present in children with ADHD. The lower the SNAP-IV-26
score, the fewer the problems. The scores provide an interpretation for severe, moderate, mild, and no clinically significant
symptoms. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Results</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We had seven enrolled patients in our
first research study. Their ages ranged from five to twelve years old. We collected the data recorded by patients&rsquo; parents
in our ATEC, GARS, VADRS, and SNAP-IV-26 questionnaires. The average (mean) values of improvement percentage of the patients based
on different questionnaires and a total score of the four questionnaires are shown in the tables and figures below. Each of the
participants of our first research study was treated by the TCM Practitioner with a personalized TCM formula. Although each patient
in the first research study was treated with a personalized TCM formulae, each personalized TCM formulae was comprised of the
TCM base formula, which remained the same among all participants, and an adjustable formula. The base formula is the product of
&ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo;. The adjustable formula was personalized to each child for different severity
of symptoms in the first research study. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>ATEC Results </I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 1 demonstrates the mean improvement
percentage of the patients&rsquo; ATEC total score. The mean improvement of the patients is 12%, 28% and 40% after 1, 2 and 3
months of treatment respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_005.jpg" ALT=""></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 1</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 2 combines the mean improvement
percentage of the patients&rsquo; ATEC total score and the 4 subscales into one graph. It indicates improvements in all areas
of autistic symptoms. The mean improvement of each category is 30%, 47%, 32% and 46% after 3 months of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0pt; text-align: center">Figure 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>GARS Results</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 3 demonstrates the mean improvement
percentage of GARS total score of patients. The mean improvement of their ASD symptoms are 10%, 27% and 32% after 1, 2 and 3 months
of treatment respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 4 combines the mean improvement
percentage of the patients&rsquo; GARS total score and the 3 subscales into one graph. It indicates improvements in all areas
of autistic symptoms. The mean improvement in each category are 39%, 16% and 33% after 3 months of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_008.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>VADRS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 5 demonstrates the mean improvement
percentage of VADRS total score of patients. The mean improvement of their ASD symptoms are 10%, 25% and 32% after 1, 2 and 3
months of treatment respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_009.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0pt; text-align: center">Figure 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 6 combines the mean improvement
percentage of VADRS total score and the 7 subscales into one graph. It indicates improvements in all areas of ADHD. The mean improvements
are 24%, 36%, 27%, 64%, 39%, 19% and 4% after 3 months of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>SNAP-IV-26 Item Scale</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 7 demonstrates the mean improvement
percentage of SNAP-IV 26-Item Scale total score. The mean improvement of their ADHD symptoms is 10%, 24% and 29% after 1, 2 and
3 months of treatment respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_011.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Figure 7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Figure 8 combines the mean improvement
percentage of SNAP-IV 26-Item Scale total score and the 3 subscales into one graph. It indicates improvements in all areas of
ADHD. The mean improvements are 24%, 36%, and 27% after 3 months of treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_012.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Conclusion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> All enrolled patients treated by the
TCM Practitioner with the use of our personalized TCM formulae showed improvement based on our assessments under ATEC, GARS, VADRS,
and SNAP. Mean 3-month improvement rates for assessments ATEC, GARS, VADRS, and SNAP were 40%, 32%, 32%, and 29%, respectively.
We believe our first research study has shown some efficacy of the personalized TCM formulae in treating ADHD and ASD patients. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of the date
hereof, the TCM Practitioner has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions.
As a result, we have three standardized TCM formulae candidates under development targeting mild, moderate, and severe ADHD and
ASD patients, each consisting of a standard base formula and a fixed adjusted formula. We plan to commence our second research
study using those three standardized TCM formulae candidates in the second quarter of 2021. However, there is no assurance that
the second research study will show the similar improvements in patients&rsquo; symptoms. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition and Competitive Advantages</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We are an early stage bioscience company
that focuses on research, development, and commercialization of our standardized TCM formulae candidates for patients afflicted
with neurocognitive disorders and degeneration, such as ADHD and ASD, for which there are unmet medical needs in the global market.
There are two main types of medication for ADHD: stimulants such as Ritalin and Adderall, and non-stimulants. For ASD, there are
only two antipsychotic drugs approved by the FDA for treating irritability and aggression symptoms: risperidone and aripiprazole,
according to Autism Speaks, an organization in the U.S. dedicated to promoting solutions, across the spectrum and throughout the
life span. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Competition</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Currently in Hong Kong, there are several
drugs approved by the FDA and Hong Kong Pharmacy and Poisons Board available to treat ADHD and ASD that are manufactured by global
pharmaceutical companies. However, we are a TCM bioscience company focusing on TCM treatments and do not compete directly with
those pharmaceutical companies. There are several key differences between the pharmaceutical drug industry and the TCM industry.
For example, pharmaceutical drugs are regulated under the Pharmacy and Poisons Ordinance (&ldquo;PPO&rdquo;), while TCM is regulated
under the Hong Kong Chinese Medicine Ordinance (&ldquo;HKCMO&rdquo;). Apart from the PPO, the Import and Export Ordinance, the
Undesirable Medical Advertisements Ordinance, the Antibiotics Ordinance and the Dangerous Drugs Ordinance also provide regulations
in the control of pharmaceutical drugs in Hong Kong, while TCM is not regulated by such ordinances and only adhere to the HKCMO.
Furthermore, all pharmaceutical manufacturers in Hong Kong must comply with the Hong Kong Good Manufacturing Practices (&ldquo;GMP&rdquo;),
whereas TCM manufacturers are not required to have GMP certifications. In terms of registration, pharmaceutical drug must be registered
with the Hong Kong Pharmacy and Poisons Board, while pCm formulae products registered with the Hong Kong Chinese Medicines Board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Further, TCM is a holistic treatment
that provides progressive improvement over time while pharmaceutical drug is targeted to short term symptomatic relief. Based
on research provided by Persistence Market Research, there are no large TCM companies providing similar ADHD and ASD products
in the market. As such, the TCM ADHD and ASD market is highly fragmented and there are no large TCM competitor in our target market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>ADHD Market Leaders</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> According to Market Research Future
(MRFR), the global ADHD therapeutics market comprises a host of key players. This list includes Eli Lilly and Company, Concordia
International Corp., NEOS Therapeutics Inc., Highland Therapeutics Inc., Pfizer Inc., Novartis AG, Noven Pharmaceuticals Inc.,
Janssen Global Services LLC, Shire, Teva Pharmaceutical and others. However, we are a TCM bioscience company focusing on TCM holistic
treatments and do not compete directly with those pharmaceutical companies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>&nbsp;</I></B>&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> According to the ADHD Parents Medication
Guide of the American Psychiatric Association, medication does not cure ADHD, but can alleviate the symptoms of ADHD when it is
taken as prescribed. Ongoing care and treatment monitoring are important since those symptoms may come back once medication is
halted. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"> Two main
types of medication for ADHD approved by the FDA are stimulants and non-stimulants. Stimulants include methylphenidate and amphetamines.
Non-stimulants which include atomoxetine and guanfacine, are alternatives for those who do not respond well to stimulants. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: #FEFEFE"> However,
these two types of medication for ADHD have multiple side effects. Common side effects of stimulants include: feeling restless
and jittery, difficulty sleeping, loss of appetite, headaches, upset stomach, irritability, mood swings, depression, dizziness,
racing heartbeat and tics. According to Help Guide, these stimulant medications may also cause personality changes, such as becoming
withdrawn, listless, rigid, or less spontaneous and talkative, others may develop obsessive-compulsive symptoms. Beyond the potential
side effects, a number of safety concerns associated with the use of stimulant medications exist such as the effect on developing
brain, heart-related problem, psychiatric problem and potential abuse, indicated by experts. Non-stimulants also have side effects
including decreased appetite, nausea, vomiting, fatigue, indigestion, dizziness, and mood swings. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>ASD Market Leaders</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> According to Fortune Business Insights,
players engaged in ASD drug therapy in the global market include AstraZeneca, Eli Lilly and Company, Fusion Autism Center, Pfizer
Inc., Otsuka Holdings Co. Ltd., and other prominent players. However, we do not compete with these players directly since they
mainly focus on prescription or over the counter drugs while we focus on TCM. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>&nbsp;</I></B>&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> There are no medications that can cure
ASD or treat the core symptoms, according to the CDC. However, there are medications that can help ASD patients with related symptoms
like&nbsp;depression,&nbsp;anxiety, aggression, irritability, seizures, insomnia, and trouble focusing and help them function
better. Medicines for treating the three core symptoms of ASD, communication difficulties, social challenges and repetitive behavior,
have long represented a huge area of unmet need. However, few drugs on the market today effectively relieve these symptoms and
individual reaction to most commonly prescribed medicines can vary materially. Although the FDA has approved two antipsychotic
drugs for treating irritability and aggression associated with the autism (risperidone and aripiprazole), the prevalent behavioral
problems associated with ASD have not been able to be improved by these medications. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp;<SUP>&nbsp;</SUP> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Antidepressants
are among the world&rsquo;s most widely prescribed medications for ASD patients, such as selective serotonin reuptake inhibitors
(SSRIs), according to an article in Harvard Health Publishing. The range of their uses has expanded from depression to anxiety,
obsessive-compulsive disorder, eating disorders, and many other psychiatric conditions. Side effects include insomnia, skin rashes,
headaches, joint and muscle pain, stomach upset, nausea, or diarrhea. Anticonvulsants are most commonly prescribed when the patient
also suffers from epilepsy, as about one-third of autism patients do, however, common side effects include confusion, fever, hair
loss, paranoia, impairs judgement and memory, anxiety and depression. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Today, most
medicines prescribed to ease ADHD and ASD symptoms are used &ldquo;off-label,&rdquo; meaning the medication is being used in a
manner not specified in the FDA&rsquo;s approved packaging label, or insert. Such off-label use is common in virtually all areas of
medicine and is usually done to relieve significant suffering in the absence of sufficiently large and targeted studies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Further, due
to the complexity of ADHD and ASD, the existing medications approved by the FDA for ADHD and ASD are used to treat a specific
symptom while the comorbid conditions remain present and will persist if no direct medications are available for treatment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>Specialty of TCM Formulae</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Compared to the main types of medication,
our core competencies span the specialty of TCM formulae and exceptional track record of over one hundred ADHD or ASD patients
being treated with the personalized TCM formulae by our TCM Practitioner. Our candidates were created specifically to address
this unmet need in the market. We will explore various ways to gain entry into markets and countries around the world and will
research the regulatory and operational requirements as needed. Depending on the regulatory environment of each country, our product
can be sold as either a drug or a dietary supplement, either directly by us or through partnerships and distributions. We will
review and analyze all options to ensure feasibility to meet the demands of the respective markets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM Practitioner has over 30 years&rsquo;
experience in treating children afflicted with ADHD and ASD. Treatment using our TCM formulae has shown some improvements in ADHD
and ASD core symptoms in the first research study. Conversely, existing ADHD and ASD medications on the market provide symptomatic
relief, with various adverse side effects, such as, feeling restless and jittery, difficulty sleeping, loss of appetite, headaches,
upset stomach, irritability, mood swings, depression, dizziness, racing heartbeat, tics, diarrhea and other stomach irritation,
rashes, hives and itching, dry mouth, fatigue and weight loss. Some other side effects could be serious and some potentially fatal.
However, there is no assurance that the second research study will show any improvements in patients&rsquo; symptoms. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our TCM formulae was created based on
the TCM brain theory, known as &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo;. The TCM brain theory is not recognized in general
literature of TCM or elsewhere. However, the TCM Practitioner has prescribed the personalized TCM formulae based
on his TCM brain theory for over 30 years to treat ADHD, ASD and many neurological disorders and obtained satisfactory clinical
treatment results. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We believe treatment using our TCM formulae
provides progressive improvements over time because it aims to correct the fundamental cause of diseases and disorders such as
ADHD and ASD. Also, the effect of existing ADHD and ASD drugs wear off after a few hours. Short-acting stimulants peak after several
hours and must be taken 2-3 times a day. Long-acting or extended-release stimulants last 8-12 hours and are usually taken just
once a day, according to HelpGuide, an independently funded nonprofit organization in the U.S. Furthermore, some patients may
require an increase in dosage over time because the body builds up tolerance and resistance. Depending on a patient&rsquo;s severity,
the duration of the TCM Practitioner&rsquo;s treatment can take one year or more and the patient will eventually live an independent
and normal life. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> All parents of the ADHD and ASD children
in our research study have witnessed pronounced improvement in three months, and have testified the benefits and effectiveness
of our TCM Practitioner&rsquo;s treatment and was preferred over their typical mainstream medication. During our study, all of
them stopped their existing medication and switched to treatment with the use of our TCM formulae. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Before the seven patients began their
treatment with our personalized TCM formulae for our first research study, they tried other treatments and therapies for various
periods. We asked their parents to provide an assessment on the efficacy of the other treatments, therapies or drugs versus our
formula as shown in the following table: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Mainstream medicine</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Other TCM formula</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Other treatments / therapies</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Acupuncture</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><B>Our formula</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 21%; vertical-align: top">Patient 1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: center">7% (speech)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">25</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">45</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Patient 2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">20% (music, speech, occupational therapy)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">60</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">Patient 3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">40% (speech)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">%</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">70</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Patient 4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">20% (speech)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">40</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">Patient 5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">65% (speech),<BR> 30% (cranial osteopathy)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">75</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Patient 6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10% (speech)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">40</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">Patient 7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">0% (speech)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">60</TD><TD STYLE="font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Currently, according to the CDC, there
is no cure for ADHD and ASD. Given the lack of effective conventional medicine, coupled with adverse side effects associated with
current drugs and rapidly growing patient diagnosis, we are well-positioned to become the leader in providing the treatment for
ADHD and ASD. However, due to the early stage of our research in three standardized TCM formulae candidates, there is no assurance
that the second research study will show similar improvements in patients&rsquo; symptoms. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B><I>TCM Practitioner with Long-period Track Record</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Over 30 years, our TCM Practitioner
has established a track record of treating children afflicted with ADHD and ASD and other patients suffering from a wide range
of neurocognitive disorders and degeneration with the personalized TCM formulae. Our research and development effort will be mainly
to fine tune and standardize the personalized TCM formulae our TCM Practitioner has been using over his practice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date hereof, the TCM Practitioner
has standardized the adjustable formula into three fixed formulae for mild, moderate and severe conditions. As a result, we have
three standardized TCM formulae candidates under development targeting mild, moderate, and severe ADHD and ASD patients, each
consisting of a standard base formula and a fixed adjusted formula. We plan to commence our second research study using those
three standardized TCM formulae candidates in the second quarter of 2021. Based on our TCM Practitioner&rsquo;s track record,
we do not anticipate high bio-pharmaceutical research and development costs relating to chemical drugs. Average research and development
to marketplace cost for a new medicine is nearly US$4 billion, and can sometimes exceed US$10 billion. In comparison, our research
and development cost were only $0.39 million and $0.23 million for the years ended June 30, 2020 and June 30, 2019, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Regulatory Approvals Prior to Commercialization in Hong
Kong</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the outcome of further research
and development, if we commercialize our liquid-based standardized TCM formulae candidates in Hong Kong, we will need to receive
a manufacturer license issued by the Hong Kong Chinese Medicines Board, which was established in 1999 under HKCMO. Once we receive
the licenses and complete pCm registrations for our standardized TCM formulae candidates, our pCm formulae products can be manufactured
and sold over the counter without the supervision and prescription of a TCM practitioner in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> When applying for registration of pCm
in Hong Kong, we will be required to provide sufficient documents to show safety, stability, quality and efficacy of our pCm formulae
products to the Hong Kong Chinese Medicines Board. To show the efficacy of our pCm formulae products, documents required include
reference materials in which the claimed therapeutic functions are supported by research studies, interpretation and principle
of formulating a prescription and a summary report on all the product efficacy documents. To prove safety, stability and quality
of our pCm formulae products, we will work with accredited laboratories, a list of which is provided by the Hong Kong Chinese
Medicines Board, to conduct all the necessary tests, such as heavy metals and toxic element test and pesticide residues test.
As for the application of manufacturer licenses, the major documents required are a brief floor plan of the premise and a list
of manufacturing equipment. GMP certification is not required for the manufacturing of pCm in Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our current primary roles include recruiting
and arranging patients to be treated by the TCM Practitioner, collecting research data from patients, conducting analysis over
research data, and planning for commercialization of our standardized TCM formulae candidates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Time and Cost Estimate Prior to the Commercialization
of Our Standardized TCM Formulae Candidates in Hong Kong</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We estimate that it will take us approximately
four years to commercialize our standardized TCM formulae candidates in Hong Kong, including as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to complete our second research study, including enrollment of qualified patients
                                         for treatment by qualified TCM practitioner(s) with the use of our standardized TCM formulae
                                         candidates, assessment and analysis;</FONT> </TD></TR>                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to develop an efficient centralized production process to manufacture our liquid-based
                                         standardized TCM formulae, in which six months to set up our centralized production facility
                                         after our second research study;</FONT> </TD></TR>                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year to prepare for efficacy documents and conduct tests, including safety, quality
                                         and stability tests upon completion of our second research study, during which time we
                                         will also apply for manufacturer license for our products with the Hong Kong Chinese
                                         Medicines Board; and</FONT> </TD></TR>                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 48px"></TD><TD STYLE="width: 24px"> &#9679; </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately
                                         one year or more for review process of our pCm registration application after submission
                                         of our application to the Hong Kong Chinese Medicines Board.</FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For costs leading up to the approval
of our pCm formulae products in Hong Kong, the total amount is approximately US$19.3 million: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second research study
    &ndash; US$2.3 million;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff salaries &ndash;
    US$11.0 million;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product and intellectual
    properties registration and legal expenses &ndash; US$0.7 million; </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facilities rental,
    renovations and equipment &ndash; US$4.2 million; </FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"> &nbsp; </TD>
    <TD STYLE="width: 24px; font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing and conferences
    &ndash; US$0.4 million; and</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous &ndash;
    US$0.7 million.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>Second Research Study</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We intend to commence our second research
study for our three standardized TCM formulae candidates for mild, moderate, and severe ADHD and ASD patients during the second
quarter of 2021 in Hong Kong. Currently, we are planning our second research study which include formulating strategy, designing
protocol and reviewing our candidates&rsquo; qualifications and outcome measures. We intend to arrange for 100 patients to be
treated by qualified TCM practitioner(s) with the use of our standardized TCM formulae candidates. They are to be separated in
three different groups with mild, moderate, and severe conditions respectively. Each group will be treated with our different
standardized TCM formulae candidates for three months and up to one year. Our assessments over enrolled patients will be conducted
every three months of the treatment. We estimate that our second research study will take one year to complete and cost is estimated
to be US$2.3 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>Setting Up Centralized Production Facility</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If the results of our second research
study are similar to that of our first research study, we will begin the next step to develop an efficient centralized production
process to manufacture and mass produce our standardized TCM formulae candidates to support the anticipated increase from the
over the counter sales of our pCm formulae products, provided that the application for the pCm registration of our pCm formulae
products are approved. In order for mass production, we will procure an industrial space, purchase new automation equipment and
set up the production lines and ensure quality control of our products. Upon completion of our production facility, we will obtain
regulatory approvals from the Hong Kong Chinese Medicines Board for a manufacturer license. After receiving our application, the
Department of Health of Hong Kong will send officers to inspect our premise and prepare a report for assessment by the Hong Kong
Chinese Medicines Board. If our application to the manufacturer license is approved by the Hong Kong Chinese Medicines Board,
we will pay the prescribed fee and the Department of Health of Hong Kong will issue and send us a manufacturer license. However,
if our application is rejected, we may initiate a review or appeal against that decision. We estimate that this process will take
about one year, commencing shortly after the conclusion of our second research study, and the cost is estimated to be US$4.2 million.&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>Preparation of Efficacy Documents and Testing Phase</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Once the Hong Kong Chinese Medicines
Board approves our manufacturer license application, we will prepare for efficacy documents required for application of pCm registration
with the Hong Kong Chinese Medicines Board for our standardized TCM formulae candidates. The Hong Kong Chinese Medicines Board
requires applicants to provide sufficient documents to support the product efficacy of their pCm formulae products. The product
efficacy documents shall include reference materials in which the claimed therapeutic functions are supported by research studies,
interpretation and principle of formulating a prescription and a summary report on all the product efficacy documents. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In addition, safety, stability and quality
tests documents are also required for the application of pCm registration. We will work with accredited laboratories, a list of
which is provided by the Hong Kong Chinese Medicines Board, to begin the testing phase. Safety test includes test for heavy metals
and toxic element test, pesticide residues test, microbial limit test, acute toxicity test, long-term toxicity test, local toxicity
test, mutagenicity test, carcinogenicity test and reproductive and development toxicity test. Quality test includes manufacturing
method, physicochemical properties of crude drugs, product specification, methods and certificate of analysis. These tests and
the preparation of documents are expected to take about one year, and the cost is estimated to be US$0.7 million. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>PCM Registration with the Hong Kong Chinese Medicines
Board</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> When all efficacy documents, tests documents
and other required documents are completed, we will submit an application for the approval of pCm registration of our pCm formulae
products. All applications for registration of pCm will be assessed and approved by the Hong Kong Chinese Medicines Board, or
the Hong Kong Chinese Medicines Committees as delegated by the Hong Kong Chinese Medicines Board. In the course of an application
assessment, the Hong Kong Chinese Medicines Board may, if it considers necessary, require the applicant to provide additional
documents or information for the registration of pCm. Even if such data and information are submitted, the Hong Kong Chinese Medicines
Board may ultimately decide that the pCm does not satisfy the applicable regulatory criteria for approval and reject our application.
If approved, a certificate will be issued, which is valid for 5 years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The approval process is lengthy and
difficult and may cost a year or more. According to section 122 of the CMO, in determining the approval of an application for
registration of a pCm, the Hong Kong Chinese Medicines Board shall in particular take into consideration the safety, quality
and efficacy of the pCm. Data obtained from our research study may be inconclusive or the Hong Kong Chinese Medicines Board
may interpret the data different to our interpretation of the same data. The Hong Kong Chinese Medicines Board shall also
take into consideration in particular the methods, standards and conditions of manufacture of the medicine; and may require
the production by the applicant of any one or a combination of the following as they deem appropriate: (i) an undertaking,
given by the manufacturer of the pCm, to permit the premises where it is or is to be manufactured, and the operations carried
on or to be carried on in the course of manufacturing it, to be inspected by or on behalf of the Hong Kong Chinese Medicines
Board; (ii) an undertaking, given by the manufacturer of the pCm, to comply with any conditions as imposed by the Hong Kong
Chinese Medicines Board; (iii) a declaration, given by or on behalf of the manufacturer of the pCm that, in relation to the
manufacture of the pCm any requirements imposed by or under the law of the place in which it is or is to be manufactured have
been or will be complied with. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Besides the cost mentioned above, in
the course of our, research study, setting up of our centralized production facility, manufacturer license and pCm registration
application, we estimate that the cost of staff salaries will be US$11.0 million, marketing and conferences will be US$0.4 million
and other miscellaneous items, such as general office expenses, will be US$0.7 million.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The TCM formulae are the core of our
business operation and TCM research and development. We seek to protect the TCM formulae candidates, including the TCM base formula
and the standardized TCM formulae candidates, and technology that we consider commercially important by filing patent applications
in Hong Kong and abroad. In addition, we also rely on trade secrets or TCM related regulatory protection to protect our intellectual
property. Our trade secrets and confidential information include unpatented know-how, technology and other proprietary information,
to maintain our competitive position and to protect our TCM formulae candidates. We seek to protect these trade secrets by limiting
access to such confidential information and by entering into non-disclosure and confidentiality agreements with parties that have
access to them, such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, contract
manufacturers, consultants, advisers and other third parties.&nbsp;Further, we also rely on or intend to rely on our trademarks,
trade names and brand names to distinguish our products from the products of our competitors, and have registered or will apply
to register a number of these trademarks. We have received trademark certificates for &ldquo;&#33126;&#36996;&#21407;<SUP>&reg;</SUP>&rdquo;
(directly translates as &ldquo;brain restoration&rdquo;) and &ldquo;RGC Regencell<SUP>&reg;</SUP>&rdquo; from the Hong Kong Registrar
of Trade Marks in July 2020. We also filed a trademark application for &ldquo;Sik-Kee Au TCM Brain Theory&trade;&rdquo; in January
2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of the prospectus, we
have a total of approximately eight full-time employees. Our employees are not represented by a labor organization or covered
by a collective bargaining agreement. We have not experienced any work stoppages. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Description of Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We currently maintain offices at Office
A &amp; B on 11th Floor, First Commercial Building, 33-35 Leighton Road, Hong Kong. The Company has entered a five-year fixed
term lease agreement for the office space on July 15, 2019. The lease expires on July 14, 2024. Our commitment for lease payments
under the operating lease as of June 30, 2020 for the next five years are a total of $483,206 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Company has a separate office rental
agreement with Ace United International Limited, which is a company wholly-owned by the our founder and CEO. The Company has paid
a monthly rent of $4,103 for the premises located at 21<SUP>st</SUP> Floor, EIB Tower, 4-6 Morrison Hill Road, Wan Chai, Hong
Kong. The terms of the agreement are renewed on an annual basis from the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December
each year. The rental payment is expensed as incurred. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company also entered a six-month lease
agreement for an office space at 5201 Great America Pkwy, Suite 320, Santa Clara, California, U.S., on October 1, 2020. The monthly
rent is $394 and we can renew the lease term 3 months prior to the end of the term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may from time to time become a party
to various legal or administrative proceedings arising in the ordinary course of our business. As of the date hereof, neither
we nor any of our subsidiaries is a party to any pending legal proceedings, nor are we aware of any such proceedings threatened
against us or our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="RB_DRS_013"></A>REGULATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white">The
Legislative Council of Hong Kong, Chinese Medicines Council, Chinese Medicines Board, and Chinese Medicines Regulatory Office
of Department of Health of Hong Kong are independent and separate entities from China. Whilst Hong Kong is part of the People&rsquo;s
Republic of China (&ldquo;PRC&rdquo;), Hong Kong and the PRC are regarded as two separate jurisdictions in law and markets. Under
the &ldquo;One Country, Two Systems&rdquo;, Hong Kong retains its own systems and way of life after the handover of sovereignty
to the PRC in 1997. The Hong Kong Basic Law (the &ldquo;Basic Law&rdquo;), being Hong Kong&rsquo;s constitutional document, gives
legal effect to the &ldquo;One Country, Two Systems&rdquo; policy.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white">Pursuant
to the Basic Law, the laws previously in force in Hong Kong, that is, the common law, rules of equity, ordinances, subordinate
legislation and customary law shall be maintained, except for any that contravene the Basic Law, and subject to any amendment
by the </FONT>Legislative Council <FONT STYLE="background-color: white">of Hong Kong. The socialist system and policies shall
not be practiced in Hong Kong, and the previous capitalist system and way of life shall remain unchanged for 50 years. Further,
Hong Kong residents and other persons in Hong Kong shall have the obligation to abide by the laws in force in Hong Kong. </FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <FONT STYLE="background-color: white">As
we have no assets or operation in PRC and operate in Hong Kong, nor have plan to commence operation in PRC, we do not believe
that PRC laws or regulations regarding the TCM industry apply to us. Hence, within Hong Kong&rsquo;s legal system, the laws and
regulations of the PRC do not apply.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulation Related to our Business Operation in Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Chinese Medicine Ordinance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Chinese Medicine Ordinance (&ldquo;CMO&rdquo;)
provides licensing requirements for the sale and distribution of our TCM formulae candidates, registration and licensing requirement
of our Chinese healthcare products, and future operations of our Chinese medicine clinics in Hong Kong. CMO was passed by the
Legislative Council of Hong Kong on July 14, 1999. CMO is not a PRC legislation but is a Hong Kong ordinance. As with all other
Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council of Hong Kong has the power and function to
amend the CMO in accordance with the provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including
but not limited to the Department of Justice, the Hong Kong Police Force, the Food and Health Bureau, the Department of Health
and etc., as well as the Chinese Medicine Council of Hong Kong, have the implementation rights of CMO. The Chinese Medicine Council
of Hong Kong is the main regulator of CMO. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Registration of TCM products and Chinese
Healthcare Products </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Some of our TCM products and Chinese
healthcare products are classified as proprietary Chinese medicine (&ldquo;pCm&rdquo;), defined below, and others are classified
as non-pCm. The key differences between pCm and non-PCM lie on their ingredients, dosage forms and intended use. Under section
2 of the CMO, pCm is defined as any proprietary product, which is formulated in a finished dose form and is known or claimed to
be used for the diagnosis, treatment, prevention or alleviation of any disease or any symptom of a disease in human beings, or
for the regulation of the functional states of the human body, composed solely of (i) any Chinese herbal medicines; (ii) any materials
of herbal, animal or mineral origin customarily used by the Chinese, which should be documented in Chinese medicine classics or
bibliographies, including but not limited to Pharmacopeia; or (iii) any medicine and materials referred to above, which is formulated
in a finished dose form and is generally known or claimed to be used for the diagnosis, treatment, prevention or alleviation of
any disease or for the regulation of the functional states of human body. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Section 119 of the CMO provides that
no person shall sell, import or possess any pCm unless the pCm is registered with the Chinese Medicines Board. Application for
registration of a pCm shall be submitted to the Department of Health Chinese Medicines Board in the manner prescribed in section
121 of the CMO. Pursuant to section 120 of the CMO, the application for registration of any pCm shall be made by the manufacturer
of the pCm manufactured in Hong Kong, or by the importer or local representative or agent of the manufacturer of pCm manufactured
outside Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person who contravenes section 119 of
the CMO commits an offence and is liable to a maximum fine of HK$100,000 and imprisonment for two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Manufacture, Sale and Distribution of TCM Products and
Chinese Healthcare Products </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> CMO provides that manufacturers and
traders in pCm shall obtain a license issued by the Chinese Medicines Board. Section 131 of the CMO provides that no person shall
manufacture any pCm, whether registered or not, without a manufacturer license, or at any place other than the premises specified
in such license. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any person who contravenes
section 131 or 134 of the CMO commits an offence and is liable to a maximum fine of HK$100,000 and imprisonment for two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Labelling Requirements and Package
Inserts for Chinese Healthcare Products </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Chinese Medicines Regulation is
not a PRC legislation but is a Hong Kong legislation. As with all other Hong Kong legislations, according to the laws of Hong
Kong, the Legislative Council of Hong Kong has the power and function to amend the Chinese Medicines Regulation in accordance
with the provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not limited to the
Department of Justice, the Hong Kong Police Force, the Food and Health Bureau, the Department of Health and etc., as well as the
Chinese Medicine Council of Hong Kong, have the implementation rights of Chinese Medicines Regulation. The Chinese Medicine Council
of Hong Kong is the main regulator of Chinese Medicines Regulation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Sections 143 and 144 of the CMO provide
that a pCm shall not be sold or possessed for the purpose of selling in Hong Kong unless the package of the product is labelled
in the prescribed manner and contains a package insert which complies with the prescribed requirements. Pursuant to Regulations
26 and 28 of the Chinese Medicines Regulation (Chapter 549F of the Laws of Hong Kong) (the &ldquo;Chinese Medicines Regulation&rdquo;),
all pCm shall be properly labelled and attached with package inserts. The label on a package of pCm shall include the following
particulars: the name of the medicine; the name of each active ingredient used (if the pCm is composed of three or more kinds
of active ingredients, the names of more than half of the active ingredients are required); the registration number on the certificate
of registration; the holder of the registration certificate or the manufacturer (if the package is the outermost one, the name
of the holder of the certificate of registration is necessary); the name of the country or territory in which the medicine is
produced; the packing specification; dosage and method of usage; expiry date; and batch number. The package insert of the pCm
shall include the following particulars: the name of the medicine; the name and quantity of each active ingredient used (if the
pCm is composed of three or more kinds of active ingredients, the names and quantities of more than half of the active ingredients
are required); the name of the holder of certificate of registration or the manufacturer; the dosage and method of usage; functions
or pharmacological action; storage instructions; and packing specification. As for the indications, contra-indications, side effects,
toxic effects and precautions, they should be included on the package insert as far as practicable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any person who contravenes
section 143 or 144 of the CMO commits an offence and is liable to a maximum fine of HK$100,000 and imprisonment for two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Food Safety Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Food Safety Ordinance (Chapter 612 of
the Laws of Hong Kong) (the &ldquo;Food Safety Ordinance&rdquo;) establishes a registration scheme for food importers and food
distributors, to require the keeping of records by persons who acquire, capture, import or supply food and to enable food import
controls to be imposed. Food Safety Ordinance is not a PRC legislation but is a Hong Kong ordinance. As with all other Hong Kong
legislations, according to the laws of Hong Kong, the Legislative Council of Hong Kong has the power and function to amend the
Food Safety Ordinance in accordance with the provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government,
including but not limited to the Department of Justice, the Hong Kong Police Force, the Food and Health Bureau, the Food and Environmental
Hygiene Department and etc., has the implementation rights of the Food Safety Ordinance. The Food and Environmental Hygiene Department
is the main regulator of the Food Safety Ordinance. As some of our Chinese healthcare products which are non-pCm fall within the
definition of food, our Company is subject to the regulations under the Food Safety Ordinance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Food Safety Ordinance may be applicable
since we cannot determine whether the ultimate product(s) to be commercialized would be classified by the regulatory body as Chinese
herbal medicines, healthcare products, food for ordinary consumption, or otherwise. The precise content of the standardized TCM
formulae candidates are subject to further changes and development along with our second research study. Accordingly, the precise
ingredients of TCM products or product candidates will be determined at a later stage of our research and development. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Registration as Food Importer or Distributor
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Sections 4 and 5 of
the Food Safety Ordinance require any person who carries on a food importation business or food distribution business to
register with the Food and Environmental Hygiene Department of Hong Kong as a food importer or food distributor. Any person
who does not register but carries on a food importation or distribution business, without reasonable excuse, commits an
offence and is liable to a maximum fine of HK$50,000 and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Record-keeping Requirement relating
to Supply of Food </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Section 24 of the Food
Safety Ordinance provides that a person who, in the course of business, supplies food in Hong Kong by wholesale must record the
following information about the supply: (i) the date the food was supplied; (ii) the name and contact details of the person to
whom the food was supplied; (iii) the total quantity of the food; and (iv) a description of the food. Such record shall be made
under this section within 72 hours after the time the supply took place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Any person, who fails
to comply with the record-keeping requirement without reasonable excuse or knowingly or recklessly includes in the record information
that is false in a material particular, commits an offence and is liable to a maximum fine of HK$10,000 and imprisonment for three
months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Import and Export Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Import and Export Ordinance is not a
PRC legislation but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the
Legislative Council of Hong Kong has the power and function to amend the Import and Export Ordinance in accordance with the provisions
of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice,
the Hong Kong Police Force, the Customs and Excise Department, the Trade and Industry Department and etc., has the implementation
rights of the Import and Export Ordinance. The Customs and Excise Department and the Trade and Industry Department are the main
regulators of the Import and Export Ordinance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to sections 6C and 6D of the
Import and Export Ordinance (Chapter 60 of the Laws of Hong Kong) (the &ldquo;Import and Export Ordinance&rdquo;) and Schedules
1 and 2 to the Import and Export (General) Regulations (Chapter 60A of the Laws of Hong Kong), any person who imports or exports
any of the Chinese herbal medicines set out in Schedule 1 to the CMO and five specific types in Schedule 2 to the CMO (namely
Flos Campsis (&#28137;&#38660;&#33457;), Processed Radix Aconiti (&#35069;&#24029;&#28879;), Processed Radix Aconiti Kusnezoffii
(&#35069;&#33609;&#28879;), Radix Clematidis (&#23041;&#38728;&#20185;) and Radix Gentianae (&#40845;&#33213;)) as well as any
pCm under the CMO shall apply for an import or export license. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Any person importing or exporting of
the aforesaid Chinese herbal medicines and pCm without an import or export license commits an offence and is liable to a fine
of HK$500,000 and imprisonment for two years, or on conviction on indictment to a fine of HK$2,000,000 and imprisonment for seven
years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Public Health and Municipal Services Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Public Health Ordinance is not a PRC
legislation but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative
Council of Hong Kong has the power and function to amend the Public Health Ordinance in accordance with the provisions of the
Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the
Hong Kong Police Force, the Food and Health Bureau, the Home Affairs Bureau, the Drainage Services Department, the Food and Environmental
Hygiene Department, the Leisure and Cultural Services Department, the Department of Health, the Lands Department, the Buildings
Department and etc., has the implementation rights of the Public Health Ordinance. The Food and Environmental Hygiene Department
is the main regulator of the Public Health Ordinance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The legal framework for food safety
control in Hong Kong is set out in Part V of the Public Health and Municipal Services Ordinance (Chapter 132 of the Laws of Hong
Kong) (the &ldquo;Public Health Ordinance&rdquo;) and the relevant sub-legislations thereunder. The Public Health Ordinance requires
the manufacturers and sellers of food to ensure that their products are fit for human consumption and comply with the requirements
in respect of food safety, food standards and labelling. As some of our Chinese healthcare products which are non- pCm fall within
the definition of food, our Company is subject to the regulations under the Public Health Ordinance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 50 of the Public Health Ordinance
prohibits manufacture, advertising and sale in Hong Kong of food or drugs that are injurious to health. Any person who fails to
comply with this section commits an offence and is liable to a maximum fine of HK$10,000 and imprisonment for three months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to section 52 of the Public Health
Ordinance, subject to the statutory defenses set out under section 53 of the Public Health Ordinance, where a seller sells to the
prejudice of a purchaser any food or drug which is not of the nature, substance or quality of the food or drug demanded by the
purchaser, the seller commits an offence and is liable to a maximum fine of HK$10,000 and imprisonment for three months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to section 54 of the Public Health
Ordinance, any person who sells or offers for sale any food intended for, but unfit for, human consumption, or any drug intended
for use by human but unfit for the purpose, commits an offence and is liable to a maximum fine of HK$50,000 and imprisonment for
six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 61(1) of the Public Health Ordinance
provides that it shall be an offence for any person who gives with any food or drug sold by him/her or displays with any food or
drug exhibited for sale by him/her any label which falsely describes the food or drug or is calculated to mislead as to its nature,
substance or quality. Furthermore, pursuant to section 61(2) of the Public Health Ordinance, it shall be an offence if any person
publishes or is a party to the publication of an advertisement falsely describing any food or drug or is likely to mislead as to
the nature, substance or quality of any food or drug. Any person who commits an offence under this section is liable to a maximum
fine of HK$50,000 and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Food and Drugs (Composition and Labelling) Regulations
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Food and Drugs (Composition and Labelling)
Regulations (Chapter 132W of the Laws of Hong Kong) (the &ldquo;Food and Drugs Regulations&rdquo;), a subsidiary legislation under
the Public Health Ordinance, regulates the advertising and labelling of food. Food and Drugs Regulations is not a PRC legislation
but is a Hong Kong legislation. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative
Council of Hong Kong has the power and function to amend the Food and Drugs Regulations in accordance with the provisions of the
Hong Kong Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the
Hong Kong Police Force, the Food and Environmental Hygiene Department and etc., has the implementation rights of the Food and
Drugs Regulations. The Food and Environmental Hygiene Department is the main regulator of the Food and Drugs Regulations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regulation 3 of the Food and Drugs Regulations
provides that the manufacturing of foods and drugs shall be up to the standards as specified under Schedule 1 to the Food and Drugs
Regulations. Any person who advertises for sale, sells or manufactures for sale any food or drug which does not conform to the
relevant requirements as to composition prescribed in Schedule 1 to the Food and Drugs Regulations commits an offence and is liable
to a fine of HK$50,000 and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regulation 4A of the Food and Drugs Regulations
demands all pre-packaged food and products sold by the Group (except for those listed in Schedule 4 to the Food and Drugs Regulations)
to be marked and labelled in the manner prescribed in Schedule 3 to the Food and Drugs Regulations. Schedule 3 to the Food and
Drugs Regulations contains labelling requirements in respect of stating the product&rsquo;s name or designation, ingredients, &ldquo;best
before&rdquo; or &ldquo;use by&rdquo; date, special conditions for storage or instruction for use, manufacturer&rsquo;s or packer&rsquo;s
name and address, and quantity, weight or volume, and also includes requirements on the appropriate language or languages for marking
or labelling of prepackaged food. Any person who contravenes such requirements commits an offence and is liable to a fine of HK$50,000
and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to regulation 4B of the Food and
Drugs Regulations, prepackaged food sold by the Group should be marked or labelled with its energy value and nutrient content in
the manner prescribed in Part 1 of Schedule 5 to the Food and Drugs Regulations, and nutrition claims, if any, made on the label
of the product or in any advertisement for the product should comply with Part 2 of Schedule 5 to the Food and Drugs Regulations.
Contravention of those requirements may result in a conviction liable to a maximum fine of HK$50,000 and imprisonment for six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Trade Marks Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Trade Marks Ordinance
(Chapter 559 of the Laws of Hong Kong) (the &ldquo;Trade Marks Ordinance&rdquo;) provides for the registration of trademarks,
the use of registered trademarks and related matters. As Hong Kong provides territorial protection for trademarks, trademarks
registered in other countries or regions are not automatically entitled to protection in Hong Kong. In order to enjoy protection
by the laws of Hong Kong, trademarks shall be registered with the Trade Marks Registry of the Intellectual Property Department
under the Trade Marks Ordinance and the Trade Marks Rules (Chapter 599A of the Laws of Hong Kong) (the &ldquo;Trade Marks Rules&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Trade Marks Ordinance is not a PRC legislation
but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council
of Hong Kong has the power and function to amend the Trade Marks Ordinance in accordance with the provisions of the Hong Kong
Basic Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the Hong Kong
Police Force, the Intellectual Property Department and etc., has the implementation rights of the Trade Marks Ordinance. The Intellectual
Property Department is the main regulator of the Trade Marks Ordinance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 10 of the Trade Marks Ordinance
provides that a registered trademark is a property right acquired through due registration under the Trade Marks Ordinance, through
which the owner of a registered trademark is entitled to the statutory rights provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By virtue of section 14 of the Trade Marks
Ordinance, the owner of a registered trademark is conferred exclusive rights in the trademark. The rights of the owner in respect
of the registered trademark come into existence from the date of the registration of the trademark. Pursuant to section 48 of the
Trade Marks Ordinance, the registration date is the filing date of the application for registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the exceptions under sections
19 to 21 of the Trade Marks Ordinance, any use of the trademark by third parties without the consent of the owner is an infringement
of the trademark. Section 18 of the Trade Marks Ordinance further specifies the conducts which amount to infringement of the registered
trademark. In event that infringement by any third party occurs, the owner of the registered trademark is entitled to remedies
under the Trade Marks Ordinance, such as infringement proceedings under sections 23 and 25 of the Trade Marks Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Trademarks which are not registered under
the Trade Marks Ordinance and the Trade Marks Rules may still be protected by the common law action of passing off, which requires
proof of the owner&rsquo;s reputation in the unregistered trademark and that use of the trademark by third parties will cause damage
to the owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sale of Goods Ordinance </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sale of Goods Ordinance (Chapter 26 of the
Laws of Hong Kong) (the &ldquo;Sale of Goods Ordinance&rdquo;) provides, inter alia, that where a seller sells goods in the course
of a business, there is an implied condition that (i) where the goods are purchased by description, the goods shall correspond
with the description; (ii) the goods supplied are of merchantable quality; and (iii) the goods shall be fit for the purpose for
which they are purchased. Otherwise, a buyer has the right to reject the defective goods unless he or she has a reasonable opportunity
to examine the goods. A breach of the implied term may give rise to a civil action for breach of contract by the customers. However,
no criminal liability arises from such breach of implied term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Sale of Goods Ordinance is not a PRC
legislation but is a Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative
Council of Hong Kong has the power and function to amend the Sale of Goods Ordinance in accordance with the provisions of the
Hong Kong Basic Law and legal procedures. As the Sale of Goods Ordinance only provides for civil courses of action, there is no
regulator or implementer for this ordinance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employment Ordinance (Chapter 57 of the Laws of Hong Kong)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Employment Ordinance (Chapter 57of
the Laws of Hong Kong), or the EO, is an ordinance enacted for, amongst other things, the protection of the wages of employees
and the regulation of the general conditions of employment and employment agencies. Employment Ordinance is not a PRC legislation
but is Hong Kong ordinance. As with all other Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council
of Hong Kong has the power and function to amend the Employment Ordinance in accordance with the provisions of the Hong Kong Basic
Law and legal procedures. The Hong Kong Government, including but not limited to the Department of Justice, the Hong Kong Police
Force, the Labor Department, the Department of Health, the Labor Tribunal and etc., has the implementation rights of the Employment
Ordinance. The Labor Department is the main regulator of the Employment Ordinance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the EO, an employee is generally entitled
to, amongst other things, notice of termination of his or her employment contract; payment in lieu of notice; maternity protection
in the case of a pregnant employee; not less than one rest day in every period of seven days; severance payments or long service
payments; sickness allowance; statutory holidays or alternative holidays; and paid annual leave of up to 14 days depending on the
period of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employees&rsquo; Compensation Ordinance (Chapter 282 of
the Laws of Hong Kong)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Employees&rsquo; Compensation Ordinance
(Chapter 282 of the Laws of Hong Kong), or the ECO, is an ordinance enacted for the purpose of providing for the payment of compensation
to employees injured in the course of employment. The ECO is not a PRC legislation but is a Hong Kong ordinance. As with all other
Hong Kong legislations, according to the laws of Hong Kong, the Legislative Council of Hong Kong has the power and function to
amend the ECO in accordance with the provisions of the Hong Kong Basic Law and legal procedures. The Hong Kong Government, including
but not limited to the Department of Justice, the Hong Kong Police Force, the Labor Department, the Department of Health and etc.,
has the implementation rights of the ECO. The Labor Department is the main regulator of the ECO. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As stipulated by the ECO, no employer shall
employ any employee in any employment unless there is in force in relation to such employee a policy of insurance issued by an
insurer for an amount not less than the applicable amount specified in the Fourth Schedule of the ECO in respect of the liability
of the employer. According to the Fourth Schedule of the ECO, the insured amount shall be not less than HKD100,000,000 per event
if a company has no more than 200 employees. Any employer who contravenes this requirement commits a criminal offence and is liable
on conviction to a fine and imprisonment. An employer who has taken out an insurance policy under the ECO is required to display
a prescribed notice of insurance in a conspicuous place on each of its premises where any employee is employed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_014"></A><B>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below is information concerning
our directors, executive officers and other key employees. The following individuals are members of the Board and executive management
of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 8%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT> </TD>
    <TD STYLE="width: 2%"> &nbsp; </TD>
    <TD STYLE="width: 53%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai Au</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder, Chief Executive Officer, and Director</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Yi-Chung Chao</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Medical Officer and Director</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Wai Hong Chung</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Strategy Officer </FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tien Hsiang Chau</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evana Yee Wah Hui</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director Appointee*</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul J. Niewiadomski</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director Appointee*</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cheung Ming Wong</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director Appointee*</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                         accepted an independent director appointment, which will be effective immediately upon
                                         effectiveness of this registration statement.</FONT> </TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is a brief biography of each
of our executive officers and directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Yat-Gai Au</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Yat-Gai Au is our CEO and has been
our director since 2014. He began his career in Investment Banking at Deutsche Bank and ING Barings and was one of the core team
members that won Merger and Acquisitions deal of the year awards in Asia from 1998 to 1999 comprising over US$4 billion worth
of deals. He is a founding partner of one of California&rsquo;s largest multifamily groups. The property group partners with the
leading pension and private equity funds with assets over US$250 billion. He is an active investor in biotech and tech startup
companies. He funds and participates several charity events for thousands of under privileged families and elderlies in Hong Kong
and the U.S. During the COVID-19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. Mr. Yat-Gai
Au is the son of the TCM Practitioner, Mr. Sik-Kee Au. Mr. Au graduated from University of California, Berkeley with a Bachelor
of Science degree from the Haas School of Business. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Dr. Yi-Chung Chao, Ph.D.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Dr. Yi-Chung Chao is our Chief Medical
Officer (&ldquo;CMO&rdquo;) and has served as our director since October 2020. He has joined us as CMO of Regencell Bioscience
Ltd. since November, 2019. He is a California board certified Chinese medicine doctor and acupuncturist, as well as a successful
entrepreneur and a management leader in Silicon Valley. As the CMO of Regencell Bioscience Ltd., he is responsible for including,
but not limited to, managing research projects and preparing research reports; developing a methodology for data collection; collecting,
recording data and presenting the findings. Dr. Chao&rsquo;s journey in TCM started when his then 7-year-old son was diagnosed
with ASD and subsequently received the TCM Practitioner&rsquo;s treatment. Intrigued by the successful treatment using Chinese
medicine, Dr. Chao started learning and eventually obtained a Master of Science in Traditional Chinese Medicine in Silicon Valley.
After passing California board certified Chinese medicine and acupuncture exam in 2017, Dr. Chao has formally immersed himself
in the research and development of the medical cases of our TCM Practitioner and continues to learn under his guidance at his
clinical practice in Hong Kong. Prior to joining Regencell Bioscience Ltd., Dr. Chao was a co-founder and Chief Technology Officer
of Telenav, Inc. in Silicon Valley. Dr. Chao obtained his Bachelor&rsquo;s degree in Mechanical Engineering at the National Taiwan
University, a Master&rsquo;s degree in Aerospace Engineering from University of Texas at Austin, and a Ph.D. in Aeronautics and
Astronautics at Stanford University. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>James Wai Hong Chung </I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Chung is our Chief Strategy
Officer (&ldquo;CSO&rdquo;). He has joined Regencell Bioscience Ltd. as senior vice president since July 2015. He brings 15
years of experience in various leading roles. Prior to Regencell, Mr. Chung managed the Asia equities and derivatives
electronic trading platform at Investment Technology Group, where he gained extensive banking and finance experience. Prior
to that, he worked at Sungard Financial Systems, providing front to back trading and risk management software solutions for
banks. He also gained experiences in different roles from sales and accounting management, project management, technology and
business analyst when he worked at a startup hedge fund IT consulting business. Mr. Chung started his career as a
telecommunication engineer at Hutchison Global Crossing and eventually led a small team of engineers. Mr. Chung is a graduate
of Quantitative Finance from the Management Science and Engineering Department at Stanford University and Telecommunications
Technology from British Columbia Institute of Technology. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Tien Hsiang Chau</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Chau is our Chief Financial Officer
(the &ldquo;CFO&rdquo;). He joined Regencell Bioscience Ltd. in January 2021. Mr. Chau brings over 15 years of finance experience.
Mr. Chau&rsquo;s CFO experience include four mainboard listed companies on the Hong Kong Stock Exchange and one mainboard listed
company on the Tokyo Stock Exchange. He also brings extensive treasury and risk management experience. Mr. Chau was Philips&rsquo;
Asia Head of Cash Management and Risk and IBM&rsquo;s China Treasurer. Prior to joining IBM, Mr. Chau worked at Merrill Lynch
and Booz Allen &amp; Hamilton where he gained investment banking, capital markets and management consulting experience. Mr. Chau
obtained his Bachelor&rsquo;s degree in finance from the University of Texas at Austin with the highest honor and obtained his
MBA from Massachusetts Institute of Technology. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Evana Yee Wah Hui </I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Ms. Evana Yee Wah Hui will serve as
our independent director upon effectiveness of this registration statement. She has over 20 years of retail and brand management
experience. Throughout her 18-year career at the Dairy Farm Company Limited, a leading pan-Asian retailer, she managed various
segments of the business both at the regional and local level. She headed the regional category development team of the Health
&amp; Baby categories across the Greater China and Asian regions covering nine markets, implementing store layout/display, category
development and management strategies. Furthermore, she was responsible for the sales and profitability of a diverse range of
categories with experience in product creation and development, brand building, and customer loyalty. She also spearheaded the
launch of both the GNC and Boots brands in Hong Kong. Prior to that, she spent three years developing and implementing market
research at Nielsen, where her major clients included Unilever, Coca-Cola, HSBC, MSD, and L&rsquo;Oreal. Ms. Hui participated
in charitable endeavors, such as promoting mental health awareness in the community and holding workshops to promote self-awareness
and reduce stigma in local high schools, co-organized by the HK Hospital Authority. She holds an MBA from University of Southern
California and graduated with a Bachelor of Arts, Mathematics (Honors) from Mills College. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Paul J. Niewiadomski</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Paul J. Niewiadomski will serve
as our independent director upon effectiveness of this registration statement. He is a partner in Lubin Olson &amp; Niewiadomski
LLP&rsquo;s Business, Finance and Workouts Practice Groups. He represents clients in a broad range of business transactions. His
practice encompasses acquisitions, dispositions, joint ventures, and financing. He has advised both publicly traded and private
companies on business matters. Mr. Niewiadomski served on the boards of several non-profit, for profit and civic organizations
and is a member of the Urban Land Institute (San Francisco) and NAIOP (Silicon Valley Chapter). He has spoken at a wide range
of seminars and conferences on business issues for Marcus &amp; Millichap, California County Counsels&rsquo; Association, California
Mortgage Association, and other organizations. Mr. Niewiadomski is recognized by Thomson Reuters as a Northern California &ldquo;Super
Lawyer&rdquo; and was selected by his peers for the inclusion of the 2018, 2019 and 2020 Editions of The Best Lawyers in America.
He is a Juris Doctor graduate from University of Michigan, Master of Laws from New York University and a Bachelor of Art from
Western Michigan University (Magna Cum Laude). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <B><I>Cheung Ming Wong </I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Mr. Cheung Ming Wong will serve as our
independent director upon effectiveness of this registration statement. He has over 20 years of experience in banking and finance.
He has served as General Manager and Head of Treasury and Global Markets for China CITIC Bank International and Managing Director
and Head of Trading for Asia Pacific for Banco Santander S.A., with responsibility for funding and liquidity management as well
as spearheading the development of the markets and trading businesses. He has also served in senior trading and structuring roles
at global institutions including HSBC, Deutsche Bank and Standard Bank PLC. He started his career as an audit professional at
Price Waterhouse and Deloitte Touche Tohmatsu. Mr. Wong is a charter holder of the Chartered Financial Analyst (CFA) and a member
of CPA Australia. He graduated from the University of Melbourne with a Bachelor of Commerce degree. He now runs a fund focused
on derivatives and quantitative strategies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None of our directors or executive officers
have a family relationship as defined in Item 401 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the best of our knowledge, none of our
directors or executive officers has, during the past ten years, been involved in any legal proceedings described in subparagraph
(f) of Item 401 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Duties of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under Cayman Islands law, all of our
directors owe three types of duties to us: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Companies
Act (2020 Revision) of the Cayman Islands imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s
fiduciary duties are not codified, however, the courts of the Cayman Islands have held that a director owes the following fiduciary
duties: (a) a duty to act in what the director bona fide considers to be in the best interests of the company, (b) a duty to exercise
their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a
duty to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and
diligence that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation
to the company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular
skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of
care to us, our directors must ensure compliance with our Articles expected to be amended and effective on or before the completion
of this offering. We have the right to seek damages if a duty owed by any of our directors is breached. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Amended and Restated Memorandum and Articles of Association
(hereinafter referred as &ldquo;Amended Articles&rdquo;)
provide that a director must disclose the nature and extent of any material interests in any contract or arrangement, provided
that the required notice has been given and subject to any separate requirement for Audit Committee approval under applicable
law or the listing rules of Nasdaq, and unless disqualified by the chairman of the relevant Board meeting, a director may vote
in respect of any contract or arrangement in which such director is interested and may be counted in the quorum at such meeting.
However, even if a director discloses his interest and is therefore permitted to vote, he must still comply with his duty to act
bona fide in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director of a Cayman Islands company
also owes to the Company a duty to exercise the powers for the purpose for which they were given and the duty to act with skill
and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree
of skill than may reasonably be expected from a person of his or her knowledge and experience. However, courts are moving towards
an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman
Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Interested Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director may vote, attend a board meeting
or sign a document on our behalf with respect to any contract or transaction in which he or she is interested. A director must
promptly disclose the interest to all other directors after becoming aware of the fact that he or she is interested in a transaction
we have entered into or are to enter into. A general notice or disclosure to the board or otherwise contained in the minutes of
a meeting or a written resolution of the board or any committee of the board that a director is a shareholder, director, officer
or trustee of any specified firm or company and is to be regarded as interested in any transaction with such firm or company will
be sufficient disclosure, and, after such general notice, it will not be necessary to give special notice relating to any particular
transaction. Any such transaction that would reasonably be likely to affect a Director&rsquo;s status as an &ldquo;Independent
Director&rdquo;, or that would constitute a &ldquo;related party transaction&rdquo; as defined by Item 7.N of Form 20F promulgated
by the SEC, shall require the approval of the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remuneration and Borrowing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may receive such remuneration
as our board of directors may determine from time to time and in accordance with the recommendations of the compensation committee
of the Board and the Company&rsquo;s corporate governance documents. Each director is entitled to be repaid or prepaid all traveling,
hotel and incidental expenses reasonably incurred or expected to be incurred in attending meetings of our board of directors or
committees of our board of directors or shareholder meetings or otherwise in connection with the discharge of his or her duties
as a director. The compensation committee will assist the directors in reviewing and approving the compensation structure for
the directors. Our board of directors may exercise all the powers of the company to borrow money and to mortgage or charge our
undertakings and property or any part thereof, to issue debentures, debenture stock and other securities whenever money is borrowed
or as security for any debt, liability or obligation of the company or of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Terms of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of our directors holds office until
a successor has been duly elected and qualified unless the director was appointed by the board of directors, in which case such
director holds office until the next following annual meeting of shareholders at which time such director is eligible for re-election.
All of our executive officers are appointed by and serve at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Qualification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no membership qualifications
for directors. Further, there are no share ownership qualifications for directors unless so fixed by us in a general meeting by
ordinary resolution of our shareholders. There are no other arrangements or understandings pursuant to which our directors are
selected or nominated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Committees of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to establish an audit committee,
a compensation committee and a nominating and governance committee prior to consummation of this offering. Each of the committees
of the Board shall have the composition and responsibilities described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Audit Committee </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Evana Yee Wah Hui, Paul J. Niewiadomski
and Cheung Ming Wong will be members of our Audit Committee, with Cheung Ming Wong serving as the chairperson. All proposed members
of our Audit Committee satisfy the independence standards promulgated by the SEC and by Nasdaq as such standards apply specifically
to members of audit committees. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have adopted Audit Committee Charter
on December 3, 2020, and the Audit Committee Charter will become effective upon effectiveness of this registration statement.
In accordance with our Audit Committee Charter, our Audit Committee shall perform several functions, including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluates the independence and performance of, and assesses the qualifications of, our independent auditor, and engages such independent auditor;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approves the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services, and approves in advance any non-audit service to be provided by the independent auditor;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitors the independence of the independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviews the financial statements to be included in our Annual Report on Form 20-F and Quarterly Reports on Form 6-K and reviews with management and the independent auditors the results of the annual audit and reviews of our quarterly financial statements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversees all aspects our systems of internal accounting control and corporate governance functions on behalf of the board;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviews and approves in advance any proposed related-party transactions and report to the full Board on any approved transactions; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provides oversight assistance in connection with legal, ethical and risk management compliance programs established by management and the Board, including Sarbanes-Oxley Act implementation, and makes recommendations to the Board regarding corporate governance issues and policy decisions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> It is determined that Cheung Ming Wong,
possesses accounting or related financial management experience that qualifies him as an &ldquo;audit committee financial expert&rdquo;
as defined by the rules and regulations of the SEC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Evana Yee Wah Hui, Paul J. Niewiadomski
and Cheung Ming Wong will be members of our Compensation Committee with Evana Yee Wah Hui serving as the chairperson. All members
of our Compensation Committee will be qualified as independent under the current definition promulgated by Nasdaq. We have adopted
Compensation Committee Charter on December 3, 2020, and the Compensation Committee Charter will become effective upon effectiveness
of this registration statement. In accordance with the Compensation Committee&rsquo;s Charter, the Compensation Committee shall
be responsible for overseeing and making recommendations to the Board regarding the salaries and other compensation of our executive
officers and general employees and providing assistance and recommendations with respect to our compensation policies and practices. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Nominating and Governance Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Evana Yee Wah Hui, Paul J. Niewiadomski
and Cheung Ming Wong will be the members of our Nominating and Governance Committee with Paul J. Niewiadomski serving as the chairperson.
All members of our Nominating and Governance Committee will be qualified as independent under the current definition promulgated
by Nasdaq. We have adopted Compensation Committee Charter on December 3, 2020, and the Compensation Committee Charter will become
effective upon effectiveness of this registration statement. In accordance with the Nominating and Governance Committee&rsquo;s
Charter, the Nominating and Corporate Governance Committee shall be responsible to identity and propose new potential director
nominees to the Board of Directors for consideration and review our corporate governance policies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our board of directors has adopted a
code of business conduct and ethics, which is applicable to all of our directors, officers and employees. We will make our code
of business conduct and ethics publicly available on our website prior to the closing of this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><A NAME="RB_DRS_015"></A><B>EXECUTIVE
COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth certain
information with respect to compensation for the year ended June 30, 2020 and 2019 earned by or paid to principal executive officer,
our principal financial officer, and our other most highly compensated executive officers (the &ldquo;named executive officers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name and Principal Position </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Year </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Salary ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Bonus ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Stock Awards ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Option Awards ($) </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Non-Equity Incentive Plan
    Compensation </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Deferred Compensation Earnings </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Other </TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"> Total ($) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Yat-Gai Au </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"> CEO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 21%"> Dr. Yi-Chung Chao </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: center"> 2020 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> 27,360 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> 6,410 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 6%; text-align: right"> 33,770 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in"> CMO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> James Wai Hong Chung </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 118,685 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 20,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 138,685 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in"> CSO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> 2019 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 105,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 17,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 122,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0in"> Tien Hsiang Chau 2020 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left"> CFO </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> - </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agreements with Named Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We entered into amended and restated
employment agreement with our CEO, Yat-Gai Au, on February 2, 2021, with retroactive effect to November 12, 2020. Our amended
and restated employment agreement will become effective on the closing date of the initial public offering of our Ordinary Shares
in the U.S. Pursuant to such agreement, he shall receive an annual base salary of US$1, and such compensation is subject to annual
review and adjustment by the board. The CEO cannot draw his compensation more than $1 until the Company reaches US$1 billion market
capitalization. Under this employment agreement, Mr. Au is employed as our CEO for a term of three years, which automatically
renews for additional three-year terms unless previously terminated on one month written notice by either party. We may terminate
the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction
or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed
duties. In such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts
by reason of the termination, and the executive officer&rsquo;s right to all other benefits will terminate, except as required
by any applicable law. We may also terminate an executive officer&rsquo;s employment without cause upon one-month advance written
notice. In such case of termination by us, we are required to provide compensation to the executive officer, including (1) a lump
sum cash payment equal to one month of the CEO&rsquo;s base salary as of the date of such termination; (2) a lump sum cash payment
equal to a pro-rated amount of his target annual bonus for the year immediately preceding the termination, if any; (3) payment
of premiums for continued health benefits under the Company&rsquo;s health plans for 12 months fo1lowing the termination, if any;
and (4) immediate vesting of 100% of the then-unvested portion of any outstanding equity awards held by Mr. Au. In the event that
we or our successor terminates the employment upon a merger, consolidation, or transfer or sale of all or substantially all of
our assets with or to any other individual(s) or entity (the &ldquo;Change of Control Transaction&rdquo;), Mr. Au shall be entitled
to the following severance payments and benefits upon such termination: (1) a lump sum cash payment equal to 1 month of his base
salary at a rate equal to the greater of his annual salary in effect immediate1y prior to the termination, or his then current
annua1 salary as of the date of such termination; (2) a lump sum cash payment equal to a pro-rated amount of his target annual
bonus for the year immediately preceding the termination; (3) payment of premiums for continued health benefits under the Company&rsquo;s
health plans for 12 months fo1lowing the termination; and (4) immediate vesting of 100% of the then-unvested portion of any outstanding
equity awards held by Mr. Au. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </P>

<!-- Field: Page; Sequence: 85; Options: NewSection; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On July 15, 2019, we entered into an
employment agreement with our CMO, Dr. Yi-Chung Chao, which became effective on November 1, 2019. Pursuant to such agreement,
he shall receive a monthly base salary of US$6,410, which shall be payable in arrears on the last day of each month during the
employment. Dr. Chao is also eligible for bonus, benefits and reasonable expenses reimbursement. Under the employment agreement,
Dr. Chao works as our CMO and the term is annual basis, which automatically renews for additional one-year terms unless previously
terminated for cause by the Company, at any time, without notice or remuneration, for certain acts of the executive officer, such
as conviction or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure
to perform agreed duties. Effective from September 1, 2020, Dr. Chao&rsquo;s base salary was adjusted to US$11,538. Dr. Chao&rsquo;s
main responsibilities include but not limited to managing research projects and preparing research reports, developing a methodology
for data collection, as well as recording data and presenting the findings. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On July 6, 2015, we entered into an
employment agreement with James Wai Hong Chung, which became effective on July 6, 2015. Pursuant to such agreement, he shall receive
a monthly base salary of US$9,615, which shall be payable in arrears on the last day of each month during the employment. Mr.
Chung is also eligible for bonus, benefits and reasonable expenses reimbursement. Under the employment agreement, Mr. Chung works
as our senior vice president and the term is annual basis, which automatically renews for additional one-year terms unless previously
terminated for cause by the Company, at any time, without notice or remuneration, for certain acts of the executive officer, such
as conviction or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure
to perform agreed duties. Mr. Chung&rsquo;s responsibilities include but not limited to exploring and soliciting potential and
lawful sources of funds for investment to the Company, introducing prospective third party investors to the Company, and implementing
decisions of the board. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> On January 18, 2021, we entered into
an employment agreement with Tien Hsiang Chau, who joined Regencell Bioscience Limited as CFO. The employment agreement became
effective on January 18, 2021. Pursuant to the employment agreement, he shall receive a monthly base salary of US$10,897, which
shall be payable in arrears on the last day of each month during the employment. The employment agreement has a six-month probation
period, during which either party can terminate the agreement with written notice or payment in lieu of notice. After six-month
probation, either party may terminate the employment agreement by giving a three months prior written notice or payment in lieu
of notice. The employment term will continue on an annual basis until terminated in accordance with the agreement. Mr. Chau&rsquo;s
main responsibilities include but not limited to identifying and establishing contact with potential investors, formulating financial
policies and strategies for the Company, ensuring effective internal controls, compliance of all accounting and financial regulations
in U.S. and Hong Kong. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> For the fiscal year ended June 30, 2020,
we did not compensate our executive directors for their services other than to reimburse them for out-of-pocket expenses incurred
in connection with their attendance at meetings of the board of directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 86; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_016"></A><B>PRINCIPAL SHAREHOLDERS</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information
with respect to beneficial ownership of our Ordinary Shares as of the date of the Prospectus by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each person who is known by us to beneficially
    own more than 5% of our standing Ordinary Shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                         of our director, director nominees and named executive officers; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All directors and named executive officers as
    a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of this prospectus, our
Company is authorized to issue 100,000,000 Ordinary Shares with a par value $0.01 each [Upon filing of the Amended Articles,
our authorized share capital is expected to be US$[&#9679;] divided into [&#9679;] Ordinary Shares with a par value of
US$[&#9679;] each and [&#9679;] Preferred Shares with a par value of US$[&#9679;] each.] The number and percentage of
Ordinary Shares beneficially owned before the offering are based on [&#9679;] Ordinary Shares issued and outstanding as of
the date of this prospectus. Information with respect to beneficial ownership has been furnished by each director, officer or
beneficial owner of more than 5% of our Ordinary Shares. Beneficial ownership is determined in accordance with the rules of
the SEC and generally requires that such person have voting or investment power with respect to securities. In computing the
number of Ordinary Shares beneficially owned by a person listed below and the percentage ownership of such person, Ordinary
Shares underlying options, warrants or convertible securities held by each such person that are exercisable or convertible
within 60 days are deemed outstanding, but are not deemed outstanding for computing the percentage ownership of any other
person. Except as otherwise indicated in the footnotes to this table, or as required by applicable community property laws,
all persons listed have sole voting and investment power for all Ordinary Shares shown as beneficially owned by them. Unless
otherwise indicated in the footnotes, the address for each beneficial owner is in the care of our Company at 11/F First
Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares<BR>
    Beneficially Owned<BR>
    Prior to this<BR>
    Offering</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares<BR>
    Beneficially Owned<BR>
    Immediately After<BR>
    This Offering</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage<BR>
    of Votes<BR>
    Held<BR>
    After this<BR>
    Offering</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percent</B></FONT> </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors and Executive Officers:</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai
    Au <SUP>(1)</SUP></FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP>%</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&mdash;</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 6%"> &nbsp; </TD>
    <TD STYLE="width: 1%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi-Chung
    Chao</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Wai Hong Chung</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tien
    Hsiang Chau</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evana
    Yee Wah Hui <SUP>(2)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    J. Niewiadomski<SUP>(2)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cheung
    Ming Wong <SUP>(2)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5%
    Shareholders:</B></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai
    Au <SUP>(1)</SUP></FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT> </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                         Ordinary Shares are held by Regencell (BVI) Ltd., a British Virgin Islands company. Since
                                         Mr. Yat-Gai Au is the 100% owner of Regencell (BVI) Ltd., he is deemed as the beneficial
                                         owners of these securities.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD><TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Has
                                         accepted an independent director appointment, which will be effective immediately upon
                                         effectiveness of this registration statement.</FONT> </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of the Prospectus, we have
[&#9679;] shareholders of record. [&#9679;] of our issued and outstanding Ordinary Shares are held by record holders in the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>History of Share Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were incorporated in the Cayman Islands
as an exempted company with limited liability on October 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the date of this prospectus, our
authorized share capital consists of US$1,000,000 divided into 100,000,000 shares, par value US$0.01 per share. Holders of Ordinary
Shares are entitled to one vote per share. [Upon adoption of the Amended Articles, the authorized capital will consist of [*]
ordinary shares, and [*] preference shares.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 30, 2014, the Company issued
one Ordinary Share to Avalon Ltd. and 9,999 Ordinary Shares to Mr. Yat-Gai Au. On the same day, Avalon Ltd. transferred its share
to Mr. Yat-Gai Au, who then owned 10,000 Ordinary Shares of the Company. On September 28, 2020, Mr. Yat-Gai Au transferred his
10,000 Ordinary Shares to Regencell (BVI) Ltd., which is wholly owned by Mr. Yat-Gai Au.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_017"></A><B>RELATED PARTY
TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Rental Agreement with Ace United International Limited
</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> During the years ended June 30, 2020
and 2019, the Company has an office rental agreement with Ace United International Limited, which is a company wholly owned by
our founder and CEO. The Company has paid a monthly rent of $4,103 and the terms of the agreement are renewed on an annual basis
from the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December each year. The rental payment is expensed as incurred. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Loan Agreement between Regencell Bioscience Ltd. and Mr.
Yat-Gai Au</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of June 30, 2020, and 2019, the Company
has outstanding Shareholder loans amounting to approximately $3.07 million and $2.08 million, respectively, from Mr. Yat-Gai Au,
the Founder and CEO. On November 10, 2020, Regencell Bioscience Ltd. entered into a loan agreement with Mr. Yat-Gai Au to evidence
the existing loan and document their oral agreements of the terms and conditions of such existing loan when such loan was initially
generated (the &ldquo;Loan Agreement&rdquo;). The Loan Agreement also sets forth that the Mr. Yat-Gai Au will continue to make
loan to the us for daily operation and research activities. The use of loan shall be agreed and determined by both parties before
granting the loan. All loans shall bear 0% interest per annual. The maturity date of such loans is June 30, 2021, subject to indefinite
extension if agreed by the parties in writing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See &ldquo;Executive Compensation &ndash;
Employment Agreement with Named Executive Officers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <B>Partnership Agreements with TCM Practitioner</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In January 2018, we entered into Strategic
Partnership Agreement with the TCM Practitioner, the father of our CEO and director. Pursuant to the Strategic Partnership Agreement
we have with TCM Practitioner, we have exclusive rights and ownership of all his TCM formulae which can provide effective solutions
for patients suffering from ADHD and ASD, and all other TCM formulae targeting different kinds of human illnesses and diseases
as well as the intellectual property rights of the TCM formulae, including research and development, trademark, copyright, patent,
and any other intellectual property rights in relation to the TCM formulae that he owns. The TCM Practitioner is authorized to
conduct research studies on these TCM formulae. Any inventions, TCM formulae, utilities, models&rsquo; improvements, research,
discoveries, designs, processes, methods of manufacture, and products conceived or made by the TCM Practitioner in relation to
TCM shall be the sole and exclusive property of us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Strategic Partnership Agreement
does not have a termination date and will remain effective indefinitely under Hong Kong law. The Strategic Partnership Agreement
can be amended or terminated by the mutual written agreement of the parties without breach. Pursuant to the Strategic Partnership
Agreement, in exchange for the rights, the Company is required to donate three percent (3.0%) of net revenue as shown in the audited
financial accounts that the Company generates in association with the use and/or commercialization of the TCM formulae to any
of charitable institutions and/or trusts of a public character anywhere in the world at the sole and absolute choice of the TCM
Practitioner and in such proportion at the sole and absolute discretion of the TCM practitioner on a yearly basis. We also undertake
to pay for all reasonable costs and expenses incurred by the TCM Practitioner in conducting research, testing, attending meetings/seminars,
compiling records, or performing any similar acts in relation to the development of the TCM formulae. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Supplemental Agreement with TCM Practitioner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> In November 2020, we entered into
Supplemental Agreement with the TCM Practitioner. Under the Supplemental Agreement, the TCM Practitioner shall provide his
research by using his best endeavors on his TCM formulae and TCM inventions under our direction and supervision. We have
authorized the TCM Practitioner, his agents, subcontractors, development team, and affiliates to use TCM formulae and TCM
inventions to conduct research. However, the authorized parties, including TCM Practitioner, shall not directly or indirectly
publish, disseminate or otherwise disclose, deliver or make available to any third party any confidential information,
without prior written consent and notice given by the Company. The confidential information includes all information,
know-how, and records in any way connected with the Company and its research, including all TCM inventions, TCM formulae, and
intellectual property rights, data, operations and testing procedures, and all patients and supplier information, etc. The
confidentiality obligations shall survive notwithstanding the termination of the Supplemental Agreement for ten (10) years
thereafter. The TCM Practitioner also shall not to be directly or indirectly concerned with or engaged or interested in any
other business which is in any respect in competition with or similar to the TCM business conducted by the Company for two
(2) years after the expiration or termination of the Supplemental Agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Supplemental Agreement shall remain
effective until the Strategic Partnership Agreement is expired or terminated. We may terminate this Supplemental Agreement for
any reason in our sole discretion and without any indemnity or damages being due to TCM Practitioner with thirty (30) days prior
written notice. The TCM Practitioner may terminate this Supplemental Agreement in the event that the Company fails to meet its
payment obligations under Supplemental Agreement which is not cured within thirty (30) days of the notification of such by the
Company. We shall pay the TCM Practitioner for his expenses on his TCM research within 30 days upon the receipt of invoice. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>


<!-- Field: Page; Sequence: 88; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_018"></A><B>DESCRIPTION OF
SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The following description of our share
capital and provisions of our Articles are summaries and do not purport to be complete. Reference is made to our Amended Articles,
which will become effective upon effectiveness of this registration statement, a copy of which is filed as an exhibit to this
registration statement of which this prospectus is a part (and which is referred to in this section as, respectively, the &ldquo;memorandum&rdquo;
and the &ldquo;articles&rdquo;). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We were incorporated as an exempted
company with limited liability under the Companies Act (2013 Revision) of the Cayman Islands, or the Cayman Companies Act (2020
Revision). A Cayman Islands exempted company:&nbsp; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is a company that conducts its business mainly
    outside the Cayman Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is prohibited from trading in the Cayman Islands
    with any person, firm or corporation except in furtherance of the business of the exempted company carried on outside the
    Cayman Islands (and for this purpose can affect and conclude contracts in the Cayman Islands and exercise in the Cayman Islands
    all of its powers necessary for the carrying on of its business outside the Cayman Islands);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to hold an annual general meeting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to make its register of members
    open to inspection by shareholders of that company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may obtain an undertaking against the imposition
    of any future taxation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register by way of continuation in another
    jurisdiction and be deregistered in the Cayman Islands;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a limited duration company;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a segregated portfolio company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of our issued and outstanding Ordinary
Shares are fully paid and non-assessable. Our Ordinary Shares are issued in registered form, and are issued when registered in
our register of members. Unless and until the directors resolve to issue share certificates, no share certificate shall be issued,
and the records of the shareholdings of each shareholder shall be in uncertified book entry form. Our shareholders who are non-residents
of the Cayman Islands may freely hold and vote their Ordinary Shares. We may not issue shares or warrants to bearer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of the date of this prospectus, the
authorized share capital of the Company is US $1,000,000 divided into 100,000,000 Ordinary Shares of US $0.01 par value each.
[Upon filing of the Amended Articles with the Cayman company registry, our authorized share capital is expected to be US$[&#9679;]
million divided into [&#9679;] Ordinary Shares with a par value of US$[&#9679;] each and [&#9679;] Preferred Shares with a par
value of US$[&#9679;] each.] Subject to the provisions of the Cayman Companies Act and the provisions, if any, of the Amended
Articles, and any directions given by any ordinary resolution and the rights attaching to any class of existing shares, the directors
may issue, allot, grant options over or otherwise dispose of shares (including any fractions of Shares) and other securities of
our company at such times, to such persons, for such consideration and on such terms as the directors may determine. Such authority
could be exercised by the directors to allot shares which carry rights and privileges that are preferential to the rights attaching
to Ordinary Shares. No share may be issued at a discount except in accordance with the provisions of the Cayman Companies Act.
The directors may refuse to accept any application for shares, and may accept any application in whole or in part, for any reason
or for no reason. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We have applied to list our Ordinary
Shares on the Nasdaq Capital Market under the symbol &ldquo;RGCB.&rdquo; There can be no assurance that we will be successful
in listing our Ordinary Shares on the Nasdaq Capital Market; however, we will not complete this offering unless we receive approval
for listing on Nasdaq Capital Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The transfer agent and registrar for
the Ordinary Shares is Vstock Transfer, LLC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the provisions of the Cayman
Companies Act and any rights for the being attaching to any class or classes of shares, the directors may declare dividends or
distributions out of our funds which are lawfully available for that purpose. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the provisions of the Cayman
Companies Act and any rights for the being attaching to any class or classes of shares, the Company may, by ordinary resolution,
declare dividends but no such dividend shall exceed the amount recommended by the directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the requirements of the Cayman
Companies Act regarding the application of a company&rsquo;s share premium account and with the sanction of an ordinary resolution,
dividends may also be declared and paid out of any share premium account. The directors when paying dividends to shareholders
may make such payment either in cash or in specie. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless provided by the rights attached
to a share, no dividend shall bear interest against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to any rights or restrictions as
to voting attached to any shares, unless any share carries special voting rights. On a poll, every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote for each share of which he or the person represented
by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled to vote at a meeting of
the holders of that class of shares. Votes may be given either personally or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Variation of Rights of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the Law and without prejudice
to article 8, all or any of the special rights for the time being attached to the shares or any class of shares may, unless otherwise
provided by the terms of issue of the shares of that class, be varied or modified with the sanction of a special resolution passed
at a separate general meeting of the holders of the shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless the terms on which a class of shares
was issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied
by the creation or issue of further shares ranking pari passu therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Alteration of share capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the Cayman Companies Act,
the Company may, by ordinary resolution: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) increase our share capital by such
sum to be divided into shares of such amount and with the attached rights, priorities and privileges and restrictions attached
to them as that ordinary resolution shall prescribe;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) consolidate and divide all or any of
our share capital into shares of larger amount than our existing shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> I divide its shares into several classes
and without prejudice to any special rights previously conferred on the holders of existing shares with any preferential, deferred,
qualified or special rights, privileges, conditions or such restrictions; </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) sub-divide our shares or any of them
into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between the amount paid
and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share
is derived;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) cancel shares which, at the date of
the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount of our
share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish the number
of shares into which our capital is divided; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) convert all or any of our paid-up shares
into stock, and reconvert that stock into paid up shares of any denomination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the Cayman Companies Act
and to any rights for the time being conferred on the shareholders holding a particular class of shares, the Company may, by special
resolution, reduce its share capital in any lawful way. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Calls on shares and forfeiture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the terms of allotment, the
directors may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and each shareholder
shall (subject to receiving at least fourteen clear days&rsquo; notice specifying when and where payment is to be made), pay to
us the amount called on his shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable
to pay all calls in respect of the share. The directors may, at their discretion, waive payment of the interest wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the requirements of the notice referenced
in the articles are not complied with, our company may forfeit the shares together with any distributions declared payable in
respect of the forfeited shares and not paid at any time before tender of payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A forfeited share may be sold or otherwise
disposed of on such terms and in such manner as the directors think fit, and at any time before a sale or disposition the forfeiture
may be cancelled on such terms as the directors think fit. The proceeds of any sale or disposition of the forfeited share may
be received and used by our company as the directors determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our company is under no obligation to refund
any moneys to the shareholder whose shares have been forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A forfeited share may be sold or otherwise
disposed of on such terms and in such manner as the directors think fit, and at any time before a sale or disposition the forfeiture
may be cancelled on such terms as the directors think fit. The proceeds of any sale or disposition of the forfeited Share may
be received and used by our company as the directors determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A person whose shares have been forfeited
shall cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding, remain liable to pay to our company
all moneys which at the date of forfeiture were payable by him to the company in respect of the shares together with interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a first and paramount lien on all
shares (whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The lien
is for all moneys payable, called or payable at a fixed time in respect of that share and for all debts, liabilities or other
obligations owed to us by the shareholder or the shareholder&rsquo;s estate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) either alone or jointly with any other
person, whether or not that other person is a shareholder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) whether or not those monies are presently
payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At any time, the directors may declare
any share to be wholly or partly exempt from lien provisions of the articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell, in such manner as the directors
may determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that such sum
is payable has been given (as prescribed by the articles) and, within fourteen days of the date on which the notice is deemed
to be given under the articles, such notice has not been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share premium account</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The directors shall establish a share
premium account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium
paid on the issue of any share or capital contributed or such other amounts required by the Cayman Companies Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Redemption and purchase of own shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the Cayman Companies Act
and any rights for the time being conferred on the shareholders holding a particular class of shares, we may by our directors: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) issue shares that are to be redeemed
or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner its
members or directors determine before the issue of those shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) with the consent by special resolution
of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide that
those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors
determine at the time of such variation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) purchase all or any of our own shares
of any class including any redeemable shares on the terms and in the manner which the directors determine at the time of such
purchase; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) permit the surrender of fully paid
shares for no consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We may make a payment in respect of
the redemption or purchase of our own shares in any manner authorized by the Cayman Companies Act, including out of any combination
of capital, our profits and the proceeds of a fresh issue of shares. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When making a payment in respect of the
redemption or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the
other) if so authorized by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by
agreement with the shareholder holding those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our board of directors may, in its absolute
discretion, refuse to consent to any transfer and decline to register any transfer of any Ordinary Share without giving any reason.
Without limiting the transfer provisions in the articles, our board of directors would generally decline to register any transfer
of any Ordinary Share that has not been fully paid up or is subject to a company lien. Our board of directors may also decline
to register any transfer of any Ordinary Share unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) the instrument of transfer is lodged
with us, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence as our board of directors
may reasonably require to show the right of the transferor to make the transfer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) the instrument of transfer is in respect
of only one class of Ordinary Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) the instrument of transfer is properly
stamped, if required;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) the Ordinary Share transferred is fully
paid and free of any lien in favor of us;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) any fee related to the transfer has
been paid to us; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) the transfer is not to more than four
joint holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our directors refuse to register a transfer,
they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor
and the transferee notice of such refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This, however, is unlikely to affect market
transactions of the Ordinary Shares purchased by investors in the public offering. Once the Ordinary Shares have been listed,
the legal title to such Ordinary Shares and the registration details of those Ordinary Shares in the Company&rsquo;s register
of members will remain with [DTC/Cede &amp; Co]. All market transactions with respect to those Ordinary Shares will then be carried
out without the need for any kind of registration by the directors, as the market transactions will all be conducted through the
DTC systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing shares may
be evidenced and transferred in accordance with the rules and regulations of the Designated Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registration of transfers may, on 14
calendar days&rsquo; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and
our register of members closed at such times and for such periods as our board of directors may from time to time determine. The
registration of transfers, however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Inspection of Books and Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Holders of our Ordinary Shares will
have no general right under the Cayman Companies Act to inspect any account or book or document or obtain copies of our register
of members or our corporate records. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As a Cayman Islands exempted company,
we are not obligated by the Cayman Companies Act to call shareholders&rsquo; annual general meetings; however, our articles provide
that the Company shall hold a general meeting as an annual general meeting. Any annual general meeting held shall be held at such
time and place as may be determined by our board of directors. All general meetings other than annual general meetings shall be
called extraordinary general meetings. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may convene general meetings
whenever they think fit. Upon the written request of shareholders entitled to exercise 10% or more of the voting rights in respect
of the matter for which the meeting is requisitioned, any one or more of the directors shall forthwith proceed to convene a meeting
of shareholders. The written request of shareholders to requisition a meeting must state the objects of the meeting and must be
signed by the shareholders requisitioning the meeting. The written request must be lodged at the registered office and may be
delivered in counterpart. If our board of directors do not proceed to convene a meeting of shareholders within 21 clear days of
the written request to requisition a meeting being lodged the requisitionists, or any of them together holding at least half of
the voting rights of all of them may convene the meeting of shareholders in the same manner as nearly as possible as which a meeting
of shareholders may be convened by a director. Where the requisitionists fail to convene the meeting of shareholders within three
months of their right to convene the meeting arising, the right to convene the meeting of shareholders shall lapse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At least 21 clear days&rsquo; notice of
an annual general meeting and 14 clear days&rsquo; notice for any other general meeting shall be given to shareholders entitled
to attend and vote at such meeting where such meeting is convened by the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the Cayman Companies Act,
a general meeting may be convened on shorter notice, if approved by a majority in number of the Members having the right to attend
and vote at the meeting, being a majority together holding not less than ninety per cent (90%) in nominal value of the issued
shares giving that right. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The presence of one or more shareholders
entitled to vote, whether in person or represented by proxy or (if a corporation) by its duly appointed representative representing
not less than one-third in nominal value of the total issued voting shares in the Company throughout the meeting, shall constitute
a quorum at a general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If, within 15 minutes (or such longer time
not exceeding one hour as the chairman of the meeting may determine to wait) from the time appointed for the meeting a quorum
is not present, the meeting, shall stand adjourned to the same day in the next week at the same time and place or to such other
time and place as is determined by the directors and if at the adjourned meeting a quorum is not present within 15 minutes from
the time appointed for the meeting the meeting then the shareholders present in person or by proxy shall constitute a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The chairman may, with the consent of a
meeting at which a quorum is present, adjourn the meeting. When a meeting is adjourned for seven (7) clear days or more, at least
seven (7) clear days&rsquo; notice of the adjourned meeting shall be given specifying the time and place of the adjourned meeting
and the general nature of the business to be transacted but it shall not otherwise be necessary to give any notice of the adjournment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At any general meeting a resolution put
to the vote of the meeting shall be decided by poll by the affirmative vote of the majority of issued shares held by persons present
in person or by proxy at the meeting entitled to vote and each shareholder shall be entitled to one vote in respect of each fully
paid share held, A declaration by the chairman that a resolution has been carried, or carried unanimously, or by a particular
majority, or not carried by a particular majority, or lost, and an entry to that effect made in the minute book of the Company,
shall be conclusive evidence of the facts without proof of the number or proportion of the votes recorded for or against the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the case of an equality of votes, on
a poll, the chairman of the meeting at shall be entitled to a second or casting vote in addition to any other votes he may have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may by ordinary resolution,
from time to time, fix the maximum and minimum number of directors to be appointed. Under the articles, we are required to have
a minimum of one director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director may be appointed by ordinary
resolution or by the directors. Any appointment may be to fill a vacancy or as an additional director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The remuneration of the directors shall
be such remuneration as the directors shall determine and in accordance with the recommendations of the compensation committee
of the Board and the Company&rsquo;s corporate governance documents. The directors shall also be entitled to be paid all travelling,
hotel and other expenses properly incurred by them in connection with their attendance at meetings of directors or committees
of directors, or general meetings of the company, or separate meetings of the holders of any class of shares or debentures of
the company, or otherwise in connection with the business of the company, or to receive a fixed allowance in respect thereof as
may be determined by the directors, or a combination of such methods. The directors may by resolution approve additional remuneration
to any director for any services other than his ordinary routine work as a director. The Board shall determine any payment to
any director or past director of the Company by way of compensation for loss of office, or as consideration for in in connection
with his retirement from office (not being payment to which the director is contractually entitled).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless removed or re-appointed, each director
shall be appointed for a term expiring at the next-following annual general meeting, if one is held. At any annual general meeting
held, our directors will be elected by an ordinary resolution of our shareholders. At each annual general meeting, each director
so elected shall hold office for a one-year term and until the election of their respective successors in office or removed.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director may at any time resign or retire
from office by giving us notice in writing. Unless the notice specifies a different date, the director shall be deemed to have
resigned on the date that the notice is delivered to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the provisions of the articles,
the office of a director may be terminated forthwith if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) he is prohibited by the law of the
Cayman Islands from acting as a director;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) he is made bankrupt or has an order
made against him, suspends payment or arranges or composition with his creditors generally;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) he resigns his office by notice to
us;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) he only held office as a director for
a fixed term and such term expires;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) becomes of unsound mind or dies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) he is given notice by the majority
of the other directors (not being less than two in number) to vacate office (without prejudice to any claim for damages for breach
of any agreement relating to the provision of the services of such director); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) without the consent of the other directors,
he is absent from meetings of directors for continuous period of six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the compensation committee and
the nominating and corporate governance committee shall consist of at least three directors and the majority of the committee
members shall be independent within the meaning of Section 5605(a)(2) of the Nasdaq Listing Rules. The audit committee shall consist
of at least three directors, all of whom shall be independent within the meaning of Section 5605(a)(2) of the Nasdaq Listing Rules
and will meet the criteria for independence set forth in Rule 10A-3 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Powers and duties of directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Subject to the provisions of the Cayman
Companies Act, our memorandum and articles, our business shall be managed by the directors, who may exercise all our powers. No
prior act of the directors shall be invalidated by any subsequent alteration of our memorandum or articles. However, to the extent
allowed by the Cayman Companies Act, shareholders may by special resolution validate any prior or future act of the directors
which would otherwise be in breach of their duties. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may delegate any of their
powers to any committee consisting of one or more persons who need not be shareholders and may include non-directors so long as
the majority of those persons are directors; any committee so formed shall in the exercise of the powers so delegated conform
to any regulations that may be imposed on it by the directors. Upon the initial closing of this offering, our board of directors
will have established an audit committee, compensation committee, and nomination and corporate governance committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The board of directors may establish any
local or divisional board of directors or agency and delegate to it its powers and authorities (with power to sub-delegate) for
managing any of our affairs whether in the Cayman Islands or elsewhere and may appoint any persons to be members of a local or
divisional board of directors, or to be managers or agents, and may fix their remuneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may from time to time and
at any time by power of attorney or in any other manner they determine appoint any person, either generally or in respect of any
specific matter, to be our agent with or without authority for that person to delegate all or any of that person&rsquo;s powers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may from time to time and
at any time by power of attorney or in any other manner they determine appoint any person, whether nominated directly or indirectly
by the directors, to be our attorney or our authorized signatory and for such period and subject to such conditions as they may
think fit. The powers, authorities and discretions, however, must not exceed those vested in, or exercisable, by the directors
under the articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The board of directors may remove any person
so appointed and may revoke or vary the delegation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors may exercise all of our powers
to borrow money and to mortgage or charge its undertaking, property and assets both present and future and uncalled capital or
any part thereof, to issue debentures and other securities whether outright or as collateral security for any debt, liability
or obligation of ours or our parent undertaking (if any) or any subsidiary undertaking of us or of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 94; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A general notice may be given at a meeting
of the board of directors to the effect that (i) the director is a member/officer of a specified company or firm and is to be
regarded as interested in any contract or arrangement which may after the date of the notice in writing be made with that company
or firm; or (ii) he is to be regarded as interested in any contract or arrangement which may after the date of the notice in writing
to the board of directors be made with a specified person who is connected with him, will be deemed sufficient declaration of
interest. Following the disclosure being made pursuant to our Amended Articles and subject to any separate requirement for Audit
Committee approval under applicable law or the listing rules of Nasdaq, and unless disqualified by the chairman of the relevant
board meeting, a director may vote in respect of any contract or arrangement in which such director is interested and may be counted
in the quorum at such meeting. However, even if a director discloses his interest and is therefore permitted to vote, he must
still comply with his duty to act bona fide in the best interest of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capitalization of profits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company may, on recommendation of the
Board, resolve to capitalize:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) any part of our profits not required
for paying any preferential dividend, if applicable(whether or not those profits are available for distribution); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) any sum standing to the credit of our
share premium account or capital redemption reserve, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amount resolved to be capitalized must
be appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same
proportions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidation Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If we are wound up, the shareholders
may, subject to the articles and any other sanction required by the Cayman Companies Act, pass a special resolution voluntarily
winding up the company. Upon being appointed, a liquidator may do either or both of the following with the authority of a special
resolution: </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) divide in specie among the shareholders
the whole or any part of our assets and, for that purpose, to value any assets and to determine how the division shall be carried
out as between the shareholders or different classes of shareholders; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) vest the whole or any part of the assets
in trustees for the benefit of shareholders as the liquidator thinks fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The directors have the authority to present
a petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed
at a general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Register of Members</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Cayman Companies Act, we must
keep a register of members and there should be entered therein: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names and addresses of our shareholders,
    a statement of the shares held by each shareholder, whether or not such shares having voting rights and of the amount paid
    or agreed to be considered as paid, on the shares of each shareholder;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the name of any person was
    entered on the register as a shareholder; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which any person ceased to be a
    shareholder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Cayman Companies Act, the
register of members of our company is prima facie evidence of the matters set out therein (that is, the register of members will
raise a presumption of fact on the matters referred to above unless rebutted) and a shareholder registered in the register of
members is deemed as a matter of the Cayman Companies Act to have legal title to the shares as set against its name in the register
of members. Upon the completion of this offering, the register of members will be immediately updated to record and give effect
to the issuance of shares by us to the custodian or its nominee. Once our register of members has been updated, the shareholders
recorded in the register of members will be deemed to have legal title to the shares set against their name. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the name of any person is incorrectly
entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register
the fact of any person having ceased to be a shareholder of our company, the person or shareholder aggrieved (or any shareholder
of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified,
and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification
of the register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 95; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Differences in Corporate Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Cayman Companies Act is derived,
to a large extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments,
and accordingly there are significant differences between the Cayman Companies Act and the current Companies Act of England. In
addition, the Cayman Companies Act differs from laws applicable to United States corporations and their shareholders. Set forth
below is a summary of certain significant differences between the provisions of the Cayman Companies Act applicable to us and
the comparable laws applicable to companies incorporated in the State of Delaware in the United States. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mergers and Similar Arrangements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Cayman Companies Act permits mergers
and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For
these purposes, (a) &ldquo;merger&rdquo; means the merging of two or more constituent companies and the vesting of their undertaking,
property and liabilities in one of such companies as the surviving company, and (b) a &ldquo;consolidation&rdquo; means the combination
of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities
of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent
company must approve a written plan of merger or consolidation, which must then be authorized by (a) a special resolution of the
shareholders of each constituent company, and (b) such other authorization, if any, as may be specified in such constituent company&rsquo;s
articles of association. The plan must be filed with the Registrar of Companies together with a declaration as to the solvency
of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking
that a copy of the certificate of merger or consolidation will be given to the shareholders and creditors of each constituent
company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is
not required for a merger or consolidation which is affected in compliance with these statutory procedures. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A merger between a Cayman parent company
and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders. For this purpose, a
subsidiary is a company of which at least 90% of the issued shares entitled to vote are owned by the parent company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consent of each holder of a fixed or
floating security interest of a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except in certain limited circumstances,
a dissenting shareholder of a Cayman Islands constituent company is entitled to payment of the fair value of his or her shares
upon dissenting from a merger or consolidation. The exercise of such dissenter rights will preclude the exercise by the dissenting
shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right
to seek relief on the grounds that the merger or consolidation is void or unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, there are statutory provisions
that facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved by a majority in number
of each class of shareholders and creditors with whom the arrangement is to be made, and who must, in addition, represent three-fourths
in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or
by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement
must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court
the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) the statutory provisions as to the
required majority vote have been met;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) the shareholders have been fairly represented
at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests
adverse to those of the class;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) the arrangement is such that may be
reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (d) the arrangement is not one that
would more properly be sanctioned under some other provision of the Cayman Companies Act. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When a takeover offer is made and accepted
by holders of 90% of the shares affected within four months the offeror may, within a two-month period commencing on the expiration
of such four-month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection
can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so
approved unless there is evidence of fraud, bad faith or collusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If an arrangement and reconstruction is
thus approved, or if a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal
rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to
receive payment in cash for the judicially determined value of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholders&rsquo; Suits </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In principle, we will normally be the proper
plaintiff to sue for a wrong done to us as a company and as a general rule, a derivative action may not be brought by a minority
shareholder. However, based on English law authorities, which would in all likelihood be of persuasive authority in the Cayman
Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in&nbsp;<I>Foss
v. Harbottle</I>&nbsp;and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action
against or derivative actions in the name of the company to challenge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) an act which is illegal or ultra vires
with respect to the company and is therefore incapable of ratification by the shareholders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) an act which, although not ultra vires,
requires authorization by a qualified (or special) majority (that is, more than a simple majority) which has not been obtained;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) an act which constitutes a &ldquo;fraud
on the minority&rdquo; where the wrongdoers are themselves in control of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Indemnification of Directors and Executive Officers and
Limitation of Liability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Cayman Islands law does not limit the
extent to which a company&rsquo;s articles of association may provide for indemnification of officers and directors, except to
the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
against civil fraud or the consequences of committing a crime. Our Articles require us to indemnify our officers and directors
for actions, proceedings, claims, losses, damages, costs, liabilities and expenses (&ldquo;Indemnified Losses&rdquo;) incurred
in their capacities as such unless such Indemnified Losses arise from dishonesty of such directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No such existing or former secretary or
officer, however, shall be indemnified in respect of any matter arising out of his own dishonesty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent permitted by law, we may
make a payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any legal costs incurred by an existing
or former secretary or any of our officers in respect of any matter identified in above on condition that the secretary or officer
must repay the amount paid by us to the extent that it is ultimately found not liable to indemnify the secretary or that officer
for those legal costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This standard of conduct is generally the
same as permitted under the Delaware General Corporation Law for a Delaware corporation. In addition, we intend to enter into
indemnification agreements with our directors and executive officers that will provide such persons with additional indemnification
beyond that provided in our articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions,
we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities
Act and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Anti-Takeover Provisions in Our Articles</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some provisions of our articles may discourage,
delay or prevent a change in control of our company or management that shareholders may consider favorable, including provisions
that authorize our board of directors to issue shares at such times and on such terms and conditions as the board of directors
may decide without any further vote or action by our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Cayman Companies Act, our
directors may only exercise the rights and powers granted to them under our articles for what they believe in good faith to be
in the best interests of our company and for a proper purpose. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Directors&rsquo; Fiduciary Duties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under Delaware corporate law, a director
of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty
of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily
prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to
shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires
that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not
use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates
that the best interests of the corporation and its shareholders take precedence over any interest possessed by a director, officer
or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have
been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the
corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence
be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction, and that
the transaction was of fair value to the corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a matter of Cayman Islands law, a director
of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that
he or she owes the following duties to the company: a duty to act bona fide in the best interests of the company, a duty not to
make a profit based on his or her position as director (unless the company permits him or her to do so) and a duty not to put
himself or herself in a position where the interests of the company conflict with his or her personal interest or his or her duty
to a third-party. However, a company&rsquo;s articles of association may permit a director to vote on a matter in which he or
she has a personal interest if he or she has disclosed the nature of his or her interest to the board of directors. Our Amended
Articles provide that a director must disclose the nature and extent of any material interests in any contract or arrangement,
and that he or she may not vote at any meeting on any resolution concerning an interested matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director of a Cayman Islands company
also owes to the company a duty to exercise the powers for the purpose for which they were given and the duty to act with skill
and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree
of skill than may reasonably be expected from a person of his or her knowledge and experience. However, courts are moving towards
an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman
Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholder Proposals</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the
notice provisions in the governing documents. The Delaware General Corporation Law does not provide shareholders an express right
to put any proposal before the annual meeting of shareholders, but in keeping with common law, Delaware corporations generally
afford shareholders an opportunity to make proposals and nominations provided that they comply with the notice provisions in the
certificate of incorporation or bylaws. A special meeting may be called by the board of directors or any other person authorized
to do so in the governing documents, but shareholders may be precluded from calling special meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Cayman Companies Act provides shareholders
with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal
before a general meeting. However, these rights may be provided in a company&rsquo;s articles of association. Our articles provide
that general meetings shall be convened on the written requisition of one or more of the shareholders entitled to attend and vote
at our general meetings who (together) hold not less than ten per cent of our paid up voting share capital deposited in accordance
with the notice provisions in the articles, specifying the purpose of the meeting and signed by each of the shareholders making
the requisition. If the directors do not convene such meeting for a date not later than twenty-one clear days&rsquo; after the
date of receipt of the written requisition, those shareholders who requested the meeting may convene the general meeting themselves
within three months after the end of such period of twenty-one clear days in which case reasonable expenses incurred by them as
a result of the directors failing to convene a meeting shall be reimbursed by us. Our articles provide no other right to put any
proposals before annual general meetings or extraordinary general meetings. As a Cayman Islands exempted company, we are not obligated
by law to call shareholders&rsquo; annual general meetings. However, our corporate governance guidelines require us to call such
meetings every year. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;<I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cumulative Voting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Delaware General Corporation
Law, cumulative voting for elections of directors is not permitted unless the corporation&rsquo;s certificate of incorporation
specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board
of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single
director, which increases the shareholder&rsquo;s voting power with respect to electing such director. As permitted under the
Cayman Companies Act, our articles do not provide for cumulative voting. As a result, our shareholders are not afforded any less
protections or rights on this issue than shareholders of a Delaware corporation. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Removal of Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, a director of a corporation with a may be removed with the approval of a majority of the outstanding shares entitled to vote,
unless the certificate of incorporation provides otherwise. Under our Memorandum and Articles, directors may be removed with or
without cause, by the directors or by an ordinary resolution of our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Transactions with Interested Shareholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Delaware General Corporation Law contains
a business combination statute applicable to Delaware public corporations whereby, unless the corporation has specifically elected
not to be governed by such statute by amendment to its certificate of incorporation or bylaws that is approved by its shareholders,
it is prohibited from engaging in certain business combinations with an &ldquo;interested shareholder&rdquo; for three years following
the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or
which owns or owned 15% or more of the target&rsquo;s outstanding voting stock or who or which is an affiliate or associate of
the corporation and owned 15% or more of the corporation&rsquo;s outstanding voting stock within the past three years. This has
the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would
not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes
an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in
the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the
terms of any acquisition transaction with the target&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> The Cayman Companies Act has no comparable
statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute.
However, although the Cayman Companies Act does not regulate transactions between a company and its significant shareholders,
under Cayman Islands law such transactions must be entered into bona fide in the best interests of the company and for a proper
corporate purpose and not with the effect of constituting a fraud on the minority shareholders. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dissolution; Winding Up</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Delaware General Corporation
Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100%
of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved
by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation to include in its
certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Cayman Companies Act and our
articles, our company may be wound up by a special resolution of our shareholders, or if the winding up is initiated by our board
of directors, by either a special resolution of our members or, if our company is unable to pay its debts as they fall due, by
an ordinary resolution of our members. In addition, a company may be wound up by an order of the courts of the Cayman Islands.
The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the
court, just and equitable to do so. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Variation of Rights of Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Delaware General Corporation
Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such
class, unless the certificate of incorporation provides otherwise. Under the Cayman Companies Act and our articles, if our share
capital is divided into more than one class of shares, the rights attaching to any class of share (unless otherwise provided by
the terms of issue of the shares of that class) may be varied with the sanction of a resolution passed by a majority of not less
than two-thirds of the holders of shares of the class present in person or by proxy at a separate general meeting of the holders
of shares of that class. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Amendment of Governing Documents</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Under the Delaware General Corporation
Law, a corporation&rsquo;s certificate of incorporation may be amended only if adopted and declared advisable by the board of
directors and approved by a majority of the outstanding shares entitled to vote, and the bylaws may be amended with the approval
of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be
amended by the board of directors. Under the Cayman Companies Act, our articles may only be amended by special resolution of our
shareholders. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-money Laundering&mdash;Cayman Islands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">In order to comply with legislation or regulations aimed at
the prevention of money laundering, we may be required to adopt and maintain anti-money laundering procedures, and may require
subscribers to provide evidence to verify their identity. Where permitted, and subject to certain conditions, we may also delegate
the maintenance of our anti-money laundering procedures (including the acquisition of due diligence information) to a suitable
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We reserve the right to request such information as is necessary
to verify the identity of a subscriber. In the event of delay or failure on the part of the subscriber in producing any information
required for verification purposes, we may refuse to accept the application, in which case any funds received will be returned
without interest to the account from which they were originally debited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also reserve the right to refuse to make any redemption
payment to a shareholder if our directors or officers suspect or are advised that the payment of redemption proceeds to such shareholder
might result in a breach of applicable anti-money laundering or other laws or regulations by any person in any relevant jurisdiction,
or if such refusal is considered necessary or appropriate to ensure our compliance with any such laws or regulations in any applicable
jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any person resident in the Cayman Islands knows or suspects
or has reason for knowing or suspecting that another person is engaged in criminal conduct or is involved with terrorism or terrorist
property and the information for that knowledge or suspicion came to their attention in the course of their business in the regulated
sector, or other trade, profession, business or employment, the person will be required to report such knowledge or suspicion
to (i) a nominated officer (appointed in accordance with the Proceeds of Crime Law (Revised) of the Cayman Islands) or the Financial
Reporting Authority of the Cayman Islands, pursuant to the Proceeds of Crime Law (Revised), if the disclosure relates to criminal
conduct or money laundering or (ii) to a police constable or a nominated officer (pursuant to the Terrorism Law (Revised) of the
Cayman Islands) or the Financial Reporting Authority, pursuant to the Terrorism Law (Revised), if the disclosure relates to involvement
with terrorism or terrorist financing and terrorist property. Such a report shall not be treated as a breach of confidence or
of any restriction upon the disclosure of information imposed by any enactment or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Data Protection in the Cayman Islands &ndash; Privacy Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This privacy notice explains the manner in which the Company
collects, processes and maintains personal data about investors of the Company pursuant to the Data Protection Law, 2017 of the
Cayman Islands, as amended from time to time and any regulations, codes of practice or orders promulgated pursuant thereto (DPL).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is committed to processing personal data in accordance
with the DPL. In its use of personal data, the Company will be characterized under the DPL as a &lsquo;data controller&rsquo;,
whilst certain of the Company&rsquo;s service providers, affiliates and delegates may act as &lsquo;data processors&rsquo; under
the DPL. These service providers may process personal information for their own lawful purposes in connection with services provided
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By virtue of making an investment in the Company, the Company
and certain of the Company&rsquo;s service providers may collect, record, store, transfer and otherwise process personal data
by which individuals may be directly or indirectly identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Your personal data will be processed fairly and for lawful
purposes, including (a) where the processing is necessary for the Company to perform a contract to which you are a party or for
taking pre-contractual steps at your request (b) where the processing is necessary for compliance with any legal, tax or regulatory
obligation to which the Company is subject or (c) where the processing is for the purposes of legitimate interests pursued by
the Company or by a service provider to whom the data are disclosed. As a data controller, we will only use your personal data
for the purposes for which we collected it. If we need to use your personal data for an unrelated purpose, we will contact you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We anticipate that we will share your personal data with the
Company&rsquo;s service providers for the purposes set out in this privacy notice. We may also share relevant personal data where
it is lawful to do so and necessary to comply with our contractual obligations or your instructions or where it is necessary or
desirable to do so in connection with any regulatory reporting obligations. In exceptional circumstances, we will share your personal
data with regulatory, prosecuting and other governmental agencies or departments, and parties to litigation (whether pending or
threatened), in any country or territory including to any other person where we have a public or legal duty to do so (e.g. to
assist with detecting and preventing fraud, tax evasion and financial crime or compliance with a court order).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 100; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Your personal data shall not be held by the Company for longer
than necessary with regard to the purposes of the data processing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not sell your personal data. Any transfer of personal
data outside of the Cayman Islands shall be in accordance with the requirements of the DPL. Where necessary, we will ensure that
separate and appropriate legal agreements are put in place with the recipient of that data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will only transfer personal data in accordance
with the requirements of the DPL, and will apply appropriate technical and organizational information security measures designed
to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction or damage
to the personal data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you are a natural person, this will affect you directly.
If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted limited partnerships)
that provides us with personal data on individuals connected to you for any reason in relation to your investment into the Company,
this will be relevant for those individuals and you should inform such individuals of the content.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> You have certain rights under the DPL,
including (a) the right to be informed as to how we collect and use your personal data (and this privacy notice fulfils the Company&rsquo;s
obligation in this respect) (b) the right to obtain a copy of your personal data (c) the right to require us to stop direct marketing
(d) the right to have inaccurate or incomplete personal data correctI(e) the right to withdraw your consent and require us to
stop processing or restrict the processing, or not begin the processing of your personal data (f) the right to be notified of
a data breach (unless the breach is unlikely to be prejudicial) (g) the right to obtain information as to any countries or territories
outside the Cayman Islands to which we, whether directly or indirectly, transfer, intend to transfer or wish to transfer your
personal data, general measures we take to ensure the security of personal data and any information available to us as to the
source of your personal data (h) the right to complain to the Office of the Ombudsman of the Cayman Islands and (i) the right
to require us to delete your personal data in some limited circumstances. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> If you consider that your personal data
has not been handled correctly, or you are not satisfied with the Company&rsquo;s responses to any requests you have made regarding
the use of your personal data, you have the right to complain to the Cayman Islands&rsquo; Ombudsman. The Ombudsman can be contacted
by calling +1 (345) 946-6283 or by email at info@ombudsman.ky. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>


<!-- Field: Page; Sequence: 101; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_019"></A><B>SHARES ELIGIBLE
FOR FUTURE SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before our initial public offering, there
has not been a public market for our Ordinary Shares, and while application has been made for the Ordinary Shares to be listed
on the Nasdaq, a regular trading market for our Ordinary Shares may not develop. Future sales of substantial amounts of our Ordinary
Shares in the public market after our initial public offering, or the possibility of these sales occurring, could cause the prevailing
market price for our Ordinary Shares to fall or impair our ability to raise equity capital in the future. Upon the closing of
the offering, we will have [&#9679;] issued and outstanding Ordinary Shares, excluding any exercise of the underwriter&rsquo;s
over-allotment option. Of that amount, [&#9679;] ordinary shares will be publicly held by investors participating in this offering,
and [&#9679;] ordinary shares will be held by our existing shareholders, some of whom may be our &ldquo;affiliates&rdquo; as that
term is defined in Rule 144 under the Securities Act. All of the Ordinary Shares sold in this offering will be freely transferable
by persons other than our &ldquo;affiliates&rdquo; without restriction or further registration under the Securities Act.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our shareholders who own more than 3% of
our shares have agreed that we will not offer, pledge, sell, contract to sell, grant any option, right or warrant to purchase,
sell any option or contract to purchase, purchase any option or contract to sell, lend, or otherwise transfer or dispose of (including
entering into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequence of
ownership interests), directly or indirectly, any of our Ordinary Shares or any securities that are convertible into or exercisable
or exchangeable for our Ordinary Shares, or file any registration statement with the SEC relating to the offering of any Ordinary
Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares without the prior written consent
of the underwriter for a period ending 180 days after the commencement of sales of the offering, except issuances pursuant to
the exercise of employee share options outstanding on the date hereof and certain other exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of our directors, officers, and existing
beneficial owners of 3% or more of our issued and outstanding Ordinary Shares has agreed, subject to some exceptions, not to offer,
pledge, sell, contract to sell, grant, lend or otherwise transfer or dispose of (including entering into any swap or other arrangement
that transfers to another, in whole or in part, any of the economic consequence of ownership interests), directly or indirectly,
any of our Ordinary Shares or any securities convertible into or exercisable or exchangeable for Ordinary Shares or make any demand
for or exercise any right with respect to, the registration of any Ordinary Shares or any security convertible into or exercisable
or exchangeable for Ordinary Shares, without the prior written consent of the underwriter for a period ending 180 days after the
commencement of sales of the offering. After the expiration of the 180-day period, Ordinary Shares held by directors, officers,
and existing beneficial owners of 3% or more of our issued and outstanding Ordinary Shares may be sold subject to the restrictions
under Rule 144 under the Securities Act or by means of registered public offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of our Ordinary Shares issued and outstanding
prior to this offering are &ldquo;restricted securities&rdquo; as that term is defined in Rule 144 under the Securities Act and
may be sold publicly in the United States only if they are subject to an effective registration statement under the Securities
Act or pursuant to an exemption from the registration requirement such as those provided by Rule 144 and Rule 701 promulgated
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, under Rule 144 as currently
in effect, beginning 90 days after the date of this prospectus, a person who is not deemed to have been our affiliate at any time
during the three months preceding a sale and who has beneficially owned restricted securities within the meaning of Rule 144 for
more than six months would be entitled to sell an unlimited number of those shares, subject only to the availability of current
public information about us. A non-affiliate who has beneficially owned restricted securities for at least one year from the later
of the date these shares were acquired from us or from our affiliate would be entitled to freely sell those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A person who is deemed to be an affiliate
of ours and who has beneficially owned &ldquo;restricted securities&rdquo; for at least six months would be entitled to sell,
within any three-month period, a number of shares that is not more than the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of Ordinary Shares then outstanding,
    in the form of Ordinary Shares or otherwise, which will equal approximately shares immediately after this offering; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                         average weekly trading volume of the Ordinary Shares on the Nasdaq Capital Market during
                                         the four calendar weeks preceding the filing of a notice on Form 144 with respect to
                                         such sale.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales under Rule 144 by our affiliates
or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements
and to the availability of current public information about us. In addition, in each case, these shares would remain subject to
lock-up arrangements and would only become eligible for sale when the lock-up period expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_020"></A><B>TAXATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Material U.S. Federal Income Tax Consequences Applicable
to U.S. Holders of Our Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
following sets forth the material U.S. federal income tax consequences related to an investment in our Ordinary Shares. It is
directed to U.S. Holders (as defined below) of our Ordinary Shares and is based upon laws and relevant interpretations thereof
in effect as of the date of this prospectus, all of which are subject to change. This description does not deal with all possible
tax consequences relating to an investment in our Ordinary Shares or U.S. tax laws, other than the U.S. federal income tax laws,
such as the tax consequences under non-U.S. tax laws, state, local and other tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
following brief description applies only to U.S. Holders (defined below) that hold Ordinary Shares as capital assets and that
have the U.S. dollar as their functional currency. This brief description is based on the federal income tax laws of the United
States in effect as of the date of this prospectus and on U.S. Treasury regulations in effect or, in some cases, proposed, as
of the date of this prospectus, as well as judicial and administrative interpretations thereof available on or before such date.
All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences
described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
brief description below of the U.S. federal income tax consequences to &ldquo;U.S. Holders&rdquo; will apply to you if you are
a beneficial owner of Ordinary Shares and you are, for U.S. federal income tax purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is
    a citizen or resident of the United States;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other
    entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state
    thereof or the District of Columbia;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income
    is subject to U.S. federal income taxation regardless of its source; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust that (1) is
    subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all
    substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a
    U.S. person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If a partnership (or
other entity treated as a partnership for United States federal income tax purposes) is a beneficial owner of our ordinary shares,
the tax treatment of a partner in the partnership will depend upon the status of the partner and the activities of the partnership.
Partnerships and partners of a partnership holding our ordinary shares are urged to consult their tax advisors regarding an investment
in our ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">WE
URGE POTENTIAL PURCHASERS OF OUR ORDINARY SHARES TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL, STATE, LOCAL AND
NON-U.S. TAX CONSEQUENCES OF PURCHASING, OWNING AND DISPOSING OF OUR ORDINARY SHARES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
following does not address the tax consequences to any particular investor or to persons in special tax situations such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment
    companies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment
    trusts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">traders that elect
    to mark-to-market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. expatriates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons liable for
    alternative minimum tax;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 103; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our
    Ordinary Shares as part of a straddle, hedging, conversion or integrated transaction;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually
    or constructively own 10% or more of our voting shares (including by reason of owning our Ordinary Shares);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who acquired
    our Ordinary Shares pursuant to the exercise of any employee share option or otherwise as compensation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our
    Ordinary Shares through partnerships or other pass-through entities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">events, hip-hop, and
    marketing industries investment trusts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies
    or instrumentalities thereof;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficiaries of a
    Trust holding our Ordinary Shares; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our
    Ordinary Shares through a trust.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
discussion set forth below is addressed only to U.S. Holders that purchase Ordinary Shares in this offering. Prospective purchasers
are urged to consult their own tax advisors about the application of the U.S. federal income tax rules to their particular circumstances
as well as the state, local, foreign and other tax consequences to them of the purchase, ownership and disposition of our Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Taxation of Dividends and Other Distributions on our Ordinary
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Subject
to the passive foreign investment company rules discussed below, the gross amount of distributions made by us to you with respect
to the Ordinary Shares (including the amount of any taxes withheld therefrom) will generally be includable in your gross income
as dividend income on the date of receipt by you, but only to the extent that the distribution is paid out of our current or accumulated
earnings and profits (as determined under U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends
will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other
U.S. corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">With
respect to non-corporate U.S. Holders, including individual U.S. Holders, dividends will be taxed at the lower capital gains rate
applicable to qualified dividend income, provided that (1) the Ordinary Shares are readily tradable on an established securities
market in the United States, or we are eligible for the benefits of an approved qualifying income tax treaty with the United States
that includes an exchange of information program, (2) we are not a PFIC for either our taxable year in which the dividend is paid
or the preceding taxable year, and (3) certain holding period requirements are met. Because there is no income tax treaty between
the United States and the Cayman Islands, clause (1) above can be satisfied only if the Ordinary Shares are readily tradable on
an established securities market in the United States. Under U.S. Internal Revenue Service authority, Ordinary Shares are considered
for purpose of clause (1) above to be readily tradable on an established securities market in the United States if they are listed
on the OTCQB Market. You are urged to consult your tax advisors regarding the availability of the lower rate for dividends paid
with respect to our Ordinary Shares, including the effects of any change in law after the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Dividends
will constitute foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend
income (as discussed above), the amount of the dividend considered for purposes of calculating the foreign tax credit limitation
will be limited to the gross amount of the dividend, multiplied by the reduced rate divided by the highest rate of tax normally
applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific
classes of income. For this purpose, dividends distributed by us with respect to our Ordinary Shares will constitute &ldquo;passive
category income&rdquo; but could, in the case of certain U.S. Holders, constitute &ldquo;general category income.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">To
the extent that the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S.
federal income tax principles), it will be treated first as a tax-free return of your tax basis in your Ordinary Shares, and to
the extent the amount of the distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to
calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that a distribution
will be treated as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital
gain under the rules described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 104; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Taxation of Dispositions of Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> Subject to
the passive foreign investment company rules discussed below, you will recognize taxable gain or loss on any sale, exchange or
other taxable disposition of a share equal to the difference between the amount realized (in U.S. dollars) for the share and your
tax basis (in U.S. dollars) in the Ordinary Shares. The gain or loss will be capital gain or loss. If you are a non-corporate
U.S. Holder, including an individual U.S. Holder, who has held the Ordinary Shares for more than one year, you will be eligible
for reduced tax rates. The deductibility of capital losses is subject to limitations. Any such gain or loss that you recognize
will generally be treated as United States source income or loss for foreign tax credit limitation purposes which will generally
limit the availability of foreign tax credits. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information Reporting and Backup Withholding</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Dividend
payments with respect to our Ordinary Shares and proceeds from the sale, exchange or redemption of our Ordinary Shares may be
subject to information reporting to the U.S. Internal Revenue Service and possible U.S. backup withholding at a current rate of
24%. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes
any other required certification on U.S. Internal Revenue Service Form W-9 or who is otherwise exempt from backup withholding.
U.S. Holders who are required to establish their exempt status generally must provide such certification on U.S. Internal Revenue
Service Form W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the U.S. information reporting
and backup withholding rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Backup
withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income
tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate
claim for refund with the U.S. Internal Revenue Service and furnishing any required information. We do not intend to withhold
taxes for individual shareholders. However, transactions effected through certain brokers or other intermediaries may be subject
to withholding taxes (including backup withholding), and such brokers or intermediaries may be required by law to withhold such
taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Under
the Hiring Incentives to Restore Employment Act of 2010, certain U.S. Holders are required to report information relating to our
Ordinary Shares, subject to certain exceptions (including an exception for Ordinary Shares held in accounts maintained by certain
financial institutions), by attaching a complete Internal Revenue Service Form 8938, Statement of Specified Foreign Financial
Assets, with their tax return for each year in which they hold Ordinary Shares. Failure to report the information could result
in substantial penalties. You should consult your own tax advisor regarding your obligation to file Form 8938.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Passive Foreign Investment Company (&ldquo;PFIC&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Based
on our current and anticipated operations and the composition of our assets, we were not likely a passive foreign investment company,
or PFIC, for U.S. federal income tax purposes for the taxable year ended June 30, 2020. Depending on the amount of cash we raise
in this offering, together with any other assets held for the production of passive income, it is possible that, for our taxable
year ending June 30, 2021 or for any subsequent year, more than 50% of our assets may be assets which produce passive income,
in which case we would be deemed a PFIC, which could have adverse US federal income tax consequences for US taxpayers who are
shareholders. We will make this determination following the end of any particular tax year. PFIC status is a factual determination
for each taxable year which cannot be made until the close of the taxable year. A non-U.S. corporation is considered a PFIC, as
defined in Section 1297(a) of the US Internal Revenue Code, for any taxable year if either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 75% of its
    gross income is passive income; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 50% of the
    value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets
    that produce or are held for the production of passive income (the &ldquo;asset test&rdquo;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">We
will be treated as owning our proportionate share of the assets and earning our proportionate share of income of any other corporation
in which we own, directly or indirectly, at least 25% (by value) of the stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We must make a separate
determination each year as to whether we are a PFIC, however, and there can be no assurance with respect to our status as a PFIC
for our current taxable year or any future taxable year. Depending on the amount of cash we raise in this offering, together with
any other assets held for the production of passive income, it is possible that, for our current taxable year or for any subsequent
taxable year, more than 50% of our assets may be assets held for the production of passive income. We will make this determination
following the end of any particular tax year. In addition, because the value of our assets for purposes of the asset test will
generally be determined based on the market price of our Ordinary Shares and because cash is generally considered to be an asset
held for the production of passive income, our PFIC status will depend in large part on the market price of our Ordinary Shares
and the amount of cash we raise in this offering. Accordingly, fluctuations in the market price of the Ordinary Shares may cause
us to become a PFIC. In addition, the application of the PFIC rules is subject to uncertainty in several respects and the composition
of our income and assets will be affected by how, and how quickly, we spend the cash we raise in this offering. We are under no
obligation to take steps to reduce the risk of our being classified as a PFIC, and as stated above, the determination of the value
of our assets will depend upon material facts (including the market price of our Ordinary Shares from time to time and the amount
of cash we raise in this offering) that may not be within our control. If we are a PFIC for any year during which you hold Ordinary
Shares, we will continue to be treated as a PFIC for all succeeding years during which you hold Ordinary Shares. If we cease to
be a PFIC and you did not previously make a timely &ldquo;mark-to-market&rdquo; election as described below, however, you may
avoid some of the adverse effects of the PFIC regime by making a &ldquo;purging election&rdquo; (as described below) with respect
to the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 105; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">If
we are a PFIC for any taxable year during which you hold Ordinary Shares, you will be subject to special tax rules with respect
to any &ldquo;excess distribution&rdquo; that you receive and any gain you realize from a sale or other disposition (including
a pledge) of the Ordinary Shares, unless you make a &ldquo;mark-to-market&rdquo; election as discussed below. Distributions you
receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the
three preceding taxable years or your holding period for the Ordinary Shares will be treated as an excess distribution. Under
these special tax rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the excess distribution
    or gain will be allocated ratably over your holding period for the Ordinary Shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated
    to the current taxable year, and any taxable year prior to the first taxable year in which we were a PFIC, will be treated
    as ordinary income, and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated
    to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable
    to underpayments of tax will be imposed on the resulting tax attributable to each such year.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
tax liability for amounts allocated to years prior to the year of disposition or &ldquo;excess distribution&rdquo; cannot be offset
by any net operating losses for such years, and gains (but not losses) realized on the sale of the Ordinary Shares cannot be treated
as capital, even if you hold the Ordinary Shares as capital assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">A
U.S. Holder of &ldquo;marketable stock&rdquo; (as defined below) in a PFIC may make a mark-to-market election for such stock to
elect out of the tax treatment discussed above. If you make a mark-to-market election for the Ordinary Shares, you will include
in income each year an amount equal to the excess, if any, of the fair market value of the Ordinary Shares as of the close of
your taxable year over your adjusted basis in such Ordinary Shares. You are allowed a deduction for the excess, if any, of the
adjusted basis of the Ordinary Shares over their fair market value as of the close of the taxable year. However, deductions are
allowable only to the extent of any net mark-to-market gains on the Ordinary Shares included in your income for prior taxable
years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition
of the Ordinary Shares, are treated as ordinary income. Ordinary loss treatment also applies to the deductible portion of any
mark-to-market loss on the Ordinary Shares, as well as to any loss realized on the actual sale or disposition of the Ordinary
Shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such Ordinary
Shares. Your basis in the Ordinary Shares will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market
election, the tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us, except
that the lower applicable capital gains rate for qualified dividend income discussed above under &ldquo;&mdash; Taxation of Dividends
and Other Distributions on our Ordinary Shares&rdquo; generally would not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">The
mark-to-market election is available only for &ldquo;marketable stock&rdquo;, which is stock that is traded in other than de minimis
quantities on at least 15 days during each calendar quarter (&ldquo;regularly traded&rdquo;) on a qualified exchange or other
market (as defined in applicable U.S. Treasury regulations), including the Nasdaq Capital Market. If the Ordinary Shares are regularly
traded on the Nasdaq Capital Market and if you are a holder of Ordinary Shares, the mark-to-market election would be available
to you were we to be or become a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">Alternatively,
a U.S. Holder of stock in a PFIC may make a &ldquo;qualified electing fund&rdquo; election with respect to such PFIC to elect
out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing fund election with respect to a PFIC
will generally include in gross income for a taxable year such holder&rsquo;s pro rata share of the corporation&rsquo;s earnings
and profits for the taxable year. However, the qualified electing fund election is available only if such PFIC provides such U.S.
Holder with certain information regarding its earnings and profits as required under applicable U.S. Treasury regulations. We
do not currently intend to prepare or provide the information that would enable you to make a qualified electing fund election.
If you hold Ordinary Shares in any year in which we are a PFIC, you will be required to file U.S. Internal Revenue Service Form
8621 regarding distributions received on the Ordinary Shares and any gain realized on the disposition of the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If you do not make a
timely &ldquo;mark-to-market&rdquo; election (as described above), and if we were a PFIC at any time during the period you hold
our Ordinary Shares, then such Ordinary Shares will continue to be treated as stock of a PFIC with respect to you even if we cease
to be a PFIC in a future year, unless you make a &ldquo;purging election&rdquo; for the year we cease to be a PFIC. A &ldquo;purging
election&rdquo; creates a deemed sale of such Ordinary Shares at their fair market value on the last day of the last year in which
we are treated as a PFIC. The gain recognized by the purging election will be subject to the special tax and interest charge rules
treating the gain as an excess distribution, as described above. As a result of the purging election, you will have a new basis
(equal to the fair market value of the Ordinary Shares on the last day of the last year in which we are treated as a PFIC) and
holding period (which new holding period will begin the day after such last day) in your Ordinary Shares for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> IRC Section 1014(a) provides for a step-up
in basis to the fair market value for our Ordinary Shares when inherited from a decedent that was previously a holder of our Ordinary
Shares. However, if we are determined to be a PFIC and a decedent that was a U.S. Holder did not make either a timely qualified
electing fund election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) our Ordinary
Shares, or a mark-to-market election and ownership of those Ordinary Shares are inherited, a special provision in IRC SectioI291(e)
provides that the new U.S. Holder&rsquo;s basis should be reduced by an amount equal to the Section 1014 basis minus the decedent&rsquo;s
adjusted basis just before death. As such if we are determined to be a PFIC at any time prior to a decedent&rsquo;s passing, the
PFIC rules will cause any new U.S. Holder that inherits our Ordinary Shares from a U.S. Holder to not get a step-up in basis under
Section 1014 and instead will receive a carryover basis in those Ordinary Shares. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">You
are urged to consult your tax advisors regarding the application of the PFIC rules to your investment in our Ordinary Shares and
the elections discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 106; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><U>Hong Kong Profits Taxation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our subsidiary incorporated in Hong
Kong were subject to 16.5% Hong Kong profits tax on their taxable income assessable profits generated from operations arising
in or derived from Hong Kong for the year of assessment of 2017/2018 and 2018/2019. As from year of assessment of 2019/2020
onwards, Hong Kong profits tax rates are 8.25% on assessable profits up to HKD2,000,000, and 16.5% on any part of assessable
profits over HKD2,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Under Hong Kong
tax laws, our Hong Kong subsidiary are exempted from Hong Kong income profits tax on its foreign-derived income profits. In addition,
payments of dividends from our Hong Kong subsidiary to us are not subject to any withholding tax in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cayman Islands Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Cayman Islands currently levies no
taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature
of inheritance tax or estate duty. There are no other taxes likely to be material to our company levied by the Government of the
Cayman Islands except for stamp duties which may be applicable on instruments executed in, or after execution brought within the
jurisdiction of the Cayman Islands. No stamp duty is payable in the Cayman Islands on the issue of shares by, or any transfers
of shares of, Cayman Islands companies (except those which hold interests in land in the Cayman Islands). The Cayman Islands is
not party to any double tax treaties that are applicable to any payments made to or by our company. The Cayman Islands is not
a party to any double tax treaties that are applicable to any payments made to us or by the Company. There are no exchange control
regulations or currency restrictions in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payments of dividends and capital in respect
of our Ordinary Shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment
of a dividend or capital to any holder of our Ordinary Shares, as the case may be, nor will gains derived from the disposal of
our Ordinary Shares be subject to Cayman Islands income or corporation tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_021"></A><B>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are offering our ordinary shares described
in this prospectus through the underwriters named below. Maxim Group LLC, or Maxim, is acting as representative of the underwriters.
We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting
agreement, each of the underwriters has severally agreed to purchase, and we have agreed to sell to the underwriters, the number
of ordinary shares listed next to its name in the following table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Underwriters</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number<BR> of&nbsp;Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -12pt; padding-left: 12pt">Maxim Group LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriting agreement provides that
the underwriters must buy all of the ordinary shares being sold in this offering if they buy any of them. However, the underwriters
are not required to take or pay for the ordinary shares covered by the underwriters&rsquo; option to purchase additional ordinary
shares as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ordinary shares are offered subject
to a number of conditions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt and acceptance of our ordinary shares
    by the underwriters; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the underwriters&rsquo; right to reject orders
    in whole or in part.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have been advised by Maxim that the
underwriters intend to make a market in our ordinary shares but that they are not obligated to do so and may discontinue making
a market at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with this offering, certain
of the underwriters or securities dealers may distribute prospectuses electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Option to Purchase Additional Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have granted the underwriters an option
to buy up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares. The underwriters have 45 days from the date of this prospectus
to exercise this option. If the underwriters exercise this option, they will each purchase additional ordinary shares approximately
in proportion to the amounts specified in the table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Underwriting Discount</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Shares sold by the underwriters to the
public will initially be offered at the initial offering price set forth on the cover of this prospectus. Any shares sold by the
underwriters to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price.
The underwriters may offer the shares through one or more of their affiliates or selling agents. If all the shares are not sold
at the initial public offering price, Maxim may change the offering price and the other selling terms. Upon execution of the underwriting
agreement, the underwriters will be obligated to purchase the shares at the prices and upon the terms stated therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table shows the per share
and total underwriting discount we will pay to the underwriters assuming both no exercise and full exercise of the underwriters&rsquo;
option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total without<BR> Over-Allotment<BR>
    Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total with<BR> Over-Allotment<BR>
    Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-indent: -10pt; padding-left: 10pt">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Underwriting discounts and commissions (7.5%)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds, before expenses to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to pay Maxim&rsquo;s out-of-pocket
accountable expenses, including Maxim&rsquo;s legal fees, up to a maximum amount of $200,000 if this offering is completed. We
have paid $25,000 to Maxim as an advance to be applied towards reasonable out-of-pocket expenses, or the Advance. Any portion
of the Advance shall be returned back to us to the extent not actually incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that the total expenses of
the offering payable by us, not including the underwriting discount, will be approximately $____________ million. We have also
agreed to reimburse the underwriters for certain expenses incurred by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Representative&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have also agreed to issue to Maxim (or
its permitted assignees) warrants to purchase a number of our shares equal to an aggregate of 2.5% of the total number of ordinary
shares sold in this offering, or the Representative&rsquo;s Warrants. The Representative&rsquo;s Warrants will have an exercise
price equal to 110% of the offering price of the ordinary shares sold in this offering and may be exercised on a cashless basis.
The Representative&rsquo;s Warrants are exercisable commencing six months after the effective date of the registration statement
related to this offering, and will expire five years after the effective date of such registration statement. The Representative&rsquo;s
Warrants are not redeemable by us. We have agreed to a one-time demand registration of the ordinary shares underlying the Representative&rsquo;s
Warrants at our expense and an additional demand registration at the holders&rsquo; expense for a period of five years from the
effective date of the registration statement related to this offering. The Representative&rsquo;s Warrants also provide for unlimited
&ldquo;piggyback&rdquo; registration rights at our expense with respect to the underlying ordinary shares during the five-year
period commencing from the effective date of the registration statement related to this offering. The Representative&rsquo;s Warrants
and the ordinary shares underlying the Representative&rsquo;s Warrants, have been deemed compensation by the Financial Industry
Regulatory Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. The underwriters
(or permitted assignees under the Rule) may not sell, transfer, assign, pledge or hypothecate the Representative&rsquo;s Warrants
or the securities underlying the Representative&rsquo;s Warrants, nor will they engage in any hedging, short sale, derivative,
put or call transaction that would result in the effective economic disposition of the Representative&rsquo;s Warrants or the
underlying securities for a period of six months from the effective date of this offering, except to any FINRA member participating
in the offering and their bona fide officers or partners. The Representative&rsquo;s Warrants will provide for adjustment in the
number and price of such Representative&rsquo;s Warrants (and the ordinary shares underlying such Representative&rsquo;s Warrants)
to prevent dilution in the event of a forward or reverse stock split, stock dividend or similar recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Right of First Refusal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to grant Maxim, for the
nine-month period following the effective date of the registration statement related to this offering, a right of first refusal
to act as lead left book runner and lead left manager and/or lead left placement agent, with at least 50.0% of the economics for
a two handed deal and 33.3% of the economics for a three handed deal, for any and all future public and private equity, convertible
or debt offerings of the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We and our directors, officers any other
holder(s) of three percent (3.0%) or more of our outstanding ordinary share as of the effective date of the Registration Statement
(and all holders of securities exercisable for or convertible into shares of ordinary share) shall enter into customary &ldquo;lock-up&rdquo;
agreements in favor of Maxim pursuant to which such persons and entities shall agree, for a period of one hundred and eighty days
(180) after the effective date of the registration statement related to this offering, that they shall neither offer, issue, sell,
contract to sell, encumber, grant any option for the sale of or otherwise dispose of any securities of the Company without Maxim&rsquo;s
prior written consent, including the issuance of shares of Ordinary Share upon the exercise of currently outstanding options approved
by Maxim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have agreed to indemnify the several
underwriters against certain liabilities, including certain liabilities under the Securities Act. If we are unable to provide
this indemnification, we have agreed to contribute to payments the underwriters may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.45pt"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some of the underwriters and their affiliates
have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business
with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>No Public Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to this offering, there has not been
a public market for our securities in the U.S. and the public offering price for our ordinary shares will be determined through
negotiations between us and the underwriters. Among the factors to be considered in these negotiations will be prevailing market
conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable
to us, estimates of our business potential, the present state of our development and other factors deemed relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We offer no assurances that the initial
public offering price will correspond to the price at which our ordinary shares will trade in the public market subsequent to
this offering or that an active trading market for our ordinary shares will develop and continue after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have applied to list our ordinary shares
on the Nasdaq Capital Market under the symbol &ldquo;RGCB.&rdquo; There can be no assurance that we will be successful in listing
our Ordinary Shares on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A prospectus in electronic format may be
made available on websites or through other online services maintained by one or more of the underwriters of this offering, or
by their affiliates. Other than the prospectus in electronic format, the information on any underwriter&rsquo;s website and any
information contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement
of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter,
and should not be relied upon by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Price Stabilization, Short Positions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with this offering, the underwriters
may engage in activities that stabilize, maintain or otherwise affect the price of our ordinary shares during and after this offering,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stabilizing transactions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases to cover positions created by short
    sales;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of penalty bids; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">syndicate covering transactions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Stabilizing transactions consist of bids
or purchases made for the purpose of preventing or retarding a decline in the market price of our ordinary shares while this offering
is in progress. Stabilization transactions permit bids to purchase the underlying security so long as the stabilizing bids do
not exceed a specified maximum. These transactions may also include making short sales of our ordinary shares, which involve the
sale by the underwriters of a greater number of ordinary shares than they are required to purchase in this offering and purchasing
ordinary shares on the open market to cover short positions created by short sales. Short sales may be &ldquo;covered short sales,&rdquo;
which are short positions in an amount not greater than the underwriters&rsquo; option to purchase additional shares referred
to above, or may be &ldquo;naked short sales,&rdquo; which are short positions in excess of that amount.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriters may close out any covered
short position by either exercising their option, in whole or in part, or by purchasing shares in the open market. In making this
determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market
as compared to the price at which they may purchase shares through the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Naked short sales are short sales made
in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing shares in the open
market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure
on the price of the ordinary shares in the open market that could adversely affect investors who purchased in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriters also may impose a penalty
bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it
because Maxim has repurchased shares sold by or for the account of that underwriter in stabilizing or short covering transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These stabilizing transactions, short sales,
purchases to cover positions created by short sales, the imposition of penalty bids and syndicate covering transactions may have
the effect of raising or maintaining the market price of our ordinary shares or preventing or retarding a decline in the market
price of our ordinary shares. As a result of these activities, the price of our ordinary shares may be higher than the price that
otherwise might exist in the open market. The underwriters may carry out these transactions on the Nasdaq Capital Market, in the
over-the-counter market or otherwise. Neither we nor the underwriters make any representation or prediction as to the effect that
the transactions described above may have on the price of the shares. Neither we, nor any of the underwriters make any representation
that the underwriters will engage in these stabilization transactions or that any transaction, once commenced, will not be discontinued
without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Determination of Offering Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to this offering, there was no public
market for our ordinary shares. The initial public offering price will be determined by negotiation between us and Maxim. The
principal factors to be considered in determining the initial public offering price include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information set forth in this prospectus
    and otherwise available to Maxim;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our history and prospects and the history and
    prospects for the industry in which we compete;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our past and present financial performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our prospects for future earnings and the present
    state of our development;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the general condition of the securities market
    at the time of this offering;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recent market prices of, and demand for,
    publicly traded shares of generally comparable companies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other factors deemed relevant by the underwriters
    and us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The estimated public offering price range
set forth on the cover page of this preliminary prospectus is subject to change as a result of market conditions and other factors.
Neither we nor the underwriters can assure investors that an active trading market will develop for our ordinary shares or that
the ordinary shares will trade in the public market at or above the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Affiliations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The underwriters and their respective affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage
activities. The underwriters and their affiliates may from time to time in the future engage with us and perform services for
us or in the ordinary course of their business for which they will receive customary fees and expenses. In the ordinary course
of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments
and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans)
for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments of us. The underwriters and their respective affiliates may also make investment recommendations and/or publish
or express independent research views in respect of these securities or instruments and may at any time hold, or recommend to
clients that they acquire, long and/or short positions in these securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Offer Restrictions Outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">No
action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the ordinary shares
the possession, circulation or distribution of this prospectus or any other material relating to us or the ordinary shares in
any jurisdiction where action for that purpose is required. Accordingly, the ordinary shares may not be offered or sold, directly
or indirectly, and neither this prospectus nor any other material or advertisements in connection with the ordinary shares may
be distributed or published, in or from any country or jurisdiction except in compliance with any applicable laws, rules and regulations
of any such country or jurisdiction.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Australia.</I></B>&nbsp;This
prospectus:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">does
                                         not constitute a product disclosure document or a prospectus under Chapter&nbsp;6D.2
                                         of the Corporations Act 2001 (Cth) (the &ldquo;Corporations Act&rdquo;);</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">has
                                         not been, and will not be, lodged with the Australian Securities and Investments Commission
                                         (&ldquo;ASIC&rdquo;), as a disclosure document for the purposes of the Corporations Act
                                         and does not purport to include the information required of a disclosure document under
                                         Chapter&nbsp;6D.2 of the Corporations Act;</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">does
                                         not constitute or involve a recommendation to acquire, an offer or invitation for issue
                                         or sale, an offer or invitation to arrange the issue or sale, or an issue or sale, of
                                         interests to a &ldquo;retail client&rdquo; (as defined in section&nbsp;761G of the Corporations
                                         Act and applicable regulations) in Australia; and</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">may
                                         only be provided in Australia to select investors who are able to demonstrate that they
                                         fall within one or more of the categories of investors, or Exempt Investors, available
                                         under section&nbsp;708 of the Corporations Act.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">The
ordinary shares may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe
for or buy the ordinary shares may be issued, and no draft or definitive offering memorandum, advertisement or other offering
material relating to any ordinary shares may be distributed in Australia, except where disclosure to investors is not required
under Chapter&nbsp;6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations.
By submitting an application for the ordinary shares, you represent and warrant to us that you are an Exempt Investor.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">As
any offer of ordinary shares under this prospectus will be made without disclosure in Australia under Chapter&nbsp;6D.2 of the
Corporations Act, the offer of those securities for resale in Australia within 12&nbsp;months may, under section&nbsp;707 of the
Corporations Act, require disclosure to investors under Chapter&nbsp;6D.2 if none of the exemptions in section&nbsp;708 applies
to that resale. By applying for the ordinary shares, you undertake to us that you will not, for a period of 12&nbsp;months from
the date of issue of the ordinary shares, offer, transfer, assign or otherwise alienate those securities to investors in Australia
except in circumstances where disclosure to investors is not required under Chapter&nbsp;6D.2 of the Corporations Act or where
a compliant disclosure document is prepared and lodged with ASIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">This prospectus
contains general information only and does not take account of the investment objectives, financial situation or particular needs
of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment
decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and
circumstances, and, if necessary, seek expert advice on those matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Canada.</I></B>&nbsp;The
ordinary shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario),
and are permitted clients, as defined in National Instrument&nbsp;31-103 Registration Requirements, Exemptions and Ongoing Registrant
Obligations. Any resale of the ordinary shares must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Securities legislation
in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised
by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory.
The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory
for particulars of these rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 111; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Pursuant to section&nbsp;3A.3
of National Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriters are not required to comply with the
disclosure requirements of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Cayman Islands.</I></B>&nbsp;This
prospectus does not constitute a public offer of the ordinary shares, whether by way of sale or subscription, in the Cayman Islands.
Ordinary shares have not been offered or sold, and will not be offered or sold, directly or indirectly, in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Dubai International
Financial Centre (&ldquo;DIFC&rdquo;).</I></B>&nbsp;This prospectus relates to an Exempt Offer in accordance with the Markets
Rules&nbsp;2012 of the Dubai Financial Services Authority (the &ldquo;DFSA&rdquo;). This prospectus is intended for distribution
only to persons of a type specified in the Markets Rules&nbsp;2012 of the DFSA. It must not be delivered to, or relied on by,
any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The
DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility
for this prospectus. The securities to which this prospectus relates may be illiquid and/or subject to restrictions on their resale.
Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand
the contents of this prospectus you should consult an authorized financial advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">In relation to
its use in the DIFC, this prospectus is strictly private and confidential and is being distributed to a limited number of investors
and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose.
The interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>European
Economic Area.</I></B>&nbsp;In relation to each Member State of the European Economic Area which has implemented the Prospectus
Directive (each, a Relevant Member State), with effect from and including the date on which the Prospectus Directive was implemented
in that Relevant Member State (the Relevant Implementation Date), an offer of the ordinary shares to the public may not be made
in that Relevant Member State prior to the publication of a prospectus in relation to the ordinary shares which has been approved
by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and
notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that,
with effect from and including the Relevant Implementation Date, an offer of ordinary shares may be made to the public in that
Relevant Member State at any time:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">to
                                         any legal entity which is a qualified investor as defined under the Prospectus Directive;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">to
                                         fewer than 100 or, if the Relevant Member State has implemented the relevant provision
                                         of the 2010 PD Amending Directive, 150 natural or legal persons (other than qualified
                                         investors as defined in the Prospectus Directive); or</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left">in
                                         any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive,
                                         provided that no such offer of securities described in this prospectus shall result in
                                         a requirement for the publication by us of a prospectus pursuant to Article&nbsp;3 of
                                         the Prospectus Directive.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"> For the purposes
of the above paragraph, the expression &ldquo;an offer of the ordinary shares to the public&rdquo; in relation to any ordinary
shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms
of the offer and the ordinary shares to be offered so as to enable an investor to decide to purchase or subscribe the ordinary
shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State.
The expression Prospectus Directive means Directive 2003/71/EC (and any amendments thereto, including the 2010 PD Amending Directive,
to the extent implemented in the Relevant Member State) and includes any relevant implementing measure in each Relevant Member
State, and the expression &ldquo;2010 PD Amending Directive&rdquo; means Directive 2010/73/EU. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Hong Kong.</I></B>&nbsp;The
ordinary shares may not be offered or sold by means of any document other than (i)&nbsp;in circumstances which do not constitute
an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), (ii)&nbsp;to &ldquo;professional
investors&rdquo; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules promulgated
thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &ldquo;prospectus&rdquo; within the
meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to the ordinary
shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or
elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except
if permitted to do so under the laws of Hong Kong) other than with respect to ordinary shares which are or are intended to be
disposed of only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; within the meaning of the Securities
and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 112; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Japan.</I></B>&nbsp;Ordinary
shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of
1948, as amended) and, accordingly, will not be offered or sold directly or indirectly in Japan or to, or for the benefit of any
Japanese person or to others, for re-offering or re-sale directly or indirectly in Japan or to any Japanese person, except in
each case pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Securities and
Exchange Law of Japan and any other applicable laws, rules and regulations of Japan. For purposes of this paragraph, &ldquo;Japanese
person&rdquo; means any person resident in Japan, including any corporation or other entity organized under the laws of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Kuwait.</I></B>&nbsp;Unless
all necessary approvals from the Kuwait Ministry of Commerce and Industry required by Law No.&nbsp;31/1990 &ldquo;Regulating the
Negotiation of Securities and Establishment of Investment Funds,&rdquo; its Executive Regulations and the various Ministerial
Orders issued pursuant thereto or in connection therewith, have been given in relation to the marketing and sale of the ordinary
shares, these may not be marketed, offered for sale, nor sold in the State of Kuwait. Neither this prospectus (including any related
document), nor any of the information contained therein is intended to lead to the conclusion of any contract of whatsoever nature
within Kuwait.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Malaysia.</I></B>&nbsp;No
prospectus or other offering material or document in connection with the offer and sale of the ordinary shares has been or will
be registered with the Securities Commission of Malaysia (the &ldquo;Commission&rdquo;) for the Commission&rsquo;s approval pursuant
to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in connection with
the offer or sale, or invitation for subscription or purchase, of the ordinary shares may not be circulated or distributed, nor
may the ordinary shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly
or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of
a Capital Markets Services License; (iii)&nbsp;a person who acquires the ordinary shares, as principal, if the offer is on terms
that the ordinary shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies)
for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse
exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual;
(v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in
the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000
(or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets
exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership
with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix)&nbsp;a bank licensee or insurance
licensee as defined in the Labuan Financial Services and Securities Act 2010; (x)&nbsp;an Islamic bank licensee or takaful licensee
as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the
Commission; provided that, in the each of the preceding categories&nbsp;(i) to (xi), the distribution of the ordinary shares is
made by a holder of a Capital Markets Services License who carries on the business of dealing in securities. The distribution
in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose
of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring
the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>People&rsquo;s
Republic of China.</I></B>&nbsp;This prospectus may not be circulated or distributed in the PRC and the ordinary shares may not
be offered or sold, and will not offer or sell to any person for re-offering or resale directly or indirectly to any resident
of the PRC except pursuant to applicable laws, rules and regulations of the PRC. For the purpose of this paragraph only, the PRC
does not include Taiwan and the special administrative regions of Hong Kong and Macau.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Qatar.</I></B>&nbsp;In
the State of Qatar, the offer contained herein is made on an exclusive basis to the specifically intended recipient thereof, upon
that person&rsquo;s request and initiative, for personal use only and shall in no way be construed as a general offer for the
sale of securities to the public or an attempt to do business as a bank, an investment company or otherwise in the State of Qatar.
This prospectus and the underlying securities have not been approved or licensed by the Qatar Central Bank or the Qatar Financial
Centre Regulatory Authority or any other regulator in the State of Qatar. The information contained in this prospectus shall only
be shared with any third parties in Qatar on a need to know basis for the purpose of evaluating the contained offer. Any distribution
of this prospectus by the recipient to third parties in Qatar beyond the terms hereof is not permitted and shall be at the liability
of such recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Saudi Arabia.</I></B>&nbsp;This
prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations issued by the Capital Market Authority. The Capital Market Authority does not make any representation as to the accuracy
or completeness of this prospectus, and expressly disclaims any liability whatsoever for any loss arising from, or incurred in
reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due
diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this prospectus
you should consult an authorized financial adviser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 113; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Singapore.</I></B>&nbsp;This
prospectus or any other offering material relating to the ordinary shares has not been registered as a prospectus with the Monetary
Authority of Singapore under the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA. Accordingly, (a)&nbsp;the
ordinary shares have not been, and will not be, offered or sold or made the subject of an invitation for subscription or purchase
of such ordinary shares in Singapore, and (b)&nbsp;this prospectus or any other document or material in connection with the offer
or sale, or invitation for subscription or purchase, of the ordinary shares have not been and will not be circulated or distributed,
whether directly or indirectly, to the public or any member of the public in Singapore other than (i)&nbsp;to an institutional
investor as specified in Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275 of the SFA)
and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the SFA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">Where the ordinary
shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(a) a corporation (which
is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and
the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(b) a trust (where the trustee
is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who
is an accredited investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&rsquo;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that
trust has acquired the ordinary shares pursuant to an offer made under Section&nbsp;275 of the SFA except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(a) to an institutional
investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to
in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"> (b) where no consideration
is or will be given for the traIer; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(c) where the transfer is
by operation of law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"> (d) as specified in Section&nbsp;276(7)
of thIFA; or </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">(e) as specified in Regulation&nbsp;32
of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Switzerland.</I></B>&nbsp;The
ordinary shares will not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards
for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated
trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to our company
or the ordinary shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus
will not be filed with, and the offer of the ordinary shares will not be supervised by, the Swiss Financial Market Supervisory
Authority, and the offer of the ordinary shares has not been and will not be authorized under the Swiss Federal Act on Collective
Investment Schemes (the &ldquo;CISA&rdquo;). The investor protection afforded to acquirers of interests in collective investment
schemes under the CISA does not extend to acquirers of the ordinary shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>Taiwan.</I></B>&nbsp;The
ordinary shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant
securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances
which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval
of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice
regarding or otherwise intermediate the offering and sale of the ordinary shares in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><B><I>United Arab
Emirates.</I></B>&nbsp;The ordinary shares have not been offered or sold, and will not be offered or sold, directly or indirectly,
in the United Arab Emirates, except: (i)&nbsp;in compliance with all applicable laws and regulations of the United Arab Emirates;
and (ii)&nbsp;through persons or corporate entities authorized and licensed to provide investment advice and/or engage in brokerage
activity and/or trade in respect of foreign securities in the United Arab Emirates. The information contained in this prospectus
does not constitute a public offer of securities in the United Arab Emirates in accordance with the Commercial Companies Law (Federal
Law No.&nbsp;8 of 1984 (as amended)) or otherwise and is not intended to be a public offer and is addressed only to persons who
are sophisticated investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.25in"><B><I>United
Kingdom.</I></B>&nbsp;This prospectus is only being distributed to and is only directed at, and any offer subsequently made may
only be directed at: (i)&nbsp;persons who are outside the United Kingdom; (ii)&nbsp;investment professionals falling within Article&nbsp;19(5)
of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the &ldquo;Order&rdquo;); or (iii)&nbsp;high
net worth companies, and other persons to whom it may lawfully be communicated, falling within Article&nbsp;49(2)(a) to (d)&nbsp;of
the Order (all such persons falling within (1)-(3) together being referred to as &ldquo;relevant persons&rdquo;). The ordinary
shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the ordinary
shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this
prospectus or any of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_022"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">The validity of
the Ordinary Shares offered in this offering and certain other legal matters as to Cayman Islands law will be passed upon for
us by Ogier, our counsel as to Cayman Islands law. Certain other legal matters as to United States Federal and New York State
law in connection with this offering will be passed upon for us by Hunter Taubman Fischer &amp; Li LLC, New York, New York. The
underwriters are being represented by Loeb &amp; Loeb LLP, New York, New York, with respect to legal matters of United States
federal and New York State law. Legal matters as to Hong Kong law will be passed upon for us by Fairbairn Catley Low &amp; Kong.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_023"></A><B>CHANGES IN AND
DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_024"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">The consolidated
financial statements as of and for the years ended June 30, 2020 and 2019, included in this prospectus have been so included in
reliance on the report of Friedman LLP, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The offices of Friedman LLP are located
at One Liberty Plaza, 165 Broadway 21st Floor, New York, NY 10006.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_025"></A><B>INTERESTS OF NAMED
EXPERTS AND COUNSEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No expert or counsel named in this prospectus
as having prepared or certified any part of this prospectus or having given an opinion upon the validity of the securities being
registered or upon other legal matters in connection with the registration or offering of the Ordinary Shares was employed on
a contingency basis, or had, or is to receive, in connection with the offering, a substantial interest, direct or indirect, in
the registrant. Nor was any such person connected with the registrant as a promoter, managing or principal Underwriter, voting
trustee, director, officer, or employee.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_026"></A><B>DISCLOSURE OF
COMMISSION POSITION ON INDEMNIFICATION</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Insofar as indemnification for liabilities
arising under the Securities Act, may be permitted to our directors, officers or persons controlling us, we have been advised
that it is the SEC&rsquo;s opinion that such indemnification is against public policy as expressed in such act and is, therefore,
unenforceable.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_027"></A><B>WHERE YOU CAN
FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have filed with the SEC a registration
statement on Form F-1, including relevant exhibits and schedules under the Securities Act, covering the Ordinary Shares offered
by this prospectus, as well as the Ordinary Shares. You should refer to our registration statements and their exhibits and schedules
if you would like to find out more about us and about the Ordinary Shares. This prospectus summarizes material provisions of contracts
and other documents that we refer you to. Since the prospectus may not contain all the information that you may find important,
you should review the full text of these documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Immediately upon the completion of this
offering, we will be subject to periodic reporting and other informational requirements of the Exchange Act, as applicable to
foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form 20-F, and other information
with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content
of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act,
and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 115; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The registration statements, reports and
other information so filed can be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street,
N.E., Washington, D.C. 20549. You can request copies of these documents upon payment of a duplicating fee, by writing to the SEC.
Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. The SEC also maintains
a website that contains reports, proxy statements and other information about issuers, such as us, who file electronically with
the SEC. The address of that website is&nbsp;<I>http://www.sec.gov</I>. The information on that website is not a part of this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No dealers, salesperson or other person
is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized
information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances
and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="RB_DRS_028"></A><B>EXPENSES RELATING TO THIS
OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Set forth below is an itemization of the
total expenses, excluding underwriting discounts, expected to be incurred in connection with the offer and sale of the Ordinary
Shares by us.&nbsp;With the exception of the SEC registration fee and the FINRA filing fee, all amounts are estimates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq listing fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA filing fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer agent fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printer fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">To be filed by amendment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 116; Value: 79 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_029"></A><B>REGENCELL BIOSCIENCE
HOLDINGS LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Index to Consolidated
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    Ended June 30, 2020 and 2019</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#RB_DRS_030"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_031"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_032"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_033"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholder&rsquo;s Deficit</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_034"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt"><A HREF="#RB_DRS_035"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7~F-14</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_013.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_030"></A><B>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Director and Shareholder of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regencell Bioscience Holdings Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying consolidated balance sheets
of Regencell Bioscience Holdings Limited and Subsidiaries (collectively, the &ldquo;Company&rdquo;) as of June 30, 2020 and 2019,
and the related consolidated statements of operations and comprehensive loss, changes in shareholder&rsquo;s deficit, and cash flows
for each of the years in the two-year period ended June 30, 2020, and the related notes (collectively referred to as the &ldquo;financial
statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects, the financial position of
the Company as of June 30, 2020 and 2019, and the results of its operations, and its cash flows for each of the years in the two-year
period ended June 30, 2020, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consideration of the Company&rsquo;s Ability to Continue as a Going
Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statements have been prepared assuming
the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has an accumulated
deficit, has incurred recurring losses from operations, has an expectation of continuing operating losses for the foreseeable future,
and needs to raise capital to finance its future operation. These factors raise substantial doubt about the Company&rsquo;s ability to
continue as a going concern. Management&rsquo;s plans in regards to these matters are also described in Note 2. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our audits. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audits in accordance with the standards of
the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audits included performing procedures to assess the risks
of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis
for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Friedman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 13, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_014.jpg" ALT=""></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_031"></A><B>REGENCELL BIOSCIENCE
HOLDINGS LIMITED AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
Balance sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; padding-bottom: 1.5pt">Cash</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">386,979</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">243,307</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386,979</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">243,307</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,321</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Long-term deposit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,718</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">127,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">514,018</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">243,307</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">LIABILITIES AND SHAREHOLDER&rsquo;S DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Shareholder&rsquo;s loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,069,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,081,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">95,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,164,910</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,081,828</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,164,910</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,081,828</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">SHAREHOLDER&rsquo;S DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Ordinary shares, $0.01 par value, 100,000,000 shares authorized, and
    10,000 shares issued and outstanding as of June 30, 2020 and 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,651,248</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,838,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total shareholder&rsquo;s deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,650,892</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,838,521</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total liabilities and shareholder&rsquo;s deficit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">514,018</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">243,307</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_032"></A><B>REGENCELL BIOSCIENCE
HOLDINGS LIMITED AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Selling and marketing</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">114,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,638</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,934</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">386,230</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">228,223</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">812,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">LOSS FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(812,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-weight: bold; text-align: left">LOSS BEFORE INCOME TAXES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(812,371</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(390,990</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">PROVISION FOR INCOME TAXES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">NET LOSS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(812,371</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(390,990</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">COMPREHENSIVE LOSS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(812,371</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(390,990</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">LOSS PER SHARE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(81.24</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(39.10</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="RB_DRS_033"></A><B>REGENCELL BIOSCIENCE
HOLDINGS LIMITED AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
STATEMENTS OF changeS in SHAREHOLDER&rsquo;S DEFICIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary
    shares</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold; text-align: center">Additional</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><B>Accumulated</B></TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Par value</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">paid-in
    capital</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">deficit</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold">BALANCE, July 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">256</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,447,887</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,447,531</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">BALANCE, June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">256</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,838,877</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,838,521</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(812,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(812,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">BALANCE, June 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">256</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,651,248</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,650,892</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying
notes are an integral part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="RB_DRS_034"></A><B>REGENCELL BIOSCIENCE HOLDINGS LIMITED
AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CONSOLIDATED
STATEMENTS OF cash flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(812,371</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(390,990</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,516</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left">Change in operating assets and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">Long-term deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,718</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">95,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(726,573</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(390,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(117,837</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(117,837</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Proceeds from shareholder&rsquo;s loans</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">988,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">480,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">988,082</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">480,994</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">NET CHANGE IN CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">143,672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,004</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH, beginning of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,307</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,303</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">CASH, end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">386,979</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">243,307</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash paid for income tax</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="RB_DRS_035"></A><B>Note 1 &ndash; Nature of business and organization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regencell Bioscience Holdings Limited (&ldquo;Regencell&rdquo;
or the &ldquo;Company&rdquo;) is a holding company incorporated as an exempted company on October 30, 2014, under the laws of
the Cayman Islands and holding all of the outstanding share capital of Regencell Limited (Hong Kong), established under the laws
of Hong Kong on November 20, 2014, and Regencell Bioscience Limited (Hong Kong), established under the laws of Hong Kong on May
12, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, through its controlling interests
in the wholly owned subsidiaries, operates an early stage bioscience company that focuses on research, development and commercialization
of Traditional Chinese Medicine (&ldquo;TCM&rdquo;) for the global treatment of neurocognitive disorder and degeneration, specifically
for Autism Spectrum Disorder (&ldquo;ASD&rdquo;) and Attention Deficit Hyperactivity Disorder (&ldquo;ADHD&rdquo;). The Company
is in the research and development stage and has not yet generated any revenue since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> In January 2018, the Company entered
into Strategic Partnership Agreement with Mr. Sik-Kee Au (the &ldquo;TCM Practitioner&rdquo;), the father of Mr. Yat-Gai Au, CEO
of the Company. Pursuant to the Strategic Partnership Agreement, the Company has exclusive rights including the intellectual property
rights and ownership of all his TCM formulae. Any inventions, TCM formulae, utilities, models&rsquo; improvements, research, discoveries,
designs, processes, methods of manufacture, and products conceived or made by the TCM Practitioner in relation to TCM shall be
the sole and exclusive property of the Company. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Strategic Partnership Agreement
does not have a termination date and will remain effective indefinitely under Hong Kong law. The Strategic Partnership Agreement
can be amended or terminated by the mutual written agreement of the parties without breach. Pursuant to the Strategic Partnership
Agreement, in exchange for the rights, the Company is required to donate three percent (3.0%) of net revenue that the Company
generates in association with the use and/or commercialization of the TCM formulae to any of charitable institutions and/or trusts
of a public character anywhere in the world at the sole and absolute choice of the TCM Practitioner and in such proportion at
the sole and absolute discretion of the TCM practitioner on a yearly basis. The Company also undertakes to pay for all reasonable
costs and expenses incurred by the TCM Practitioner in relation to the research and development of the TCM formulae for ADHD and
ASD. All research and development costs and expenses incurred by the TCM Practitioner are charged to operations as incurred. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has funded its operations primarily
from shareholder&rsquo;s loans (&ldquo;SH Loans&rdquo;) provided by Mr. Yat-Gai Au (&ldquo;Founder and CEO&rdquo;). The accompanying
consolidated financial statements reflect the activities of the Company and each of the following entities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 14%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Name of
        Entity</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    Activities</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place
    and Date of Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership</B></FONT></TD></TR>
<TR>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Bioscience Ltd. (Hong Kong)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&middot; Research and Development</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.05pt; text-indent: -14.05pt">&middot;&nbsp;Day-to-day
        operations</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, incorporated on May 12, 2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned Regencell Bioscience Holdings Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Ltd. (Hong Kong)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&middot; Production and testing laboratory</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&middot; Research and Development</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong, incorporated on November 20, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned Regencell Bioscience Holdings Ltd.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash;Going Concern </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Accounting Standards Update
(&ldquo;ASU&rdquo;) 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern (Subtopic
205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about the Company&rsquo;s ability to continue as a going concern within one year after the date that the consolidated financial
statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has incurred recurring negative
cash flows since inception and has funded its operations primarily from shareholder loans. The Company had an accumulated deficit
of approximately $2.65 million and $1.84 million as of June 30, 2020 and 2019, respectively. The Company had net losses of approximately
$0.81 million and $0.39 million for the years ended June 30, 2020 and 2019. The Company has received funding in the form of periodic
shareholders loans to support its capital needs. The Company&rsquo;s ability to continue as a going concern is highly contingent
on the ability to raise additional capital for ongoing research and development as the Company expects to continue incurring losses
for the foreseeable future. The Company has received additional funding subsequent to June 30, 2020 in the form of additional
shareholders loans of $465,947.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> The Company intends to pursue a public
offering of its ordinary shares to fund future operations. If the Company is unable to complete a public offering for a sufficient
amount in a timely manner, it would need to pursue other financing alternatives such as private financing of debt or equity or
collaboration agreements. There can be no assurances, however, that the current operating plan will be achieved or that additional
funding will be available on terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding,
it could be required to delay its development efforts, limit activities and reduce research and development costs, which could
adversely affect its business prospects. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the Company&rsquo;s recurring losses
and negative cash flows from operations since inception, expectation of continuing operating losses and negative cash flows from
operations for the foreseeable future, and the need to raise additional capital to finance its future operations, the Company&rsquo;s
management concluded that there is substantial doubt about the Company&rsquo;s ability to continue as a going concern within one
year after the issuance date of the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial
statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the
realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 &ndash; Summary of significant accounting policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Basis of presentation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;)
pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Principles of consolidation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the Company and
its subsidiaries have been eliminated upon consolidation.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsidiaries are those entities in which
the Company, directly or indirectly, controls more than one half of the voting power; or has the power to govern the financial
and operating policies, to appoint or remove the majority of the members of the board of directors, or to cast a majority of votes
at the meeting of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of estimates and assumptions</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the periods presented. Significant accounting estimates reflected in
the Company&rsquo;s consolidated financial statements required to be made by management include, but are not limited to, the useful
lives of property and equipment, impairment of long-lived assets and uncertain tax position. Actual results could differ from
these estimates.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Risks and Uncertainties</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in an industry that
is subject to intense competition, government regulations and rapid technological changes. Operations are subject to significant
risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential risk
of business failure.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Segment</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments are defined as components
of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision
maker (&ldquo;CODM&rdquo;), or decision making group, in deciding how to allocate resources and in assessing performance. The
CODM is comprised of certain members of the Company&rsquo;s management team. The Company has one operating segment. The Company&rsquo;s
CODM manages the Company&rsquo;s operations on a consolidated basis for the purpose of allocating resources. All of the Company&rsquo;s
long-lived assets are held in Hong Kong.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Foreign currency translation and transaction </U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reporting currency of the Company is
the United States dollar (&ldquo;US$&rdquo;). The Company conducts its businesses in Hong Kong in the local currency, Hong Kong
Dollar (&ldquo;HK$&rdquo;), as its functional currency. The consolidated balance sheet accounts, statement of operations accounts
and equity accounts are all translated at the exchange rate as quoted by the Hong Kong Monetary Authority (&ldquo;HKMA&rdquo;).
The Company considers the foreign exchange risk in relation to transactions denominated in HK$ with respect to US$ is not significant
as HK$ is pegged to US$. The HKMA guarantees to exchange US dollars into Hong Kong dollars, or vice versa, at the rate of HK$7.80
to US$1.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Monetary assets and liabilities denominated
in currencies other than the functional currency are translated into the functional currency at the rates of exchange existing
at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into the
functional currency at the applicable rates of exchange prevailing at the transaction date. Transaction gains and losses are recognized
in &ldquo;other income, net&rdquo;. Assets and liabilities denominated in foreign currencies are translated at the exchange rates
at the balance sheet date. Equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses
are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments
and are shown as a separate component of other comprehensive loss in the consolidated statements of changes in shareholders&rsquo;
deficit and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cash </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash represents demand deposits placed with
banks or other financial institutions, which are unrestricted as to withdrawal or use, and which have original maturities of three
months or less and are readily convertible to known amounts of cash. All of the cash balances as at June 30, 2020 and 2019, were
maintained at financial institutions in Hong Kong, and were insured by the Hong Kong Deposit Protection Board up to a limit of
HK $500,000 (approximately $64,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Property and equipment, net</U></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost
less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the
assets. The estimated useful lives are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 49%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; white-space: nowrap; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Useful&nbsp;Life</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold&nbsp;&nbsp;improvement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Shorter of the remaining lease</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">terms or estimated useful lives</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost and related accumulated depreciation
of assets sold or otherwise retired are eliminated from the accounts and any gain or loss is included in the consolidated statements
of operations and comprehensive loss. Expenditures for maintenance and repairs are charged to earnings as incurred, while additions,
renewals and betterments, which are expected to extend the useful life of assets, are capitalized. The Company also re-evaluates
the periods of depreciation to determine whether subsequent events and circumstances warrant revised estimates of useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Long-term deposit</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-term deposit presents the deposit
paid to the landlord as required on the signing of the lease agreement and thereafter, to be held by the landlord as security
for the performance of the Company&rsquo;s obligations under the lease agreement. The deposit is classified as either current
or non-current based on the terms of the respective agreement. The deposit is unsecured and is reviewed periodically to determine
whether its carrying value has become impaired.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Impairment for long-lived assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets, including property and
equipment with finite lives are reviewed for impairment whenever events or changes in circumstances (such as a significant adverse
change to market conditions that will impact the future use of the assets) indicate that the carrying value of an asset may not
be recoverable. The Company assesses the recoverability of the assets based on the undiscounted future cash flows the assets are
expected to generate and recognize an impairment loss when estimated undiscounted future cash flows expected to result from the
use of the asset plus net proceeds expected from disposition of the asset, if any, are less than the carrying value of the asset.
If an impairment is identified, the Company would reduce the carrying amount of the asset to its estimated fair value based on
a discounted cash flows approach or, when available and appropriate, to comparable market values. As of June 30, 2020, and 2019,
no impairment of long-lived assets was recognized.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Fair value measurement </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 requires certain disclosures regarding
the fair value of financial instruments. Fair value is defined as the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy
prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and
minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                         1 &mdash; inputs to the valuation methodology are quoted prices (unadjusted) for identical
                                         assets or liabilities in active markets.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &mdash; inputs
    to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices
    for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs
    derived from or corroborated by observable market data.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &mdash; inputs
    to the valuation methodology are unobservable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise disclosed, the fair value
of the Company&rsquo;s financial instruments including cash and shareholder&rsquo;s loans approximates their recorded values due
to their short-term maturities. The fair value of the long-term deposit approximates their carrying amounts because the deposit
was paid in cash.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Research and development </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development costs are charged
to operations as incurred. The Company accounts for nonrefundable advance payments for goods and services that will be used in
future research and development activities as expenses when the goods have been received or when the service has been performed
rather than when the payment is made. Research and development expenses consist of costs incurred by the Company for the discovery
and development of the Company&rsquo;s product candidates. Research and development costs include, but are not limited to, payroll
and personnel expenses including stock-based compensation, research studies supplies, fees for research studies services, consulting
costs, and allocated overhead, including rent, equipment, and utilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Employee benefit plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employees of the Company located in Hong
Kong participate in a compulsory saving scheme (pension fund) for the retirement of residents in Hong Kong. Employees are required
to contribute monthly to mandatory provident fund schemes provided by approved private organizations, according to their salaries
and the period of employment. The Company is required to contribute to the plan based on certain percentages of the employees&rsquo;
salaries, up to a maximum amount specified by the local government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Operating leases</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A lease for which substantially all the benefits
and risks incidental to ownership remain with the lessor is classified by the lessee as an operating lease. All leases of the
Company are currently classified as operating leases. The Company records the total expenses on a straight-line basis over the
lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Related Parties </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parties, which can be a corporation or individual,
are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant
influence over the other party in making financial and operational decisions. Companies are also considered to be related if they
are subject to common control or common significant influence, such as a family member or relative, shareholder, or a related
corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Income taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for current income taxes
in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist
between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary,
to reduce deferred tax assets to the amount expected to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An uncertain tax position is recognized as
a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained in a tax examination. The
amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax
positions not meeting the &ldquo;more likely than not&rdquo; test, no tax benefit is recorded. Penalties and interest incurred
related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or
interest relating to income taxes have been incurred during the years ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>(Loss) earnings per share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes (loss) earnings per
share (&ldquo;EPS&rdquo;) in accordance with ASC 260, &ldquo;Earnings per Share&rdquo;. ASC 260 requires companies to present
basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average ordinary share outstanding for
the period. Diluted EPS presents the dilutive effect on a per share basis of the potential Ordinary Shares (e.g., convertible
securities, options and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if
later. Potential Ordinary Shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss
per share) are excluded from the calculation of diluted EPS. For the years ended June 30, 2020 and 2019, there were no dilutive
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Commitments and Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the normal course of business, the Company
is subject to contingencies, including legal proceedings and claims arising out of the business that relate to a wide range of
matters, such as government investigations and tax matters. The Company recognizes a liability for such contingency if it determines
it is probable that a loss has occurred and a reasonable estimate of the loss can be made. The Company may consider many factors
in making these assessments including historical and the specific facts and circumstances of each matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Concentration of credit risk</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentration of credit risks consist primarily of cash, the balances of which are stated on the consolidated balance
sheets which represent the Company&rsquo;s maximum exposure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company places its cash in good credit
quality financial institutions in Hong Kong. The Company deposits its cash in financial institutions that it believes have high
credit quality and have not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk
beyond the normal credit risk associated with commercial banking relationships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Recently issued accounting pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers the applicability and
impact of all accounting standards updates (&ldquo;ASUs&rdquo;). Management periodically reviews new accounting standards that
are issued. Under the Jumpstart Our Business Startups Act of 2012, as amended (&ldquo;the JOBS Act&rdquo;), the Company meets
the definition of an emerging growth company, or EGC, and has elected the extended transition period for complying with new or
revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2016, the FASB issued Accounting
Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02). ASU 2016-02 requires an entity to recognize lease assets and lease
liabilities on the balance sheet and to disclose key information about the entity&rsquo;s leasing arrangements. ASU 2016-02 is
effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. A modified retrospective
approach is required. In January 2018, the FASB issued ASU 2018-01, Leases: Land Easement Practical Expedient for Transition.
This ASU clarifies the accounting and reporting of land easements. In July 2018, the FASB issued ASU No. 2018-10, &ldquo;Codification
Improvements to Topic 842, Leases,&rdquo; (&ldquo;ASU 2018-10&rdquo;), to clarify how to apply certain aspects of the new lease
accounting standard. The amendments in this update, among other things, better articulates the requirement for a lessee&rsquo;s
reassessment of lease classification as of the effective date of a modification, clarifies that a change to an index or rate for
variable lease payments does not constitute a resolution of a contingency that would result in the remeasurement of lease payments,
and requires entities that apply Topic 842 retrospectively to each reporting period and do not adopt the practical expedients
to write off any prior unamortized initial direct costs that do not meet the definition under Topic 842 to equity. The amendments
in this update have the same effective date and transition requirements as the new lease standard summarized above. Also, in July
2018, the FASB issued ASU No. 2018-11, &ldquo;Leases (Topic 842): Targeted Improvements,&rdquo; (&ldquo;ASU 2018-11&rdquo;), to
provide an additional transition method. An entity can now elect not to present comparative financial information under Topic
842 if it recognizes a cumulative-effect adjustment to retained earnings upon adoption. On November 15, 2019, the FASB issued
ASU 2019-10, which amends the effective dates for certain major new accounting standards, including Topic 842, to give implementation
relief to certain types of entities. As an emerging growth company, the Company can adopt Topic 842 on July 1, 2021. The Company
is evaluating the impact this ASU will have on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> In June 2016, the FASB amended guidance
related to the impairment of financial instruments as part of ASU2016-13 Financial Instruments &ndash; Credit Losses (Topic 326):
Measurement of Credit Losses on Financial Instruments, which was effective from January 1, 2020. The guidance replaces the incurred
loss impairment methodology with an expected credit loss model for which a company recognizes an allowance based on the estimate
of expected credit loss. In November 2018, the FASB issued ASU No. 2018-19, Codification Improvements to Topic 326, Finance&ndash;l
Instruments - Credit Losses, which clarified that receivables from operating leases are not within the scope of Topic 326 and
instead, impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842. On May
15, 2019, the FASB issued ASU 2019-05, 9 which provides transition relief for entities adopting the Board&rsquo;s credit losses
standard, ASU 2016-13. Specifically, ASU 2019-05 amends ASU 2016-13 to allow companies to irrevocably elect, upon adoption of
ASU 2016-13, the fair value option for financial instruments that (1) were previously recorded at amortized cost and (2) are within
the scope of the credit losses guidance in ASC 326-20, (3) are eligible for the fair value option under ASC 825-10, and (4) are
not held-to-maturity debt securities. For entities that have adopted ASU 2016-13, the amendments in ASU 2019-05 are effective
for fiscal years beginning after December 15, 2019, including interim periods therein. An entity may early adopt the ASU in any
interim period after its issuance if the entity has adopted ASU 2016-13. For all other entities, the effective date will be the
same as the effective date of ASU 2016-13. The Company does not expect this guidance will have a material impact on its consolidated
financial statements. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2018, the FASB Accounting Standards
Board issued ASU No. 2018-13, &ldquo;Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements
for Fair Value Measurement&rdquo; (&ldquo;ASU 2018-13&rdquo;). ASU 2018-13 modifies the disclosure requirements on fair value
measurements. ASU 2018-13 is effective for public entities for fiscal years beginning after December 15, 2019, with early adoption
permitted for any removed or modified disclosures. The removed and modified disclosures will be adopted on a retrospective basis
and the new disclosures will be adopted on a prospective basis. The Company does not expect this guidance will have a material
impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for the above-mentioned pronouncements,
there are no new recent issued accounting standards that will have a material impact on the consolidated financial position, statements
of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 &ndash; Property and equipment, net</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Property and equipment consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
    2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt">Leasehold improvement</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">117,837</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,516</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">108,321</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Depreciation expense for the years ended
June 30, 2020 and 2019 amounted to $9,516 and nil, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 5 &ndash; Related Party Transaction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended June 30, 2020 and
2019, the Company has an office rental agreement with Ace United International Limited, which is a company wholly owned by the
Company&rsquo;s Founder and CEO. The Company has paid a monthly rent of $4,103 and the terms of the agreement are renewed on an
annual basis from the 1<SUP>st</SUP> of January to the 31<SUP>st</SUP> of December each year. The rental payment is expensed as
incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2020, and 2019, the Company
has outstanding Shareholder Loans amounting to approximately $3.07 million and $2.08 million, respectively, from the Founder and
CEO. The amounts borrowed are non-interest bearing and due on-demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Note 6 &ndash; Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Income tax</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Cayman Islands</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the current laws of the Cayman Islands,
the Company is not subject to tax on income or capital gains. Additionally, upon payments of dividends to the shareholders, no
Cayman Islands withholding tax will be imposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Hong Kong</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Entities incorporated in Hong Kong are subject
to Hong Kong profits tax at a rate of 16.5% on the estimated assessable profit for the years ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table reconciles statutory
tax rates to the Company&rsquo;s effective tax rate for the periods indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For
                                         the year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30,</B></P>
                                                                                                                                                                    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2020</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For
                                         the year ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June
                                         30,<BR>
                                         2019</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt">Tax benefit calculated at statutory tax
    rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16.5</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Effective tax rate</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table sets forth the significant
components of the aggregate deferred tax assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of
    June&nbsp;30, <BR>
    2020</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of
    June&nbsp;30, <BR>
    2019</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -19.8pt; padding-left: 19.8pt">Net operating loss carry forwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">437,456</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">303,415</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -19.8pt; padding-left: 19.8pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(437,456</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(303,415</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate realization of deferred tax
assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become
deductible. Management considers the cumulative earnings and projected future taxable income in making this assessment. Recovery
of substantially all of the Company&rsquo;s deferred tax assets is dependent upon the generation of future income, exclusive of
reversing taxable temporary differences. Based upon historical operating results and projections for future taxable income, management
provided full valuation allowance for the deferred tax assets for the years ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates each uncertain tax
position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized
benefits associated with the tax positions. As of June 30, 2020, and 2019, the Company did not have any significant unrecognized
uncertain tax positions. The Company did not incur any interest and penalties related to potential underpaid income taxes for
the years ended June 30, 2020 and 2019. The Company also does not anticipate any significant increases or decreases in unrecognized
tax benefits in the next 12 months from June 30, 2020.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Note 7 &ndash; Shareholder&rsquo;s deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regencell Bioscience Holdings Ltd. (Cayman)
was established under the laws of Cayman Islands on October 30, 2014. The authorized number of ordinary shares is 100,000,000
shares with a par value of $0.01 per ordinary share, and 10,000 ordinary shares were issued and outstanding as of June 30, 2020
and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2020, and 2019, additional
paid-in capital in the consolidated balance sheets represented the combined contributed capital of the Company&rsquo;s subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Note 8 &ndash; Commitments and contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Office lease commitments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into two lease agreements
for office space with the latest expiring date of July 14, 2024. The Company&rsquo;s commitment for lease payments under the operating
leases as of June 30, 2020 and for the next five years are as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year ending June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Office leases</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">136,923</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,308</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2025</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,359</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total payments</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">483,206</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Rent expense for the years ended June 30,
2020 and 2019 was $151,538 and $49,231, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><U>Contingencies</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may be subject
to certain legal proceedings, claims and disputes that arise in the ordinary course of business. Although the outcomes of these
legal proceedings cannot be predicted, the Company does not believe these actions, in the aggregate, will have a material adverse
impact on its financial position, results of operations or liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9 &ndash; Subsequent events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated all events and transactions
that occurred after June 30, 2020 up through the date the Company issued these consolidated financial statements on November 13,
2020, for disclosure or recognition in the consolidated financial statements of the Company as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Impact of COVID-19</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, a novel strain of coronavirus,
or COVID-19, surfaced and it has spread rapidly to many parts of China and other parts of the world, including the United States.
The epidemic has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in China and
elsewhere. The COVID-19 pandemic may affect the Company&rsquo;s ability to initiate and complete research studies, delay the initiation
of its future research studies, disrupt regulatory activities or have other adverse effects on its business, results of operations,
financial condition and prospects. In addition, the pandemic has caused substantial disruption in the financial markets and may
adversely impact economies worldwide, both of which could adversely affect its business, operations and ability to raise funds
to support its operations.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Loan Agreement with Mr. Yat-Gai Au</U></I></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 10, 2020, the Company signed
a loan agreement to obtain HKD 3,634,387 (USD 465,947) from Mr. Yat-Gai Au, the Founder and CEO of the Company. The amounts borrowed
are non-interest bearing and due June 30, 2021, but subject to indefinite extension if agreed by Mr. Yat-Gai Au and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFORMATION NOT
REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. Indemnification of Directors and Officers</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Amended Articles provide that the Company
shall indemnify each existing or former director (including alternate director), secretary and other officer of the Company (including
an investment adviser or an administrator or liquidator) and their personal representatives against:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 38.25pt"></TD><TD STYLE="text-align: justify; width: 33.75pt">(a)</TD><TD STYLE="text-align: justify">all actions, proceedings, costs, charges, expenses, losses,
                                         damages or liabilities incurred or sustained by the existing or former director (including
                                         alternate director), secretary or officer in or about the conduct of the Company&rsquo;s
                                         business or affairs or in the execution or discharge of the existing or former director&rsquo;s
                                         (including alternate director&rsquo;s), secretary&rsquo;s or officer&rsquo;s duties,
                                         powers, authorities or discretions; and</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -33.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 38.25pt"></TD><TD STYLE="text-align: justify; width: 33.75pt">(b)</TD><TD STYLE="text-align: justify">all costs, expenses, losses or liabilities incurred by
                                         the existing or former director (including alternate director), secretary or officer
                                         in defending (whether successfully or otherwise) any civil, criminal, administrative
                                         or investigative proceedings (whether threatened, pending or completed) concerning the
                                         Company or its affairs in any court or tribunal, whether in the Cayman Islands or elsewhere.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -33.75pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to our Memorandum of Association
and Articles, no such existing or former director (including alternate director), secretary or officer, however, shall be indemnified
in respect of any matter arising out of his own dishonesty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7. Recent Sales of Unregistered Securities</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the past three years, we did not
issue any securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibits and Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(a) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See Exhibit Index beginning on page II-4
of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(b) Financial Statement Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Schedules have been omitted because the
information required to be set forth therein is not applicable or is shown in the Consolidated Financial Statements or the Notes
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9. Undertakings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(1) To file, during any period in which offers or
sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(i) To include any prospectus required by Section
10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(ii) To reflect in the prospectus any facts or events
arising after the effective date of this registration statement (or the most recent post-effective amendment hereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would
not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation
of Registration Fee&rdquo; table in the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(iii) To include any material information with respect
to the plan of distribution not previously disclosed in this registration statement or any material change to such information
in this registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(2) That, for the purpose of determining any liability
under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(4) That, for the purpose of determining liability
under the Securities Act of 1933 to any purchaser:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(i) If the Registrant is relying on Rule 430B (&sect;230.430B
of this chapter):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in">(A) Each prospectus filed by the registrant pursuant
to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part
of and included in the registration statement; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9in">(B) Each prospectus required to be filed pursuant
to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made
pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities
Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of
prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described
in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration
statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of
the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such
effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the
registration statement or made in any such document immediately prior to such effective date; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(ii) If the Registrant is subject to Rule 430C, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in
a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to
a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date
of first use.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(5) That, for the purpose of determining liability
of the Registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned
Registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(i) Any preliminary prospectus or prospectus of the
undersigned Registrant relating to the offering required to be filed pursuant to Rule 424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(ii) Any free writing prospectus relating to the
offering prepared by or on behalf of the undersigned Registrant or used or referred to by the undersigned Registrant;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(iii) The portion of any other free writing prospectus
relating to the offering containing material information about the undersigned Registrant or its securities provided by or on
behalf of the undersigned registrant; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(iv) Any other communication that is an offer in
the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(6) To file a post-effective amendment to the registration
statement to include any financial statements required by item 8.A. of Form 20-F at the start of any delayed offering or throughout
a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished,
provided, that the Registrant includes in the prospectus, by means of a post-effective amendment, financial statements required
pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at
least as current as the date of those financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(7) For purposes of determining any liability under
the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in
reliance upon Rule 430A and contained in a form of prospectus filed by the registrant under Rule 424(b)(1) or (4) or 497(h) under
the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">(8) For the purpose of determining any liability
under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Insofar as indemnification for liabilities arising under
the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing
provisions, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in such Act and will be governed by the final adjudication of such
issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT> </TD>
    <TD STYLE="vertical-align: top; width: 2%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Memorandum and Articles
    of Association**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Certificate for Ordinary Shares**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative&rsquo;s Warrants (included
    in Exhibit 1.1)**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Ogier regarding the validity of
    the Ordinary Shares being registered**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea134389ex8-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Hunter Taubman Fischer &amp; Li LLC regarding certain U.S. Federal Income Taxation matters*</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex10-1_regencell.htm">Deed
    of Rights Transfer, Strategic Partnership and Undertaking between Sik-Kee Au and Regencell Bioscience Limited dated January
    1, 2018*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea134389ex10-2_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Employment Agreement by and between CEO Yat-Gai Au and the Company dated February 2, 2021*</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex10-3_regencell.htm">Supplemental
    Agreement of Deed of Rights Transfer, Strategic Partnership and Undertaking between Sik-Kee Au and Regencell Bioscience Limited
    dated November 10, 2020*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex10-4_regencell.htm">Loan
    Agreement between Yat-Gai Au and the Company dated November 10, 2020*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex10-5_regencell.htm">Employment
    Agreement between Dr. Yi-Chung Chao and Regencell Bioscience Limited dated July 15, 2019*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex10-6_regencell.htm">Employment
    Agreement between Mr. James Wai Hong Chung and Regencell Bioscience Limited dated July 6, 2019*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex10-7_regencell.htm">Employment
    Agreement between Mr. Tien Hsiang Chau and Regencell Bioscience Limited dated January 18, 2021*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea134389ex10-8_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Extension Agreement between Yat-Gai Au and the Company dated February 2, 2021*</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Friedman LLP**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea134389ex8-1_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Hunter Taubman Fischer &amp; Li LLC (included in Exhibit 8.1)*</FONT> </A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics of the
    Registrant**</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex99-2_regencell.htm">Consent
    of Evana Yee Wah Hui*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex99-3_regencell.htm">Consent
    of Paul J. Niewiadomski*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex99-4_regencell.htm">Consent
    of Cheung Ming Wong*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea134389ex99-5_regencell.htm">Consent
    of Persistence Market Research*</A></FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6</FONT> </TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD><A HREF="ea134389ex99-6_regencell.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Fortune Business Insights*</FONT> </A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                         herewith</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         be filed by amendment</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the
Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Hong Kong, [&#9679;], 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell Bioscience Holdings Limited</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp; </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai Au </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and
    Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT> </TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 31%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capacity</B></FONT> </TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    </I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director </FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai
    Au</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/</I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer and Director</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi-Chung
    Chao</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/</I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Strategy Officer</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Wai Hong Chung</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0.8pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/</I></FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;],
    2021</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tien
    Hsiang Chau</FONT> </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE
IN THE UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the Securities Act of 1933
as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration
statement thereto in [&nbsp;&nbsp;&nbsp;] on [&nbsp;&nbsp;&nbsp;], 2021. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1.5pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="padding-right: 0.8pt; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>







































































































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right; background-color: white"><B>Exhibit 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex8-1_001.jpg" ALT="" STYLE="height: 132px; width: 381px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">February 3, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regencell Bioscience Holdings Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11/F First Commercial Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">33-35 Leighton Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Causeway, Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as U.S. counsel to Regencell
Bioscience Holdings Ltd., a Cayman Islands company (the &ldquo;Company&rdquo;), in connection with the proposed public offering
of ordinary shares, par value $0.01 per share, of the Company covered by a Draft Registration Statement on Form F-1 to be submitted
by the Company (together with amendments thereto and prospectuses and prospectus supplements related to such offering, the &ldquo;Registration
Statement&rdquo;) with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have examined the Registration Statement
and such other documents, certificates and records, and have reviewed such questions of law, as we have considered necessary and
appropriate for the purposes of our opinion set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In rendering our opinion set forth below,
we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures and the conformity
to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant
hereto of all natural persons and, with respect to all parties to agreements or instruments relevant hereto other than the Company,
that such parties had the requisite power and authority (corporate or otherwise) to execute, deliver and perform such agreements
or instruments, that such agreements or instruments have been duly authorized by all requisite action (corporate or otherwise),
executed and delivered by such parties and that such agreements or instruments are the valid, binding and enforceable obligations
of such parties. As to questions of fact material to our opinion, we have relied upon factual statements and factual representations
of officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon and subject to the limitations,
qualifications, exceptions and assumptions set forth herein, we are of the opinion that the statements made in the Registration
Statement, under the caption &ldquo;Taxation &ndash; Material U.S. Federal Income Tax Consequences Applicable to U.S. Holders of
Our Ordinary Shares,&rdquo; constitute, in all material respects, an accurate summary of the United States federal income tax consequences
of the ownership and disposition of the Ordinary Shares that are anticipated to be material to U.S. holders who hold the Ordinary
Shares pursuant to the Registration Statement, subject to the qualifications set forth in such statements, and, to the extent that
such statements set forth any specific legal conclusion under United States federal income tax law, except as otherwise provided
therein, they represent our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is given under Item 601 of
Regulation S-K, as our opinion regarding tax matters. All such statements are based upon laws and relevant interpretations thereof
in effect as of the date of this opinion, all of which are subject to change. Further, there can be no assurance that the Internal
Revenue Service or a court will not take a contrary position.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">www.htflawyers.com | info@htflawyers.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">800 Third Avenue, Suite 2800, New York,
NY 10022 | Office: (212) 530-2210 | Fax: (212) 202-6380</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion expressed above is limited
to the federal tax laws of the United States. We assume no obligation to revise or supplement this opinion letter in the event
of any changes in law or fact arising after the date hereof; provided, however, that our opinions set forth in the Registration
Statement will be revised, if needed to remain accurate in all material respects as of the effective date of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this
opinion as an exhibit to the Registration Statement, to the use of our name under the captions &ldquo;Taxation&rdquo; and &ldquo;Legal
Matters&rdquo; in the prospectus included in the Registration Statement and to the discussion of this opinion in the prospectus
included in the Registration Statement. In giving such consent, we do not thereby admit that we are within the category of persons
whose consent is required under Section 7 of the Act or the rules or regulations of the SEC promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ HUNTER TAUBMAN FISCHER &amp; LI LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>HUNTER TAUBMAN FISCHER &amp; LI LLC</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">www.htflawyers.com | info@htflawyers.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">800 Third Avenue, Suite 2800, New York,
NY 10022 | Office: (212) 530-2210 | Fax: (212) 202-6380</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><U>Dated
the 1<SUP>st </SUP>day of January 2018</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AU,
SIK KEE (</B></FONT><B><FONT STYLE="font-family: PMingLiU,serif; font-size: 10pt">&#21312;&#37675;&#27231;</FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>REGENCELL
BIOSCIENCE LIMITED </B></FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(</B></FONT><B><FONT STYLE="font-family: PMingLiU,serif; font-size: 10pt">&#33126;&#20877;&#29983;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;</FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><U>_______________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>DEED OF
RIGHTS TRANSFER, STRATEGIC PARTNERSHIP AND UNDERTAKING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><U>_______________________________________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This <B>DEED
OF RIGHTS TRANSFER, STRATEGIC PARTNERSHIP AND UNDERTAKING</B> is made on the 1<SUP>st</SUP> day of January 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>BETWEEN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>AU, SIK
KEE (<FONT STYLE="font-family: PMingLiU,serif">&#21312;&#37675;&#27231;</FONT>)</B>, the holder of Hong Kong Identity Card No.
K*******, of 22/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong, being the Listed Chinese Medicine
Practitioner with the Listed No. of L***** maintained by the Chinese Medicine Practitioners Board of the Chinese Medicine Council
of Hong Kong (&ldquo;<B>The Chinese Medicine Practitioner</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>REGENCELL
BIOSCIENCE LIMITED (<FONT STYLE="font-family: PMingLiU,serif">&#33126;&#20877;&#29983;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;</FONT>)</B>,
a company incorporated in Hong Kong as a private company with limited liability with the Company no. 2236362, whose registered
office and whose principal place of business in Hong Kong is 21/F, EIB Tower, 4-6 Morrison Hill Road, Wan Chai, Hong Kong (&ldquo;<B>Regencell</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">(collectively,
referred hereunder as to &ldquo;<B>the Parties</B>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>WHEREAS:-
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">A.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Chinese Medicine Practitioner is the founder, creator and developer of certain Traditional
                                         Chinese Medicine (&ldquo;<B>TCM</B>&rdquo;) formulae which can provide effective solutions
                                         for patients suffering from Attention Deficit and Hyperactivity Disorder (&ldquo;<B>ADHD</B>&rdquo;)
                                         and Autism Spectrum Disorders (&ldquo;<B>ASD</B>&rdquo;), which are supported by the
                                         research data of over 100 patients who suffered from ADHD and ASD , and all other TCM
                                         formulae targeting different kinds of human illnesses and diseases (collectively, &ldquo;<B>the
                                         TCM Formulae</B>&rdquo;), as well as all of the Intellectual Property Rights (as defined
                                         hereinunder) (collectively, &ldquo;<B>the TCM Formulae and All Intellectual Property
                                         Rights</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">B.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Chinese Medicine Practitioner is also the sole legal and beneficial owner of the intellectual
                                         property rights of the TCM Formulae, including research and development, trademark, copyright,
                                         patent, and any other intellectual property rights, whether registered, unregistered,
                                         registrable, unregistrable or otherwise, in relation to and/or in connection with the
                                         TCM Formulae (&ldquo;<B>the Intellectual Property Rights</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">C.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Regencell
                                         was incorporated in Hong Kong as a private limited company on 12<SUP>th</SUP> May 2015,
                                         with an objective to provide and further research and development of TCM Formulae and
                                         All Intellectual Property Rights to be sold and marketed commercially around the world.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">D.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By
                                         entering into this Deed, both The Chinese Medicine Practitioner and Regencell acknowledge
                                         that they have read and understood the matters set out herein and that they are of lawful
                                         and legally competent to execute this Deed. Both The Chinese Medicine Practitioner and
                                         Regencell further acknowledge that they understand and have been advised of their respective
                                         right to obtain independent legal advice before entering into this Deed and are aware
                                         of its legal implication.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">E.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Parties acknowledge that the terms and conditions set out in this Deed are contractual
                                         in nature and they are intended to have legal effect and are not merely a warning or
                                         recital.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">F.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Parties confirm that they enter into this Deed out of its/his own free will without any
                                         undue influence, pressure, representation or inducement by any others.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">G.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Parties have agreed to enter into this Deed for The Chinese Medicine Practitioner to
                                         effect the transfer of ownership of the TCM Formulae and All Intellectual Property Rights
                                         and the TCM Inventions (as defined hereinafter) to Regencell and for Regencell to give
                                         an undertaking to The Chinese Medicine Practitioner in accordance with the terms set
                                         out in this Deed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">NOW THIS
DEED WITNESSES that: -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>INTERPRETATION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In
                                         this Deed, words importing the singular include the plural and vice versa, words importing
                                         gender or the neuter include both genders and the neuter and references to persons include
                                         bodies corporate or unincorporated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In
                                         this Deed, headings are for convenience only and shall not affect the construction of
                                         this Deed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In
                                         construing this Deed:-</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the
                                         rule known as the ejusdem generis rule shall not apply and accordingly general words
                                         introduced by the word &ldquo;other&rdquo; shall not be given a restrictive meaning by
                                         reason of the fact that they are preceded by words indicating a particular class of acts,
                                         matters or things; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">general
                                         words shall not be given a restrictive meaning by reason of the fact that they are followed
                                         by particular examples intended to be embraced by the general words.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>TRANSFER
                                         OF OWNERSHIP OF TCM FORMULAE AND ALL INTELLECTUAL PROPERTY RIGHTS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Chinese Medicine Practitioner hereby irrevocably agrees that he shall assign all his
                                         legal and beneficial ownership in relation to and/or in connection with the TCM Formulae
                                         and All Intellectual Property Rights to Regencell upon execution of this Deed (&ldquo;<B>the
                                         Transfer</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In
                                         consideration of the Transfer, Regencell undertakes to The Chinese Medicine Practitioner
                                         and agrees to donate three percent (3.0%) of net revenue generated in association with
                                         the use and/or commercialization of the TCM Formulae and All Intellectual Property Rights
                                         (&ldquo;<B>the Donation</B>&rdquo;) upon the Transfer to any of the charitable institutions
                                         and/or trusts of a public character anywhere in the world (&ldquo;<B>the Charitable Organization</B>&rdquo;)
                                         at the sole and absolute choice of the Chinese Medicine Practitioner (or someone assigned
                                         by him in writing) and in such proportion at the sole and absolute discretion of the
                                         Chinese Medicine Practitioner (or someone assigned by him in writing) on a yearly basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Regencell
                                         agrees that the calculation of the Donation will be relied on the net revenue as shown
                                         in the breakdown of the audited financial accounts of Regencell and The Chinese Medicine
                                         Practitioner is at his liberty to request Regencell to submit the audited financial accounts
                                         for his inspection at any time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Regencell
                                         agrees that for proving the compliance of its obligation under the clause 2.2 hereof,
                                         Regencell shall submit all payment slips regarding its Donation to the Charitable Organizations
                                         on a yearly basis or as requested by The Chinese Medicine Practitioner.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">2.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Regencell
                                         undertakes to pay for all costs and expenses incurred by the Chinese Medicine Practitioner
                                         in conducting research, testing, attending meetings/seminars, compiling records/reports
                                         or performing any similar acts in relation to the development of the TCM Formulae.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt .25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">2.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Upon
                                         the execution of this Deed, The Chinese Medicine Practitioner acknowledges that the legal
                                         and beneficial ownership of the TCM Formulae and All Intellectual Property Rights shall
                                         vest and continue to vest in Regencell. Any products or services further developed by
                                         the use of the TCM Formulae and All Intellectual Property Rights or acquired thereunder
                                         shall remain the exclusive property of Regencell.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt .25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">2.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Chinese Medicine Practitioner shall do and perform or procure to be executed, done and
                                         performed by Regencell all such further acts, agreements, assignments, assurances, deeds
                                         and documents upon the request from Regencell to vest effectively the legal and beneficial
                                         ownership of the TCM Formulae and All Intellectual Property Rights in Regencell.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>STRATEGIC
                                         PARTNERSHIP</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Regencell
                                         hereby forms a strategic partnership with The Chinese Medicine Practitioner whereas Regencell
                                         undertakes to continuously carry out its obligation under Clause 2.2 and The Chinese
                                         Medicine Practitioner accepts Clause 3.2 and Clause 3.3.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         inventions, TCM formulae, utilities, models improvements, research, discoveries, designs,
                                         processes, methods of manufacture, distribution or management, products, works of authorship,
                                         creations and the like, including all of their Intellectual Property Rights, conceived
                                         or made by The Chinese Medicine Practitioner, either individually or jointly with others,
                                         and in relation to TCM (individually, an &ldquo;<B>TCM Invention</B>&rdquo;, and collectively,
                                         &ldquo;<B>TCM Inventions</B>&rdquo;), shall be the sole and exclusive property of Regencell,
                                         its successors, assigns and nominees, without any compensation in addition to that set
                                         forth in this Deed. The Chinese Medicine Practitioner is, however, permitted to continue
                                         to use or make use of the TCM Inventions solely in his practice and for his research
                                         as a Chinese Medicine practitioner. Without limiting the generality of the foregoing:</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">If
after the execution of this Deed, The Chinese Medicine Practitioner, either individually or jointly with others, conceives, authors,
makes or first actually reduces to practice any TCM Invention, The Chinese Medicine Practitioner shall promptly disclose to Regencell
full details thereof, including without limitation any notes, recipes, formulae, drawings and models relating thereto, and agrees
to assign and does hereby assign and transfer to Regencell, its successors, assigns and nominees, all The Chinese Medicine Practitioner&rsquo;s
right, title and interest in and to such TCM Invention. At the expense and request of Regencell at any time and from time to time,
The Chinese Medicine Practitioner shall execute and deliver all documents and do all things necessary or desirable to enable Regencell,
its successors, assigns and nominees, to obtain the full benefit of an entire right, title and interest in and to such TCM Invention,
and to obtain, maintain, defend and enforce patent or other appropriate forms of protection for such TCM Invention throughout
the world, including without limitation the execution of all necessary applications, declarations, affidavits and other documentation.
All decisions as to the patenting and exploitation of any such TCM Invention shall be in the sole discretion of Regencell. The
Chinese Medicine Practitioner irrevocably appoints Regencell to be The Chinese Medicine Practitioner&rsquo;s attorney-in-fact,
in The Chinese Medicine Practitioner&rsquo;s name and on The Chinese Medicine Practitioner&rsquo;s behalf, to execute and deliver
such documents or instruments and do all such things that are necessary or desirable for the purpose of giving to Regencell, its
successors, assigns and nominees the full benefit of the provisions of this Clause 3.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Chinese Medicine Practitioner shall promptly disclose to Regencell all works in which
                                         copyright or design right exists which are originated, conceived, written or made by
                                         The Chinese Medicine Practitioner, either individually or jointly with others, and shall,
                                         until such rights are fully and absolutely vested in Regencell, its successors, assigns
                                         and nominees, hold them in trust for Regencell. The Chinese Medicine Practitioner agrees
                                         to assign and does hereby assign and transfer to Regencell, its successors, assigns and
                                         nominees, all copyright, design right and other proprietary and/or intellectual property
                                         rights, if any, therein for the full terms thereof throughout the world. At the expense
                                         and request of Regencell at any time and from time to time, The Chinese Medicine Practitioner
                                         shall execute and deliver all documents and do all things necessary or desirable to enable
                                         Regencell, its successors, assigns and nominees, to obtain the full benefit of an entire
                                         right, title and interest in and to such rights, and to secure copyright or other forms
                                         of intellectual property protection for them throughout the world, and otherwise to establish
                                         and substantiate the rights of Regencell under this Clause 3.3.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>DISCLOSURE
                                         OF THIS DEED</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This
                                         Deed and/or any of the terms and conditions herein may be disclosed partially or entirely
                                         by either of the Parties for and only for the following purposes (&ldquo;<B>the Disclosure</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">4.1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">where
                                         the Disclosure, in the opinion of Regencell, is of use in promoting, marketing and commercializing
                                         the business of Regencell and/or the TCM Formulae and All Intellectual Property Rights
                                         to all potential investors.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">4.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">where
                                         the Disclosure, in the opinion of Regencell, is necessary to demonstrate and prove its
                                         legal and beneficial ownership of the TCM Formulae and All Intellectual Property Rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">4.1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">where
                                         the Disclosure is required by law, by a court of competent jurisdiction or by another
                                         appropriate governmental, supervisory or regulatory body, within the extent permitted
                                         by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>GENERAL</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Parties represent and warrant that this Deed is executed on their behalf with full authorization
                                         and power and they are entitled to take any necessary measures to perform this Deed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No
                                         variation or amendment to this Deed shall be effective unless in writing and signed by
                                         the authorised representatives of all the Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         provisions of this Deed held invalid or unenforceable shall not affect the enforceability
                                         of the other provisions that shall remain valid.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt .25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt .25in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt .25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>TRANSFER
                                         OF BENEFIT</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Chinese Medicine Practitioner agrees that Regencell can transfer this Deed, on the same
                                         terms and conditions, to Regencell&rsquo;s successors, assigns and nominees as may from
                                         time to time be requested by Regencell.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>SEVERABILITY</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: .25in"><FONT STYLE="font-size: 10pt">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If
                                         any of the provisions in this Deed are found to be invalid, illegal or unenforceable
                                         by any applicable laws, regulations or competent courts, such invalidity, illegality
                                         and unenforceability shall not affect the remaining provisions of this Deed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>GOVERNING
                                         LAW AND DISPUTE RESOLUTION</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This Deed
shall be governed by and construed in accordance with the laws of Hong Kong Special Administrative Region, and any conflict or
dispute arising from or related to this Deed shall be subject to the non-exclusive jurisdiction of the Hong Kong courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>IN WITNESS
WHEREOF, the undersigned, intending to be legally bound, have duly executed and delivered this Deed to become effective as of
the date first above written.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED, SEALED AND DELIVERED</FONT></TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AU, SIK KEE (</B></FONT><B><FONT STYLE="font-family: PMingLiU,serif; font-size: 10pt">&#21312;&#37675;&#27231;</FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></B></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><I>/s/
    Sik Kee Au</I></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holder of Hong
    Kong Identity Card No</B>.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HKID No. K763****</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the
    presence of :-</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><I>/s/
    Mandy Au</I></FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED with the Common Seal
    of</FONT></TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGENCELL BIOSCIENCE</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIMITED (</B></FONT><B><FONT STYLE="font-family: PMingLiU,serif; font-size: 10pt">&#33126;&#20877;&#29983;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;</FONT></B><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></B></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><I>/s/
    Yat-Gai Au</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and SIGNED by its Director(s)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the
    presence of :-</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><I>/s/
    James Wai Hong Chung</I></FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED EMPLOYMENT AGREEMENT</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT</B> (the &ldquo;<U>Agreement</U>&rdquo; or &ldquo;<U>Amendment</U>&rdquo;), is entered
into as of February 2, 2021, by and between Regencell Bioscience Holdings Limited, incorporated under the laws of the Cayman Islands
(the &ldquo;Company&rdquo;), and Yat-Gai Au, a holder of Hong Kong Identity Card Number ******** (the &ldquo;Executive&rdquo;).
Except with respect to the direct employment of the Executive by the Company, the term &ldquo;Company&rdquo; as used herein with
respect to all obligations of the Executive hereunder shall be deemed to include the Company and all of its subsidiaries and affiliated
entities (collectively, the &ldquo;Group&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
The Company desires to employ the Executive as its Chief Executive Officer and to assure itself of the services of the Executive
during the term of Employment (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
The Executive desires to be employed by the Company as its Chief Executive Officer during the term of Employment and upon the
terms and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
The parties entered into an employment agreement, dated as of November 12, 2020 (the &ldquo;<U>Original Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
The parties desire to amend and restate Original Agreement to reflect the change of the compensation as described in this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
Section 16 of the Original Agreement provides that the Original Agreement may not be amended, modified or changed (in whole or
in part), except by a formal, definitive written agreement expressly referring to the Original Agreement, which agreement is executed
by both of the parties hereto. This Amendment is intended to evidence the written agreement of each of the parties to amend and
restate the Original Agreement set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POSITION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Executive hereby accepts a position of Chief Executive Officer (the &ldquo;Employment&rdquo;) of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERM</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to the terms and conditions of this Agreement, the initial term of the Employment shall be three (3) years, commencing on
    the effective date of the Company&rsquo;s registration statement with the U.S. Securities and Exchange Commission (the &ldquo;Effective
    Date&rdquo;), unless terminated earlier pursuant to the terms of this Agreement. The Employment will be renewed automatically
    for additional 3-year terms if neither the Company nor the Executive provides a 1-month prior written notice of termination
    of the Employment to the other party, or otherwise proposes to renegotiate the terms of the Employment with the other party
    within three (3) months prior to the expiration of the applicable term, or unless the Employment is terminated earlier pursuant
    to the terms of this Agreement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DUTIES
    AND RESPONSIBILITIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive&rsquo;s duties at the Company will include all jobs assigned by the Company&rsquo;s Board of the Directors (the
    &ldquo;Board&rdquo;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive shall devote all of his working time, attention and skills to the performance of his duties at the Company and shall
    faithfully and diligently serve the Company in accordance with this Agreement, the Memorandum and Articles of Association
    of the Company, as amended and restated from time to time (the &ldquo;Charter Documents&rdquo;), and the guidelines, policies
    and procedures of the Company approved from time to time by the Board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Executive shall use his best efforts to perform his duties hereunder. The Executive shall not, without the prior written consent
of the Board, become an employee of any entity other than the Company and any subsidiary or affiliate of the Company, and shall
not be concerned or interested in any business or entity that engages in the same business in which the Company engages (any such
business or entity, a &ldquo;Competitor&rdquo;), provided that nothing in this clause shall preclude the Executive from holding
any shares or other securities of any Competitor that is listed on any securities exchange or recognized securities market anywhere
if such shares or securities represent less than 5% of the competitors outstanding shares and securities. The Executive shall
notify the Company in writing of his interest in such shares or securities in a timely manner and with such details and particulars
as the Company may reasonably require.</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NO
    BREACH OF CONTRACT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Executive hereby represents to the Company that: (i)&nbsp;the execution and delivery of this Agreement by the Executive and the
performance by the Executive of the Executive&rsquo;s duties hereunder shall not constitute a breach of, or otherwise contravene,
the terms of any other agreement or policy to which the Executive is a party or otherwise bound, except for agreements entered
into by and between the Executive and any member of the Group pursuant to applicable law, if any; (ii)&nbsp;that the Executive
has no information (including, without limitation, confidential information and trade secrets) relating to any other person or
entity which would prevent, or be violated by, the Executive entering into this Agreement or carrying out his duties hereunder;
(iii)&nbsp;that the Executive is not bound by any confidentiality, trade secret or similar agreement (other than this) with any
other person or entity except for other member(s) of the Group, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intentionally
Omitted</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPENSATION
    AND BENEFITS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Base
    Salary</U>. The Executive shall receive a base salary of one U.S. dollar (US$1) per year during the employment term set forth
    in section 2, paid on June 30 of each year, and such arrangement is subject to annual review and adjustment by the Board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bonus</U>.
    The Executive shall not draw a bonus prior to and during the employment term, and such arrangement is subject to annual review
    and adjustment by the Board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equity
    Incentives</U>. To the extent the Company adopts and maintains a share incentive plan, the Executive will be eligible to participate
    in such plan pursuant to the terms thereof as determined by the Board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Benefits</U>.
    The Executive is eligible for participation in any standard employee benefit plan of the Company that currently exists or
    may be adopted by the Company in the future, including, but not limited to, any retirement plan, life insurance plan, health
    insurance plan and travel/holiday plan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses</U>.
    The Executive shall be entitled to reimbursement by the Company for all reasonable ordinary and necessary travel and other
    expenses incurred by the Executive in the performance of his duties under this Agreement; provided that he properly accounts
    for such expenses in accordance with the Company&rsquo;s policies and procedures.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Condition to
    Draw Compensation.</U> The Executive shall not draw the compensation and benefits set forth in this section more than US$1
    unless the Company reaches US$1billion market capitalization, and such arrangement is subject to annual review and adjustment
    by the Board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TERMINATION
    OF THE AGREEMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>By
    the Company.</U></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;<U>For
Cause</U>. The Company may terminate the Employment for cause, at any time, without notice or remuneration (unless notice or remuneration
is specifically required by applicable law, in which case notice or remuneration will be provided in accordance with applicable
law), if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Executive is convicted or pleads guilty to a felony or to an act of fraud, misappropriation or embezzlement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the Executive has been grossly negligent or acted dishonestly to the detriment of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
the Executive has engaged in actions amounting to willful misconduct or failed to perform his duties hereunder and such failure
continues after the Executive is afforded a reasonable opportunity to cure such failure; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
the Executive violates Section 8 or 10 of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination for cause, the Executive shall be entitled to the amount of base salary earned and not paid prior to termination.
However, the Executive will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination,
and the Executive&rsquo;s right to all other benefits will terminate, except as required by any applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;<U>For
death and disability</U>. The Company may also terminate the Employment, at any time, without notice or remuneration (unless notice
or remuneration is specifically required by applicable law, in which case notice or remuneration will be provided in accordance
with applicable law), if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Executive has died, or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the Executive has a disability which shall mean a physical or mental impairment which, as reasonably determined by the Board,
renders the Executive unable to perform the essential functions of his employment with the Company, with or without reasonable
accommodation, for more than 120 days in any 12-month period, unless a longer period is required by applicable law, in which case
that longer period would apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination for death or disability, the Executive shall be entitled to the amount of base salary earned and not paid prior to
termination. However, the Executive will not be entitled to receive payment of any severance benefits or other amounts by reason
of the termination, and the Executive&rsquo;s right to all other benefits will terminate, except as required by any applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;<U>Without
Cause</U>. The Company may terminate the Employment without cause, at any time, upon one-month prior written notice. Upon termination
without cause, the Company shall provide the following severance payments and benefits to the Executive: (1)&nbsp;a lump sum cash
payment equal to 1 months of the Executive&rsquo;s base salary as of the date of such termination; (2)&nbsp;a lump sum cash payment
equal to a pro-rated amount of his target annual bonus for the year immediately preceding the termination, if any; (3)&nbsp;payment
of premiums for continued health benefits under the Company&rsquo;s health plans for 12 months fo1lowing the termination, if any;
and (4)&nbsp;immediate vesting of 100% of the then-unvested portion of any outstanding equity awards held by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination without cause, the Executive shall be entitled to the amount of base salary earned and not paid prior to termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;<U>Change
of Control Transaction</U>. If the Company or its successor terminates the Employment upon a merger, consolidation, or transfer
or sale of all or substantially all of the assets of the Company with or to any other individual(s) or entity (the &ldquo;<U>Change
of Control Transaction</U>&rdquo;), the Executive shall be entitled to the following severance payments and benefits upon such
termination: (1)&nbsp;a lump sum cash payment equal to 1 months of the Executive&rsquo;s base salary at a rate equal to the greater
of his/her annual salary in effect immediately prior to the termination, or his/her then current annua1 salary as of the date
of such termination; (2)&nbsp;a lump sum cash payment equal to a pro-rated amount of his/her target annual bonus for the year
immediately preceding the termination; (3)&nbsp;payment of premiums for continued health benefits under the Company&rsquo;s health
plans for 12 months fo1lowing the termination; and (4)&nbsp;immediate vesting of 100% of the then-unvested portion of any outstanding
equity awards held by the Executive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>By
    the Executive</U>. The Executive may terminate the Employment at any time with a one-month prior written notice to the Company,
    if (1)&nbsp;there is a material reduction in the Executive&rsquo;s authority, duties and responsibilities, or (2)&nbsp;there
    is a material reduction in the Executive&rsquo;s annual salary. Upon the Executive&rsquo;s termination of the Employment due
    to either of the above reasons, the Company shall provide compensation to the Executive equivalent to 1 months of the Executive&rsquo;s
    base salary that he is entitled to immediately prior to such termination. In addition, the Executive may resign prior to the
    expiration of the Agreement if such resignation is approved by the Board or an alternative arrangement with respect to the
    Employment is agreed to by the Board.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notice
    of Termination.</U>&nbsp;Any termination of the Executive&rsquo;s employment under this Agreement shall be communicated by
    written notice of termination from the terminating party to the other party. The notice of termination shall indicate the
    specific provision(s) of this Agreement relied upon in effecting the termination.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIALITY
    AND NON-DISCLOSURE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Confidentiality
    and Non-disclosure</U>. The Executive hereby agrees at all times during the term of the Employment, to hold in the strictest
    confidence, and not to use, except for the benefit of the Company, or to disclose to any person, corporation or other entity
    without prior written consent of the Company, any Confidential Information. The Executive understands that &ldquo;<U>Confidential
    Information</U>&rdquo; means any proprietary or confidential information of the Company, its affiliates, or their respective
    clients, customers or partners, including, without limitation, technical data, trade secrets, research and development information,
    product plans, services, customer lists and customers, supplier lists and suppliers, software developments, inventions, processes,
    formulas, technology, designs, hardware configuration information, personnel information, marketing, finances, information
    about the suppliers, joint ventures, franchisees, distributors and other persons with whom the Company does business, information
    regarding the skills and compensation of other employees of the Company or other business information disclosed to the Executive
    by or obtained by the Executive from the Company, its affiliates, or their respective clients, customers or partners, either
    directly or indirectly, in writing, orally or otherwise, if specifically indicated to be confidential or reasonably expected
    to be confidential. The confidentiality obligations under this Clause shall survive notwithstanding the termination of this
    Employment Agreement for ten (10) years thereafter. Notwithstanding the foregoing, Confidential Information shall not include
    information that is generally available and known to the public through no fault of the Executive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company
    Property</U>. The Executive understands that all documents (including computer records, facsimile and e-mail) and materials
    created, received or transmitted in connection with his work or using the facilities of the Company are property of the Company
    and subject to inspection by the Company at any time. Upon termination of the Executive&rsquo;s employment with the Company
    (or at any other time when requested by the Company), the Executive will promptly deliver to the Company all documents and
    materials of any nature pertaining to his work with the Company and will provide written certification of his compliance with
    this Agreement. Under no circumstances will the Executive have, following his&nbsp;termination, in his possession any property
    of the Company, or any documents or materials or copies thereof containing any Confidential Information.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Former
    Employer Information</U>. The Executive agrees that he has not and will not, during the term of his employment, (i)&nbsp;improperly
    use or disclose any proprietary information or trade secrets of any former employer or other person or entity with which the
    Executive has an agreement or duty to keep in confidence information acquired by Executive, if any, or (ii)&nbsp;bring into
    the premises of the Company any document or confidential or proprietary information belonging to such former employer, person
    or entity unless consented to in writing by such former employer, person or entity. The Executive will indemnify the Company
    and hold it harmless from and against all claims, liabilities, damages and expenses, including reasonable attorneys&rsquo;
    fees and costs of suit, arising out of or in connection with any violation of the foregoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Third
    Party Information</U>. The Executive recognizes that the Company may have received, and in the future may receive, from third
    parties their confidential or proprietary information subject to a duty on the Company&rsquo;s part to maintain the confidentiality
    of such information and to use it only for certain limited purposes. The Executive agrees that the Executive owes the Company
    and such third parties, during the Executive&rsquo;s employment by the Company and thereafter, a duty to hold all such confidential
    or proprietary information in the strictest confidence and not to disclose it to any person or firm and to use it in a manner
    consistent with, and for the limited purposes permitted by, the Company&rsquo;s agreement with such third party.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Section 8 shall survive the termination of this Agreement for any reason. In the event the Executive breaches this Section 8,
the Company shall have right to seek remedies permissible under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFLICTING
    EMPLOYMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Executive hereby agrees that, during the term of his employment with the Company, he will not engage in any other employment,
occupation, consulting or other business activity related to the business in which the Company is now involved or becomes involved
during the term of the Executive&rsquo;s employment, nor will the Executive engage in any other activities that conflict with
his obligations to the Company without the prior written consent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.5pt; text-align:left; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-COMPETITION
AND NON-SOLICITATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the compensation and benefits paid to the Executive by the Company and subject to applicable law, the Executive
agrees that during the term of the Employment and for a period of two (2) years following the termination of the Employment for
whatever reason:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive will not approach clients, customers or contacts of the Company or other persons or entities introduced to the Executive
    in the Executive&rsquo;s capacity as a representative of the Company for the purposes of doing business with such persons
    or entities which will harm the business relationship between the Company and such persons and/or entities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive will not assume employment with or provide services as a director or otherwise for any Competitor, or engage, whether
    as principal, partner, licensor or otherwise, in any Competitor; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Executive will not seek, directly or indirectly, by the offer of alternative employment or other inducement whatsoever, to
    solicit the services of any employee of the Company employed as at or after the date of such termination, or in the year preceding
    such termination.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions contained in Section&nbsp;10 are considered reasonable by the Executive and the Company. In the event that any such
provisions should be found to be void under applicable laws but would be valid if some part thereof was deleted or the period
or area of application reduced, such provisions shall apply with such modification as may be necessary to make them valid and
effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Section 10 shall survive two (2) years after the termination of this Agreement for any reason. In the event the Executive breaches
this Section 10, the Executive acknowledges that there will be no adequate remedy at law, and the Company shall be entitled to
injunctive relief and/or a decree for specific performance, and such other relief as may be proper (including monetary damages
if appropriate). In any event, the Company shall have right to seek all remedies permissible under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WITHHOLDING
TAXES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything else herein to the contrary, the Company may withhold (or cause there to be withheld, as the case may be) from any amounts
otherwise due or payable under or pursuant to this Agreement such national, provincial, local or any other income, employment,
or other taxes as may be required to be withheld pursuant to any applicable law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is personal in its nature and neither of the parties hereto shall, without the consent of the other, assign or transfer
this Agreement or any rights or obligations hereunder; provided, however, that (i)&nbsp;the Company may assign or transfer this
Agreement or any rights or obligations hereunder to any member of the Group without such consent, and (ii)&nbsp;in the event of
a Change of Control Transaction, this Agreement shall, subject to the provisions hereof, be binding upon and inure to the benefit
of such successor and such successor shall discharge and perform all the promises, covenants, duties, and&nbsp;obligations of
the Company hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SEVERABILITY</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any provision of this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or
applications of this Agreement which can be given effect without the invalid provisions or applications and to this end the provisions
of this Agreement are declared to be severable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;ENTIRE
    AGREEMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement constitutes the entire agreement and understanding between the Executive and the Company regarding the terms of the
Employment and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter, including any
prior agreements between the Executive and a member of the Group. The Executive acknowledges that he has not entered into this
Agreement in reliance upon any representation, warranty or undertaking which is not set forth in this Agreement. Any amendment
to this Agreement must be in writing and signed by the Executive and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GOVERNING
LAW; JURISDICTION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by and construed in accordance with the laws of Hong Kong and each of the parties irrevocably consents
to the jurisdiction and venue of the courts located in Hong Kong.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may not be amended, modified or changed (in whole or in part), except by a formal, definitive written agreement expressly
referring to this Agreement, which agreement is executed by both of the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WAIVER</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the failure nor any delay on the part of a party to exercise any right, remedy, power or privilege under this Agreement shall
operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege preclude any other
or further exercise of the same or of any right, remedy, power or privilege, nor shall any waiver of any right, remedy, power
or privilege with respect to any occurrence be construed as a waiver of such right, remedy, power or privilege with respect to
any other occurrence. No waiver shall be effective unless it is in writing and is signed by the party asserted to have granted
such waiver.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices, requests, demands and other communications required or permitted under this Agreement shall be in writing and shall be
deemed to have been duly given and made if (i)&nbsp;delivered by hand, (ii)&nbsp;otherwise delivered against receipt therefor,
or (iii)&nbsp;sent by a recognized courier with next-day or second-day delivery to the last known address of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COUNTERPARTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original as against any party whose
signature appears thereon, and all of which together shall constitute one and the same instrument. This Agreement shall become
binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all of the parties
reflected hereon as the signatories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Photographic
copies of such signed counterparts may be used in lieu of the originals for any purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">

    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NO
INTERPRETATION AGAINST DRAFTER</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party recognizes that this Agreement is a legally binding contract and acknowledges that he has had the opportunity to consult
with legal counsel of choice. In any construction of the terms of this Agreement, the same shall not be construed against either
party on the basis of that party being the drafter of such terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Remainder
of this page has been intentionally left blank.]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, this Agreement has been executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regencell Bioscience Holdings
    Limited</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></P></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; width: 35%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
        Yi-Chung Chao</I></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yi-Chung Chao&nbsp;&nbsp; &nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Medical Officer &nbsp; &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yat-Gai Au</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yat-Gai Au</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align:left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.3</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUPPLEMENTAL
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Supplemental Agreement (the &ldquo;<B>Supplemental Agreement</B>&rdquo;) of the Deed of Rights Transfer, Strategic Partnership
and Undertaking Agreement is made and entered into on November 10, 2020 (&ldquo;<B>Effective Date</B>&rdquo;) by and between:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)</B></FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Regencell
Bioscience limited</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, a limited liability company
incorporated in Hong Kong, whose business address is at 11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong
Kong; (the &ldquo;<B>Company</B>&rdquo;); and</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)</B></FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mr.
Sik-Kee Au</B>, the holder of Hong Kong Identity Card No. ********, being the Listed Chinese Medicine Practitioner with the Listed
No. L05*** maintained by the Chinese Medicine Practitioners Board of the Chinese Medicine Council of Hong Kong (the &ldquo;<B>TCM
Practitioner</B>&rdquo;).</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Company
and TCM Practitioner are sometimes referred to herein individually as a &ldquo;<B>Party</B>&rdquo; and collectively as the &ldquo;<B>Parties</B>&rdquo;.
All terms not herein defined shall have the meaning given to them in the Partnership Agreement (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Recitals:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Company is an early stage bioscience company that focuses on research, development, and commercialization of Traditional Chinese
Medicine (&ldquo;TCM&rdquo;) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity
Disorder (&ldquo;<B>ADHD</B>&rdquo;) and Autism Spectrum Disorder (&ldquo;<B>ASD</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
The TCM Practitioner has been practicing TCM under the guidance of the Chinese Medicine Ordinance (Chapter 549 of the Laws of
Hong Kong) and has accumulated over thirty years of research and clinical practice experience.;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Parties have entered Deed of Rights Transfer, Strategic Partnership and Undertaking agreement (the &ldquo;<B>Partnership Agreement</B>&rdquo;)
on January 1, 2018, pursuant to which the TCM Practitioner transfers his legal and beneficial ownership of the intellectual property
rights of the his TCM Formulae and TCM Inventions and the Company undertakes to pay for all costs and expenses incurred by the
TCM Practitioner in his research, testing, attending meetings/seminars, compiling records/reports or performing any similar acts
in relation to the development of his TCM Formulae. Unless the context otherwise requires, words defined in the Partnership Agreement
shall have the same meaning in this Supplemental Agreement. The rules of interpretation set out in the Partnership Agreement shall
apply to this Supplemental Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Parties desire to enter this Supplemental Agreement to provide the terms and conditions upon which the TCM Practitioner accepts
the supervisions and direction of the Company on his TCM Formulae research, non-competition, and the non-disclosure restrictions
in his practice under the Partnership Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE,</B> in consideration of the foregoing premises and the mutual promises, covenants, agreements, representations, warranties
and indemnities and conditions contained in this Supplemental Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which are acknowledged by the Parties, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitions</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate&rdquo;
</B>means (i) all business units and divisions of a party or its parent company/corporation and (ii) any entity controlled by,
controlling, or under common control with such party. Such entity shall be deemed to be an &ldquo;Affiliate&rdquo; only so long
as such control exists.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable
Laws</B>&rdquo; means all applicable laws, treaties, statutes, codes, rules, regulations, regulatory policies, practices, guidelines,
ordinances, judgments, orders, rulings or decisions of any governmental authorities and other pronouncements having the effect
of law of any national, multinational, city or other political subdivision, domestic or foreign, in each case binding on or applicable
to a Party referred to in the context in Hong Kong.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Business</B>&rdquo;
means all business and affiliates carried out by the Company and its Affiliates from time to time, including but not limited to
the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically
ADHD and ASD.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Confidential
Information</B>&rdquo; means all information, know-how and records (in whatever form held) in any way connected with the Company,
its Business and the Research, whether proprietary or otherwise, including (without prejudice to the generality of the foregoing)
without limitation all TCM Inventions, TCM Formulae, the intellectual property rights, designs, specifications, drawings, data,
operations and testing procedures, manuals and instructions and all customer, patient, and supplier information and lists, sales
information, business plans and methods, processes, systems, research and development, forecasts and all technical or other expertise,
and all accounting and tax records, correspondence, orders and enquiries that are confidential or not generally known.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
Information shall include information in written, oral, electronic or any other form whether or not it is clearly identified in
writing at the time of disclosure as confidential. For avoidance of doubt, Confidential Information shall not include information
that (i) is or becomes a part of the public domain through no act or omission of the other Party; (ii) was in the other Party&rsquo;s
lawful possession prior to the disclosure and had not been obtained by the other Party either directly or indirectly from the
disclosing Party; (iii) is lawfully disclosed to the other Party by a third party without restriction on disclosure; or (iv) is
independently developed by the other Party without use of or reference to the other Party&rsquo;s Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Research</B>&rdquo;
means all services, materials, products, TCM Formulae, TCM Inventions, or intellectual property provided, developed, and researched
by TCM Practitioner to the Company and its Affiliates under this Supplemental Agreement and the Partnership Agreement or as otherwise
agreed by the Parties from time to time.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Results</B>&rdquo;
means all data and information generated or derived from the Research and from other research performed by the TCM Practitioner
under this Supplemental Agreement and Partnership Agreement, including but not limited to new TCM Formulae, TCM Inventions, and
intellectual property.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scope
of the Supplemental Agreement</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner shall perform the Research, in accordance with the terms and conditions of this Supplemental Agreement. TCM Practitioner
shall use reasonable efforts to perform the Research and to meet all standards, obligations and completion dates described in
this Supplemental Agreement or to be agreed by the Parties.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has full discretion to assign, refine, update or redesign tasks of the Research to the TCM Practitioner from time-to-time.
Such instructions and changes shall be effective upon notice to TCM Practitioner.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner shall provide the Research in accordance with the terms and conditions set forth in this Supplemental Agreement and
all Applicable Laws.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
request by the Company, which shall be made from time to time, TCM Practitioner shall transfer all: (i) Results, and/or (ii) any
other materials, data, information and all other data it possesses with regard to each Research to the Company, in such form as
requested by the Company or as is then currently in the possession of TCM Practitioner.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner may assign appropriately qualified personnel to perform any and some of the Research with the Company&rsquo;s prior
written consent (the &ldquo;<B>Development Team</B>&rdquo;). The Development Team shall use high professional standards while
performing the Research and maintaining full compliance with any and all specification and instructions set by the Company from
time to time.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner shall protect, promote and act in the best interests of the Company, including but not limited to:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">devote
the whole of his attention and skill to the interests and affairs of the Company in the discharge of the Research;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
the discharge of the Research and in the exercise of such powers, comply with all and any lawful directions and instructions from
time to time made or given to him by the Company according to the best of his skills and ability, and comply with all resolutions
and regulations from time to time passed or made by the Company;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">faithfully
and diligently perform the Research with due care and skill, and exercise only such powers as are consistent with the Research
in relation to, and use commercially reasonable efforts to promote, the interests of the Company;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">keep
the Company promptly and fully informed of his and the Development Team&rsquo;s conduct of the Research and give promptly to the
Company (in writing if so requested) all such information as the Company may reasonably require in relation to its conduct of
the Research insofar as such information is or ought to be within the knowledge of TCM Practitioner and provide such written explanations
to the Company may require in connection therewith; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
commercially reasonable efforts to ensure that they are available at all times on reasonable notice to provide the Research as
the Company may require.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner shall not subcontract or delegate the performance of all or part of the Research to any personnel other than the
Development Team, without written consent given by the Company.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
Fees and Payment</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of due performance of TCM Practitioner&rsquo;s obligations under this Supplemental Agreement and Partnership Agreement,
TCM Practitioner shall be entitled to receive with effect from the Effective Date during the Term (defined hereunder) a research
fee covering all costs and expenses incurred by the TCM Practitioner in conducting research, testing, attending meetings/seminars,
compiling records/reports or performing any similar acts in relation to the development of the TCM Invention, TCM Formulae and
all intellectual property rights &nbsp;(including any tax and duties payable by TCM Practitioner pursuant to the Applicable Laws
and any compensation rights that TCM Practitioner may have as a result of his compliance with Clause 7 hereunder) (&ldquo;<B>Research
Fee</B>&rdquo;).</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner shall issue an invoice of Research Fees to the Company on monthly basis. The Research Fee shall be due within thirty
(30) days from the date of the invoice.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall only be responsible for retaining and discharging, and paying Research Fee that are the reasonable fees, charges
and expenses related to the performance of the Research incurred by the TCM Practitioner.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
of such Research Fees to TCM Practitioner shall be made by the Company. Payment in full or in part of the Research Fees shall
be without prejudice to any claims or rights of the Company against TCM Practitioner in respect of the provision of the Research.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Research Fees are inclusive of taxes, charges or remittance fees. Each Party shall pay any and all tax due under Applicable Laws
by such Party in respect of all payments it receives or makes under this Supplemental Agreement. Each Party shall be solely responsible
for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under
this Supplemental Agreement and the Partnership Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
payments due under this Supplemental Agreement and the Partnership Agreement to TCM Practitioner shall be made via check or bank
wire transfer which is notified by TCM Practitioner in advance in immediately available funds to a bank account designated by
the TCM Practitioner, free and clear of any withholding tax, administrative fees, bank charges, transfer fees or other similar
charges under the Applicable Laws.</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representations
and Warranties</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Party represents, warrants and covenants to the other Party that:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
Party has taken all actions to authorize the execution, delivery and performance of the obligations undertaken in this Supplemental
Agreement, and no other corporate actions are necessary with respect thereto; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">when
executed and delivered by it, this Supplemental Agreement will constitute a legal, valid and binding obligation of it, enforceable
against it in accordance with this Supplemental Agreement&rsquo;s terms.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TCM Practitioner further represents and warrants to the Company that as of the Effective Date and at all times during the Term
of the Supplemental Agreement:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Supplemental Agreement has been duly executed and delivered by, and is the legal and valid obligations upon TCM Practitioner and
the entry into, the execution and delivery of, and the carrying out and other performance of its obligations under this Supplemental
Agreement by TCM Practitioner: (a) does not conflict with, or contravene or constitute any default under, any agreement, instrument
or understanding, oral or written, to which he is a party, and (b) does not violate Applicable Laws;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner shall not enter into any other agreements which would interfere with or prevent the performance of the obligations
described herein;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TCM
Practitioner maintains and shall maintain during the Term of this Supplemental Agreement equipment and personnel sufficient to
enable him to perform the Research in accordance with the Supplemental Agreement;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
TCM Formulae, TCM Inventions, and its intellectual property rights to be developed in the future under the Partnership Agreement
by the TCM Practitioner will be original, and will not be subject to any third party&rsquo;s rights or claims; the TCM Formulae,
TCM Inventions and its intellectual property rights will not be published, in whole or part, without the Company&rsquo;s prior
written consent;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
third party shall acquire, own, or possess any right or interest in any TCM Formulae, TCM Inventions, and its intellectual property
rights to be developed in the future that arises out of or is made as a consequence of any Research by TCM Practitioner pursuant
to this Supplemental Agreement and Partnership Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidentiality;
Non-Disclosure</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TCM Practitioner, his agents, subcontractors, development team, and Affiliates shall, during or after the Term, directly or indirectly
publish, disseminate or otherwise disclose, deliver or make available to any third party any Confidential Information, without
prior written notice given by the Company. The TCM Practitioner shall use the Confidential Information solely for the purpose(s)
set forth in this Supplemental Agreement, the Partnership Agreement, or for such other purposes as may be agreed upon by the Parties
in writing. The confidentiality obligations under this Clause 6 shall survive notwithstanding the termination of this Supplemental
Agreement for ten (10) years thereafter.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TCM Practitioner, his agents, subcontractors, development team, and Affiliates undertake to use the Confidential Information only
for the fulfilment of the Research, and shall not at any time:</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">divulge
or communicate to any person any Confidential Information except those of the employees of the Company or the third party without
the Company&rsquo;s prior written consent; and</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
any failure to exercise all due care and diligence cause any unauthorized disclosure of any Confidential Information (including
without limitation): relating to the Research, dealings, organization, business, finance, transactions or any other affairs of
the Company.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TCM Practitioner agrees, on behalf of himself, his agents, subcontractors, development team and Affiliates, not to publish or
present any and all information, data and/or documents, whether patentable or not, as generated in the course of and/or as a result
of the Research.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TCM Practitioner shall not disclose the terms herein of this Supplemental Agreement and the Partnership Agreement and/or any relationship
between TCM Practitioner and the Company to any third party.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restraint
on Activities of TCM Practitioner; Non-Competition</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Term, TCM Practitioner undertakes and shall cause himself to undertake to the Company that he will devote his time and attention
to the Company and will use his best endeavors to develop the business and interests of the Company and will not be concerned
with any other business other than the Business.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
two (2) years after the expiration or termination of this Supplemental Agreement, whichever is earlier, the TCM Practitioner shall
not be directly or indirectly concerned with or engaged or interested in any other business which is in any respect in competition
with or similar to the Business conducted by the Company.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term;
Termination</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise earlier terminated pursuant to this Clause 8.2-8.4, this Supplemental Agreement shall be effective on the Effective
Date and shall remain effective until the Partnership Agreement is expired or terminated (&ldquo;<B>Term</B>&rdquo;). In the event
that both Parties agree to extend the Term or to renew this Supplemental Agreement, the Parties may do so by executing a separate
written agreement or extension or renewal.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may terminate this Supplemental Agreement for any reason in the Company&rsquo;s sole discretion and without any indemnity
or damages being due to TCM Practitioner with thirty (30) days prior written notice.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT></P>


<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Company may terminate this Supplemental Agreement:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
any breach by TCM Practitioner of his obligations under this Supplemental Agreement which is not cured within thirty (30) days
of the notification of such; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
if TCM Practitioner is no longer able to perform the Research; commits any act of gross or willful misconduct or any serious,
willful, grossly negligent or material breach of any of the provisions contained in this Supplemental Agreement; commits any fraud
or act of dishonesty, engages in any conduct which, in the reasonable opinion of the Company, has caused or is likely to cause
detriment to the interests of the Company, is otherwise prohibited by Applicable Laws from providing the Research, refuses to
carry out any reasonable lawful order given to TCM Practitioner by the Company in the Term, is incompetent or fail to diligently
attend to the Research.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TCM Practitioner may terminate this Supplemental Agreement in the event that the Company fails to meet its payment obligations
under Clause 4.2 of this Supplemental Agreement which is not cured within thirty (30) days of the notification of such by the
Company.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
expiration or termination of this Supplemental Agreement, the TCM Practitioner shall:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
deliver to the Company all Confidential Information and all other property of or relating to the Company which may then be in
TCM Practitioner&rsquo;s possession or under TCM Practitioner&rsquo;s power or control and all copies thereof or extracts therefrom;
and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immediately
delete all Confidential Information from any computer discs, USB devices, tapes or other re-useable material in TCM Practitioner&rsquo;s
possession or control and destroy all other documents and tangible items in TCM Practitioner&rsquo;s possession or under TCM Practitioner&rsquo;s
control which contain or refer to any Confidential Information.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
of this Supplemental Agreement shall not limit either Party from pursuing other remedies available to it, including injunctive
relief. For the avoidance of doubt, if the Supplemental Agreement hereunder is terminated by Company for cause, Company shall
not be obligated to continue making any additional Research Fees as of the date of termination. &nbsp; &nbsp; &nbsp; &nbsp; 8.7
In the event of expiration or termination of this Supplemental Agreement, Clauses 1, 6, 7, 8.5-8.7, 9 and 10, as well as any provisions
which are to survive by nature, shall survive such expiration or termination.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governing
Law and Jurisdiction</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Supplemental Agreement is governed by and shall be construed in all respects in accordance with the laws of Hong Kong.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
dispute, controversy, difference or claim arising out of or relating to this Supplemental Agreement, including the existence,
validity, interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising
out of or relating to it shall be referred to and finally resolved by arbitration administered by the Hong Kong International
Arbitration Centre (HKIAC) under the HKIAC Administered Arbitration Rules in force when the Notice of Arbitration is submitted.
The arbitration proceeding shall be conducted in Hong Kong. There shall be three (3) arbitrators, each Party shall appoint one
(1) arbitrator and the third arbitrator shall be jointly appointed by the appointed arbitrators.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Miscellaneous</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Supplemental Agreement, and the rights and obligations hereunder, may not be assigned or transferred by either Party without prior
written consent of the other Party, except that Company may assign this Supplemental Agreement to an Affiliate or in connection
with a merger, consolidation or sale of all or substantially all of its assets.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise provided in this Supplemental Agreement, no changes, amendments or alternations to this Supplemental Agreement shall
be allowed unless in writing and are signed by duly authorized representatives of both Parties.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any one or more of the provisions contained in this Supplemental Agreement, shall for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions
of this Supplemental Agreement and the Partnership Agreement, and all other provisions in this Supplemental Agreement and the
Partnership Agreement shall remain in full force and effect. If any of the provisions of this Supplemental Agreement are held
to be excessively broad, it shall be reformed and construed by limiting and reducing it so as to be enforceable to the maximum
extent permitted by the Applicable Laws.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
Parties shall be held liable for nonfulfillment or delayed performance of this Supplemental Agreement or of part thereof due directly
or indirectly to any cause outside the defaulting Party&rsquo;s control, provided that notice of its inability to perform and
the causes thereof shall be given immediately by the affected Party to the other.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Supplemental Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which,
when taken together, shall constitute one original instrument.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headings
to clauses herein are for the convenience of the parties only and are not intended to be or to affect the meaning or interpretation
of this Supplemental Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notice, requests, demands, approvals or consents, or other communications hereunder shall be in writing and shall be deemed given
if delivered: (i) by electronic mail stated below, (ii) by registered mail with acknowledgement of receipt, or (iii) personally
to the appropriate party at the address below:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If to the Company:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">Address:</TD>
    <TD STYLE="text-align: justify; width: 30%"><FONT STYLE="font-size: 10pt">11/F First Commercial Building</FONT></TD>
    <TD STYLE="width: 56%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">33-35 Leighton Road</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Causeway Bay, Hong Kong</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Email:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Attention:</TD>
    <TD><FONT STYLE="font-size: 10pt">Mr. Yat-Gai Au</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If to TCM Practitioner:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Address:</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">22/F First Commercial Building</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">33-35 Leighton Road</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Causeway Bay, Hong Kong</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Email:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Attention:</TD>
    <TD><FONT STYLE="font-size: 10pt">Mr. Sik-Kee Au</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page to follow]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF,</B> the Parties have executed this Supplemental Agreement in two (2) originals by their respective officers duly
authorized as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Regencell bioscience limited</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Yat-Gai Au</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yat-Gai Au</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="display: none; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>sik-kee au</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Sik-Kee Au</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Sik-Kee Au</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">TCM Practitioner</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LOAN AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entered
into between:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mr.
Yat-Gai Au</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(&ldquo;the Lender&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regencell
Bioscience Limited</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(&ldquo;the Borrower&rdquo;)</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>LOAN AGREEMENT </B>(hereinafter referred to as the &ldquo;<B>Agreement</B>&rdquo;) is made and entered into on November 10,
2020, by and between Yat-Gai Au, a holder of Hong Kong Identity Card Number: P*******, 11/F First Commercial Building, 33-35 Leighton
Road, Causeway Bay, Hong Kong (hereinafter referred to as the &ldquo;<B>Lender</B>&rdquo;) and Regencell Bioscience Limited, a
limited company duly established under the laws of Hong Kong, having its registered office at 11/F First Commercial Building,
33-35 Leighton Road, Causeway Bay, Hong Kong (hereinafter referred to as the &ldquo;<B>Borrower</B>&rdquo;). The Lender and the
Borrower collectively shall be referred to as the &ldquo;<B>Parties</B>&rdquo; and respectively as the &ldquo;<B>Party</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
immediately prior to effectiveness of this Agreement, the Lender has provided certain loans to the Borrower in an aggregate amount
of HK$23,945,298 as of June 30, 2020 and an additional HK$3,634,387 from July 1, 2020 to November 10, 2020. (the &ldquo;<B>Existing
Loan</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Parties desire to enter this Agreement to evidence the Existing Loan and document their oral agreements of the terms and conditions
of such Existing Loan when such loan was initially generated; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Lender further agrees to make Loan (as defined below) to the Borrower in connection with the daily operation and research
of the Borrower in accordance with the terms and conditions set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B>, the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
1 &ndash; Definitions and interpretation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Definitions</U></B>;
In this Agreement, the following expressions shall have the following meanings:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Business
Day</B>&rdquo; means a day (other than a Saturday, Sunday or public holiday) on which commercial banks are open for normal banking
business in Hong Kong.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Effective
Date</B>&rdquo; means the date this Agreement is signed upon by both parties as mentioned in the beginning of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Loan</B>&rdquo;
means the loan facility made available in HK dollar, without limit on the number or duration, through wire transfer to Borrower&rsquo;s
bank account upon the effectiveness of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Loan
Date</B>&rdquo; means the Business Day on which the Lender makes available the Loan to the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Maturity
Date</B>&rdquo; means the 30<SUP>th</SUP> day of June 2021, subject to indefinite extension if agreed by the Parties in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax</B>&rdquo;
means any tax, levy, impost, duty or other charge or withholding of a similar nature (including any related penalty or interest).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Interpretation</U></B>;
In this Agreement, unless the context otherwise requires:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
headings and underlining are for convenience only and shall not affect the interpretation of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
words importing the singular shall include the plural and vice versa;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
words importing a gender shall include any gender; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
references to &ldquo;HK$&rdquo; or &ldquo;HK dollar&rdquo; shall refer to the official currency of Hong Kong.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
2 &ndash;  The Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Loan</U></B>;
Subject to the terms of this Agreement, the Lender agrees to make the Loan available to the Borrower in a timely manner or make
payments on the Borrower&rsquo;s behalf, according to the needs of the operations and research activities of the Borrower and
its subsidiaries or parent company.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Purpose
of the Loan</U></B>; The Loan is strictly for the use by the Borrower and its subsidiaries or parent company for daily operation
and research activities. The use of Loan shall be agreed and determined by the Parties before granting the Loan.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
3 &ndash; Interest</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Interest
Rate</U></B>; The Loan and Existing Loan shall bear 0% interest per annum.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Article
4 &ndash; Payment of the Loan and Existing Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Payment</U></B>;
The Borrower shall repay the Loan and Existing Loan on the Maturity Date. If agreed by the Parties in writing, the Maturity Date
may be extended indefinitely.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Prepayment</U></B>;
The Borrower may repay, at any time and from time to time and any other sum then due to the Lender under any provisions of this
Agreement, in whole or in part.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Method
of Payment</U></B>; Payment by the Borrower shall be denominated in HK dollar or any other denomination agreed upon by the Parties
and shall be made by telegraphic transfer to such bank and bank account as the Lender shall designate in writing.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Article
5 &ndash; Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Borrower shall be responsible for the payment of all present or future taxes and/or duties assessed or imposed by the Government
of Hong Kong or a governmental agency thereof with respect to the execution and/or performance of this Agreement and the repayment
of the Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
6 &ndash; Assignment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Lender shall be entitled to assign or transfer any of his rights or obligations under this Agreement to a third party by providing
the Borrower with a 7-day prior written notice. The Borrower shall not assign any of its rights or obligations under this Agreement
to any party without the prior written approval by the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
7 &ndash; Amendment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
provision of this Agreement may be amended or supplemented only if the Parties so agree in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
8 &ndash; Costs and Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
as otherwise provided, each Party shall bear its own legal and other costs and expenses incurred in relation to the preparation,
execution, performance or enforcement of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
9 &ndash; Notices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
notice under this Agreement shall be given in writing by first class pre-paid post and be addressed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Lender:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mr.
Yat-Gai Au</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
to the Borrower:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regencell
Bioscience Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:
11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices
addressed as provided above shall be deemed to have been duly given when delivered (in the case of personal delivery), 2 (two)
days after posting (in the case of letters sent within the same country), or 5 (five) days after posting (in the case of letters
sent internationally), provided that notices to the Lender shall be effective only upon their actual receipt by the Lender. In
each of the above cases any notice received on a non-working day or after business hours in the country of receipt shall be deemed
to be given on the next following day in such country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Article
10 - Miscellaneous </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Governing
Law</U></B>; This Agreement is subject to and is to be construed in accordance with the laws for the time being and from time
to time in force in Hong Kong.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Dispute
Settlement</U></B>; Any dispute arising out of or in connection with this Agreement, including any question regarding its existence,
validity or termination, shall be referred to and finally resolved by arbitration in Hong Kong in accordance with the Arbitration
Rules of the Hong Kong International Arbitration Centre for the time being in force, which rules are deemed to be incorporated
by reference in this clause. The Tribunal shall consist of three (3) arbitrator(s). The language of the arbitration shall be English.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3 </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Counterparts</U></B>;
This Agreement may be executed in counterparts.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the Parties have caused this Agreement to be executed as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>Lender</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><B>Borrower</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Yat-Gai Au </B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Regencell Bioscience Limited</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ <I>Yat-Gai Au</I></FONT></P>

</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ <I>Yat-Gai Au</I></FONT></P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD>Yat-Gai Au</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>Yat-Gai Au</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD>Chairman
    and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS AGREEMENT</B> is made on 15<SUP>th</SUP>
July 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BETWEEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">(1)</TD><TD STYLE="text-align: justify">Regencell Bioscience Limited, registration number 2236362, a company which has its registered office
at 21/F, EIB Tower, 4-6 Morrison Hill Road, Wan Chai, Hong Kong (the &ldquo;<B>Company</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">(2)</TD><TD STYLE="text-align: justify">Mr. CHAO, Yi-Chung, holder of USA Passport No.********* (the &ldquo;<B>Employee</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IT IS AGREED</B> as follows:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Definitions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">In this Agreement the following expressions have the following meanings:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; width: 47%; text-align: justify"><B>&ldquo;Board&rdquo;</B></TD>
    <TD STYLE="width: 53%; text-align: justify">means the board of directors of the Company from time to time;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><B>&ldquo;Business&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means all and any trades or other commercial activities of the Company which the Employee has been informed of or concerned or involved with to any material extent at any time during his appointment by the Company which the Company carries on with a view to profit;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means any and all information of &nbsp;the Company (irrespective of whether recorded in documentary form or otherwise and whether contained in a list, database or other form of storage) including but not limited to knowledge of proprietary Chinese medicine, prescriptions, techniques, skills and/or methods of Related Personnel financial information, investment history or strategies, business methods or affairs, corporate plans, management systems, marketing plans, finances, pricing information, suppliers, customers, new business opportunities or research and development projects of the Company and any and all trade secrets, secret formulae, processes and techniques, inventions, designs, know-how, improvements, discoveries, technical specifications, drawings, plans, or other technical information relating to the creation, production or supply of any past, present or future product or service of the Company disclosed to the Employee during the course of the Employment, which the Employee knows or ought reasonably to have known to be confidential, concerning the business and/or affairs of the Company or its subsidiary or its customers;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; width: 47%">&ldquo;<B>Chinese Medicine Practitioners</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; width: 53%">means Chinese medicine practitioners registered and listed under the Chinese Medicine Ordinance (Chapter 549, the laws of Hong Kong); </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Directors</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means the directors of the Company from time to time; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Employment</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means the Employee&rsquo;s employment in accordance with the terms and conditions of this Agreement;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Hong Kong</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means Hong Kong Special Administrative Region of the People&rsquo;s Republic of China; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Parties</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means collectively the Company and the Employee, or any of them a &lsquo;Party&rsquo;; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Related Personnel</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means (i) the Directors; (ii) officers, employees, consultants, agents and representatives of the Company; (iii) listed Chinese Medicine Practitioner Mr. AU Sik Kee (<FONT STYLE="font-family: Times New Roman, Times, Serif">&#21312;&#37675;&#27231;</FONT>) (listing number: 05950); and (iv) all other listed Chinese Medicine Practitioners engaged by the Company (if any); </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; width: 47%">&ldquo;<B>USA</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; width: 53%">means the United States of the America;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Working Day</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means Monday to Saturday excluding statutory holidays, a day on which banks generally are open in Hong Kong for transaction of normal banking business.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 182.4pt; text-align: justify; text-indent: -182.4pt">&nbsp;</P>


<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">In this Agreement, unless the context otherwise requires, words denoting a singular number only
shall include the plural and vice versa and words denoting the masculine gender shall include the feminine and vice versa.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify">The heading in this Agreement are inserted only for convenience and shall not affect its construction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify">Any reference in this Agreement to an Ordinance shall be deemed to include any statutory modification
or re-enactment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify">Any reference to person shall include body corporate, unincorporated body and individual.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Appointment and Job Description</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">Conditional upon the Employee&rsquo;s production to the satisfaction of the Company valid identification
documents and valid employment visa (where applicable) or proof of permanent residency in Hong Kong on his capacity and eligibility
to work in Hong Kong (the &ldquo;<B>Conditions Precedent</B>&rdquo;), the Company shall employ the Employee and the Employee shall
serve the Company as Clinical Research Scientist subject to and upon the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">Subject to Clause 11, the Employee shall diligently and faithfully and to the best of his skill
and ability serve the Company and perform all of the following duties:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Manage research projects and prepare research reports;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Develop a methodology for data collection;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Collect, record data and present the findings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Attend meetings and events;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Work closely with other healthcare professionals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Visit hospitals and clinics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Collaborate with existing employees on business ventures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">Work on ad-hoc projects that may arise in a dynamic business environment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify">The Employment shall begin on 15<SUP>th</SUP> July 2019 or upon the fulfilment of all of the Conditions
Precedent unless waived by the Company in its sole and absolute discretion, whichever is the later (the &ldquo;<B>Effective Date</B>&rdquo;),
and will be subject to a probation period of six (6) months. The Employment shall continue on annual basis until terminated in
accordance with the provisions of Clause 12 herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify">The Employee represents and warrants that he is not bound by or subject to any court order, agreement,
arrangement, commitment or undertaking which is in any way restricts or prohibits him from entering into this Agreement or from
performing his duties hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Duties</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify">During the Employment, the Employee shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">diligently and faithfully and to the best of his skill and ability serve the Company and perform
all such duties and exercise all such powers as are lawfully and properly assigned to him from time to time by the manager;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">comply with all directions lawfully and properly given to him by the manager;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">unless prevented by sickness, injury or other incapacity, devote all of his working hours, attention
and abilities to the Business of the Company for which he is required to perform duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">use his best endeavors to protect, promote and act in the best interests of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">promptly provide the manager with all such information as he may require in connection with the
business or affairs of the Company for which he is required to perform duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">comply with all laws and regulations applicable to the Employee or the Employment and any codes
of conduct, policies or rules adopted by the Company from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify">The Employee&rsquo;s normal working hours shall be 0900 hours to 1800 hours from Monday to Saturday
but may be subject to change. The Employee acknowledges and agrees that working on Sunday may be required. Under these circumstances,
an irregular rest day shall be appointed by the Employer and the Employee&rsquo;s normal working hours may be amended by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify">The Employee&rsquo;s normal place of work is the Company&rsquo;s office in Hong Kong unless and
until the Employee is relocated at the request of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify">The Employee agrees to travel outside Hong Kong as may be required for the proper performance of
his duties under the Employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Salary and Bonus</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">The Employee&rsquo;s monthly salary is Hong Kong Dollars Fifty Thousand (HK$50,000), less any
                                                           deductions or withholdings required by law (&ldquo;Base Salary&rdquo;). Any revision to the Base Salary shall be at the absolute
                                                           discretion of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">The Employee&rsquo;s Base Salary shall accrue on a daily basis, and shall be payable in arrears
on the last day of each month during the Employment, provided that if the Employment is terminated prior to the end of a month
the Employee shall only be entitled to a proportionate part of such Base Salary in respect of the period of employment during the
relevant month up to the date of termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.3</TD><TD STYLE="text-align: justify">Subject to the absolute discretion of the Board, the Employee is entitled to shares of the Company
(if approved) to be determined at a later date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">Subject to the Board&rsquo;s discretion and determination, the Employee may be entitled to an annual
performance bonus in such sum as may be determined by the Board at its absolute discretion on completion of every twelve (12) months&rsquo;
service (&ldquo;<B>Discretionary Bonus</B>&rdquo;). The payment of Discretionary Bonus for a year does not imply any entitlement
to Discretionary Bonus in any other year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.5</TD><TD STYLE="text-align: justify">The Employee shall be reimbursed for all out-of-pocket expenses necessarily and reasonably incurred
by him in the proper performance of his duties, which expenses shall be evidence in such manner as the Board may require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">Pension</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">The Employee must join the Company&rsquo;s
Mandatory Provident Fund Scheme (the &ldquo;<B>Scheme</B>&rdquo;), subject to the terms and conditions of the Scheme from time
to time in force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">Annual Leave</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">The Employee is entitled to fifteen (15) Working Days&rsquo; paid holiday (inclusive of relevant
statutory annual leave) per year upon completion of the 6-month probation period (plus statutory holidays in Hong Kong.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify">Annual leave must be taken with the Company&rsquo;s prior written approval at such time or times
convenient to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.3</TD><TD STYLE="text-align: justify">To the extent permitted by applicable law, untaken holiday entitlement may not be carried forward
to a future calendar year and the Employee has no entitlement to be paid in lieu of accrued but untaken holiday.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.4</TD><TD STYLE="text-align: justify">On termination of the Employment, the Employee will be paid in lieu of any accrued and untaken
annual leave in respect of the final calendar year of the Employment. Payment in respect of any accrued and untaken annual leave
entitlement in excess of statutory annual leave entitlement will be based on the Employee&rsquo;s annual Base Salary only.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.5</TD><TD STYLE="text-align: justify">If on termination of the Employment, the Employee has taken more Working Days&rsquo; paid annual
leave than his accrued entitlement, the Company is authorized to deduct the appropriate amount from his final salary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">Taxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The Employee shall be responsible for filing tax returns and payment of all taxes that may be imposed
by reason of his receipt of Base Salary, Discretionary Bonus and any other benefits referred to in or contemplated under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">Nothing in this Clause 7 limits the rights of the Company to withhold or make deductions from amounts
payable to the Employee under this Agreement that are required by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">Sickness and Other Incapacity</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify">Subject to the Employee&rsquo;s compliance with the Company&rsquo;s policy on notification and
certification of periods of absence from work, the Employee will continue to be paid his salary during any period of absence from
work due to sickness, injury or other incapacity, up to the maximum number of paid sickness days to which the Employee is entitled
under the Employment Ordinance (Chapter 57, the laws of Hong Kong) at the time of absence.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.2</TD><TD STYLE="text-align: justify">The Employee shall not be paid during any period of absence from work (other than due to holiday,
sickness, injury or other incapacity) without the prior written permission of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.3</TD><TD STYLE="text-align: justify">If on termination of Employment, the Employee has taken more Working Days&rsquo; paid sick leave
than his accrued entitlement by law, the Employee must repay the un-accrued sick leave pay, which may (at the sole and absolute
discretion of the Company) be repaid by way of deduction from any monies due to the Employee on termination of the Employment.
The Company is authorized to deduct the appropriate amount from his salary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify">Conflict of Interests</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">During the Employment the Employee shall not (without the Company&rsquo;s prior written consent)
be directly or indirectly employed, engaged, concerned or interested in any other business activity, trade or occupation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.2</TD><TD STYLE="text-align: justify">The Employee confirms that, to the best of his knowledge, he has fully disclosed to the Company
all circumstances in respect of which there is a conflict of interest between the Company and the Employee or any connected person.
As soon as the Employee is aware of any such conflict of interest arises during the Employment, the Employee shall promptly inform
the Company of such conflict and provide confirmation in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">Confidentiality</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">The Employee hereby irrevocably acknowledges and agrees:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">that all communications between the Company and the Employee and all information and other materials
supplied to or received by any Party from the other Party which is either marked &lsquo;Confidential&rsquo; or is by its nature
intended to be for the knowledge of the recipient alone, and all information concerning the business transactions and the financial
arrangements of the Company with any person with whom any of them is in a confidential relationship with regard to the matter in
question coming to the knowledge of the recipient shall be strictly kept confidential by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">that the Confidential Information is valuable to the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">that the Employee is provided with access to Confidential Information so that the Employee is properly
able to carry out the duties pursuant to this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">that the Employee owes, without limitation, a duty of trust and confidence to the Company and a
duty to act at all times during his Employment in the best interests of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">that the disclosure of any Confidential Information to any person or company including customer,
actual or potential competitor of the Company, or any third party may seriously jeopardize the Company&rsquo;s position and may
cause immeasurable damage to the Company and therefore the restrictions contained in Clause 10 of this Agreement are reasonable
to protect the interest of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.2</TD><TD STYLE="text-align: justify">The Employee undertakes that he shall keep secret and shall not at any time (whether during the
Employment or thereafter) divulge, communicate to person or use any Confidential Information for his own or another&rsquo;s advantage,
or reveal to any person, including but not limited to his spouse, family members and friends, firm, company or organization, and
shall use his best endeavours to prevent the publication or disclosure of, any Confidential Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.3</TD><TD STYLE="text-align: justify">The restrictions in this clause shall not apply:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to any disclosure or use authorized by the Company or required by the Employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">to disclosure to the extent required by law, provided that the Employee:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">provides the Company with as much prior written notice as possible of such a requirement so that
the Company may seek a protective order or other appropriate remedy, to the extent permitted; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">reveals only that part of the Confidential Information which he is legally obliged to disclose;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">to information or knowledge which has come into the public domain without fault on the part of
the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.4</TD><TD STYLE="text-align: justify">Clause 10 of this Agreement shall survive notwithstanding termination of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.5</TD><TD STYLE="text-align: justify">In the event the Employee fails to observe or comply with Clause 10 of this Agreement, the Company
may institute legal proceedings against the Employee or take whatever action that the Company may deem appropriate to protect its
rights over the Confidential Information including but not limited to seeking injunctive relief and/or monetary damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.6</TD><TD STYLE="text-align: justify">All notes, memoranda, records and writings made by the Employee in relation to the business of
the Company or concerning any of his dealings or affairs or the dealings or affairs of any clients or customers of the Company
shall be and shall remain the property of the Company and shall be handed over by him to the Company from time to time on demand
and in any event upon his termination of the Employment and the Employee shall not retain any copy thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify">Restrictions on the Employee</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">The Employee undertakes to the Company that at any time during the term of the Employment and for
a period of eighteen (18) months after expiry or termination of this Agreement, whichever is later, he shall not:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in Hong Kong either on his own account or in conjunction with or as an agent or in such other capacity
on behalf of any person, firm or company, carry on or be engaged, concerned or interested directly or indirectly whether as shareholder,
director, employee, partner, agent, consultant, adviser or otherwise in carrying on any business in direct or indirect competition
with the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">either on his own account or in conjunction with or on behalf of any other person, firm or company
solicit or entice away or attempt to solicit or entice away from the Company the customer of any person, firm, company or organization
who is or shall at any time within two (2) years prior to such cessation have been a customer, client, identified prospective customer
or client, representative, agent or correspondent of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">either on his own account or in conjunction with or on behalf of any other person, firm or company
solicit or entice away or attempt to solicit or entice away from the Company any person who is or shall have been at the date of
or within two (2) years prior to such cessation a director, officer, manager, consultant or employee of the Company whether or
not such person would commit a breach of contract by reason of leaving such employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">receive on his own account or in conjunction with or on behalf of any other person, firm or company
any benefit (monetary or otherwise), directly or indirectly, from the prospective investor, investor or any related persons (including
their respective shareholders, directors, officers, employees).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify">Termination</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify">During the first month of the probation period, no notice period or payment in lieu by either Party
is required. From the second month of the probation period onwards, seven (7) days&rsquo; prior written notice or payment in lieu
of notice (&ldquo;<B>Payment in Lieu</B>&rdquo;) should be given by either Party. After the probation period and upon confirmation
of employment, either Party may terminate the Employment by giving the other 1 month&rsquo;s prior written notice or Payment in
Lieu.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify">For the avoidance of doubt, the Employee shall not be entitled to receive any payment in addition
to the Payment in Lieu in respect of any leave entitlement that would have accrued during the period for which the Payment in Lieu
is made. The Payment in Lieu shall be subject to such deductions as may be required by law and shall be made in full and as final
settlement of any claims (other than statutory claims) either Party may have against the other Party arising from the Employment
or the termination thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.3</TD><TD STYLE="text-align: justify">The Company may also terminate the Employment immediately and with no liability to make any further
payment to the Employee (other than in respect of amounts accrued due at the date of termination and any amount required by law)
if the Employee:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">commits any serious or repeated breach of any of his obligations under this Agreement or his Employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">is guilty of serious misconduct which, in the Company&rsquo;s reasonable opinion, has damaged or
may damage the business or affairs of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">is guilty of conduct which, in the Company&rsquo;s reasonable opinion, brings or is likely to bring
him and/or the Company into disrepute;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">is convicted of a criminal offence;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">is declared bankrupt or is being filed against a petition for bankruptcy order;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This clause shall not restrict
any other right the Company may have (whether at common law or otherwise) to terminate the Employment summarily.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any delay by the Company in exercising
its rights under this clause shall not constitute a waiver of those rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.4</TD><TD STYLE="text-align: justify">On termination of the Employment for whatever reason (and whether in breach of contract of otherwise)
the Employee shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">as soon as possible deliver to the Company originals and copies of all books, documents, computer
records, materials, notes, memoranda, statements, files, computer hardware/software, and any other property regardless of form,
format or media, relating to the business of or belonging to the Company which is in his possession or under his control. The Employee
is not entitled to retain copies or reproductions of any such property;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">as soon as possible resign from any office he holds with the Company without any compensation for
loss of office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.5</TD><TD STYLE="text-align: justify">The Employee shall not at any time after termination of the Employment represent himself as being
in any way concerned with or interested in the affairs of the business of, or employed by, the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.6</TD><TD STYLE="text-align: justify">The Employee shall not at any time after termination of the Employment contact, approach, liaise,
communicate with or solicit business from any of the Company&rsquo;s customers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify">Miscellaneous</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">This Agreement, together with any other documents referred to in this Agreement, supersedes all
other agreements both oral and in writing between the Company and the Employee and for any terms of employment previously in force
between the Company and the Employee, if any, whether or not on a legal or formal basis (which shall be deemed to have been terminated
by mutual consent). The Employee acknowledges that he has not entered into this Agreement in reliance upon any representation,
warranty or undertaking which is not set out in this Agreement or expressly referred to in it as forming part of the Employee&rsquo;s
contract of employment. Nothing in this clause shall exclude any liability for, or remedy in respect of, fraudulent misrepresentation
by a Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.2</TD><TD STYLE="text-align: justify">If any term or other provision of this Agreement is held to be invalid, illegal or incapable of
being enforced by law, all other provisions of this Agreement shall nevertheless remain in full force.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.3</TD><TD STYLE="text-align: justify">Unless expressly provided to the contrary in this Agreement, a person who is not a party to this
Agreement has no right under the Contracts (Rights of Third Parties) Ordinance (Chapter 623 of the Laws of Hong Kong) to enforce
or to enjoy the benefit of any term of this Agreement, and whether so provided in this Agreement or not, no consent of third party
is required for the amendment to (including the waiver or compromise of any obligation), rescission of or termination of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.4</TD><TD STYLE="text-align: justify">This Agreement shall be governed by, and interpreted in accordance with, Hong Kong law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.5</TD><TD STYLE="text-align: justify">Except as expressly provided otherwise in this Agreement, the courts of Hong Kong are to have exclusive
jurisdiction to settle any disputes (including claims for set-off and counterclaims) which may arise in connection with this Agreement.
For such purposes each Party irrevocably submits to the jurisdiction of the Hong Kong courts.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Parties have executed
this Agreement on the date first written above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: justify"><B><U>The Employee</U></B></TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify"><B>&nbsp;</B></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">SIGNED By CHAO, Yi-Chung</TD>
    <TD STYLE="text-align: center">) </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"> <I><U STYLE="text-decoration: none">/s/ Yi-Chung Chao</U></I></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">holder of USA Passport No. *******</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">in the presence of: James Chung</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"> <I><U STYLE="text-decoration: none">/s/ James Chung</U></I></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B><U>The Company</U></B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">SIGNED by AU, Yat-Gai</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"> <I><U STYLE="text-decoration: none">/s/ Yat-Gai Au</U></I></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">for and on behalf of</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Regencell Bioscience Limited</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">) </TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">in the presence of: James Chung</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><I><U STYLE="text-decoration: none">/s/ James Chung</U></I></TD>
    </TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">12</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.6</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYMENT
AGREEMENT</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS
AGREEMENT</B> is made on 6<SUP>th</SUP> July, 2015</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BETWEEN</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
                                         Biotechnology Limited, registration number 2236362, a company which has its registered
                                         office at 21/F, EIB Tower, 4-6 Morrison Hill Road, Wanchai, Hong Kong (the &ldquo;<B>Company</B>&rdquo;);
                                         and</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                         CHUNG James Wai Hong, a holder of Hong Kong Identity Card Number******* (the &ldquo;<B>Senior
                                         Vice President</B>&rdquo;) or (the &ldquo;<B>SVP</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IT
IS AGREED</B> as follows:-</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         this Agreement the following expressions have the following meanings:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; width: 47%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Board&rdquo;</B></FONT></TD>
    <TD STYLE="width: 53%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    the board of directors of the Company from time to time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Business&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means all and any
    trades or other commercial activities of the Company which the SVP has been informed of or concerned or involved with to any
    material extent at any time during his appointment by the Company which the Company carries on with a view to profit;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Confidential
    Information</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means any and all
    information of &nbsp;the Company (irrespective of whether recorded in documentary form or otherwise and whether contained
    in a list, database or other form of storage) including but not limited to knowledge of proprietary Chinese medicine, prescriptions,
    techniques, skills and/or methods of Related Personnel financial information, investment history or strategies, business methods
    or affairs, corporate plans, management systems, marketing plans, finances, pricing information, suppliers, customers, new
    business opportunities or research and development projects of the Company and any and all trade secrets, secret formulae,
    processes and techniques, inventions, designs, know-how, improvements, discoveries, technical specifications, drawings, plans,
    or other technical information relating to the creation, production or supply of any past, present or future product or service
    of the Company disclosed to the SVP during the course of the Employment, which the SVP knows or ought reasonably to have known
    to be confidential, concerning the business and/or affairs of the Company or its subsidiary or its customers;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Chinese
    Medicine Practitioners</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify; width: 53%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means
    Chinese medicine practitioners registered and listed under the Chinese Medicine Ordinance (Chapter 549, the laws of Hong Kong);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Directors</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the directors
    of the Company from time to time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Employment</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the SVP&rsquo;s
    employment in accordance with the terms and conditions of this Agreement;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Hong Kong</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means Hong Kong
    Special Administrative Region of the People&rsquo;s Republic of China;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Parties</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means collectively
    the Company and the SVP, or any of them a &lsquo;Party&rsquo;;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Related
    Personnel</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means (i) the Directors;
    (ii) officers, employees, consultants, agents and representatives of the Company; (iii) listed Chinese Medicine Practitioner
    Mr. AU Sik Kee (&#21312;&#37675;&#27231;) (listing number: 05950); and (iv) all other listed Chinese Medicine Practitioners
    engaged by the Company (if any);</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; width: 47%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B>Specified
    Period</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify; width: 53%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">means
    the period of six (6) months commencing from the Effective Date, or such other later date as the Company may agree in
    writing;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;<B>Working
    Day</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">means Monday to
    Friday excluding statutory holidays, a day on which banks generally are open in Hong Kong for transaction of normal banking
    business.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 182.4pt; text-align: justify; text-indent: -182.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         this Agreement, unless the context otherwise requires, words denoting a singular number
                                         only shall include the plural and vice versa and words denoting the masculine gender
                                         shall include the feminine and vice versa.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         heading in this Agreement are inserted only for convenience and shall not affect its
                                         construction.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                         reference in this Agreement to an Ordinance shall be deemed to include any statutory
                                         modification or re-enactment thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                         reference to person shall include body corporate, unincorporated body and individual.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
                                         and Job Description</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company shall employ the SVP and the SVP shall serve the Company as Senior Vice President
                                         subject to and upon the terms of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                         to Clause 11, the SVP shall diligently and faithfully and to the best of his skill and
                                         ability serve the Company and perform all of the following duties:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exploring
                                         and soliciting potential and lawful sources of funds (in Hong Kong or elsewhere) for
                                         investment in the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">introducing
                                         prospective third party investors to the Company;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting
                                         and facilitating investment in the Company including but not limited to verifying the
                                         source and lawfulness of prospective funds;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">liaising
                                         and negotiating with prospective investor on terms and conditions of investments and
                                         ancillary documents as per directions of the Board;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
                                         decisions of the Board;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attending
                                         to any other matters arising from or in connection with any of the above duties; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
                                         with all other lawful directions given to him by the Board.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         performing his duties hereunder, the SVP has no authority whatsoever to commit with any
                                         prospective investor, oral or in writing, on behalf of the Company on any terms and/or
                                         conditions relating to investment in the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Employment shall begin on 6<SUP>th</SUP> July, 2015 (the &ldquo;<B>Effective Date</B>&rdquo;)
                                         and will be subject to a probation period of three (3) months. The Employment shall continue
                                         until terminated in accordance with the provisions of Clause 11 herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP represents and warrants that he is not bound by or subject to any court order, agreement,
                                         arrangement, commitment or undertaking which is in any way restricts or prohibits him
                                         from entering into this Agreement or from performing his duties hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duties</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                         the Employment, the SVP shall:-</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diligently
                                         and faithfully and to the best of his skill and ability serve the Company and perform
                                         all such duties and exercise all such powers as are lawfully and properly assigned to
                                         him from time to time by the Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
                                         with all directions lawfully and properly given to him by the Directors;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unless
                                         prevented by sickness, injury or other incapacity, devote all of his working hours, attention
                                         and abilities to the Business of the Company for which he is required to perform duties;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use
                                         his best endeavours to protect, promote and act in the best interests of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">promptly
                                         provide the Board with all such information as he may require in connection with the
                                         business or affairs of the Company for which he is required to perform duties; and</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">comply
                                         with all laws and regulations applicable to the SVP or the Employment and any codes of
                                         conduct, policies or rules adopted by the Company from time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP&rsquo;s normal working hours shall be 0900 hrs to 1800 hrs from Monday to Friday.
                                         The SVP acknowledges and agrees that working outside normal working hours may be required
                                         from time to time in the proper performance of his duties. The SVP agrees to consider
                                         in good faith to work such additional hours as required and acknowledges that he has
                                         no entitlement to additional remuneration for such additional hours worked in excess
                                         of his normal working hours.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP&rsquo;s normal place of work is the Company&rsquo;s office in Hong Kong unless and
                                         until the SVP is relocated at the request of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP agrees to travel outside Hong Kong as may be required for the proper performance
                                         of his duties under the Employment.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary
                                         and Bonus</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP&rsquo;s monthly salary is Hong Kong dollars Seventy Five Thousand Dollars (HK$75,000),
                                         less any deductions or withholdings required by law (&ldquo;<B>Base Salary</B>&rdquo;).
                                         Any revision to the Base Salary shall be at the absolute discretion of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP&rsquo;s Base Salary shall accrue on a daily basis, and shall be payable in arrears
                                         on the last day of each month during the Employment, provided that if the Employment
                                         is terminated prior to the end of a month the SVP shall only be entitled to a proportionate
                                         part of such Base Salary in respect of the period of employment during the relevant month
                                         up to the date of termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                         to the absolute discretion of the Board, the SVP is entitled to shares of the Company
                                         (if approved) to be determined at a later date.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signing
                                         Bonus of HK$80,000 to be paid within one (1) month of the employment date.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                         to the Board&rsquo;s discretion and determination, the SVP may be entitled to an annual
                                         performance bonus in such sum as may be determined by the Board at its absolute discretion
                                         on completion of every twelve (12) months&rsquo; service (&ldquo;<B>Discretionary Bonus</B>&rdquo;).
                                         The payment of Discretionary Bonus for a year does not imply any entitlement to Discretionary
                                         Bonus in any other year.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP shall be reimbursed for all out-of-pocket expenses necessarily and reasonably incurred
                                         by him in the proper performance of his duties, which expenses shall be evidence in such
                                         manner as the Board may require.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pension</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SVP must join the Company&rsquo;s Mandatory Provident Fund Scheme (the &ldquo;<B>Scheme</B>&rdquo;), subject to the terms and
conditions of the Scheme from time to time in force.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
                                         Leave</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP is entitled to fifteen (15) Working Days&rsquo; paid holiday (inclusive of relevant
                                         statutory annual leave) per calendar year (from January to December) during his Employment
                                         (plus statutory holidays in Hong Kong.)</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
                                         leave must be taken with the Company&rsquo;s prior written approval at such time or times
                                         convenient to the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                         the extent permitted by applicable law, untaken holiday entitlement may not be carried
                                         forward to a future calendar year and the SVP has no entitlement to be paid in lieu of
                                         accrued but untaken holiday.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                         termination of the Employment, the SVP will be paid in lieu of any accrued and untaken
                                         annual leave in respect of the final calendar year of the Employment. Payment in respect
                                         of any accrued and untaken annual leave entitlement in excess of statutory annual leave
                                         entitlement will be based on the SVP&rsquo;s annual Base Salary only.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         on termination of the Employment, the SVP has taken more Working Days&rsquo; paid annual
                                         leave than his accrued entitlement, the Company is authorized to deduct the appropriate
                                         amount from his final salary.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP shall be responsible for filing tax returns and payment of all taxes that may be
                                         imposed by reason of his receipt of Base Salary, Discretionary Bonus and any other benefits
                                         referred to in or contemplated under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
                                         in this Clause 7 limits the rights of the Company to withhold or make deductions from
                                         amounts payable to the SVP under this Agreement that are required by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sickness
                                         and Other Incapacity</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
                                         to the SVP&rsquo;s compliance with the Company&rsquo;s policy on notification and certification
                                         of periods of absence from work, the SVP will continue to be paid his full salary during
                                         any period of absence from work due to sickness, injury or other incapacity, up to the
                                         maximum number of paid sickness days to which the SVP is entitled under the Employment
                                         Ordinance (Chapter 57, the laws of Hong Kong) at the time of absence.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP shall not be paid during any period of absence from work (other than due to holiday,
                                         sickness, injury or other incapacity) without the prior written permission of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         on termination of Employment, the SVP has taken more Working Days&rsquo; paid sick leave
                                         than his accrued entitlement by law, the SVP must repay the un-accrued sick leave pay,
                                         which may (at the sole and absolute discretion of the Company) be repaid by way of deduction
                                         from any monies due to the SVP on termination of the Employment. The Company is authorized
                                         to deduct the appropriate amount from his salary.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflict
                                         of Interests</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                         the Employment the SVP shall not (without the Company&rsquo;s prior written consent)
                                         be directly or indirectly employed, engaged, concerned or interested in any other business
                                         activity, trade or occupation.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP confirms that, to the best of his knowledge, he has fully disclosed to the Company
                                         all circumstances in respect of which there is a conflict of interest between the Company
                                         and the SVP or any connected person. As soon as the SVP is aware of any such conflict
                                         of interest arises during the Employment, the SVP shall promptly inform the Company of
                                         such conflict and provide confirmation in writing.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP hereby irrevocably acknowledges and agrees:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         all communications between the Company and the SVP and all information and other materials
                                         supplied to or received by any Party from the other Party which is either marked &lsquo;Confidential&rsquo;
                                         or is by its nature intended to be for the knowledge of the recipient alone, and all
                                         information concerning the business transactions and the financial arrangements of the
                                         Company with any person with whom any of them is in a confidential relationship with
                                         regard to the matter in question coming to the knowledge of the recipient shall be strictly
                                         kept confidential by the SVP;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         the Confidential Information is valuable to the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         the SVP is provided with access to Confidential Information so that the SVP is properly
                                         able to carry out the duties pursuant to this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         the SVP owes, without limitation, a duty of trust and confidence to the Company and a
                                         duty to act at all times during his Employment in the best interests of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                         the disclosure of any Confidential Information to any person or company including customer,
                                         actual or potential competitor of the Company, or any third party may seriously jeopardize
                                         the Company&rsquo;s position and may cause immeasurable damage to the Company and therefore
                                         the restrictions contained in Clause 10 of this Agreement are reasonable to protect the
                                         interest of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP undertakes that he shall keep secret and shall not at any time (whether during the
                                         Employment or thereafter) divulge, communicate to person or use any Confidential Information
                                         for his own or another&rsquo;s advantage, or reveal to any person, including but not
                                         limited to his spouse, family members and friends, firm, company or organization, and
                                         shall use his best endeavours to prevent the publication or disclosure of, any Confidential
                                         Information.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         restrictions in this clause shall not apply:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         any disclosure or use authorized by the Company or required by the Employment;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         disclosure to the extent required by law, provided that the SVP:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provides
                                         the Company with as much prior written notice as possible of such a requirement so that
                                         the Company may seek a protective order or other appropriate remedy, to the extent permitted;
                                         and</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reveals
                                         only that part of the Confidential Information which he is legally obliged to disclose;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                         information or knowledge which has come into the public domain without fault on the part
                                         of the SVP.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clause
                                         10 of this Agreement shall survive notwithstanding termination of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                         the event the SVP fails to observe or comply with Clause 10 of this Agreement, the Company
                                         may institute legal proceedings against the SVP or take whatever action that the Company
                                         may deem appropriate to protect its rights over the Confidential Information including
                                         but not limited to seeking injunctive relief and/or monetary damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                         notes, memoranda, records and writings made by the SVP in relation to the business of
                                         the Company or concerning any of his dealings or affairs or the dealings or affairs of
                                         any clients or customers of the Company shall be and shall remain the property of the
                                         Company and shall be handed over by him to the Company from time to time on demand and
                                         in any event upon his termination of the Employment and the SVP shall not retain any
                                         copy thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restrictions
                                         on the SVP</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP undertakes to the Company that at any time during the term of the Employment and
                                         for a period of eighteen (18) months after expiry or termination of this Agreement, whichever
                                         is later, he shall not:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                         Hong Kong either on his own account or in conjunction with or as an agent or in such
                                         other capacity on behalf of any person, firm or company, carry on or be engaged, concerned
                                         or interested directly or indirectly whether as shareholder, director, employee, partner,
                                         agent, consultant, adviser or otherwise in carrying on any business in direct or indirect
                                         competition with the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
                                         on his own account or in conjunction with or on behalf of any other person, firm or company
                                         solicit or entice away or attempt to solicit or entice away from the Company the customer
                                         of any person, firm, company or organization who is or shall at any time within two (2)
                                         years prior to such cessation have been a customer, client, identified prospective customer
                                         or client, representative, agent or correspondent of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either
                                         on his own account or in conjunction with or on behalf of any other person, firm or company
                                         solicit or entice away or attempt to solicit or entice away from the Company any person
                                         who is or shall have been at the date of or within two (2) years prior to such cessation
                                         a director, officer, manager, consultant or employee of the Company whether or not such
                                         person would commit a breach of contract by reason of leaving such employment;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receive
                                         on his own account or in conjunction with or on behalf of any other person, firm or company
                                         any benefit (monetary or otherwise), directly or indirectly, from the prospective investor,
                                         investor or any related persons (including their respective shareholders, directors,
                                         officers, employees).</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
                                         the first month of the probation period, no notice period or payment in lieu by either
                                         Party is required. From the second month of the probation period onwards, seven (7) days&rsquo;
                                         prior written notice or payment in lieu of notice (&ldquo;<B>Payment in Lieu</B>&rdquo;)
                                         should be given by either Party. After the probation period and upon confirmation of
                                         employment, either Party may terminate the Employment by giving the other 1 month&rsquo;s
                                         prior written notice or Payment in Lieu.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                         the avoidance of doubt, the SVP shall not be entitled to receive any payment in addition
                                         to the Payment in Lieu in respect of any leave entitlement that would have accrued during
                                         the period for which the Payment in Lieu is made. The Payment in Lieu shall be subject
                                         to such deductions as may be required by law and shall be made in full and as final settlement
                                         of any claims (other than statutory claims) either Party may have against the other Party
                                         arising from the Employment or the termination thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company may also terminate the Employment immediately and with no liability to make any
                                         further payment to the SVP (other than in respect of amounts accrued due at the date
                                         of termination and any amount required by law) if the SVP:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commits
                                         any serious or repeated breach of any of his obligations under this Agreement or his
                                         Employment;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                         guilty of serious misconduct which, in the Company&rsquo;s reasonable opinion, has damaged
                                         or may damage the business or affairs of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                         guilty of conduct which, in the Company&rsquo;s reasonable opinion, brings or is likely
                                         to bring him, the Company into disrepute;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                         convicted of a criminal offence;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is
                                         declared bankrupt or is being filed against a petition for bankruptcy order; or</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
clause shall not restrict any other right the Company may have (whether at common law or otherwise) to terminate the Employment
summarily.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay by the Company in exercising its rights under this clause shall not constitute a waiver of those rights.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                         termination of the Employment for whatever reason (and whether in breach of contract
                                         of otherwise) the SVP shall:</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                         soon as possible deliver to the Company originals and copies of all books, documents,
                                         computer records, materials, notes, memoranda, statements, files, computer hardware/software,
                                         and any other property regardless of form, format or media, relating to the business
                                         of or belonging to the Company which is in his possession or under his control. The SVP
                                         is not entitled to retain copies or reproductions of any such property;</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                         soon as possible resign from any office he holds with the Company without any compensation
                                         for loss of office.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP shall not at any time after termination of the Employment represent him as being
                                         in any way concerned with or interested in the affairs of the business of, or employed
                                         by, the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         SVP shall not at any time after termination of the Employment contact, approach, liaise,
                                         communicate with or solicit business from any of the Company&rsquo;s customers.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                         Agreement, together with any other documents referred to in this Agreement, supersedes
                                         all other agreements both oral and in writing between the Company and the SVP and for
                                         any terms of employment previously in force between the Company and the SVP, if any,
                                         whether or not on a legal or formal basis (which shall be deemed to have been terminated
                                         by mutual consent). The SVP acknowledges that he has not entered into this Agreement
                                         in reliance upon any representation, warranty or undertaking which is not set out in
                                         this Agreement or expressly referred to in it as forming part of the SVP&rsquo;s contract
                                         of employment. Nothing in this clause shall exclude any liability for, or remedy in respect
                                         of, fraudulent misrepresentation by a Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         any term or other provision of this Agreement is held to be invalid, illegal or incapable
                                         of being enforced by law, all other provisions of this Agreement shall nevertheless remain
                                         in full force.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                         Agreement shall be governed by, and interpreted in accordance with, Hong Kong law.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
                                         as expressly provided otherwise in this Agreement, the courts of Hong Kong are to have
                                         exclusive jurisdiction to settle any disputes (including claims for set-off and counterclaims)
                                         which may arise in connection with this Agreement. For such purposes each Party irrevocably
                                         submits to the jurisdiction of the Hong Kong courts.</FONT></TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the Parties have executed this Agreement on the date first written above</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.05pt; text-align: left; text-indent: -60.05pt"><FONT STYLE="font-size: 10pt"><B><U>The
Employee</U></B></FONT></P>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: left"><FONT STYLE="font-size: 10pt">SIGNED By</FONT></TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 45%; text-align: left"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">CHUNG James Wai Hong</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt; text-decoration: none"><I>/s/
    James Wai Hong Chung</I></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">holder of Hong Kong identity card no. *********</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">in the presence of: Belinda Mak</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt; text-decoration: none"><I>/s/
    Belinda Mak</I></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B><U>The Company</U></B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">SIGNED by AU, Yat-Gai</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt; text-decoration: none"><I>/s/
    Yat-Gai Au</I></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">for and on behalf of</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Regencell Biotechnology Limited</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: left"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">in the presence of: Belinda Mak</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt; text-decoration: none"><I>/s/
    Belinda Mak</I></FONT></TD>
    </TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CHIEF FINANCIAL OFFICER EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS AGREEMENT</B> is made on January
18<SUP>th</SUP>, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BETWEEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">(1)</TD><TD STYLE="text-align: justify">Regencell Bioscience Limited, registration number 2236362, a company which has its registered office
at 11/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong (the &ldquo;<B>Company</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">(2)</TD><TD STYLE="text-align: justify">Chau, Tien Hsiang, holder of HKID number ******* (the &ldquo;<B>Chief Financial Officer</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IT IS AGREED</B> as follows:-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD STYLE="text-align: justify">Definitions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify">In this Agreement the following expressions have the following meanings:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; width: 47%; text-align: justify"><B>&ldquo;Board&rdquo;</B></TD>
    <TD STYLE="width: 53%; text-align: justify">means the board of directors of the Company from time to time;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify"><B>&ldquo;Business&rdquo;</B></TD>
    <TD STYLE="text-align: justify">means all and any trades or other commercial activities of the Company which the Employee has been informed of or concerned or involved with to any material extent at any time during his appointment by the Company which the Company carries on with a view to profit;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means any and all information of the Company (irrespective of whether recorded in documentary form or otherwise and whether contained in a list, database or other form of storage) including but not limited to knowledge of proprietary Chinese medicine, prescriptions, techniques, skills and/or methods of Related Personnel financial information, investment history or strategies, business methods or affairs, corporate plans, management systems, marketing plans, finances, pricing information, suppliers, customers, new business opportunities or research and development projects of the Company and any and all trade secrets, secret formulae, processes and techniques, inventions, designs, know-how, improvements, discoveries, technical specifications, drawings, plans, or other technical information relating to the creation, production or supply of any past, present or future product or service of the Company disclosed to the Chief Financial Officer during the course of the Employment, which the Chief Financial Officer knows or ought reasonably to have known to be confidential, concerning the business and/or affairs of the Company or its subsidiary or its customers;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; width: 47%">&ldquo;<B>Chinese Medicine Practitioners</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; width: 53%">means Chinese medicine practitioners registered and listed under the Chinese Medicine Ordinance (Chapter 549, the laws of Hong Kong); </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Directors</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means the directors of the Company from time to time; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Employment</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means the Chief Financial Officer&rsquo;s employment in accordance with the terms and conditions of this Agreement;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Hong Kong</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means Hong Kong Special Administrative Region of the People&rsquo;s Republic of China; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Parties</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means collectively the Company and the Chief Financial Officer, or any of them a &lsquo;Party&rsquo;; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Related Personnel</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means (i) the Directors; (ii) officers, employees, consultants, agents and representatives of the Company; (iii) listed Chinese Medicine Practitioner Mr. AU Sik Kee (<FONT STYLE="font-family: Times New Roman, Times, Serif">&#21312;&#37675;&#27231;</FONT>) (listing number: 05950); and (iv) all other listed Chinese Medicine Practitioners engaged by the Company (if any); </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; width: 47%">&ldquo;<B>USA</B>&rdquo;</TD>
    <TD STYLE="text-align: justify; width: 53%">means the United States of the America; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify">&ldquo;<B>Working Day</B>&rdquo;</TD>
    <TD STYLE="text-align: justify">means Monday to Friday excluding statutory holidays, a day on which banks generally are open in Hong Kong for transaction of normal banking business.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 182.4pt; text-align: justify; text-indent: -182.4pt">&nbsp;</P>


<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify">In this Agreement, unless the context otherwise requires, words denoting a singular number only
shall include the plural and vice versa and words denoting the masculine gender shall include the feminine and vice versa.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify">The heading in this Agreement are inserted only for convenience and shall not affect its construction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify">Any reference in this Agreement to an Ordinance shall be deemed to include any statutory modification
or re-enactment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify">Any reference to person shall include body corporate, unincorporated body and individual.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD STYLE="text-align: justify">Appointment and Job Description</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify">Conditional upon the Chief Financial Officer&rsquo;s production to the satisfaction of the Company
valid identification documents, valid employment visa (where applicable) or proof of permanent residency in Hong Kong on his capacity
and eligibility to work in Hong Kong and upon the completion of a positive background check, including but not limited to the verification
of employment history and professional qualifications of the Chief Financial Officer, at the Company&rsquo;s sole and absolute
discretion (the &ldquo;<B>Conditions Precedent</B>&rdquo;), the Company shall employ the Chief Financial Officer and the Chief
Financial Officer shall serve the Company as its chief financial officer subject to and upon the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">Subject to Clause 11, the Chief Financial Officer shall diligently and faithfully and to the best
of his skill and ability serve the Company and perform all of the following duties:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Proactively identify and establish contact with target investors, organizing and preparing investor
meeting (including briefing company&rsquo;s CEO), and leading and/or moderating such meetings;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Serve as the key point of contact for the investor community, developing close relationships and
opportunities to influence via a detailed IR communication strategy;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Formulate financial policies and strategies for the Company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Work closely with the senior executives to lead and drive the commercial growth and success of
the company;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Manage relationships with banks and financial institutions in relation to fund-raising activities
and transactional platforms;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Ensure effective internal controls, compliance of all accounting, financial, US and HK regulatory
reporting and tax laws, regulations, policies, standards, obligations, requirements and all systems of all relevant jurisdictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Ensure compliance with applicable GAAP reporting requirements, SEC filings, proxy statements and
organizing conference calls and annual meetings;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">Drive strategic initiatives and preparing in full alignment with CEO, the content for board meetings,
board reporting, treasury management and cash flow management;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Strategically plan and optimize the mix of shareholders in subsequent funding rounds;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">Follow up on information requests/due diligence requests by investors; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">Collaborate on ad-hoc projects as required.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify">The Employment shall begin on 18<SUP>th</SUP> January 2021 or upon the fulfilment of all of the
Conditions Precedent unless waived by the Company in its sole and absolute discretion, whichever is the later (the &ldquo;<B>Effective
Date</B>&rdquo;), and will be subject to a probation period of six (6) months. The Employment shall continue on an annual basis
until terminated in accordance with the provisions of Clause 12 herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify">The Chief Financial Officer represents and warrants that he is not bound by or subject to any court
order, agreement, arrangement, commitment or undertaking which is in any way restricts or prohibits him from entering into this
Agreement or from performing his duties hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD STYLE="text-align: justify">Duties</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify">During the Employment, the Chief Financial Officer shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">diligently and faithfully and to the best of his skill and ability serve the Company and perform
all such duties (including but not limited to those stipulated in Clause 2.2 of this Agreement) and exercise all such powers as
are lawfully and properly assigned to him from time to time by the CEO and Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">comply with all directions lawfully and properly given to him by the CEO and Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">unless prevented by sickness, injury or other incapacity, devote all of his working hours, attention
and abilities to the Business of the Company for which he is required to perform duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">use his best endeavors to protect, promote and act in the best interests of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">promptly provide the Board with all such information and answer as he may require in connection
with the business or affairs of the Company for which he is required to perform duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">comply with all laws and regulations applicable to the Chief Financial Officer or the Employment
and any codes of conduct, policies or rules adopted by the Company from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify">The Chief Financial Officer&rsquo;s normal working hours shall be 09:00 hours to 18:00 hours from
Monday to Friday but may be subject to change. The Chief Financial Officer acknowledges and agrees that working on Saturday and
Sunday may be required. Under these circumstances, an irregular rest day shall be appointed by the Employer and the Chief Financial
Officer&rsquo;s normal working hours may be amended by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify">The Chief Financial Officer&rsquo;s normal place of work is the Company&rsquo;s office in Hong
Kong unless and until the Chief Financial Officer is relocated at the request of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify">The Chief Financial Officer agrees to travel outside Hong Kong as may be required for the proper
performance of his duties under the Employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">4.</FONT></TD><TD STYLE="text-align: justify">Salary and Bonus</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">The Chief Financial Officer&rsquo;s monthly salary is Hong Kong Dollars Eighty Five Thousand (HK$85,000),
less any deductions or withholdings required by law (&ldquo;<B>Base Salary</B>&rdquo;). Any revision to the Base Salary shall be
at the absolute discretion of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">The Chief Financial Officer&rsquo;s Base Salary shall accrue on a daily basis, and shall be payable
in arrears on the last day of each month during the Employment, provided that if the Employment is terminated prior to the end
of a month the Chief Financial Officer shall only be entitled to a proportionate part of such Base Salary in respect of the period
of employment during the relevant month up to the date of termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.3</TD><TD STYLE="text-align: justify">Subject to the absolute discretion of the Board and on completion of the first twelve (12) months&rsquo;
service, the Chief Financial Officer is entitled to stock options of the Company (if approved) to be determined before IPO but
with a vesting period not less than twelve (12) months.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">Subject to the Board&rsquo;s discretion and determination, the Chief Financial Officer may be entitled
to an annual performance bonus in such sum as may be determined by the Board at its absolute discretion on completion of every
twelve (12) months&rsquo; service (&ldquo;<B>Discretionary Bonus</B>&rdquo;). The payment of Discretionary Bonus for a year does
not imply any entitlement to Discretionary Bonus in any other year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.5</TD><TD STYLE="text-align: justify">The Chief Financial Officer shall be reimbursed for all out-of-pocket expenses necessarily and
reasonably incurred by him in the proper performance of his duties, which expenses shall be evidence in such manner as the Board
may require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">5.</FONT></TD><TD STYLE="text-align: justify">Pension</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt; text-align: justify">The Chief Financial Officer
must join the Company&rsquo;s Mandatory Provident Fund Scheme (the &ldquo;<B>Scheme</B>&rdquo;), subject to the terms and conditions
of the Scheme from time to time in force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">6.</FONT></TD><TD STYLE="text-align: justify">Annual Leave</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">The Chief Financial Officer is entitled to fifteen (15) Working Days&rsquo; paid holiday (inclusive
of relevant statutory annual leave) per year upon completion of the 6-month probation period (plus statutory holidays in Hong Kong.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify">Annual leave must be taken with the Company&rsquo;s prior written approval at such time or times
convenient to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.3</TD><TD STYLE="text-align: justify">To the extent permitted by applicable law, untaken holiday entitlement may not be carried forward
to a future calendar year and the Chief Financial Officer has no entitlement to be paid in lieu of accrued but untaken holiday.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.4</TD><TD STYLE="text-align: justify">On termination of the Employment, the Chief Financial Officer will be paid in lieu of any accrued
and untaken annual leave in respect of the final calendar year of the Employment. Payment in respect of any accrued and untaken
annual leave entitlement in excess of statutory annual leave entitlement will be based on the Chief Financial Officer&rsquo;s annual
Base Salary only.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.5</TD><TD STYLE="text-align: justify">If on termination of the Employment, the Chief Financial Officer has taken more Working Days&rsquo;
paid annual leave than his accrued entitlement, the Company is authorized to deduct the appropriate amount from his final salary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">7.</FONT></TD><TD STYLE="text-align: justify">Taxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The Chief Financial Officer shall be responsible for filing tax returns and payment of all taxes
that may be imposed by reason of his receipt of Base Salary, Discretionary Bonus and any other benefits referred to in or contemplated
under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">Nothing in this Clause 7 limits the rights of the Company to withhold or make deductions from amounts
payable to the Chief Financial Officer under this Agreement that are required by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">8.</FONT></TD><TD STYLE="text-align: justify">Sickness and Other Incapacity</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify">Subject to the Chief Financial Officer&rsquo;s compliance with the Company&rsquo;s policy on notification
and certification of periods of absence from work, the Chief Financial Officer will continue to be paid his salary during any period
of absence from work due to sickness, injury or other incapacity, up to the maximum number of paid sickness days to which the Chief
Financial Officer is entitled under the Employment Ordinance (Chapter 57, the laws of Hong Kong) at the time of absence.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.2</TD><TD STYLE="text-align: justify">The Chief Financial Officer shall not be paid during any period of absence from work (other than
due to holiday, sickness, injury or other incapacity) without the prior written permission of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.3</TD><TD STYLE="text-align: justify">If on termination of Employment, the Chief Financial Officer has taken more Working Days&rsquo;
paid sick leave than his accrued entitlement by law, the Chief Financial Officer must repay the un-accrued sick leave pay, which
may (at the sole and absolute discretion of the Company) be repaid by way of deduction from any monies due to the Chief Financial
Officer on termination of the Employment. The Company is authorized to deduct the appropriate amount from his salary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">9.</FONT></TD><TD STYLE="text-align: justify">Conflict of Interests</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">During the Employment the Chief Financial Officer shall not (without the Company&rsquo;s prior
written consent) be directly or indirectly employed, engaged, concerned or interested in any other business activity, trade or
occupation that competes with the company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.2</TD><TD STYLE="text-align: justify">The Chief Financial Officer confirms that, to the best of his knowledge, he has fully disclosed
to the Company all circumstances in respect of which there is a conflict of interest between the Company and the Chief Financial
Officer or any connected person. As soon as the Chief Financial Officer is aware of any such conflict of interest arises during
the Employment, the Chief Financial Officer shall promptly inform the Company of such conflict and provide confirmation in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">10.</FONT></TD><TD STYLE="text-align: justify">Confidentiality</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">The Chief Financial Officer hereby irrevocably acknowledges and agrees:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">that all communications between the Company and the Chief Financial Officer and all information
and other materials supplied to or received by any Party from the other Party which is either marked &lsquo;Confidential&rsquo;
or is by its nature intended to be for the knowledge of the recipient alone, and all information concerning the business transactions
and the financial arrangements of the Company with any person with whom any of them is in a confidential relationship with regard
to the matter in question coming to the knowledge of the recipient shall be strictly kept confidential by the Chief Financial Officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">that the Confidential Information is valuable to the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">that the Chief Financial Officer is provided with access to Confidential Information so that the
Chief Financial Officer is properly able to carry out the duties pursuant to this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">that the Chief Financial Officer owes, without limitation, a duty of trust and confidence to the
Company and a duty to act at all times during his Employment in the best interests of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">that the disclosure of any Confidential Information to any person or company including customer,
actual or potential competitor of the Company (whether a person or company is a potential competitor of the Company is subject
to the Company&rsquo;s absolute discretion), or any third party may seriously jeopardize the Company&rsquo;s position and may cause
immeasurable damage to the Company and therefore the restrictions contained in Clause 10 of this Agreement are reasonable to protect
the interest of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.2</TD><TD STYLE="text-align: justify">The Chief Financial Officer undertakes that he shall keep secret and shall not at any time (whether
during the Employment or thereafter) divulge, communicate to person or use any Confidential Information for his own or another&rsquo;s
advantage, or reveal to any person, including but not limited to his spouse, family members and friends, firm, company or organization,
and shall use his best endeavors to prevent the publication or disclosure of, any Confidential Information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.3</TD><TD STYLE="text-align: justify">The restrictions in this clause shall not apply:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to any disclosure or use authorized by the Company or required by the Employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">to disclosure to the extent required by law, provided that the Chief Financial Officer:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">provides the Company with as much prior written notice as possible of such a requirement so that
the Company may seek a protective order or other appropriate remedy, to the extent permitted; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">reveals only that part of the Confidential Information which he is legally obliged to disclose;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">to information or knowledge which has come into the public domain without fault on the part of
the Chief Financial Officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.4</TD><TD STYLE="text-align: justify">Clause 10 of this Agreement shall survive notwithstanding termination of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.5</TD><TD STYLE="text-align: justify">In the event the Chief Financial Officer fails to observe or comply with Clause 10 of this Agreement,
the Company may institute legal proceedings against the Chief Financial Officer or take whatever action that the Company may deem
appropriate to protect its rights over the Confidential Information including but not limited to seeking injunctive relief and/or
monetary damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.6</TD><TD STYLE="text-align: justify">All notes, memoranda, correspondences, emails, written and unwritten records and writings made
by the Chief Financial Officer in relation to the business of the Company or concerning any of his dealings or affairs or the dealings
or affairs of any clients or customers of the Company, including all intellectual property rights thereof, shall be and shall remain
the property of the Company and shall be handed over by him to the Company from time to time on demand and in any event upon his
termination of the Employment and the Chief Financial Officer shall not retain any copy thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">11.</FONT></TD><TD STYLE="text-align: justify">Restrictions on the Chief Financial Officer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">The Chief Financial Officer undertakes to the Company that at any time during the term of the Employment
and for a period of eighteen (18) months after expiry or termination of this Agreement, whichever is later, he shall not:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">either on his own account or in conjunction with or as an agent or in such other capacity on behalf
of any person, firm or company, carry on or be engaged, concerned or interested directly or indirectly whether as shareholder,
director, employee, partner, agent, consultant, adviser or otherwise in carrying on any business in direct or indirect competition
with the Company. Whether a business is in direct or indirect competition with the Company is subject to the Company&rsquo;s absolute
discretion. Such discretion shall not be unreasonably exercised;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">either on his own account or in conjunction with or on behalf of any other person, firm or company
solicit or entice away or attempt to solicit or entice away from the Company the customer of any person, firm, company or organization
who is or shall at any time within two (2) years prior to such cessation have been a customer, client, identified prospective customer
or client, representative, agent or correspondent of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">either on his own account or in conjunction with or on behalf of any other person, firm or company
solicit or entice away or attempt to solicit or entice away from the Company any person who is or shall have been at the date of
or within two (2) years prior to such cessation a director, officer, manager, consultant or employee of the Company whether or
not such person would commit a breach of contract by reason of leaving such employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">receive on his own account or in conjunction with or on behalf of any other person, firm or company
any benefit (monetary or otherwise), directly or indirectly, from the prospective investor, investor or any related persons (including
their respective shareholders, directors, officers, employees).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">12.</FONT></TD><TD STYLE="text-align: justify">Termination</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify">During the six-month (6) probation period, seven (7) days&rsquo; prior written notice or payment
in lieu of notice (&ldquo;<B>Payment in Lieu</B>&rdquo;) should be given by either Party. After the probation period and upon confirmation
of employment, either Party may terminate the Employment by giving the other three (3) month&rsquo;s prior written notice or Payment
in Lieu.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify">For the avoidance of doubt, the Chief Financial Officer shall not be entitled to receive any payment
in addition to the Payment in Lieu in respect of any leave entitlement that would have accrued during the period for which the
Payment in Lieu is made. The Payment in Lieu shall be subject to such deductions as may be required by law and shall be made in
full and as final settlement of any claims (other than statutory claims) either Party may have against the other Party arising
from the Employment or the termination thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.3</TD><TD STYLE="text-align: justify">The Company may also terminate the Employment immediately and with no liability to make any further
payment to the Chief Financial Officer (other than in respect of amounts accrued due at the date of termination and any amount
required by law) if the Chief Financial Officer:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">commits any serious or repeated breach of any of his obligations under this Agreement or his Employment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">is guilty of serious misconduct which, in the Company&rsquo;s reasonable opinion, has damaged or
may damage the business or affairs of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">is guilty of conduct which, in the Company&rsquo;s reasonable opinion, brings or is likely to bring
him and/or the Company into disrepute;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">is convicted of a criminal offence;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 66pt; text-align: justify; text-indent: 6pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">is declared bankrupt or is being filed against a petition for bankruptcy order;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This clause shall not restrict
any other right the Company may have (whether at common law or otherwise) to terminate the Employment summarily.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any delay by the Company in exercising
its rights under this clause shall not constitute a waiver of those rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.4</TD><TD STYLE="text-align: justify">On termination of the Employment for whatever reason (and whether in breach of contract of otherwise)
the Chief Financial Officer shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">as soon as possible deliver to the Company originals and copies of all books, documents, computer
records, materials, notes, memoranda, statements, files, computer hardware/software, and any other property regardless of form,
format or media, relating to the business of or belonging to the Company which is in his possession or under his control. The Chief
Financial Officer is not entitled to retain copies or reproductions of any such property;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">as soon as possible resign from any office he holds with the Company without any compensation for
loss of office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.5</TD><TD STYLE="text-align: justify">The Chief Financial Officer shall not at any time after termination of the Employment represent
himself as being in any way concerned with or interested in the affairs of the business of, or employed by, the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.6</TD><TD STYLE="text-align: justify">The Chief Financial Officer shall not at any time after termination of the Employment contact,
approach, liaise, communicate with or solicit business from any of the Company&rsquo;s customers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">13.</FONT></TD><TD STYLE="text-align: justify">Miscellaneous</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">This Agreement, together with any other documents referred to in this Agreement, supersedes all
other agreements both oral and in writing between the Company and the Chief Financial Officer and for any terms of employment previously
in force between the Company and the Chief Financial Officer, if any, whether or not on a legal or formal basis (which shall be
deemed to have been terminated by mutual consent). The Chief Financial Officer acknowledges that he has not entered into this Agreement
in reliance upon any representation, warranty or undertaking which is not set out in this Agreement or expressly referred to in
it as forming part of the Chief Financial Officer&rsquo;s contract of employment. Nothing in this clause shall exclude any liability
for, or remedy in respect of, fraudulent misrepresentation by a Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.2</TD><TD STYLE="text-align: justify">If any term or other provision of this Agreement is held to be invalid, illegal or incapable of
being enforced by law, all other provisions of this Agreement shall nevertheless remain in full force.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.3</TD><TD STYLE="text-align: justify">Unless expressly provided to the contrary in this Agreement, a person who is not a party to this
Agreement has no right under the Contracts (Rights of Third Parties) Ordinance (Chapter 623 of the Laws of Hong Kong) to enforce
or to enjoy the benefit of any term of this Agreement, and whether so provided in this Agreement or not, no consent of third party
is required for the amendment to (including the waiver or compromise of any obligation), rescission of or termination of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -48pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.4</TD><TD STYLE="text-align: justify">This Agreement shall be governed by, and interpreted in accordance with, Hong Kong law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.5</TD><TD STYLE="text-align: justify">Except as expressly provided otherwise in this Agreement, the courts of Hong Kong are to have exclusive
jurisdiction to settle any disputes (including claims for set-off and counterclaims) which may arise in connection with this Agreement.
For such purposes each Party irrevocably submits to the jurisdiction of the Hong Kong courts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.6</TD><TD STYLE="text-align: justify">Any notice, claim, demand, court process or other communication under this Agreement (collectively
&ldquo;<B>communication</B>&rdquo; in this Clause 13.6) may be served or given personally or sent to the address stated after the
relevant party&rsquo;s name at the beginning of this Agreement or to such other address as may from time to time be notified in
writing by one party to the other with specific reference to this Agreement, by the following means and the addressee of such communication
shall be deemed to have received the same within the time stated adjacent to the relevant means of dispatch:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 43%; padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify"><U>Means of dispatch</U></TD>
    <TD STYLE="width: 50%; padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify"><U>Time of deemed receipt</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify">Local mail or courier</TD>
    <TD STYLE="padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify">24 hours</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify">Air courier/Speedpost</TD>
    <TD STYLE="padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify">3 days</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify">Airmail</TD>
    <TD STYLE="padding-right: 1.4pt; padding-left: 1.4pt; text-align: justify">5 days</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">A communication served in accordance
with this Clause 13.6 shall be deemed sufficiently served and in proving service and/or receipt of a communication it shall be
sufficient to prove that such communication was left at the addressee&rsquo;s address or that the envelope containing such communication
was properly addressed and posted or dispatched to the addressee&rsquo;s address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Nothing in this Clause 13.6 shall
preclude the service of communication or the proof of such service by any mode permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the Parties have executed
this Agreement on the date first written above</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; text-align: justify"><B><U>The Chief Financial Officer</U></B></TD>
    <TD STYLE="text-align: center; width: 12%">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: justify"><B>&nbsp;</B></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">SIGNED by Chau, Tien Hsiang</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><I><U STYLE="text-decoration: none">/s/ Tien Hsiang Chau</U></I></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">holder of HKID number ********</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">in the presence of: James Chung</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><I><U STYLE="text-decoration: none">/s/ James Chung</U></I></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B><U>The Company</U></B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">SIGNED by AU, Yat-Gai</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><I><U STYLE="text-decoration: none">/s/ Yat-Gai Au</U></I></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">for and on behalf of</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Regencell Bioscience Limited</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="text-align: justify"></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">in the presence of: James Chung</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"> <I><U STYLE="text-decoration: none">/s/ James Chung</U></I></TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">15</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LOAN
EXTENSION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Loan Extension Agreement (the &ldquo;<U>Extension Agreement</U>&rdquo;) is dated as of this February 2, 2021, by and between Mr.
Yat-Gai Au (&ldquo;the <U>Lender</U>&rdquo;) and Regencell Bioscience Limited (&ldquo;the <U>Borrower</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms
not otherwise defined herein shall have the meaning ascribed to such terms in the loan agreement entered into between the Lender
and the Borrower on November 10, 2020 (the &ldquo;<U>Loan Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Lender agrees to make the Loan available to the Borrower in a timely manner or make payments on the Borrower&rsquo;s behalf,
according to the needs of the operations and research activities of the Borrower and its subsidiaries or parent company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B>,
the Maturity Date of the Loan and Existing Loan is June 30, 2021 and is subject to indefinite extension if agreed by the Parties
in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
the Lender and the Borrower agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
According to the needs of the operations and research activities of the Borrower and its subsidiaries and parent company for the
period from January 1, 2021 to June 30, 2022, the Lender agrees to provide up to US$3 million in the form of Loan or make payments
on the Borrower&rsquo;s behalf during the period from January 1, 2021 to June 30, 2022. This US$3 million amount can be adjusted
based on the needs of the operations and research activities of the Borrower and its subsidiaries and parent company and agreed
by both Parties in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
The Maturity Date of the Loan and Existing Loan shall be extended from June 30, 2021 to December 31, 2022 and is subject to indefinite
extension by the Parties in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Except as specifically amended hereby, the parties hereto acknowledge and confirm that the Loan Agreement remain in full force
and effect and enforceable in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, intending to be legally bound, the parties hereto have caused this Agreement to be signed by their duly authorized
officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
February 2, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Lender</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Borrower</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
        Yat-Gai Au</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;&nbsp;</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
        Yat-Gai Au</I></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Yat-Gai Au</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
    Signer: Yat-Gai Au</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    Chairman and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF EVANA YEE WAH HUI </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
Bioscience Holdings Ltd. (the &ldquo;Company&rdquo;) intends to file a Registration Statement on Form F-1 (together with any amendments
or supplements thereto, the &ldquo;Registration Statement&rdquo;) registering securities for issuance in its initial public offering.&nbsp;As
required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration
Statement as a Director Nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
January 11, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 41%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 100%; font: 12pt Cambria, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <I>Evana Yee Wah Hui</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Cambria, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evana
    Yee Wah Hui</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Cambria, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF PAUL J. NIEWIADOMSKI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
Bioscience Holdings Ltd. (the &ldquo;Company&rdquo;) intends to file a Registration Statement on Form F-1 (together with any amendments
or supplements thereto, the &ldquo;Registration Statement&rdquo;) registering securities for issuance in its initial public offering.&nbsp;As
required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration
Statement as a Director Nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
January 10, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 41%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 100%; font: 12pt Cambria, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <I>Paul J. Niewiadomski</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Cambria, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paul
    J. Niewiadomski</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Cambria, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>13
<FILENAME>filename13.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF CHEUNG MING WONG</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regencell
Bioscience Holdings Ltd. (the &ldquo;Company&rdquo;) intends to file a Registration Statement on Form F-1 (together with any amendments
or supplements thereto, the &ldquo;Registration Statement&rdquo;) registering securities for issuance in its initial public offering.&nbsp;As
required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registration
Statement as a Director Nominee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
January 11, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 41%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 100%; font: 12pt Cambria, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <I>Cheung Ming Wong</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Cambria, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cheung
    Ming Wong</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Cambria, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>14
<FILENAME>filename14.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.5</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
12<SUP>th</SUP>, 2021</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regencell
Bioscience Holdings Limited</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/F
First Commercial Building</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33-35
Leighton Road</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Causeway
Bay, Hong Kong</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:
Consent of Persistence Market Research </B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen,</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
understand that Regencell Bioscience Holdings Limited (the <B>&ldquo;Company&rdquo;</B>) intends to file a draft registration
statement (the <B>&ldquo;Registration Statement&rdquo;</B>) with the United States Securities and Exchange Commission (the <B>&ldquo;SEC&rdquo;</B>)
in connection with its proposed initial public offering (the <B>&ldquo;Proposed IPO&rdquo;</B>).</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the references to our name and the inclusion of information, data and statements from our research reports and
amendments thereto, including but not limited to the industry research report titled &ldquo;Industry Overview&rdquo; (the <B>&ldquo;Report&rdquo;</B>),
and any subsequent amendments to the Report, as well as the citation of our research report and amendments thereto, (i) in the
Registration Statement and any amendments thereto, (ii) in any written correspondences with the SEC, (iii) in any other future
filings with the SEC by the Company, including, without limitation, filings on Form 20-F, Form 6-K or other SEC filings (collectively,
the <B>&ldquo;SEC Filings&rdquo;</B>), (iv) on the websites of the Company and its subsidiaries and affiliates, (v) in institutional
and retail road shows and other activities in connection with the Proposed IPO, and in other publicity materials in connection
with the Proposed IPO.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further hereby consent to the filing of this letter as an exhibit to the Registration Statement and any amendments thereto and
as an exhibit to any other SEC Filings. In giving such consent, we do not thereby admit that we come within the category of persons
whose consent is required under Section 7 of the U.S. Securities Act of 1933, as amended, or the rules and regulations of the
SEC thereunder.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
faithfully</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and on behalf of</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Persistence
Market Research </B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">/s/
    <I>Sudip Saha</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify; width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sudip
    Saha</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director &amp; Chief
    Operating Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>15
<FILENAME>filename15.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-6_001.jpg" ALT="">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office No. 308, 3<SUP>rd</SUP> Floor, Supreme Head
        Quarters, Sr No : 36/2</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Banglore Highway Road. Baner, PUNE, Maharashtra. India, 411045.</P></TD>
    <TD STYLE="width: 10%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 35%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel. no.: +91-7720054618</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: info@fortunebusinessinsights.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Web: www fortunebusinessinsights.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CIN: U93000PN2019PTC181 106.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">February 3<SUP>rd</SUP>, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regencell Bioscience Holdings Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">11/F First Commercial Building</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">33-35 Leighton Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Causeway Bay, Hong Kong</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Re: Consent of Fortune Business Insights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We understand that Regencell Bioscience
Holdings Limited (the <B>&ldquo;Company&rdquo;</B>) intends to file a draft registration statement (the <B>&ldquo;Registration
Statement&rdquo;</B>) with the United States Securities and Exchange Commission (the <B>&ldquo;SEC&rdquo;</B>) in connection with
its proposed initial public offering (the <B>&ldquo;Proposed IPO&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the references to
our name and the inclusion of information, data and statements from our research reports and amendments thereto, including but
not limited to the industry research report titled &ldquo;Industry Overview&rdquo; (the <B>&ldquo;Report&rdquo;</B>), and any subsequent
amendments to the Report, as well as the citation of our research report and amendments thereto, (i) in the Registration Statement
and any amendments thereto, (ii) in any written correspondences with the SEC, (iii) in any other future filings with the SEC by
the Company, including, without limitation, filings on Form 20-F, Form 6-K or other SEC filings (collectively, the <B>&ldquo;SEC
Filings&rdquo;</B>), (iv) on the websites of the Company and its subsidiaries and affiliates, (v) in institutional and retail road
shows and other activities in connection with the Proposed IPO, and in other publicity materials in connection with the Proposed
IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further hereby consent to the filing
of this letter as an exhibit to the Registration Statement and any amendments thereto and as an exhibit to any other SEC Filings.
In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section
7 of the U.S. Securities Act of 1933, as amended, or the rules and regulations of the SEC thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Yours faithfully</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">For and on behalf of </TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><B>Fortune Business Insights Pvt. Ltd.</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><I>/s/ Rahul Bhandari</I></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: justify">Mr. Rahul Bhandari</TD>
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Title: &nbsp;</TD>
    <TD STYLE="text-align: justify">CEO</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L ',# 2(  A$! Q$!_\0
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MF%F)9RWWBS'DD^M8^TPOLDFO>O\ KK^'0TY:W.W?2QE>%M?N=?$K3K:*J(A
M@\S<"WKO 'Y9JK9^-ENO+C>S\JXDO%MT1GX>,N4\Q3CG!!!':M[3M)@TO_CW
MFNW4*$59[AI%4#I@$\57'AO2Q'9I]G/^ASM<0L7.Y7+;CSW!/:MG6P+J3;C[
MKM;RW_X!GR8GDC9Z]2&?5M3GU.[M-)L;>866T3M<2E-S,-P5, ]NYXIOB#7I
M]':P1([56N=^\W+L%3: <94$GKZ5:OO#VGZC<O<3+.DDB!)3#.T8E4= P!YJ
M6^TBVU!K=I6N(WMPPB>"9HV ( (R.>@%1"KA%*#<=%OIY>NNI3A7M*SUZ%:?
M6)8(M%)CA=M0G6)RC':H*ELKD GIWJW/?-#J]C9",%;E)6+9Y78%/ZYJ.[T2
MTOK2UMYWN2+5P\4@G82!@",[NI/)IMSH5I=QVJR2W@:U5ECE2Y99,'&<L#D]
M!UK.^%=KZ;WT^Y[E6K*_R_X)G>/8UD\&7VX9V[&'UWBO%*]J\=LL/@F]0EN1
M&BD\DG<.I_"O%:^WX3O]3EVYF?.YY_'7H%%%%?4'BA7H'PMOQ'?7VGL<>=&L
MJ#U*\']#^E>?U?T74Y-'UBUOX\DPOEE'\2]&'XC-<&:87ZUA)TENUIZHZL%6
M]C7C-GT!14=O<175O%<0.'AE4.C#N#R*DK\BE%Q;B]T?=IIJZ"BBBI&%%%%
M!1110 444$@ DD #DD]J:5W9"."^*-^(M+L[ 'YII3*P_P!E1@?J?TKRVMSQ
M;K7]N^(9[E&S;Q_NH/\ <'?\3D_C6'7ZQDF$>%P4*<MWJ_F?$9C75;$2DMM@
MHHHKU3A"BBB@#T#X>^*EM'71;Z3$+MFVD8\(QZH?8GI[_6O3Z^<*]"\)_$'[
M.D=AK;DQ* L=WU*CT?U'O^=?%\09#*<GBL,M>J_5'T65YFHI4:S]&>FT4R*6
M.>%989%DC<95T.01[&GU\,TXNS/HTTU=!1112&%%%(2%4LQ 4#)). *:3>B%
M>PM<%\0/%:VMN^BV,@-Q*,7+J?\ 5K_=^I[^@^M-\5?$*&W22RT202SD;7NA
M]V/_ '?4^_0>]>8,S.Q9F+,QR23DD^M?99!D$G)8G$JR6R_5G@9GF<5%T:+U
MZL2BBBONSYD**** "BBB@ HHHH T](\0:GH<FZPNGC4G+1-\R-]5/%=MI_Q3
M7:JZCIISWDMGX_[Y/^->;45YV+RC!XMWJPU[K1G90QU>AI"6A[)#\1O#LN T
M]Q$2,GS(#Q^6:=+\1/#<72ZFEX_@@;^N*\9HKRO]4\#?>7WG;_;>)MLCTV^^
M*=NJD:?ILLC=FN'"C\AD_K7&:SXJU?704N[HK ?^6$0VI^([_CFL6BO2PF2X
@+"N].&O=ZG'7S#$5E:4M HHHKU#B"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $H G # 2(  A$! Q$!_\0
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M4\-:?;7NL_#OQ!?-XT\#VLJ3^(O#VM@']B__  _%_P"";'_1<-<_\-%\7/\
MYBJ/^'XO_!-C_HN&N?\ AHOBY_\ ,57\,/C7P=XA^'?C+Q9\/_%UI;6'BKP/
MXDUGPGXDLK/4;+5[2TUS0+^?3-3M[75--FN-/U&WCN[>58;RSGD@GCVR(1DJ
MO,T ?WB?\/Q?^";'_1<-<_\ #1?%S_YBJ/\ A^+_ ,$V/^BX:Y_X:+XN?_,5
M7\'=% ']XG_#\7_@FQ_T7#7/_#1?%S_YBJ/^'XO_  38_P"BX:Y_X:+XN?\
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M7/\ PT7Q<_\ F*K^,3X4?%GPK#X7N_@?\=$U;5?@5KFJSZWI6M:/;QZCXT^
M?CJ_2.WE^*/PTMYWC%_87R1V\'Q-^&K7%OI/Q%T2!)86L/&.F:#K4' _&'X4
M>*/@?\2?$_PN\8R:9<Z[X9FT]CJ&BW+W.E:QI&MZ79:]X=URQ%Q';ZA8P:WH
M&IZ=J@TC6K/3]?T8W9TO7=-L-4M;JUC /[>?^'XO_!-C_HN&N?\ AHOBY_\
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MC^Q-=_Z 'B#_ ,$6K_\ R'7^H]10!_EP_P!B:[_T /$'_@BU?_Y#H_L37?\
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M>[T^"2<006=K:V&FZ?IEMIVE:5IFG6MGI>D:5I]M;V.F:796EC:0QP6Z*/\
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MXB06VH_&K6K)+Z[6W\!V6B:3>_Z-Q (((!!!!!&00>""#P01U%*      !@
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MJJ^'M?55 55&@ZL J@8  %E@  8 ' %+_8FN_P#0 \0?^"+5_P#Y#K_4>HH
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M_>>)K+2)5U:UGN[<6EQI^J74A2."[LW682V<.US*RA"X*$L"OQ=_PV7\7O\
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M)-1_^7M'_#9?Q>_Y]?!?_@DU'_Y>T ?JA17Y7_\ #9?Q>_Y]?!?_ ()-1_\
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M)7EE=(T9A^L7P"^ 6F?"?3!JVK"VU/QWJ=L%U'45'F6^D6\@5VT?1V< K"K
M"]O0J2W\JC(2W2&)0#SO]L"74YO@SX1FUJUMK'5Y?%NA2:G9V5PUW:6M^^@:
MXUU;VUT\<+7$$4Q=(Y6C0NBAL<Y/YHU^NG[3?P\\5_$KP)I6A^#[&WO]2M?%
M5CJD\-S?VVGQK90:;JUM)()KIEC9Q-=P*(P=[!BP&%-?#/\ PR=\<O\ H6])
M_P#"FTC_ ./4 ?.-%?1W_#)WQR_Z%O2?_"FTC_X]1_PR=\<O^A;TG_PIM(_^
M/4 ?.-%?1W_#)WQR_P"A;TG_ ,*;2/\ X]1_PR=\<O\ H6])_P#"FTC_ ./4
M ?.-?G-9^*?C[X6OOVG_ (O:E_PG&L>'? ?QI\;:#X*L-:^(7B?6?"Z^ =/\
M;^ -%NQ8?L_Z;X&L%?1_#7@O4O%VOZ3XTTSQMK-S<W&F'4QI=U&)H(OVG_X9
M.^.7_0MZ3_X4VD?_ !ZGC]E+X[!D<>'],#QA1&X\4Z2&C"?<",)\J$_A"D;>
MV* /POUW]H?]H#QQ#X@\1>$M<C\ ?#CPM\7?A]I-GJEM\&_$]YKWC+P'XC_:
M"^,/P]EU.2\\07]K+IFB2^"/ G@V^N+ZS\.O-,?%\/B-[C3='OM,C/*2_M-?
MM?>!?"7P_P!!U/1?"?B;6;OP1\.]?U3XF>+/ /CW1=.FUSQ%\%O#/C*T^&>O
MZ?H0\3WUSXNU_P 77.OZ1=>)-,LHM4FFTJ]T^T\+P>(YK/3YOW^/[*_QZ+B0
MZ'IYD&[#GQ7I9<;U"/AOM&X;T54;!^90%.0 *%_96^/2$E-"T]20X)7Q7I:D
MB4[I 2+@$B1N7!X<\MDT ?C_ ./O&WQ]US]FOQWXGM;B]T+X@ZA\?/#W@KPC
MI/@C3]=\$:UH'@.Q_:B\.?#:^M9_$KV_BG6I7U_P+!J>HZSX[M/#5I%8Z-JE
MYJFG:+#:6\4Z^&:;^T!^U'X \0P^ ;C0#/=-\6O'NG7]I\6;CQSX_NM$CT_Q
M/\,-&\)?!S0/BOH/@VWN_B)%XP\'>)->^+_A7XBP^''FCTK5K;PM):F+P#XM
M6U_?#_AE+X[;MW_"/Z9NV[-W_"4Z3NV;/+V9\_.WR_DVYQL^7&WBGK^RM\>4
M4HFA:>J%#$47Q7I:J8RQ8QE1< ;"S,Q3&TL22,DF@#\ M3_;(_:@M[;6[.P\
M%^"I+K3O'7B72'\<W_@7X@VOPXLAI_A[6-4\)> DN+2+4O%EWX@\5:MIJZ5J
M*ZKX1T'Q7X?91I]KI&N:IXA\,37/:Z5^U/\ M">+/C#<?#;0/#=AI.F:EXU\
M/>'O[:UKX2>)8V\!PI\4I?!7BG39HY_%L?\ ;4T_AX)K.C:UXO'@R<Q-9>+7
M\-0^%=8M+6/]R?\ AECX]@AAHE@&6/R5;_A+-,RL7_/('[1D1_[ ^7VI#^RM
M\>F01MH6GM&J[%C/BO2RBI@C:%-QM"X)&T#&"1C!H _!V?\ :%_:9\16'AOQ
M3X:UK2K?6O#O@/XS^//'W@(? 7XB6F@Z)XF\,_#BV\26'P#U^]U7Q';2^*_%
MFC>(+(Z/;>+-$EL+RREU2YN!H&KW&I:/;VWH7[5?Q$^(_A/XB_#Z^\*^,_B)
MI=A+X*\-ZE8_"OP59^(](U;QCXIU#QY:+J$GA36T^''CKX?_ !5\10:(8_#^
MM?!SXCWW@"TT_1+B+Q/IWB.RN-8FU/1OV@/[*WQY;;G0M/.P($SXKTL[!&=T
M87-Q\HC;YD P$/*X-(G[*OQXC61(]!TZ-91B54\5:4JR#D8D"S@.,$\,".3Z
MT ?A1IW[4_QW\&V.K>%M5TB?XH_$2;XB76E>"=(;X9^+=%O_ !/:I\9?V@-!
M\4^&'O=+%QHVGP>$?"?@[X56NG^(;NXM8K6T\8Z3J%P-876-/GD\^M_VI?VD
M+36/%VOZ'?GXEZ+)JVBZ2GB*;X;^//!'PV\":9JVC?LH0>+/$W_"+:LMY=W%
MG\.M4\<?$J.[N+G4+VV.JV^NW-Y<6EGI'B>TL_Z&O^&5_CWL:/\ L.P\ME5&
M3_A+-+V,B+L167[1M*HORJI&%7@ #BE/[+/Q\9E=M%L6="I1SXMTPLI3<%*L
M;C*E0[A2"-NYL8W'(!^.7P+_ &B?C7XW^-7@;P!\1=!\+67A[Q7\.4\0WMSX
M)\(^.O*T?48O#UIJZ^(=;UCQO;^%=2T+1O$%PTT>AB'PWX@T&XDN[3PVVL:?
MXDMIOM/(Z;^T;^TKXJ\2Z-X3T72_#.A:AXA\37FD^+;C4?@]XZU"/X :A9ZW
M\5+*T\!>(9KKQ+I&E?$+6]?\->#/#GBZR\3V5_HVEVD6I3E[2?2_$'AB2OVX
M;]E7X\NAC?0=.>,N92C>*M*9#(WWI"IG*ESDY?&X]S0?V5?CPRJC:#IS*B>6
MBGQ5I158R0Q109\*A95.T +D XR!0!^1WQ*N?B%\2?A7^R7XZM_%'Q?^%OB7
MQY\1OV=M+^)6A?"7Q'KGA2WM_#/Q-DLKCXD6NM:<^FW]_:P:-B2VLM7U007W
MA>V:5+BZ2:664^$?$?Q]\4;/X??&>UM/BM^T;H7[1VG1?M):'IG@GPAX:DUK
MPMX0\$Z#IGBBT^$'C^**_P#"TVD6JQ^'K;P/XM\,_$G1]6U?Q1XZ^)&MR:%?
MV&IV5UK&C:)^\W_#*7QUW.W_  CVF;I PD;_ (2C2=SA_OASY^6#_P 08D-W
MS3Q^RM\>0J(-"T\)&V^-!XKTL+&_)WHHN,*V2?F4 \GGF@#\6_V<_B3^T!XX
M^/TMM\1)/&.E>#/"W[.NM_#O5/#.H>'Y-,\.Z[\?/A'\0O"?AWX@_%>"ZN-,
MMS>7/C6YUN_M/";V]]_9.H>&-(N;_2;6>WEENU^5/@'^TG^T)X>\ P:UXC\=
M>+_B'=Z_\+?@4VK:SJV@^._B78?#GXK>)/$_B#3_ !KIWC5?'^B?"6V\#^+-
M3TA;!W\/Z-K^O?#_ ,.QZ7-/<P'6=2\/VNL?TF-^RE\=F4*WA_3&4; %;Q3I
M)4"-2B  SD#8I*I@?*I*C )%3-^RW\?G=9'T:R9T#*CMXNTUG57&'56-R2H<
M<, 0&'!S0!_/Q9_ML?M.W>D0:C_PJ_0WU#6?AA\.?%+Z59^ O'D4'PSN-?/P
MHA\;^*?B+)K$UGKNG67AN/QAXSUFQTFTT/Q!X>U*RT&VT[_A*+'5O#GC"S7V
MWQSXR^/_ ,0?@W^RW?Z%]OT_QO\ $/XT2:1X[3X6>,O%OPHTK7/!%AX0^,-Q
M8W[^-M2\ ^(/$?@O0==E\/>$-?N&E\+365QJTUKI&E:K=Z-J&G:E>?LP?V6/
MCV=N=$L#LD,J9\6:7\LIZRK_ *1\LA[N,,?6HS^RE\=F:1F\/Z86ESYK'Q3I
M):3+!CYA,^7RRJQW$Y90>H% 'XB_$#]H+]H;X=ZGXG\#^%=%M-8U[PF\/AC3
M?#7B;P?X^^(WB*#PW'\._"FO67[0/B'XIV=SH.E^/=#U3X@:QJOPY?P_#I>@
MZE?W%@EZ;FRU6VU.T3;U+XT?M4:+XOURS,?@W7O#F@>+/$NEPV=O\'?%EAJO
MB#2/"O[27@;X'P"'6(O&MU8V=QXM\)>+]4^(ZZA!87=MI<?AN!M.M]0\/3ZM
M?P?M"O[*OQX5%C70=.6-7,BQKXJTH(KD$%U43[0Y!(+ 9()!.#2?\,I_'<
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MD_93^.TSF2;P_IDLC8!>3Q3I+N0!@ LTY8X' R>!TH ^;J*^CO\ AD[XY?\
M0MZ3_P"%-I'_ ,>H_P"&3OCE_P!"WI/_ (4VD?\ QZ@#YQHKZ._X9.^.7_0M
MZ3_X4VD?_'J/^&3OCE_T+>D_^%-I'_QZ@#YQHKW+Q+^SC\6_"&@ZIXEU[0M-
MM='T>V:\U"XAU_3+J6*W5E0LEO#*TLK;G4!$!8YX%>8>$O">O>./$.G>&/#5
MDU]JVI2[(DY6"V@4@W%]>S!6%M8VD9\VXG8':H"(KS21QN >K?LX7WQ"M?B?
MI4/P]C^TRW?EKXFM+IY4T63PXDH^UW&L21J_D?9=Y?3;A$:Z^WM';VZ2K//#
M)^P]>3_"#X2Z#\(_#,>CZ:%O-6O/+N/$.NO$$N=6OU3''5H;"UW-%8688K!$
M6=R]Q-/+)ZQ0!^>G_!6;_E&=^W/_ -FS?%;_ -1B]K_/=D_UDG^^W_H1K_0B
M_P""LW_*,[]N?_LV;XK?^HQ>U_GNR?ZR3_?;_P!"-=,O]TH_]A.)_P#3.$.2
M'^_XC_L#PG_J1C1E%%%<QUA7NO[,GB_P]X!^/7PX\9>++Z+3?#F@W?B:XU:\
MGN+ZTB6&[\#>*=,M[9KS3(+G4+,ZC>WUKIL=Y9V\L]I+>)<JN(BP\*HH _1Q
M?B#^SSK,(@TX>!;V/P_\.OA5HGP+TOXQZYJ-RW@+P9<^)O&/B/XN^!_B-XE\
M7^"/B7I6N?%G1O&&NVKV6M-H/_"-Z[\,HY8_ /\ PCVH7BZ KM&U_P#8_OI-
M,O->T?X6>'=.TCXJ_$670=!T2'7M8L/&.FZWIOCI_ &L_$.]UKPC/\1_!7P[
M\#^+H?"D,NB3R>)='\4^ -3T:6X\&Z?K.@^(;?4?SAHH ^ZM<U[X+7MEJR>%
M[7]GCP[\84\%>"(]-US5XF\3?!^XF7Q3XIG\;6MR\OP\\/?#Q/B>OAV;P+;Q
MZSI?@%/"]UH5EXETZQU";QO,;ZX]+^)?C']D>3Q?HFB^"=*^ :Z?<WGQBU0^
M*=*\!^(XO!%GX]_X0+P'I_P<3Q/%J%C_ ,)%'\$H/&A\<ZF?#]OIT[M>26MY
MXNLK[0[)M.K\RJ* /O?0OBGX)\*^ G\)^)I_V=/%.J>(_CC^SCK/BBT\*>!_
M[1\)P> O#^F?%73O'VM3Z<^A:;X-G\56^D^(=)T;Q)K_ (7TI7BT_4X(M!D.
MNKJNI1_%?C*/08O&?C.+PI(LOA.+QAXJC\*2H\\D<OA9-?U%?#DL<ET!=R1R
M:*+%XWNP+IT96N0)S(!SE% !1110 5RWCG_D2?&'_8K>(/\ TTW==37+>.?^
M1)\8?]BMX@_]--W6^%_WK"_]A.&_]2,.<V,_W/&?]@>+_P#43%'^IEX)_P"1
M,\(_]BQH'_IJM*Z>N8\$_P#(F>$?^Q8T#_TU6E?%O[47QA^)/@#X@Z7HWA#Q
M/+HVF7'A2QU&:U33M(NU>]EU35[>2?S+^PNI@6AMH$V+((QY>0@9F+93^.?^
M.?\ Z5(VI_PX?X(?^D0/OFBOQU_X:9^.?_0^W'_@D\-?_*>C_AIGXY_]#[<?
M^"3PU_\ *>I+/V*HK\=?^&F?CG_T/MQ_X)/#7_RGH_X:9^.?_0^W'_@D\-?_
M "GH _8JBOQU_P"&F?CG_P!#[<?^"3PU_P#*>C_AIGXY_P#0^W'_ ()/#7_R
MGH _8JBOQU_X:9^.?_0^W'_@D\-?_*>C_AIGXY_]#[<?^"3PU_\ *>@#]BJ^
M8/VM=)U37OAAIVC:+87.IZKJ7CCPW:6%A:(9)[FXD%_M11PJ*H#/++(RQ0Q(
M\LKI&C,/A3_AIGXY_P#0^W'_ ()/#7_RGI#^TQ\<C@GQY.2#D$Z'X9)4X(RI
M.C<'!*Y&#M)&<$@@'W[\ _@%IGPGTT:MJPM]3\=ZG;A-1U)1YEOI-O)AFT?1
MV< K"I %[>@)+?RJ"=ELD,2_1U?CK_PTS\<_^A]N/_!)X:_^4]'_  TS\<_^
MA]N/_!)X:_\ E/0!^Q5%?CK_ ,-,_'/_ *'VX_\ !)X:_P#E/1_PTS\<_P#H
M?;C_ ,$GAK_Y3T ?L517XZ_\-,_'/_H?;C_P2>&O_E/1_P -,_'/_H?;C_P2
M>&O_ )3T ?L517XZ_P##3/QS_P"A]N/_  2>&O\ Y3T?\-,_'/\ Z'VX_P#!
M)X:_^4] '[%45^.O_#3/QS_Z'VX_\$GAK_Y3T?\ #3/QS_Z'VX_\$GAK_P"4
M] '[%45^.O\ PTS\<_\ H?;C_P $GAK_ .4]9NH_M9_%C1XI)]9^+.F:+!"(
M6FGUE/!&DP0K<.\=LTLVH6-M'$MS)%+';-(RBXDAFCA+O%(J@'[.45^,%[^U
MQ\4],T^#5M3^+VCZ9I%T(6M=7U)O FGZ1=K<Q^;;&TU2\LX;"Z%S$#-;F"XD
M$\0,L6^,%AJ1_M-_'&:..:'X@2SPS1I+#-!H_AB:&>*5!)%-#-%I#1S12Q,L
MD4L;-')&RR(S(02 ?L717XZC]IKXY-NV^/IVV$A]FB^&6*, "5D"Z.=C ,K%
M6PVUE;&&4F*?]J#XUVL33W?Q%^R0(I=YKO2_"MM"J*"S.TL^E1QJB*"SN6"H
MH+,0 30!^Q]%?CO_ ,-+_'7('_"=W63T']A>&\GZ#^QN:JW?[4OQGT^VGO=0
M^),>G6-K&9;J^U#3O"5C8VL*D S75Y=Z7#;6T0) ,L\L: LH+9(! /V2HK\:
M]/\ VJ/C'JUI#J&D?$VWU?3K@,;?4=(LO!^J:?<!)&BD,%]8:;<6DWERH\4G
ME3/LE1XVPZLHM+^TU\<G4.GCZ:1#]V2/1O#+HW)'RNFD,K<@C@GD$=0: /V*
MHK\=3^TU\<@VP^/I@^W?Y9T;PR)-@(4OY?\ 9&_8&95+[=H9E4G+ &.']I_X
MVW'F?9_B&;GR9I;:;[-I7A:X\BZ@(6>UG\G27\FZMV(6XMI=D\#$++&A(! /
MV.HK\<Y?VG?C?!&9I_B$\$(95,T^D>%X(0TCK'&IEETE(PTDKI%&I;=)*Z1H
M&=U4I#^T[\;[B**XMOB#)<V\ZJ\%Q;Z1X7G@GC<!DD@FBTAXIHW4AD>-V1E(
M920<T ?L;17XXO\ M/\ QLCEB@D^(ACGG<QP0/I?A5)YI%CDF:.&%M*$LL@@
MBFG*1HSB"&:;'E12.LO_  TQ\=!G/CNYXZ_\2/PWQ]?^)-Q^- '[$T5^.O\
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M^&!V@Z_XZ(50JYU31SM4$D*N="X4$D@#C))QDFD_X8H^%_\ T'O'/_@ST?\
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MCG_P9Z/_ /**C_ABCX7_ /0>\<_^#/1__E%0!^85%?I[_P ,4?"__H/>.?\
MP9Z/_P#**C_ABCX7_P#0>\<_^#/1_P#Y14 ?F%17Z>_\,4?"_P#Z#WCG_P &
M>C__ "BH_P"&*/A?_P!![QS_ .#/1_\ Y14 ?F%17Z>_\,4?"_\ Z#WCG_P9
MZ/\ _**C_ABCX7_]![QS_P"#/1__ )14 ?F%17Z>_P##%'PO_P"@]XY_\&>C
M_P#RBH_X8H^%_P#T'O'/_@ST?_Y14 ?F%17Z>_\ #%'PO_Z#WCG_ ,&>C_\
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MKGQ*/"^DW&IKHT6M7%EJ4.E-J#0+;_VA)I]\MH',QM+C9Y3_ ,YA_P"#F;Q
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MW/\ B)GU_P#Z,-B_\2FL_P#YPE'_ !$SZ_\ ]&&Q?^)36?\ \X2C][_+E/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV,_W/&?]@>+_ /43%'^IEX)_Y$SPC_V+&@?^FJTKIZYCP3_R)GA'_L6- _\
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MK>#]%L/"GP1\9?LQP?%?P#X=L_!_C>'3+/X>>(O&VNZAX2\,_ SPUXU7X?\
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M:_SW9/\ 62?[[?\ H1K_ $(O^"LW_*,[]N?_ +-F^*W_ *C%[7^>[)_K)/\
M?;_T(UTR_P!TH_\ 83B?_3.$.2'^_P"(_P"P/"?^I&-&4445S'6%%%% !111
M0 4444 %%%% !1110 5RWCG_ )$GQA_V*WB#_P!--W74URWCG_D2?&'_ &*W
MB#_TTW=;X7_>L+_V$X;_ -2,.<V,_P!SQG_8'B__ %$Q1_J9>"?^1,\(_P#8
ML:!_Z:K2NGKF/!/_ ")GA'_L6- _]-5I73UE/XY_XY_^E2-J?\.'^"'_ *1
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M\$/_ $B 4445)84444 %%%% !1110 4444 %%%% 'X,^)?\ D9O$W_8R:_\
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M=-Y"7>FZA'!<7%M]LL+BVN'M;BXM))'MKB:*3E[C]B30KNX^UW/[*^G2S_\
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M\,_"35;/6?&ES:^(?AG/::9=Z)>K8W&C7IUNXMXDC:"')\2?MN^&OASXCLO
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M /C%<!<036D\]M=126]Q:RRP7,$RF.6">!VCFAF1L-')%(C)(C %&5E8 @T
M;7A?Q3KW@K7;#Q-X:U"33-7TR3S(+A/FBDC.!/:7D)(CNK&Z0&*ZMI<I)&<@
MJZHZ_LY\*?'%W\1O NB>+;[0;SP]=:E"WG6-TI$4S1'8;_3'<^=-I-\09["6
M=(Y6A8!E<*LTOPC^SC^S?)XODLO'GCVR>+PI$Z7.A:%<*4D\2NA#17U]&P#)
MH2,-T,+8;5F 9@+ #[7^F,<:1(D42)''&BQQQQJ$2-$ 5$1% 5450%55 "@
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M"<3_ .F<(<D/]_Q'_8'A/_4C&C****YCK"BBB@ HHHH **** "BBB@ HHHH
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M(P%K^B6@#\]/^"LW_*,[]N?_ +-F^*W_ *C%[7^>[)_K)/\ ?;_T(U_H1?\
M!6;_ )1G?MS_ /9LWQ6_]1B]K_/=D_UDG^^W_H1KIE_NE'_L)Q/_ *9PAR0_
MW_$?]@>$_P#4C&C****YCK"BBB@ HHHH **** "BBB@ HHHH *Y;QS_R)/C#
M_L5O$'_IINZZFN6\<_\ (D^,/^Q6\0?^FF[K?"_[UA?^PG#?^I&'.;&?[GC/
M^P/%_P#J)BC_ %,O!/\ R)GA'_L6- _]-5I73US'@G_D3/"/_8L:!_Z:K2NG
MK*?QS_QS_P#2I&U/^'#_  0_](@%%%%26%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <=\0?"TOC;P5XE\)0WB:>_B'2Y]+%\\1G6U6YVI
M)/Y(9/-:./<R1EE5W"JS*I+!G@'P#X;^&WANS\,>&;,6]G;#S+BYDVO>ZG>N
MJB?4=1N JFXN[@J"S$!(D"00)%!%'&O:44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7C7[0N?^%*?$@ $D^&[E55069F:6 *J
MJH+,S,0JJH+,Q"J"2!7LM1RPQ3H8IXHYHR48QRHLB%D=9$)1P5)1U5T)&5=5
M88(! !\0?LW?LV_V$+#XA?$*Q!UXA+KPYX<ND5ET)6&Z+4]4B8$-K3*0]M:M
ME=*!#N#J!'V3[CHHH **** "BBB@#Y$_;3_Y)-I?_8\Z+_Z;-<K\NJ_47]M/
M_DDVE_\ 8\Z+_P"FS7*_+J@!R$*ZL>BL"<=< @U\":S^Q3'X@\'^(X-?\7:]
MXA\877Q)^)GBGP=IFK>,M:B^&G@?PY\5/CDGCGQC9>'=#TC2M,U+3]9\4_#0
M7/@_7Y[FZU:)KO4]7M+&XM]-U&XNC]\T4 ?F_<?L?_$J#Q+=ZG87O@"]\.:=
MXQOM<UGPU=^+/'FFV_[2GAF7XNQ>/O"WA#XOP6FC76F^!;'X:>"XH/ 7AB/P
M[:^,K.[AT^TLWM]/\)-)H:\+HO[%W[1ND_#GPW\+[/QY\.M%TG3]-BU/4];T
MGQ?\31=P:VGP G^$%QX"T>S&CVEX?!.HZQ&FHWWBN;7+;7FT76M1NH= 3Q)8
MQW-]^K5% 'R=\!/@-J?PN^)/Q(\>7?@_X6^#[/XA>#O"&B6.@_#K5?%6J_\
M"()X4\9_$?5[;PFM]XIT^WFUC1?[&\8:-<#5;(^']-AUK3;W3](\$Z-HT>GO
M7UC110!/:_\ 'Y9?]?MG_P"E,5?OS7X#6O\ Q^67_7[9_P#I3%7[\T ?GI_P
M5F_Y1G?MS_\ 9LWQ6_\ 48O:_P ]V3_62?[[?^A&O]"+_@K-_P HSOVY_P#L
MV;XK?^HQ>U_GNR?ZR3_?;_T(UTR_W2C_ -A.)_\ 3.$.2'^_XC_L#PG_ *D8
MT91117,=84444 %%%% !1110 4444 %%%% !7+>.?^1)\8?]BMX@_P#33=UU
M-<MXY_Y$GQA_V*WB#_TTW=;X7_>L+_V$X;_U(PYS8S_<\9_V!XO_ -1,4?ZF
M7@G_ )$SPC_V+&@?^FJTKIZYCP3_ ,B9X1_[%C0/_35:5T]93^.?^.?_ *5(
MVI_PX?X(?^D0"BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *MY?6>GQI-?75O9PR7%O:)+<RI#&US=S);VL >0JOFW%Q)'!"F
M=TLTB1H"[JIM5\\_M49_X4;XR()!5] 8,I*LK+XBTLJRLI!5E;!5@058 @@@
M&O(?V;OVDAKGV'X>_$*_"ZX!':>&_$=TX5=;50$ATO5)F(5=94 ):W3D+JH
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MZC-X27X<IXUL)?"R2VUG/KMV]Y;^*[:_L90#];_^%G?$G_HH'C3_ ,*;6/\
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MBBB@">U_X_++_K]L_P#TIBK]^:_ :U_X_++_ *_;/_TIBK]^: /ST_X*S?\
M*,[]N?\ [-F^*W_J,7M?Y[LG^LD_WV_]"-?Z$'_!6ETC_P""9?[=,DCK'&G[
M,GQ79W=@J(H\+WQ+,S$!5 Y))  ZU_GFR:SHWF2?\3C2?OM_S$[+^\?^F]=,
MDWA*-DW_ +3B=DW_ ,N<+V3..+2Q^(NTO]CPF[2_YB,;W:+]%9O]LZ-_T&-)
M_P#!G9?_ !^C^V=&_P"@QI/_ (,[+_X_6'++^67_ (#/_P"0.KFC_-'_ ,"A
M_P#)FE16;_;.C?\ 08TG_P &=E_\?H_MG1O^@QI/_@SLO_C]'++^67_@,_\
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M4QY;:&W*P'S9_P ,J?'3_H4K+_PIO#__ ,GU^O-% 'Y#?\,J?'3_ *%*R_\
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MCCC4)'''&E\$CCC152.-%5$1515"@ ?KU10!^0W_  RI\=/^A2LO_"F\/_\
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M%% !1110!\B?MI_\DFTO_L>=%_\ 39KE?EU7ZA_MJLJ?"72BS*H_X3K1!EB
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M'GX1_P#S(4?\,)_L0_\ 1F_[*O\ XCS\(_\ YD***/K6*_Z"L3_X4XC_ .:
M^I8+_H#P?_A)A/\ YE#_ (83_8A_Z,W_ &5?_$>?A'_\R%*/V%/V(@58?L<?
MLK!E964C]GKX1@JRD,K*1X0R&5@&4CD$ @Y%%%'UK%?]!6)_\*<1_P#- ?4L
M'_T!X/\ \),)_P#,I]31QI$B11(D<4:+'''&H1(T0!41$4!515 554 *
M*?116!TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 A .,@'!R,C.#ZCT/O2T44 %%%% !1110!7N;2TO8Q%>6UO=Q!Q((KF&
M.>,.H(5PDJNH<!F 8#(#$ X)JC_8&A?] 72?_!=9_P#QFBB@ _L#0O\ H"Z3
M_P""ZS_^,T?V!H7_ $!=)_\ !=9__&:** #^P-"_Z ND_P#@NL__ (S1_8&A
M?] 72?\ P76?_P 9HHH /[ T+_H"Z3_X+K/_ .,T?V!H7_0%TG_P76?_ ,9H
@HH !H.A@@C1M)!!!!&G6>00<@@^3P0>0>QK6HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &(!$P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ>H:KJ/A[QG\2=:TRXAB>Q%G*T4D083?*H*DYXR">1SG\J /:/[1L?M$]O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7':K_R5GPW_P!@V]_]"AKL:XGQ2FJV7C;0];L=
M%NM4@M[2Z@E2V>,,K.8ROWV''RF@#MJ*X[_A,=;_ .A"US_O[;__ !RC_A,=
M;_Z$+7/^_MO_ /'* .QHKCO^$QUO_H0M<_[^V_\ \<H_X3'6_P#H0M<_[^V_
M_P <H [&BN._X3'6_P#H0M<_[^V__P <H_X3'6_^A"US_O[;_P#QR@#L:*X[
M_A,=;_Z$+7/^_MO_ /'*/^$QUO\ Z$+7/^_MO_\ '* .QHKCO^$QUO\ Z$+7
M/^_MO_\ '*/^$QUO_H0M<_[^V_\ \<H [&BN._X3'6_^A"US_O[;_P#QRC_A
M,=;_ .A"US_O[;__ !R@#L:*X[_A,=;_ .A"US_O[;__ !RC_A,=;_Z$+7/^
M_MO_ /'* .QHKCO^$QUO_H0M<_[^V_\ \<H_X3'6_P#H0M<_[^V__P <H [&
MBN)B\=ZK-//!'X&UMI(&"RJ);?Y20&'_ "T]"*E_X3'6_P#H0M<_[^V__P <
MH [&BN._X3'6_P#H0M<_[^V__P <H_X3'6_^A"US_O[;_P#QR@#L:*X[_A,=
M;_Z$+7/^_MO_ /'*/^$QUO\ Z$+7/^_MO_\ '* .QHKCO^$QUO\ Z$+7/^_M
MO_\ '*/^$QUO_H0M<_[^V_\ \<H [&BN._X3'6_^A"US_O[;_P#QRC_A,=;_
M .A"US_O[;__ !R@#L:*X[_A,=;_ .A"US_O[;__ !RC_A,=;_Z$+7/^_MO_
M /'* .QHKCO^$QUO_H0M<_[^V_\ \<H_X3'6_P#H0M<_[^V__P <H [&BN._
MX3'6_P#H0M<_[^V__P <H_X3'6_^A"US_O[;_P#QR@#L:XOX3?\ )-=+_P"N
MES_Z425)_P )CK?_ $(6N?\ ?VW_ /CE3?#C3+W1_ >FV.HV[6]VAF9XF()3
M=*[ $@D=&% '54444 %%%% !1110 4444 %%%% !1110 5GZ];RW?AW4[:!"
M\TUI+&BCNQ0@#\ZT** /.O#GBK4]'\+Z3ID_@CQ*\UG90V\C1PPE2R(%)&9
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M[[_H1?%'_?B'_P".ULW/_(ZZ7_V#KS_T9;5LT <;_P )W??]"+XH_P"_$/\
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MCKNI6LYCDABE-LX4'84&,\CGY@>M '1T5';Q-!;QQ/-).RC!EDQN;W. !GZ
M5R.OS:\NO7%II%Y<.9;)9U@40@IB55;RRZXW%<_?)&?2@#LJ*YG2_$(>_L['
M4+H"[>W1=D<9\N20@[GW8P 2CA1D9 8X/%=-0 4444 8FD?\C%XA_P"N\/\
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M %%%% !1110 4444 %%%% !1THHH YFYUC3/^$RTU_[1M-JZ?=@GSUP"9+?
MZ^Q_*NDCD26-9(W5T895E.01[&OFGQ1\)99?C/;Z7:1,FDZFYO-ZCB*,',JC
MTP>!_O+7TI;P16MM%;P1K'#$@1$48"J!@ ?A0!)1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M85D<R2-DL\CGJSL268^Y)J_10!2&D6 M[R!K97BO2QN5DR_F[A@@YSD8XQT
MX%0Z+X?TSP_;R0Z9;>2LC!G+2-(S$  99B2<  #G@"M.B@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9*)&A<1,$D*D*Q&0#
MV.* ,>/_ )'FY_[!L7_HV2MNOFRW^(_Q"D^)1T3R=/75GD&GOFW.T*KD[L;N
MF"3GTKZ20,$4,VY@.3C&30 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?V[^*/$'B/7X;/Q$
M-/MK"Z6".);-),@H&R2?K6A_PCWC#_H=3_X+HJ;X-_Y&;QC_ -A%/_12UV5
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M["B@#C_^$>\8?]#J?_!=%1_PCWC#_H=3_P""Z*NPHH X_P#X1[QA_P!#J?\
MP714?\(]XP_Z'4_^"Z*NPHH X_\ X1[QA_T.I_\ !=%1_P (]XP_Z'4_^"Z*
MNPHH \ZU]?%WAJTMM0?Q2+N,WD,+PM8QJ&5W"GD<C@UZ+7'?$K_D6K;_ +"-
MK_Z-6NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XWP;_R,WC'_ +"*?^BE
MKLJXWP;_ ,C-XQ_["*?^BEKLJ "JNHW$UIIUQ<00B:2*,N(RVW=@9QFK54M7
MD,>CWC+%)*WDL D:[F8D8  H Y?2_'DEU/HJWVF&VCUG<+9TE#X8#.& ^G6N
MK;4[);Y;%KJ(73#(B+?,:\M\.Z5J.@+HFN?V/?7*K$;6\LYE+2VI))\V($\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW\%']H67_/W!_P!_!7/?\*V\(?\ 0$A_[[?_ .*H_P"%;>$/^@)#_P!]O_\
M%4 =#_:%E_S]P?\ ?P4?VA9?\_<'_?P5SW_"MO"'_0$A_P"^W_\ BJ/^%;>$
M/^@)#_WV_P#\50!T7V^S_P"?N#_OX*3^T++_ )^X/^_@KS_Q5X$\,64>DFWT
MB*/S=2BBDQ(_S(=V0>>G%;__  K;PA_T!(?^^W_^*H Z'^T++_G[@_[^"C^T
M++_G[@_[^"N>_P"%;>$/^@)#_P!]O_\ %4?\*V\(?] 2'_OM_P#XJ@#H?[0L
MO^?N#_OX*/[0LO\ G[@_[^"N>_X5MX0_Z D/_?;_ /Q5'_"MO"'_ $!(?^^W
M_P#BJ .A_M"R_P"?N#_OX*/[0LO^?N#_ +^"N>_X5MX0_P"@)#_WV_\ \51_
MPK;PA_T!(?\ OM__ (J@#H?[0LO^?N#_ +^"C^T++_G[@_[^"N>_X5MX0_Z
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M-/\ 5:)_V%8/_9JZ>N5UC2_$.KK9*QTV+[-=)<YW.=VW/'3WK3W>(O[FF?\
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MQ16/N\1?W-,_[Z>C=XB_N:9_WT] &Q16/N\1?W-,_P"^GHW>(O[FF?\ ?3T
M;%%8^[Q%_<TS_OIZ;;:AJ::S%8W\5KMEB9U>!FR".QS0!M4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:'9/K8U=ED-X(C#GS#MV'MMZ5#%X9TF&*XB6VRDXVL&8G:N<@+_=&>>*UZ*
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M9=00X7=('5"S*PR!PG(R " >C2ZA#;ZA<B?4[&."WM1/+"Y"R1+ELRNQ; 3
MQRH^Z3N/0/LM8TS4;B>"QU&TNIK<@31P3J[1$YQN .1T/7TKS+Q+I%U*OC34
M[SPW);V=WX:PTLYMVW7$2.^Y@KL2PR@#8/*=< $]#X:TJZGUW2]5_LC^R;6Q
MTC["%+1G[1N9&&T1L<1KL)&[:<O]T<T =S1110 4444 %%%% !1110 4444
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M  .:NSHH XS_ (5U!_T,.O\ _@<U'_"NH/\ H8=?_P# YJ[.B@#C/^%=0?\
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MO_\ @<U'_"NH/^AAU_\ \#FKLZ* .,_X5U!_T,.O_P#@<U'_  KJ#_H8=?\
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M* "BBN!\2>)/%W_"P(O"_A>'1-W]E_VC)+J@EQCS3'@>6?H>GKS0!WU%>?\
M_%W_ /J1O_)NC_B[_P#U(W_DW0!Z!17G_P#Q=_\ ZD;_ ,FZ/^+O_P#4C?\
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M* "BBB@ HHHH **** .+^'_^M\2_]AB?^==I7%_#_P#UOB7_ +#$_P#.NTH
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MX8U>YU&RU:)M.N+SR3!=0W468BI(.5]",?C0!/XPUNZ7P6FL:%?K$7:(QR%
MRLKL!T_&M+6-7F\/>$WU%XWOIH(E+ 84N3CFJ?BG0M0U/PHFE:<+59M\9)<;
M$ 5@W 'TQ3-4TS7M<T>ZTZ=;.UC>WVH4<N6D'3/ P* *GBKQ=);^&[[[%'=Q
M:A#:K-(T48;[,6Y&[/\ G%==8R-+86\CG<[1J2?4XKBKSPGKLAU86]Q:>7K%
MJD=PK@_N957;E?4$5UFF0ZA;L8;IH#;QQ(L10'<2!\V?QZ4 :-%%% !1110
M4444 <9\1/\ 4Z!_V%X?Y-79UP'Q7N+RUTO0Y;"P^W7 U:';!YPBW':V/F/
MYP/QJ_\ \)%XR_X1[[;_ ,()_P 3/[7Y7]G_ -KP_P"IV9\WS,;?O?+MZ]Z
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MPS_TG:@#T"BBB@ J.?\ X]Y/]P_RJ2HY_P#CWD_W#_*@#D_AA_R(5C_O2?\
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MO^2T?\(5K/\ T.^K_DM ':4@ !) '/6N,_X0K6?^AWU?\EH_X0K6?^AWU?\
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M^2T =I17%_\ "%:S_P!#OJ_Y+1_PA6L_]#OJ_P"2T =I17%_\(5K/_0[ZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MKGD\6Q3;VMM'U>XB61XQ+%; JQ5BIQENF0: .AHK _X2AO\ H7]<_P# 4?\
MQ5'_  E#?]"_KG_@*/\ XJ@#?HK _P"$H;_H7]<_\!1_\51_PE#?]"_KG_@*
M/_BJ -^BL#_A*&_Z%_7/_ 4?_%4?\)0W_0OZY_X"C_XJ@#?HK _X2AO^A?US
M_P !1_\ %4?\)0W_ $+^N?\ @*/_ (J@#?HK _X2AO\ H7]<_P# 4?\ Q5'_
M  E#?]"_KG_@*/\ XJ@#?HK _P"$H;_H7]<_\!1_\51_PE#?]"_KG_@*/_BJ
M -^BL#_A*&_Z%_7/_ 4?_%4?\)0W_0OZY_X"C_XJ@#?HK _X2AO^A?US_P !
M1_\ %4?\)0W_ $+^N?\ @*/_ (J@#?HK _X2AO\ H7]<_P# 4?\ Q5'_  E#
M?]"_KG_@*/\ XJ@#?HJCI.JP:Q8_:X$FC7S'B9)DVNC(Q5@1[$&KU !1110
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M<.L"!;?Y9U*H1D!>!^]48/\ >]Z %O?&%[IFJSP75K;/:PV OV>-FW>69=G
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M -'O6_0 4444 %%%% !1110!S/B*UM[SQ/X:ANH(IXC+<$I*@92?)/8UJ?\
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M&]G5F+;9 3A\!BO;C% #X8O"4]]%8KI^GBZE1W2)[(*Q"%0W!7C!9>/>K_\
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MQZD4O0ES<W4<\%SL)>%51%VDEOFY0$YX.3GUH ZC_A'=$_Z ^G_^ R?X4?\
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M_?U?\: +5%5?[3L/^?ZV_P"_J_XT?VG8?\_UM_W]7_&@"U157^T[#_G^MO\
MOZO^-']IV'_/];?]_5_QH M455_M.P_Y_K;_ +^K_C1_:=A_S_6W_?U?\: +
M5%5?[3L/^?ZV_P"_J_XT?VG8?\_UM_W]7_&@"U157^T[#_G^MO\ OZO^-']I
MV'_/];?]_5_QH M455_M.P_Y_;;_ +^K_C1_:=A_S_6W_?U?\: +5%5?[3L/
M^?ZV_P"_J_XT?VG8?\_UM_W]7_&@"U157^T[#_G^MO\ OZO^-']IV'_/];?]
M_5_QH M455_M.P_Y_K;_ +^K_C1_:=A_S_6W_?U?\: +5%5?[3L/^?ZV_P"_
MJ_XT?VG8?\_UM_W]7_&@"U157^T[#_G^MO\ OZO^-']IV'_/];?]_5_QH @U
M[_D!W?\ N?UK1KA?B7J^IP>#IY_#5U9S7:.OF6[8D:6,G!"C/4$@_@:ZS1AJ
M"Z-9_P!K/&^H&)3<&)=J[R.0!Z#I^% %ZBBB@#G)?#<TVJ37C7.T^9YD)5V!
M!P>6'? .![?E4EWI^HR>&IH)VCGN_LABVPC:K,>N,X[ "M^B@!J8V+A=HQPN
M.E<O::#>1.][9D6L\ER2T<YW*8A*Q&%' .T\?7M7544 %%%% !1110 4444
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M 6J>'?&.L^([6QT?S]1QMC\^0"#/+[?D_B;!]NE==YWBK_GRT?\ \"I/_B*
M-VBL+SO%7_/EH_\ X%2?_$4>=XJ_Y\M'_P# J3_XB@#=HK"\[Q5_SY:/_P"!
M4G_Q%'G>*O\ GRT?_P "I/\ XB@#=HK"\[Q5_P ^6C_^!4G_ ,11YWBK_GRT
M?_P*D_\ B* -VBL+SO%7_/EH_P#X%2?_ !%'G>*O^?+1_P#P*D_^(H W:*YN
M?5M?T^>R-]8Z=]GN+J.W8P7#EEWG (!0 _G724 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K!\)?\@NZ_["%U_Z.:MZL'PE_P @NZ_["%U_Z.:@#>HHHH **** "N-:
MRU&76Q->0275I'>7!E@!'*L%\E\'A@H##'8G-=E10!P^H#6[*YNA;/+9:=#
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M=%_[\2__ !5'E^+?^?G1?^_$O_Q5;]% &!Y?BW_GYT7_ +\2_P#Q5'E^+?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#0KW'_ (%P_P#Q5 &_16!_;.M_]"O<?^!</_Q5']LZW_T*]Q_X%P__ !5
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M_B]:UM(TB?2[B4"Z#V9C18X0F-C 8)SZ57_MG6_^A7N/_ N'_P"*H_MG6_\
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M+;_T,5T% !1110 4444 %%%% !1110 5A>-/^1-U7_KW-;M87C3_ )$W5?\
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M\6L:+<(CI%&@6.X905"(ICX' !5F#=\XK;_MO6O^A6NO_ J'_P"*H_MO6O\
MH5KK_P "H?\ XJ@#!T^PU2'Q1817B7#1VVY@5F8J 2^.2,,H#+GOD"K:Z'KM
MOK>H7ML;<1WD[C:[Y,*E %E3Y>&R.5Z$8YXK3_MO6O\ H5KK_P "H?\ XJC^
MV]:_Z%:Z_P# J'_XJ@#$?PYX@7RWCF&5VL$%V^(W!CR1QSNVN<'IN^M1Z+IV
MHW9,C)<QR'4(IFDE<X"(6SP>0Q'!['-;_P#;>M?]"M=?^!4/_P 51_;>M?\
M0K77_@5#_P#%4 ;]%8']MZU_T*UU_P"!4/\ \51_;>M?]"M=?^!4/_Q5 &_1
M6!_;>M?]"M=?^!4/_P 51_;>M?\ 0K77_@5#_P#%4 ;]%8']MZU_T*UU_P"!
M4/\ \51_;>M?]"M=?^!4/_Q5 ">+?^/72_\ L*6W_H8KH*Y+49-:UE]/@.@3
M6J1WL,\DLES$0JHV3P"2:ZV@ HHHH **** "BBB@ HHHH *PO&G_ ")NJ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M EL# 2(  A$! Q$!_\0
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MRF/<?E '7:O(_A.03QFKEI\3_#5Y:7=U'+=K#;V\=P#):NIG1VV*8P1E\O\
M)QWJ.Q\!36FK6]TVK"2WM=2N[Z"'[/AE%PCAD+;N<-(2#CH,5FS?">.?1XM/
MDU;(BTB'3E8VX(W13"59"">1D %?3O0!J7/Q0\/VEG#-+%J)ED,ZFV2T9IHF
MAV^:'4?=VA@V>F.<U:T7QO;ZYXNO]$M[*Y,-O;07,5Z$/ERK(NX<XXXQCU^;
MTK-M_AT4CMMUU8V[QVM[;LEA8>1$QN%1=VW<>5V=R<^V*T/#G@Z?P[JZ74.I
MK+;MIEM93PM!@N\"E5<-GY1@G*X/UH PM'^),D^JZF=4NM)CL;.]>T-M;B1K
MJ/\ ?B%)),G:$)(R<=Q6[>_$/1K%9I9(-1>VM[J2UN+J.T9HH61@K%FZ!=QQ
M^!XXK.3X>7GV#7=+FUN&32]3:XD2(6(62&65]ZMYF_YMK<XP,X'2LS4OA#)J
M&D6%@=>R(+:2*9YK7S-\KR^:TR#> KEL@DYXX&* -O1_'"-J>IV.JM^]34;R
M&U\J(X\F!(W.X^OS_C5T>/=),NE#R-0$&II$UO=&U;R2TJ[D0OTWD=AGG@UC
M7_PVNI[R2\L=>-I<R7]W<[S:B0".XC1'3!;J-@(;]*KQ_"ITU71;HZT)(M,6
MR"+);;G'V=0NU&WX17ZD8)SWH ETGXF1:K'IE[/&VE6DCWPN8[JW<ED@4G<C
M\   9;(/.5ZBM%/B;H#6,ER\6I1,DT,7V>2R<3,903$RIU(;:<8K._X5<9K5
M+&ZU@R643:@(42W"NL=T#D%MQR59B<XYX&*EMOAW>O<Q7NIZ\+N^CN[*7S$M
M!&OE6Q8JFW<>6+DEL_04 :6H^.[2/P))XETVWEN"SB"&VF4Q.9S)Y01P?NX?
MK]#6+J7C/Q#X5U32(O$T%G)%<K=/*ND0RS%UC2-E(#<KC+Y/3 SQTK8D\!Q3
M^#K_ ,/RW\@-S>2WD=S&FUH9&F,JD#/.TX^N.U0?\(7K%]=6MYK7B)+RYMX+
MJ!3'9")0LR(O #'H5SSUSCC% %X_$#0?[2M+-)9Y!<K 1<)"QAC,PS"KM_"7
M'0>XSC-8^I?$JT:+3KO36EBT]M4C@N+R[MF2&6 K*6>)S@$9CZ_IR*BT_P"%
MD6G:O87JW-A<K#;VD,XN]/$K[H$"!HFW?N]P49X;!&12?\*NEN?#]IX>U/6Q
M>:-972R6]N;4(PB"R#8SAN6_>#YL#&P<<T 2/X[N9M<V0NEM82C36A%S;,9#
M]HDD4@@$%20JX)X'>IKOXHV*Q:5<6.E:G=VM_?\ V1)A;,%==K'?'P=_*].#
MC)[4B?#NY>6WGN]<,]Q$=/W2FWP9/LLCN"?F/+!@"?49YSBJT/PSO(&>YBUN
M""\_M.+4(Q!8[+=61'0_NMY^9PY+$$<@<4 =)J>KW<7C70M&M618KB*XNKLE
M<DQH%50/3+N#G_9]ZXT?$G7KW2O$%Y8V6FPG3XVU"U^T^81=6(,J[QM/WRT7
MTPU=)XGT34;SQ3I=[IY:,26-YI\UPH#?9C(JM')MR,@,F,>XK)3X1Z?8P-%I
M5_/;>=I$^EW)E+S>:'4!7 9\)M8%MHX.<<4 5KCQUXDM-0T/3;R?PW9W.I6I
MNO-G\X1MEU5(TYSO(;OQQ5^+Q+XKURRUC4M)@TVWTF#[5#:O(7:X:2(,!)C[
MI4NN-O7'.:O7W@O46U?2M3TO6H;2XL;#[ WG6(G$B;E8D#>-IRH]:IOX4USP
M[9ZR='U9KG3)%N;BWTG[*N\S2*Q""4GA-[;NF??U .KT/5X]6\.:;JS%8UO;
M:*?!. "Z@X_6N?\ &NN>)M$O])31X](>VU"Z2R'VP2[UE8.=WRG&W"_7-:%A
MX1TY_!VC:%K%E;WJ6%O"NV5=R^8B;=P_7\ZM>(-!_MR31W^T^3_9VH1WN-F[
MS-JLNWKQG=U]J .<F^*&F0Z;?.L%S<7=K:331E+=U@O'AXE$+D?,JMU/89/.
M*OVWQ L'M]'ENM.U6V74EBQ*]FXBB>1MJ*SD8&6Z>Q!.,BLFV^%[(K6ESK+2
MZ;!;7EO80K;A7@%SG>6?)WD D#@5%)\,+ZZO-*N+[7H;AK%;4?-9<CR)-P\O
MY\1[A@-P22!]* )Y/'&IVGPYN?$$D,$EU'?RVQ9D810H+EHA(X7+%54 G')K
M4M/&MO%'I%I>NE_J-_'YN[1XGFA$1?:)2>2J9(&3G!SZ9J6V\,:CIGA>32]+
MU>.&Y:[FN//EM!(A625G*,A;D8;&01T_"L?1_AO<^'KG3;G2M=$,L4307NZS
M4K.C3&8A%R!'RS =< ^HH OI\3?#KK>R;KQ8+6"2X69K9A'<1QMM=HF_C )&
M:?%\1M$EN;6 Q:A&9S&&:6T95M_,8K%YN?N;R/ESV()QFL(?"F9M,FTR;7O,
MLX;&>QTU?LH#6Z2LK,7.[]X0%"CIP/6M74/A]'=>,EU^.6P?S!!Y\=Y8"=@8
MNC1,6&PD8!X/0&@#MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%'_T$-3_ / Q_P#&C^PH_P#H(:G_ .!C_P"-:M% &5_84?\ T$-3_P# Q_\
M&C^PH_\ H(:G_P"!C_XUJT4 97]A1_\ 00U/_P #'_QH_L*/_H(:G_X&/_C6
MK10!E?V%'_T$-3_\#'_QH_L*/_H(:G_X&/\ XUJT4 97]A1_]!#4_P#P,?\
MQH_L*/\ Z"&I_P#@8_\ C6K10!E?V%'_ -!#4_\ P,?_ !H_L*/_ *"&I_\
M@8_^-:M% &5_84?_ $$-3_\  Q_\:/["C_Z"&I_^!C_XUJT4 97]A1_]!#4_
M_ Q_\:/["C_Z"&I_^!C_ .-:M% &5_84?_00U/\ \#'_ ,:/["C_ .@AJ?\
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M_P#($N/^ _\ H0H TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPC_[Y%'V.V_YX1_]\BIZ* (/L=M_SPC_ .^11]CMO^>$?_?(J>B@"#[';?\
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M$7_?8H^V6W_/Q%_WV* )J*A^V6W_ #\1?]]BC[9;?\_$7_?8H FHJ'[9;?\
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M_ ?_ $(5I5FZ_P#\@2X_X#_Z$* -*BBB@ HHHH **** "BBB@ HHHH ****
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MHH&4]4_Y!D_^[_6KE4]4_P"09/\ [O\ 6KE !1110 4444 %%%% !6=H/_(
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M 6:*S[&YNY;"WDE@WR/&&9E(4'(STS5CSKC_ )]3_P!]B@"Q15?SKC_GU/\
MWV*/.N/^?4_]]B@"Q15?SI_^?4_]]BCSI_\ GU/_ 'V* +%%5_.G_P"?4_\
M?8JCJ.O6^DQ*]Z!&6.$0.&>0^BJ.6/TII-NR$Y)*[-6LK4]?L=+D6!V>>\<9
MCM;==\K_ / 1T'N<#WK-:3Q#K@&R%](L&')RING'ZK'^I^E:&F:7!I$;+::=
MM=SF25I TDA]68G)/UJ^6,?B,^:4OAT7<I?8-:USYM2G.FV1_P"7.U?,KC_;
MD'3Z+^=;5AIUGIELMM96\<$2_P *#&3ZGU/O3_-G_P"?4_\ ?8H\ZX_Y]3_W
MV*F4V].@XTTM=V6**K^=<?\ /J?^^Q1YT_\ SZG_ +[%2:%BBJ_G7'_/J?\
MOL4>=<?\^I_[[% $?_,9/_7O_P"S5<K+$T_]LG_17S]G'?C[WKT_"KGG7'_/
MJ?\ OL4 6**K^=<?\^I_[[%'G7'_ #ZG_OL4 6**K^=<?\^I_P"^Q1YUQ_SZ
MG_OL4 6**K^=<?\ /J?^^Q1YUQ_SZG_OL4 6**K^=<?\^I_[[%'G7'_/J?\
MOL4 6**K^=<?\^I_[[%'G7'_ #ZG_OL4 6**K^=<?\^I_P"^Q1YUQ_SZG_OL
M4 6**K^=<?\ /J?^^Q1YUQ_SZG_OL4 6**K^=<?\^I_[[%'G7'_/J?\ OL4
M6**K^=<?\^I_[[%'G7'_ #ZG_OL4 6**K^=<?\^I_P"^Q1YUQ_SZG_OL4 6*
M*K^=<?\ /J?^^Q1YUQ_SZG_OL4 6*SM!_P"0!8?]<5_E5GSI_P#GU/\ WV*K
M:!_R+]AD8/D+Q^% &C1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 075G:WT!@N[:&XB)R8YD#KGZ&HH])TV%XGBT^U1HHS%&
MRPJ"B'JHXX'M5RB@"".RM(I(Y([6%)(H_*C98P"B?W0>P]NE5-?_ .0)<?\
M ?\ T(5I5FZ__P @2X_X#_Z$* -*BBB@ HHHH **** "BBB@"KIO_(+M/^N*
M?R%6JJZ9_P @NT_ZXI_(5:H ***CFGBMX6EFE2.-1EG<X 'N: ;L255OM0M-
M-MFN;VXC@A7J\C8'_P"NL5M>O=78Q^'K421=#?W(*PC_ '!]Z3\,#WJQ8^&H
M(KI;[4)I-1OUY$]QC$?^XG1/PY]S5\B7Q&7.Y?!]Y6_M'6-<^72H#869_P"7
MV[C^=AZQQ'^;8^AJ]IGAZRTV4W(#W%ZXP]W<-OE;VSV'L,"M8"BASTLM$-4]
M;RU8M%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6=H/_ " +#_KBO\JT:SM!_P"0!8?]
M<5_E0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "LW7_ /D"7'_ ?_0A6E6;K_\ R!+C_@/_ *$* -*BBB@
MHHHH **** "BBB@"KIG_ ""[3_KBG\A5JJNF?\@NT_ZXI_(5:H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *SM!_Y %A_P!<5_E6C6=H/_(
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M7K7_ $"K7_P-/_QN@#4HK+^UZU_T"K7_ ,#3_P#&Z/M>M?\ 0*M?_ T__&Z
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M2W"O&9!()DPJ<JI"9&"1GGK7J7VO6O\ H%6O_@:?_C='VO6O^@5:_P#@:?\
MXW0!Y)9OXIT+P]-#;W&IPP-";E8?LIRC"ZD!AC98V*%TQRP;D@\ U[192/+8
M6\DD<D;O$K,DN-ZDCD-CC/KBJ7VO6O\ H%6O_@:?_C='VO6O^@5:_P#@:?\
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M/(KIHM,U#0/$L5Q:V-QJ-I_: #":%ANN#]Z0;1SM#N [<$AL_=4T >O4444
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M_P#$4 :=%9G]FW__ $';S_OU#_\ $4?V;?\ _0=O/^_4/_Q% &G169_9M_\
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M^S;_ /Z#MY_WZA_^(H_LV_\ ^@[>?]^H?_B* -.BLS^S;_\ Z#MY_P!^H?\
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &] FX# 2(  A$! Q$!_\0
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MIVC\T1PS*S;<X)P#ZUS\GPZMY;N\E?4IQ%<W$%P;>.-5CW12+)N9>A<[0I;
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MAW;K<RNNIW AE-D[Q;%Y>U*[&!QD9" $>^:J'X66CV<UG+JUT]J+>6VM$,:
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M,K^81(8BC@NV6(;.[DYS0!(?B'HZ)JDTL5Y%;::[Q7$[QKM\Q6"[% 8L26(
MXY-6K?Q=#+J6G65QIFHV+W[21Q&[C5/G10^.">JY(_W2#@UC2_#"QGDUH2W\
MGDZI,]P^VWC66*0NLBE9<;B%900#D5>/AG5YM9T&XU#5Q?Q:=/-<O*\2Q.SF
M/RT5508P-SDDG.<?@ =;7&+\4?#;>&[S7/,N1;VDXMWB,)\UG/(VKW!&3GT!
M]*Z>#2K*VU*XU"*$K=7  E?>QW =."<#IV%<6OPFTI4C!O;IBEA+9]%PS/O"
MRD="ZK*X!]#0!UD?B+1Y+F.U_M&W6YDB$HA>0!PI7=R.WR\X].:B_P"$M\/?
M8FO#K5B+99/*:0S* 'QN"_4@9 [UA#X<6B:Y)J*7\P\P!BI0%DE$/E"1&_A.
M #T//MQ3=*^&UOI]Q%<3:I<W<ZWD%XSR(/G:*)XP#G)Y#Y)SU% '17?B33+6
MSTZ\$_GVVHW,5M;2V^'5FD^Z<CMQUJNOC7PN[[%\0Z86W*F/M*=6X Z^M5(/
M!%K!H&CZ0MY-Y>EWR7L;[1EV5V?:?;YL<>E9+?"K3FTTV?V^XV_V8=-W[$SM
M,WF[^G7/% '4_P#"3Z%]NELO[8LOM4*NTD/GKN0)]_(SQCO4:^+_  XPMBNN
M:>1<L5@(G7$A!V\<\\\?6N5@^&LUUJ&IW&I:DRP37MY<VUO BX0S1F/>S$;B
M0I/R],XJY>_#6TNEABCU*X@MS80:?=QI&A^T11'*X)'R').2/7\: .F/B'1A
M$LIU2T$;"5E8S+@B,XD/_ 3P?2J\OB_PY!:Q7,VMV$<,I81N\Z@,5(##D]B1
MGTS6!>?"_2KZ?7'EN[H1ZFN$C4@"U)=9'*<?Q.JL<^E*GPULO(VR79,K6]Y!
M(\<"J'-PJJSD'/S (._/>@#H5\4Z ]G-=IK-B]O#+Y,DBSJ0K]EX/6E/BC05
MNK>U.L6(GN AAC\]<R!OND<\Y[>M<Y??#.RO"TB7\\,PDMY8F"#:C0Q&(9 Q
MD%6.>1[5)'\-]/CC=$N70,MBN(XE55^S2%QM';<3R* -2/QOH,_A[4=<M;O[
M19Z?Y@N#$I+*4)!&#CTX]:;:^.-#FBN6NKAM-DMIA!-#? 1.C%0X[D'Y3G@G
MBH3X+1O#>MZ$^HS-9ZG),Z_NU#0"5BS '^+YF.,_2JNK_#;1[^UL8;%4TXV9
MDVB*(,D@D4*^]>-Q( YS^8H W)_%.@6TT\,VLV,<EN@DF1IU!13C!//&=RX]
M<BI$\1Z++<6]NFJ6C37*"2%!*,NI!((^H!Q]#7/S_#JQ:UNH[>[DMI9+JVNX
M)$B0^1) B(@"D89?DSM/J:0_#VWD\1)K-Q?O<3MY3W"RPKB26-=JNN,!#] ?
M;% &C=>/?"UKIUQ?G6[26WMVC65H)!(5WG"Y"Y/)_D?2K\?B31);LVJ:K9F=
M8S*4\X9" !B?H 03Z"N8D^%]B^E"Q74+A-NFPZ>LBHF1Y4OFJ^,8)W=1TJ'6
M/AO=:A/>WXUR>YO9()T@2Y4>6KRP^4>G1>X '&3UH Z9?&/AMK9K@:W8F%7\
MLOYPP&QG'Y<_3FME'61%=&#(PRK*<@CUKS&Q^%UU=6,::K>1136\SM R#SC(
MCQJD@F)"[R=HQTP !S7I-C:1V%A;V<*A8K>)8D"C  48'';I0!/1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5RGCPZ[_ &=9?V*L[+]H)NA;Y\PH$;:!M((!?:"0<@>V:ZNB@#RM8/&]U?W)
MN&U6R^29Y5B<2QA,1&&.+D9?(<%A@]23TKJO"$GB!9KVWUZWF,B;,7+29C?C
M&$7Z#)/<D^PKJJ* *5[=SPW-K;V\<;/.6YD8@ *,]@:-VJ?\\[/_ +^-_A45
M[_R&=,^LO_H-://I0!3W:I_SSL_^_C?X4;M4_P">=G_W\;_"KG/I1SZ4 4]V
MJ?\ /.S_ ._C?X4;M4_YYV?_ '\;_"KG/I1SZ4 4]VJ?\\[/_OXW^%&[5/\
MGG9_]_&_PJYSZ4<^E %/=JG_ #SL_P#OXW^%&[5/^>=G_P!_&_PJYSZ4<^E
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MYSZ4<^E %/=JG_/.S_[^-_A1NU3_ )YV?_?QO\*N<^E'/I0!3W:I_P \[/\
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M?RH ,^QHS[&C/U_*C/U_*@ S[&C/L:,_7\J,_7\J #/L:,^QHS]?RHS]?RH
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MZ_E5)S_Q/(/^O:3_ -"2@"]1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%8_B+Q%;>&K*&YN8995FF
M$*B-D7!()RS.RJ!A3R3Z4 ;%%<?<_$;2K:ZG@-I?/Y;21I)'&I662/9YBJ=W
M\.]>3@=<$XK;T37[3Q!%+-8AS"A4;WP-Q(R0!G/'0Y[@XSB@!][_ ,AG3/\
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MZ%'GQ?\ /5/^^A0 _(HR*9Y\7_/5/^^A1Y\7_/5/^^A0 _(HR*9Y\7_/5/\
MOH4>?%_SU3_OH4 /R*,BF>?%_P ]4_[Z%'GQ?\]4_P"^A0 _(HR*9Y\7_/5/
M^^A1Y\7_ #U3_OH4 /R*,BF>?%_SU3_OH4>?%_SU3_OH4 /R*,BF>?%_SU3_
M +Z%'GQ?\]4_[Z% #\BC(IGGQ?\ /5/^^A1Y\7_/5/\ OH4 /R*,BF>?%_SU
M3_OH4>?%_P ]4_[Z% #\B@G(/-,\^+_GJG_?0H\^+_GJG_?0H @TX_\ $NM\
ML6.P<GK5K(JGI\T0T^W!D3[@_B%6?/B_YZI_WT*"8?"A^11D4SSXO^>J?]]"
MCSXO^>J?]]"@H?D49%,\^+_GJG_?0H\^+_GJG_?0H ?D52<_\3R#_KVD_P#0
MDJUY\7_/5/\ OH54+H^N0;75O]&DZ'/\24 7Z*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/UG1K;7+
M$V=W)<K V1(L$S1^8I!!5L'E2#TK0HH YR+P-H=O=37%O#- TJ,@6.=PL08*
M'*#/R%@B@D<\5=TOPWI6C7MS=V%L(9+@*KA6.T = !T K6HH S;T ZSI@(!Y
MEZ_[M:&Q/[J_E6?>_P#(9TSZR_\ H-:.!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"
M@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C
M8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T
M%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?
MW5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?
MRI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"
M@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*C
M8G]U?RI<#T%&!Z"@!-B?W5_*C8G]U?RI<#T%&!Z"@!-B?W5_*@HN/NK^5+@>
M@JK?7UKI\'F7#A03A5 RS'T ZDTTFW9"E)15V&GHITZW^4?ZL=JL[$_NK^50
M6)#V,#>48\H#L8 $>QJQ@>@I-6T".R$V)_=7\J-B?W5_*EP/048'H*!B;$_N
MK^5&Q/[J_E2X'H*,#T% ";$_NK^54V4#7(, #_1I.@_VDJ[@>@JDX UR#C_E
MVD_]"2@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!FWO_(9TSZR_P#H-:.!6=>_\AG3
M/K+_ .@UHX]S0 8%&!1CW-&/<T &!1@48]S1CW- !@48%&/<T8]S0 8%&!1C
MW-&/<T &!1@48]S1CW- !@48%&/<T8]S0 8%&!1CW-&/<T &!1@48]S1CW-
M!@48%&/<T8]S0 8%&!1CW-&/<T &!1@48]S1CW- !@48%&/<T8]S0 8%&!1C
MW-&/<T &!1@48]S1CW- !@48%&/<T8]S0 8%&!1CW-,EEB@C:265411DLS8
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M<>YJD_\ R'(.?^7:3_T)* +U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445RWC_3=?U;PU-::!*L<S
MJQ?$YAD;"G:J.!Q\VW/3@8R,T =317EA\-^++G4;N2[:^C#+,TCV]\"LRD1^
M3$@+#;M*ODD+U/)S74^$+3Q!8SWL&MH)1A-EWYQ8RX&,!<\ #'. 2<DYSF@#
M8O?^0SIGUE_]!K1P?6LV_P!QUC3-I .9>HS_  U>Q/\ WX_^^#_C0!)@^M&#
MZU'B?^_'_P!\'_&C$_\ ?C_[X/\ C0!)@^M&#ZU'B?\ OQ_]\'_&C$_]^/\
M[X/^- $F#ZT8/K4>)_[\?_?!_P :,3_WX_\ O@_XT 28/K1@^M1XG_OQ_P#?
M!_QHQ/\ WX_^^#_C0!)@^M&#ZU'B?^_'_P!\'_&C$_\ ?C_[X/\ C0!)@^M&
M#ZU'B?\ OQ_]\'_&C$_]^/\ [X/^- $F#ZT8/K4>)_[\?_?!_P :,3_WX_\
MO@_XT 28/K1@^M1XG_OQ_P#?!_QHQ/\ WX_^^#_C0!)@^M&#ZU'B?^_'_P!\
M'_&C$_\ ?C_[X/\ C0!)@^M&#ZU'B?\ OQ_]\'_&C$_]^/\ [X/^- #R#CJ:
MK:=N.GPEG9B5R2QR3^-3$3X^_'_WP?\ &JVG";^SX,/']P?P'_&@G[1=P?6C
M!]:CQ/\ WX_^^#_C1B?^_'_WP?\ &@HDP?6C!]:CQ/\ WX_^^#_C1B?^_'_W
MP?\ &@"3!]:,'UJO//\ 9HFEGN8(HUZLXP!^M97]N7%V2NE6K7F>DQ0QQ#_@
M1Z_\!!I7(E4C'=F[SZUGWFM6-C)Y,D^^X/2")2\A_P" CFJATK4[[!U'4MB=
M[>T4QK^+YW'\,5;MK"WTJ!OLZ6UO&!EF$>,^Y.>?J:-61S3>RLO,J^?K>H?\
M>]O'I\)_Y:7&'D(]D!P/Q/X52N;2QM[E4G$VL:D?F2*5LA??'W4'OC\ZM?;+
M_5R8].=8;7HUX8_O?]<P3S_O'CTS5^QTU=/C*6^S+'+NREF<^K'/)K3D4?CW
M[&/*ZCTU7=_HOU*]KI#R3)=ZG(LTZ\QQ*,10_P"Z.Y]SS]*UL'UJ/$_]^/\
M[X/^-&)_[\?_ 'P?\:4I.6YTPIQ@K(DP?6C!]:AD=X4+R30HHZEE('\ZJ?;;
MJ?BTC5U_YZNA5?PYR:2BV:)7+EL#]FCY_A%2X/K56T\\VD1+H#M'5#_C4V)_
M[\?_ 'P?\:'N#W),'UHP?6H\3_WX_P#O@_XT8G_OQ_\ ?!_QI"),'UHP?6H\
M3_WX_P#O@_XT8G_OQ_\ ?!_QH DP?6J3_P#(<@Y_Y=I/_0DJSB?^_'_WP?\
M&JA$@UR#>RG_ $:3H,?Q)[T :%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;>_\ (9TS
MZR_^@UH\^U9U[_R&=,_[:_\ H-:.3Z4 '/M1S[49/I1D^E !S[4<^U&3Z49/
MI0 <^U'/M1D^E&3Z4 '/M1S[49/I1D^E !S[4<^U&3Z49/I0 <^U'/M1D^E&
M3Z4 '/M1S[49/I1D^E !S[4<^U&3Z49/I0 <^U'/M1D^E&3Z4 '/M1S[49/I
M1D^E  <X/ JIIA8Z;!N4 [.@.:MDG'2J%O=066DPRW4J0(%&6D8*!^=!#T=V
M7^?:C)]JQO[;GO"5TJPEN >D\O[J+ZY(R?P!I/[(O;W#:I?NRGK;VN8D^A.=
MQ_,?2E?L3[6_P*_Y%B[UVQM)3 9#-<_\\(%,C_D.GXU7\S7-0_U446FPG^*7
M$LI'^Z/E'XD_2M&TL;6PB\JTMHX4]$4#/UJSD^E%@Y)R^)_<9,'A^T243W.^
M]N <B6Y;?CZ#[J_@!6L!CH!29QU%9$NJ3WLK6VD(KE3B2Z?_ %<9]!_>/L/Q
M-5&%]A-PI+1?YLN7^IP:>JB3+S/Q'#&-SN?8?UZ5233;G4W$VK;1&#E+-#E!
M[N?XC^GUZU:L-+BLF:4EIKJ3_63R'+-[>P]AQ5_)]*OF4=(_>+V<JFM3;M_G
MW_(0#:    *7GVJM/?0P-L8EI3TC0;F/X"HO]/NNPM8S]&<_T'ZU/*]V="19
MGNH;9=TTBIGH">3]!WJMY]Y=<6\(@3_GI,.?P7_&I8+&&W;>J%I3UD<[F/XF
MK.3Z472V#1%./3HPXDF+7$HZ-(<X^@Z"KAS@X HR?2C)QTI-M[@W<AM-WV2+
M=C.T9[5-S[5#:Y%K'GGY1S4V3Z4/<3#GVHY]J,GTHR?2D <^U'/M1D^E&3Z4
M '/M5)\_VY!_U[2?^A)5W)]*I/\ \AR#C_EVD_\ 0DH O4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-,B"3RRZA\9VYYQ]* '
M4444 %%%% !1110 4444 %%%% &;>_\ (9TS_MK_ .@UHY]C6=>_\AG3/K+_
M .@UHY^OY4 &?8T9]C1GZ_E1GZ_E0 9]C1GV-&?K^5&?K^5 !GV-&?8T9^OY
M49^OY4 &?8T9]C1GZ_E1GZ_E0 9]C1GV-&?K^5&?K^5 !GV-&?8T9^OY49^O
MY4 &?8T9]C1GZ_E1GZ_E0 9]C1GV-&?K^5&?K^5 !GV-&?8T9^OY4R:>*")I
M9I%CC499F. !]: ;MN/S[&H+N^MK&!I[J9(8AU9SBLLZO=ZD=FC6^8N]Y< B
M/_@*]7_0>]36FAP13B[NY)+V\'2:;^#_ '5Z+^'/O2OV,?:.7P+Y]/\ @D'V
M[4]5XL(39VQ_Y>;A/G8?[$9_FV/H:?IVB6:)%=3Q27%UC_6W+>8P^G9?PQ6S
MGZ_E45L?]&C^GI3MH4J2WEJ_ZZ$N<?PFC/L:,_7\J,C_ "*#0,^QJM>7]O80
M>;</L7. .I8^@ Y)JI=ZL?M#6>GQ?:;L?>&<)%[NW;Z=:6TTQ()?MM]-]HN\
M?ZUQA8QZ*.BC]3W-:*"6LC!U')\M/[^G_!*_V>]UGYKP/:V)Z6RG#R#_ &R.
M@_V1^)[5KPQQV\2Q0Q".-1A54  "JQU#S3MLX6G/]_[J#\>_X9I/L4MQS>SE
MQ_SRC!5/Q[FB5WOHC2%%0U>_<?)J,0<Q0JT\HZK'SCZGH*9Y-Y<_\?$ODH?^
M6<)Y_%O\,5;CCCA0)&@11T"C I^?K^53S);&E^Q#!;0VRE88@N>I Y/U/>IL
M^QHS]?RHS]?RJ6[[B#/L:,^QHS]?RHS]?RH ,^QHS[&C/U_*J]S?V]J0LCYD
M;[L:@EC] .:3DEJQI-Z(?;'_ $:/@_=%2Y]C4%F^^SB;:RY4<,.14^?K^5.]
M]4#W#/L:,^QHS]?RHS]?RH$&?8T9]C1GZ_E1GZ_E0 9]C5)S_P 3R#C_ )=I
M/_0DJ[GZ_E5)S_Q/(/\ KVD_]"2@"]1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5Y)XR:33_ !W+?II-_/(I@>+RB3',4VL"Y6-F
M !7@*W)7D $D^MUY;JL%I=_$R(SV,,-_%?P/',^H1;I(P%Q\FTN/N\*,9.>0
M": /3H)&EMXY'C:-G0,4;JI(Z'Z5)110 4444 %%%% !6)XJ\0CPOH<NJ-:-
M<QQ<NBN%.,9XSU/' _45MU1U71['6K7[-J$+2P\Y02,@8$8(.TC(()R#Q0!R
MLGQ(A%W)#!H]Y.F94@>-E)E>+9Y@VC) &\<\YP?;.[X=\36OB2.:6U79''MP
M&D7><C))4<@ Y&3UP<<<E$\'Z!'<7$\>FQ1R3QF*0H64;2%#  '"Y"J#C&<#
M-7;+1--TV\GN[.SCAFN !(R#&0.@ Z ?2@"._=4UC3"Q &9>3_NU>^TP_P#/
M5?SJE>_\AG3/^VO_ *#6ED>M $7VF'_GJOYT?:8?^>J_G4N1ZT9'K0!%]IA_
MYZK^='VF'_GJOYU+D>M&1ZT 1?:8?^>J_G1]IA_YZK^=2Y'K1D>M $7VF'_G
MJOYT?:8?^>J_G4N1ZT9'K0!%]IA_YZK^='VF'_GJOYU+D>M&1ZT 1?:8?^>J
M_G1]IA_YZK^=2Y'K1D>M $7VF'_GJOYT?:8?^>J_G4N1ZTF1ZB@"/[3#_P ]
M5_.D-S  294  R23TK.N==B$[6NGPM?7:\,D1^6,_P"V_1?IU]JB71Y]082:
MU<B9>HM(<K"/KW?\>/:E?L9.K?2"O^0DWB$7,C0:1$MVXX,[-M@3ZM_%]%S^
M%)%I4$\JW&K7@OI@<JC<11G_ &4_J<FMN-(XHU2-51%& JC  IV1ZT6[@J5]
M9N_Y$8N( ,"1/SH^TP_\]5_.I<CUHR/6F:D7VF'_ )ZK^=16UQ"+>,&1>GK5
MG(]:R+O68=.MHHPC3W3K\D$?+'Z^@]ZN,7+1"E)15V:$U_:V\+2S7$:1J.69
ML 5C2WTVJ#(G^P:>?^6K';+-_N@_='OU^E-@T_4-0F6ZO]BN#E$<96+_ '4[
MG_:;\ *V(;""-Q(Y,TH_Y:2')'T[#\*TM&GYLRY95/BT7;J_7L4;6:*" 6^F
M6Z11#_EI+\H)]<=6/N?SJ=;>W=@]W<_:''0,<(/HO3\\UHY'K1D>M9N;Z&RM
M%6BK$0N( ,"1 ![TOVF'_GJOYU+D>M&1ZU $7VF'_GJOYT?:8?\ GJOYU+D>
MM)D>HH C^TP_\]5_.C[3#_SU7\ZKWFK:?8?\?5[;P^TD@%4+OQ-;1PA[*WN;
M]S]U;>(D'\<8J)5(QW9I&C4ELC7^T0_\]%_.JLVKVL9V1L9Y>FR+YC^)Z#\:
MP#=>(=1ZZ1)&A/W);E8EQ[[=S']*M6^G^(3&$^W:?81_W+:W+G_OIB!_X[4<
M\I?"K&WU>,/CDOO_ ,KE_==79_?7*6T9_P"6<+;G/U;M^'YTXSZ1I"$O<6UO
MNZO+( 6^I/)JB/#'G'-_K&I77&"OG^4I_",+5FW\+Z':OOCTVW,G_/21=[?F
M<FFH/>WWB;I)6<G\E;\RW8WEM+8PR1SQNC("K*V01[58^TP_\]5_.FV@5;2(
M   *.!4V1ZUI'9&$OB=B/[3#_P ]5_.C[3#_ ,]5_.I<CUHR/6F21?:8?^>J
M_G1]IA_YZK^=2Y'K1D>M $7VF'_GJOYU4,J2:Y!L<-BVDZ'_ &DK0R/6J+G_
M (GD'_7M)_Z$E %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KSK4_MMO\2?.MK:58)9;:.2:.]:.(GY?]:H<#=M+!5VG.%ZYX]%
MKS+5[BPA^*82Y-I(S36I5)$D#"3A5P%<*[#<I#%3M'?C  /3:*** "BBB@ H
MHHH **** "BBB@#-O?\ D,Z9]9?_ $&M+ ]*S;W_ )#.F?\ ;7_T&M+ H ,#
MTHP/2C HP* # ]*,#THP*,"@ P/2D(&*7 I,"@""R+/:1M(Q=CU) ]?:I\#T
MJO8 ?8HOI_6K&!0B8_"A<#THP/2C I,"@H,#THX]*HZAJUGIVU9G+3/_ *N&
M,%I'^BCFJ/D:MJW,[G3;0_\ +*)@9G'NW1?H,GWI7,Y5$G:.K+5]K5K:3?9H
MU>YO#TMX!N;ZGLH]R0*J_P!G:AJOS:I/]GMS_P N=LV,CT=^"?H,#ZUIV6G6
MFG0^5:0+&I.6(ZL?4GJ3[FK.!1;N3R2E\;^7];D5M:6]G L%M"D42]$1< 5-
M@>E)@48'I3-4DE9"X'I28'I1@4V1XXD+R,JJ.I)P!0,=@>E0W-U;V<)EN)$C
M0=V-8\FN2W\K6^BP>>P.&N'XB3\>Y]A5FST1$E%U?2F[NNH=Q\J?[J]!_.M?
M9\NL]/+K_P  CG3=HZB+<7NI?\>R&TMC_P MI%^=A_LKV^IJSIME!:VZLBYD
M89:1N6;ZFK-Q/#:V[SSR+'%&I9G8X"@=S7/6WB99K>,6&EZA>@KQ(D/EH?<%
MR./I42J*UMC>%*<U=(Z7 ]*,#TKGS=>)KD?NM,LK-3WN+@R,/^ J,?\ CU+_
M &1KER/]+U\QJ1REG;*GZMN-9\W9%>Q2^*27X_D;V5'7 K.N]?TBP;;=:C:Q
M-G&UI!G\NM4AX0TZ3F\DN[TGK]HN78'_ (#G;^E:5IHVFV'_ !Z6%M![QQA3
M^E'O!:BNK?RM^9FGQ7:2G%C9:A>$G&8K5E7_ +Z< ?K1_:'B&Y'^CZ)#;@_Q
M7=T,C_@*!OYUL7%U;VB@S2*F>@[GZ#O57S[V[XMX1;QG_EK,/F/T7_&H<K:7
MU\BTX;J'WM_\ S9+37FC,E[KEM9QXY^S6PX_X$Y/\JI_V&E\2//U&_!ZR75R
MT<7_ 'RN,_ECWKHHM+A5Q+.6N)AR'E.<?0=!^%7<4N24M]!_67'X?P27_!_$
MP+'PAI-HXE:SMVE'(VQ  ?U/XDUO*BJH55  Z "EP/2EP*N-.,=D8U*LZCO-
MW$P/2EP/2C HP*LS# ]*0@8Z4N!2$#!H @L762RA=?NE 1D5/@>E4]*'_$JM
M?^N8JY@4EL5-6DQ<#THP/2C HP*9(8'I1@>E&!1@4 &!Z51?_D.0?]>TG_H2
M5>P*HO\ \AR#_KVD_P#0DH O4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>96,<>F^/9KFX\2Z+=7#W1MWMYV9[A"[Y14!8[&"MM
MPH"]SS7IM>;WTD=K\3W8W4<<9EM_EC8Q89MJ[6Q$?,9BR_QC@CH* /2****
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M ,=I_/M1S[4!N,V2_P#/7_QVC9+_ ,]?_':?S[4<^U #-DO_ #U_\=HV2_\
M/7_QVG\^U'/M0 S9+_SU_P#':IE6&N0;GW?Z-)VQ_$E7^?:J3_\ (<@_Z]I/
M_0DH O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M><ZG9RS?%&-GDNX0)()(72(N64#YE5A( D9YW H<\\^GHU>5:[IT6J_$V:"&
M6>VECFM9'FC4,P<+E64^0^W ZAG4'TQU /5:*:BE452Q8@8+'J?>G4 %%%%
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M)]*,GTH .?0?G1SZ#\Z,GTHR?2@ Y]!^=4GS_;D&1_R[2?\ H25=R?2J3_\
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ME6,#THP*,"KV.=MMW8N!Z48'I28%&!0(7 ]*,#TI,"C H 7 ]*,#TI,"C H
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MGTJD_P#R'(/^O:3_ -"2KWX51?\ Y#D'_7M)_P"A)0!>HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P * +E%4_[23_GWN_\ P';_  H_M)/^?>[_ / =O\* +E%4_P"TD_Y][O\
M\!V_PH_M)/\ GWN__ =O\* +E%4_[23_ )][O_P';_"C^TD_Y][O_P !V_PH
M N453_M)/^?>[_\  =O\*/[23_GWN_\ P';_  H N453_M)/^?>[_P# =O\
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M]KZ;_P!!&T_[_+_C0!E7D^J_VOII.GVH/[W ^UGGY?\ <K0^T:O_ - ZU_\
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M_P#H'6O_ (&'_P"-T?:-7_Z!UK_X&'_XW4O]KZ;_ -!&T_[_ "_XT?VOIO\
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MZN0MA;QVTINO(,MJ?,C*VL4L:+@88[F?KUP1VJ[8^(-3U.+3]&FLH+35Y[B
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M:WI8-WS^]P?+']V@#6^R6W_/O%_WP*/LEM_S[Q?]\"F>1=?\_G_D,4>1=?\
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M,S ?WF)H'A'1_,LG-IKI^R2B95"(JO('#AF4  MD 9&"1P:]!HH Y/1;#3]
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M9(D"*7BRQ &.3GDU+_;'_4-U#_OQ_P#7K2HH S?[8_ZANH?]^/\ Z]']L?\
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7,*1P.I:9-H)++@#GV-:E% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" && F4# 2(  A$! Q$!_\0
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M+G:>1U&3CTR:>VFV+RI*UG;M(DIF5S$"5<C!8''7'&: #4+Z/3;&2[E21T3
MVQKEF)(  'J216?_ ,)!+_T =7_[]1__ !=2>)/^0))_UVA_]&I6M0!B_P#"
M02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?
M_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\
MT =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\
M\76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"
M02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?
M_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\
MT =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\
M\76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"
M02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?
M_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\
MT =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\
M\76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"
M02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?
M_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\
MT =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\
M\76U10!B_P#"02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"
M02_] '5_^_4?_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?
M_P 71_PD$O\ T =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 71_PD$O\
MT =7_P"_4?\ \76U10!B_P#"02_] '5_^_4?_P 74EIKJW-_'9RZ??6DDJ,R
M&XC4*VW&1D,>>:UJR;[_ )&32/\ KG/_ "6@#6HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,GQ)_P @
M23_KM#_Z-2M:LGQ)_P @23_KM#_Z-2M:@ HHHH **** "BBB@ HHHH ****
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M,-)66XEL+R_L7E*[3'-Y@C&R1&"B3< &65OH<8Q5\^!M/.H65X)IE>SE1HP
MIPB!0D>2,@#;G/4[F&<&@#2\2D#0Y">!YT/_ *-2M/SH_P#GHG_?0K+\2@-H
M4@(!!EAR#W_>I6C]DMO^?>+_ +X% #_.C_YZ)_WT*/.C_P">B?\ ?0IGV2V_
MY]XO^^!1]DMO^?>+_O@4 /\ .C_YZ)_WT*/.C_YZ)_WT*9]DMO\ GWB_[X%'
MV2V_Y]XO^^!0 _SH_P#GHG_?0H\Z/_GHG_?0IGV2V_Y]XO\ O@4?9+;_ )]X
MO^^!0 _SH_\ GHG_ 'T*/.C_ .>B?]]"F?9+;_GWB_[X%'V2V_Y]XO\ O@4
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M@4?9+;_GWB_[X% #_.C_ .>B?]]"CSH_^>B?]]"F?9+;_GWB_P"^!1]DMO\
MGWB_[X% #_.C_P">B?\ ?0H\Z/\ YZ)_WT*9]DMO^?>+_O@54\[3?[5_LW[.
M/M/E>=C[.=NW.,[L;>O;.: +WG1_\]$_[Z%'G1_\]$_[Z%,^R6W_ #[Q?]\"
MC[);?\^\7_? H ?YT?\ ST3_ +Z%'G1_\]$_[Z%,^R6W_/O%_P!\"C[);?\
M/O%_WP* '^='_P ]$_[Z%'G1_P#/1/\ OH4S[);?\^\7_? H^R6W_/O%_P!\
M"@!_G1_\]$_[Z%95XZMXETG:P/[N?H?9*TOLEM_S[Q?]\"LN[ABB\2Z28XT3
M,<^=J@=DH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#)\2?\ ($D_Z[0_^C4K6K)\2?\ ($D_Z[0_
M^C4K6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LD_\C>O_7@?
M_1@K6K)/_(WK_P!>!_\ 1@H UJ*** "BBB@ HHHH *R;[_D9-(_ZYS_R6M:L
MF^_Y&32/^N<_\EH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBO//!FNZM<>)[VWU;6+.>VEFG2S"743F9E93A%7YE"*#D-S\
MPZXS0!Z'1110 4444 49-9TN**2634K-(XY/*=VG4!7_ +I.>#[5(FI6,LC1
MQWEN\BR^2560$A\9VXSUP"<>@KS*_P#!>M7#ZY<0Z6$EN;F.6R N85:*15E4
M2'";3$/,'RD%SELYXK8M_"VLV'BF#4[01A'N,7 9U8;3@R2*#]W<3( !R..<
M$B@#J?$G_($D_P"NT/\ Z-2M:LCQ,"="E .T^;#@XSC]ZE7O(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
M6:*K>1<_\_C?]^UH\BY_Y_&_[]K0!9HJMY%S_P _C?\ ?M:/(N?^?QO^_:T
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M DG_ %VA_P#1J5K5D^)/^0))_P!=H?\ T:E:U !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9^E:C+J*W326AMQ#</"N9
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M )\W_P"^U_QK-N9)'\2Z3YD#1XCGP2P.>$]* -NBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"O?W)LM.N;H1M*8(GD$:]6V@G ^N*
M\W^%4ND7=_J=U$7757)9XD:8P)&VUCY0D4;?F(4CGE..,5Z>V[8VP@-CC/3-
M<3X(U?6M2OKB/5-7M[T6Z.G^B:;-#$SB3!;S7&U\8P OOUQF@#MZ*** "BBB
M@!-H]!US1@>@]:6B@#)\2?\ ($D_Z[0_^C4K6K)\2?\ ($D_Z[0_^C4K6H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)PI.<
M<=?2O+(/$6K:GI#3:;XH>=I]86STZ2.* M,AV[C*H4[5 69U^ZQ4#/44 >J5
MDZ!_J;[_ *_Y_P#T,URFBZ_JL'BU=*U6[>XC>XF2&2(J5D8 9!X!VI@C !P6
MP3\M=7H'^IOO^O\ G_\ 0S0!K451O-8T^P.+F[B1O[N[+'\!S5+^W+JZXT[2
MKB4'I)/^Z3]>3^54H-F;JQ6ES;J*>Y@MH_,GFCB0?Q.P _6LG[#K=Y_Q]:C'
M:H>L=I'S_P!]-_A4L'AO38I!++";F;_GI<L9#^O IVBMV+GF_A7WD;>);61B
MMA#<7S?],(R5_P"^C@?K2;O$%[]U+73XSW8^;)^0P/YULJBHH55"@= *=1S)
M;(.23^*7W:&(/#D4YW:C=W5\>ZR/M3_OE<"M2VLK6S39;6\4*^B*!4]%)R;W
M*C3C'9!1114EA1110 4444 %9)_Y&]?^O _^C!6M62?^1O7_ *\#_P"C!0!K
M4444 %%%% !1110 5DWW_(R:1_USG_DM:U9-]_R,FD?]<Y_Y+0!K4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><^ ;EW\4:U;?V
M3>62Q22[_,GN'C7,@*@"0[,MEFRG''H:]&KS?X=S^?K^KF65'N=\V[?<W,DH
M'G'&Y7'E#C'W/;M0!Z11110 4444 %%</J7Q$.EOJ$5SH[QRV=U% YDN4$06
M1'=79QD+PG(/3<OK5ZP\:Q7NOR:0UJ()EG9%:28 ,@!^89 R20,*,Y!SG@T
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M\%9EU/#-XETD12QN1'/G:P..$H VJ*** "BBB@ HHHH **** "BBB@ HHHH
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MM(WJ34MC86^G6JV]LFU!R3U+'N2>YJS3<NB%&#OS2W_(3:/05DZ !Y-]P/\
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M^&C[$/\ GXN?^_AJU10!5^Q#_GXN?^_AH^Q#_GXN?^_AJU10!5^Q#_GXN?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!63??\C)I'_7.?\ DM:U9-]_R,FD?]<Y_P"2T :U%%% !1110 4444 %%%%
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M_O\ '_XFLRY:9O$ND^;$B#RY\;7W=D]A6W63??\ (R:1_P!<Y_Y+0!K4444
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M. !6%^_\2-SO@T@?\!>Y_P $_4TZ*TN-=F6YU"-HK%3NALVZOZ-)_1?SK=
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M#_WR?\*/[0M?^>A_[Y/^%6:* *W]H6O_ #T/_?)_PH_M"U_YZ'_OD_X59HH
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M"S1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DWW_ ",FD?\ 7.?^
M2UK5DWW_ ",FD?\ 7.?^2T :U%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %#5=9L=%@BFOY71)9!%&$B>1F<@
MG 5 2>%)Z=J@MO$FEWE\UG!.SW"S&'9Y; E@"21D?=&TC=TR,=:J^,?#\WB3
M1/[/@-HKE\B6X1F,)VD;X]K AQG(-9B>"9X/$$&JVM\L,BS*9]@*F:,!<[L$
M!F9@V[/'S=,J#0!N^)/^0))_UVA_]&I6M61XF ;0I5/0RP@X./\ EJE7OL,'
M_33_ +^O_C0!9HJM]A@_Z:?]_7_QH^PP?]-/^_K_ .- %FBJWV&#_II_W]?_
M !H^PP?]-/\ OZ_^- %FBJWV&#_II_W]?_&C[#!_TT_[^O\ XT 1ZQ_R ]0_
MZ]I/_034FG?\@RT_ZXI_Z"*IZO90#1+\CS,BVD_Y:M_=/O3]/L8#IMJ?WG^I
M3_EJW]T>] &E15;[#!_TU_[^O_C1]A@_Z:_]_7_QH LT56^PP?\ 37_OZ_\
MC1]A@_Z:_P#?U_\ &@"S15;[#!_TU_[^O_C1]A@_Z:_]_7_QH LT56^PP?\
M37_OZ_\ C1]A@_Z:_P#?U_\ &@"S15;[#!_TU_[^O_C1]A@_Z:_]_7_QH LT
M56^PP?\ 37_OZ_\ C1]A@_Z:_P#?U_\ &@"S15;[#!_TU_[^O_C1]A@_Z:_]
M_7_QH LT56^PP?\ 37_OZ_\ C1]A@_Z:_P#?U_\ &@"S15;[#!_TU_[^O_C1
M]A@_Z:_]_7_QH LT56^PP?\ 37_OZ_\ C1]A@_Z:_P#?U_\ &@"S15;[#!_T
MU_[^O_C1]A@_Z:_]_7_QH LT56^PP?\ 37_OZ_\ C1]A@_Z:_P#?U_\ &@"S
M15;[#!_TU_[^O_C1]A@_Z:_]_7_QH LT56^PP?\ 37_OZ_\ C1]A@_Z:_P#?
MU_\ &@"S15;[#!_TU_[^O_C1]A@_Z:_]_7_QH LT56^PP?\ 37_OZ_\ C1]A
M@_Z:_P#?U_\ &@"S15;[#!_TU_[^O_C1]A@_Z:_]_7_QH LT56^PP?\ 37_O
MZ_\ C1]A@_Z:_P#?U_\ &@"S15;[#!_TU_[^O_C1]A@_Z:_]_7_QH LUDWW_
M ",FD?\ 7.?^2U=^PP?]-?\ OZ_^-9MS;QP^)=)*;N8Y_O.6[)ZF@#;HHHH
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M\=H V**Q_*\2_P#/[I/_ (!R?_':/*\2_P#/[I/_ (!R?_': -BBL?RO$O\
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M7B7_ )_=)_\  .3_ ..T ;%%8_E>)?\ G]TG_P  Y/\ X[1Y7B7_ )_=)_\
M .3_ ..T ;%%8_E>)?\ G]TG_P  Y/\ X[5.WN/$D^H7EK]JTE?LQ0;OLLGS
M;ES_ ,].* .DHK'\KQ+_ ,_ND_\ @')_\=H\KQ+_ ,_ND_\ @')_\=H V**Q
M_*\2_P#/[I/_ (!R?_':/*\2_P#/[I/_ (!R?_': -BBL?RO$O\ S^Z3_P"
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M@_Z#=G_X+S_\<K,\/6>NMX>T\QZS:*A@7 -@21QZ^90!UE%8WV+Q!_T&[/\
M\%Y_^.4?8O$'_0;L_P#P7G_XY0!LT5C?8O$'_0;L_P#P7G_XY1]B\0?]!NS_
M /!>?_CE &S7&06DK_%6>]_LN[MH8K,PB[5<QW;-M)+G=P$"A5&.I8^F=K[%
MX@_Z#=G_ ."\_P#QRC[%X@_Z#=G_ ."\_P#QR@#A+6T^(,$,4Z7NHS730J?)
MN?)\L2/!-NS@#A9%AQSQGODU):0>-9;N*1;C6H[&)XVA2Z\GS9%,T2N)L#LI
MF(QC@#T%=A+_ &M!,(9O$FFQRE#($>SPVT=6P9>@]:@BO+R8H(O%NCR;PQ79
M;*=P49;'[WG Y/I0!Q>BZ%XITZ>SNHVU=+B"&"VF,S1R>://GWYS]Y55E9>1
MUKN_!1U7_A&8!K2W(O%=P6N2/,D7<<,0/NY'.WG'3)J5+77I8UDCUVR9& 96
M6P)!![C]Y3OL7B#_ *#=G_X+S_\ '* -FBL;[%X@_P"@W9_^"\__ !RC[%X@
M_P"@W9_^"\__ !R@#9HK&^Q>(/\ H-V?_@O/_P <H^Q>(/\ H-V?_@O/_P <
MH V:R-._Y&#6?]Z'_P! IOV+Q!_T&[/_ ,%Y_P#CE9=A9ZZ=<U8+K-H'#1;B
M; \_)Q_RTH ZVBL;[%X@_P"@W9_^"\__ !RC[%X@_P"@W9_^"\__ !R@#9HK
M&^Q>(/\ H-V?_@O/_P <H^Q>(/\ H-V?_@O/_P <H V:XKQ[IM[J%SHAT^PF
MN+F"\CE$B( J*)$+9DW Q\ \@'.,=ZW/L7B#_H-V?_@O/_QRC[%X@_Z#=G_X
M+S_\<H Y/Q'9^,)M9U.?3;[4XK=3(+:*#RMA"VRNF-P)YF!4\^HX!S5=X/&]
MWK!A:?5;:"6[VW<B&$(D9D.PVYP2!Y?WL\YQWKKKA-8M$#W/B+3H4+!0TEEM
M!)Z#)EZU%+/J$/G>;XITI/)94EW6H&QF^Z&_>\$]LT <*- \57LT<UV^L1WC
M/;W1F62/;$XL9$;8#D*WFX4C'1AZYKK_  B_B)]6U$ZTEV87A@:-I@B(C[/G
M1%&<X/.[/.<8XK3C@UR;?Y6OV+[&*-ML,[6'4'][UI_V+Q!_T&[/_P %Y_\
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M)X@MTOV=X22.0#N(D^;^=2:9X+UK1-3TRYLBK>288KCS) X;"#S)0&&1DEP
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MP)O^@_J__?R/_P"(H RM=TB\U+QQHT[:-'/IMFK2/=*\8D,A#(%;/S&,*S'
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MO_W\C_\ B*/[ F_Z#^K_ /?R/_XB@#/^(.CW>N^%IM/L;/[3/-E5^>-0A*D
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (J F$# 2(  A$! Q$!_\0
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M5ZI87.-Y@F 4$_Q9!PW]X**]6U+P1X;U>2[DO])AG>[ECFG8E@7>-2JMP>"
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M]VYD:VB,P E* N <C..:X?2?A;H@\,:3IOB&T@U.YL%?;+EU"AG+%!SDH,X
M.>!7=JH50JC  P * %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#^Q=,_Y\H?\ OFC^Q=,_Y\H?^^: +]%4/[%TS_GRA_[YH_L73/\ GRA_[YH
MOT50_L73/^?*'_OFC^Q=,_Y\H?\ OF@"_15#^Q=,_P"?*'_OFC^Q=,_Y\H?^
M^: +]%4/[%TS_GRA_P"^:/[%TS_GRA_[YH OT50_L73/^?*'_OFC^Q=,_P"?
M*'_OF@"_15#^Q=,_Y\H?^^:/[%TS_GRA_P"^: +]%4/[%TS_ )\H?^^:/[%T
MS_GRA_[YH OT50_L73/^?*'_ +YH_L73/^?*'_OF@"_15#^Q=,_Y\H?^^:/[
M%TS_ )\H?^^: +]%4/[%TS_GRA_[YH_L73/^?*'_ +YH OT50_L73/\ GRA_
M[YH_L73/^?*'_OF@"_15#^Q=,_Y\H?\ OFC^Q=,_Y\H?^^: +]%4/[%TS_GR
MA_[YH_L73/\ GRA_[YH OT50_L73/^?*'_OFC^Q=,_Y\H?\ OF@"_15#^Q=,
M_P"?*'_OFC^Q=,_Y\H?^^: +]%4/[%TS_GRA_P"^:/[%TS_GRA_[YH OT50_
ML73/^?*'_OFC^Q=,_P"?*'_OF@"_15#^Q=,_Y\H?^^:9+HVFB%R+*'(4_P -
M &E16?\ B?SHH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JO:?=F_P"NS?SJQ5>T^[-_UV;^= %BBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDW
M^HD_W3_*GTR;_42?[I_E0!2HHHH T**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JO:?=F_Z[-_.K%5[3[LW_79OYT 6****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "F3?ZB3_=/\J?3)O]1)_NG^5 %*BBB@#0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\[\2>&-9OM7OVL+=C:W4D<C2
M&1(Y!((RBLK Y*(=K8/.[IFO1** .7\':5JFCB\M;X;K8;/LTK,"Y7!^4X..
M..PY)ZUN6PF/G;9$ \YN"A/?ZU<JO:?=F_Z[-_.@!^V?_GK'_P!^S_C1MG_Y
MZQ_]^S_C4M% $6V?_GK'_P!^S_C1MG_YZQ_]^S_C4M% $6V?_GK'_P!^S_C1
MMG_YZQ_]^S_C4M% $6V?_GK'_P!^S_C1MG_YZQ_]^S_C4M% $6V?_GK'_P!^
MS_C1MG_YZQ_]^S_C4M% $6V?_GK'_P!^S_C1MG_YZQ_]^S_C4M% $6V?_GK'
M_P!^S_C1MG_YZQ_]^S_C4M% $6V?_GK'_P!^S_C1MG_YZQ_]^S_C4M% $6V?
M_GK'_P!^S_C1MG_YZQ_]^S_C4M% $6V?_GK'_P!^S_C1MG_YZQ_]^S_C4M%
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MHHH **** "BBB@ JO:?=F_Z[-_.K%5[3[LW_ %V;^= %BBBB@ HHHH ****
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M_/*3\A_C1YQ_YY2?D/\ &@"6BHO./_/*3\A_C1YQ_P">4GY#_&@"6BHO./\
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M% !4,ERL=S% 5<M)D@A<@8]3VJ:JL_\ R$+3Z/\ R% %JBBB@ HHHH ****
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M(]O7D*O/;\:J_"S0]C/KD/B9-;L#%);VKI:&#:SR>9+D'D_.!CVH ],HHHH
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M**** "BBB@ HHHH **** "JFGBZ$4OVOR-_FMM\G=C;GC.>]6Z9%T;_>/\Z
M'T444 %%%% !1110 4R;_42?[I_E3Z9-_J)/]T_RH I4444 :%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Q'CN[U/2-9\/ZS8Z=<ZI#:-<+/8V
MLF)&WH '"?Q[>?INJ[\/K?4XO#<DVJVLMG-=7MQ=1VDK[FMXWD+*A/MG]:RO
MB5:7R7&A:SIVM:5I%U8S2(D^HDX?S5"[%&"#G'/?@>]=)X5?56T0#6M1L;^^
M261))K$8C&&QM^HP0: -NBBB@ HHIID0$@NN00",]">E #JKVGW9O^NS?SJ<
M,K#*D'OP:@M/NS?]=F_G0!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  )N ?P_&I;;1M&L+G_0[9M3U%>LTI\UE/N['"_0?E6Y_9]U>\ZC<8C/_+M
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M $6R7_GM_P".BF1)+AOWW\1_@'K5BF1=&_WC_.@!NR7_ )[?^.BC9+_SV_\
M'14M% $6R7_GM_XZ*-DO_/;_ ,=%2T4 1;)?^>W_ (Z*-DO_ #V_\=%2T4 1
M;)?^>W_CHIDR2^1)^^_A/\(]*L4R;_42?[I_E0!2HHHH T**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#!U;QCH>AZW9:5J%_!!<72.X,DJJL84
MY?)XST'K@U9T#Q#8>)+*>\TYR\$5S);>9QM<HV"RD'E3U!KAOB9IV@_V[H]U
M-X2?Q#K5R)8H;:-P@>-0"Q<D'.W(Q]376^"@R^&8(V\.CP^$9E6P#*VP9ZY
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M)9)[822P/ [,<QN02.?;BK-1Q=&_WC_.E*2:T5BX0E%W<K_<24445!J%%%%
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M0B@B2-!T51@4><?^>,GY#_&CSC_SQD_(?XUHVV0D2T5%YQ_YXR?D/\:/./\
MSQD_(?XTADM%1><?^>,GY#_&CSC_ ,\9/R'^- $M%1><?^>,GY#_ !H\X_\
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M/MVPJ"0 "S-R1P%4GUXX!K4K.UC1+/7((8;P2;8I!(/+?:3P05/^R02"/0T
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MY?SIOD1?\\D_[Y%'D1?\\D_[Y% #MZ?WE_.C>G]Y?SIOD1?\\D_[Y%'D1?\
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MW_79OYU8JO:?=F_Z[-_.@"Q1110 4444 %%%% !1110 4444 %%%% !1110
M5!>7D%C:O<7#A(T&2?Z>YIUS<PV=N]Q/((XD&68]JR;2VFU6Z34;Z-DA0YM;
M9OX?]MA_>]!V^M7&/5[&-2HT^2&[_#S'6-I/?W2ZGJ*%"O\ Q[6Q_P"60_O'
M_;/Z=/6MFBBE*3DRJ=-07F%%%%2:!1110 4444 %%%% !1110 4444 %%%%
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M0,%AU/3\Z 'U7M/NS?\ 79OYU,DB2 %'5@1G(.>*AM/NS?\ 79OYT 6****
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M4U% $/E3?\_!_P"^11Y4W_/P?^^14U% $/E3?\_!_P"^11Y4W_/P?^^14U%
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MBCRIO^?@_P#?(J:B@"'RIO\ GX/_ 'R*/*F_Y^#_ -\BIJ* (?*F_P"?@_\
M?(H\J;_GX/\ WR*FHH A\J;_ )^#_P!\BCRIO^?@_P#?(J:B@"'RIO\ GX/_
M 'R*/*F_Y^#_ -\BIJ* (?*F_P"?@_\ ?(H\J;_GX/\ WR*FHH A\J;_ )^#
M_P!\BF31R^1)^_/W3_ /2K-,F_U$G^Z?Y4 4OQHHHH T**** "BBB@ HHHH
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M +Z% $M%1>9)_P \6_[Z%'F2?\\6_P"^A0!+147F2?\ /%O^^A1YDG_/%O\
MOH4 2TC?=/TJ/S)/^>#?]]#_ !I'>0HP,+<C^\/\: ,B>XFU67^SK&1HX8P%
MNKE?X>/N*?[WJ>WUK8MK:&TMT@@C6.)!A57H!5>QA2SLHH+>U*1JHPH(_P :
ML>9)_P \&_[Z%7*5]%L94Z;3YI;O^K(EHJ+S)/\ GBW_ 'T*/,D_YXM_WT*@
MU):*B\R3_GBW_?0H\R3_ )XM_P!]"@"6BHO,D_YXM_WT*/,D_P">+?\ ?0H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %,F_U$G^Z?Y4^F3?ZB3_ '3_ "H I4444 :%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57M/NS?]=F
M_G5BJ]I]V;_KLW\Z +%%%% !1110 4444 %(WW3]*6D;[I^E #8O]2G^Z*?3
M(O\ 4I_NBGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MR;_42?[I_E3Z9-_J)/\ =/\ *@"E1110!H4444 %%%% !1110 4444 %%%%
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MI]V;_KLW\Z +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !3)O]1)_NG^5/IDW^HD_P!T_P J *5%%% &
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4457FO
MK2W<I-=01L-H*O( 1N)"]?4@@>N* +%5[3[LW_79OYT^&Y@N5#031RJ0&!1@
MPP>AXIEI]V;_ *[-_.@"Q1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4R;_42?[I_E3Z9-_J)/]T_RH I
M4444 :%%%% !15/^U=/_ .?ZW_[^"C^U=/\ ^?ZW_P"_@H N453_ +5T_P#Y
M_K?_ +^"C^U=/_Y_K?\ [^"@"Y15/^U=/_Y_K?\ [^"C^U=/_P"?ZW_[^"@"
MY15/^U=/_P"?ZW_[^"C^U=/_ .?ZW_[^"@"Y15/^U=/_ .?ZW_[^"C^U=/\
M^?ZW_P"_@H N453_ +5T_P#Y_K?_ +^"C^U=/_Y_K?\ [^"@"Y15/^U=/_Y_
MK?\ [^"C^U=/_P"?ZW_[^"@"Y15/^U=/_P"?ZW_[^"C^U=/_ .?ZW_[^"@"Y
M15/^U=/_ .?ZW_[^"C^U=/\ ^?ZW_P"_@H MG)!P<'UKS[6/ &IZEJ=W=2:E
M:W2W2)'()H=C !70GY<CY0^5Z<D].M=M_:NG_P#/];_]_!1_:NG_ //];_\
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M*MO\N,#(8-PO0#CI^- '5V%Q#J=M!/::S-(LT8E108MVWW&WL>#Z&KGV*?\
MZ"-U^4?_ ,37,Z#H6CZ!J(N[?5XF @,)C^10WW>3CTVG_OHUTW]JZ?\ \_UO
M_P!_!0 ?8I_^@C=?E'_\31]BG_Z"-U^4?_Q-']JZ?_S_ %O_ -_!1_:NG_\
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M.2TTIQ)* 8Q<2JBD$G!]<85LG& <#OFNK^QR^<)_[+TWS02PDWG=DD$G.SU
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M?^_[?_$4;]2_Y][7_O\ M_\ $4 7,#THP/2J>_4O^?>U_P"_[?\ Q%&_4O\
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MMO[US_X%2?\ Q5 %RBJ?]EVW]ZY_\"I/_BJ/[+MO[US_ .!4G_Q5 %RBJ?\
M9=M_>N?_  *D_P#BJ/[+MO[US_X%2?\ Q5 %RO,[CP?K6H3;#:K:VI\\!#)&
MQB#3O(I4X.,[H\XZA6![5Z!_9EM_>N?_  )D_P#BJY*;Q=H5OYRS0ZDDD#.L
MT;71#)M?9G_6?,,]USC!SB@#H_#5M?V>A06^I"/[3&7!*'.X;CAC[D<GZUK5
ME6$%CJ-E%=P-=&&4;D)N9.1G@_>[U9_LNV_O7/\ X%2?_%4 7**I_P!EVW]Z
MY_\  J3_ .*H_LNV_O7/_@5)_P#%4 7**I_V7;?WKG_P*D_^*H_LNV_O7/\
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MS_X%2?\ Q5,FTRV\B3YKG[I_Y>9/3_>H 2BDP/?\Z* -&D;[C?2EI'^XWTH
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MX"@IM)4Y);.T'.&J"Q\3>(UMX?MMU*90F3%Y:AU8.A!?Y0"K X!7&-P!R>0
M;L_A/P_/ (2-86/*DA89<,5QMS\G./ZTGACP[8>'FAGDDO;F\B5HQ(+"104)
M) P5)R-S<Y_B/H,4F\5^(+#7KV VAN89+X0P"?$:+'N<$JP'^R!@Y.>>AJO>
M>.=<O+.)+.U6WO IF)$3LI 3CMRI;=R#SM]Z .@U'0?#VJ:G)J%W::@]Q(-K
M$6\P&,(,?=_Z9C\SZU4C\)>'8Y5D\O52RP^1_P >\@^7GG 0<\_Y.:V-!URZ
MU:UE\^V.\7+6_FVP^0*%#!\MV.>P.#P1P37+OXG\06%E!;(?M$[QM,]S=1'*
M@2LI.U% VJJ#/?+J: .Y34K:.-46*\PH '^B2_\ Q-._M6W_ .>5Y_X!R_\
MQ-<,GBO6-3L]9NHC]B%M$!%N7:K8F()!93AV7Y>00#@XJ1O'FK NL>EH6"2%
M890XE&T-C> N 1M!;':1<4 =K_:MO_SRO/\ P#E_^)JO::I %F_=7?\ K6_Y
M=)?7_=JCH6OZCJ$E\EYIFS[/>_94\AP3@9!=@2,#C/T8<5MVGW9O^NS?SH B
M_M6W_P">5Y_X!R__ !-']JV__/*\_P# .7_XFKM% %+^U;?_ )Y7G_@'+_\
M$T?VK;_\\KS_ , Y?_B:NT4 4O[5M_\ GE>?^ <O_P 31_:MO_SRO/\ P#E_
M^)J[10!2_M6W_P">5Y_X!R__ !-9.K6.E:W<1R7T>HR1I$\)@%M*$8,5)S\F
M<Y12"#VKHZ@GO+6V+">YAB*QF4AW"X0=6Y[#(YH Y[3](T33+^WO;>WU$3P0
M?9T+6\Q^3  S\O. H K;_M6W_P">5Y_X!R__ !-307EK<G$%S#*>?]7(&Z8S
MT^H_,5/0!2_M6W_YY7G_ (!R_P#Q-']JV_\ SRO/_ .7_P")J[10!2_M6W_Y
MY7G_ (!R_P#Q-']JV_\ SRO/_ .7_P")J[10!2_M6W_YY7G_ (!R_P#Q-']J
MV_\ SRO/_ .7_P")J[10!CZCJD!M5'E7?^NB_P"727_GHO\ LU;_ +5M_P#G
ME>?^ <O_ ,33M2_X]%_Z[0_^C%JW0!2_M6W_ .>5Y_X!R_\ Q-']JV__ #RO
M/_ .7_XFKM% %+^U;?\ YY7G_@'+_P#$T?VK;_\ /*\_\ Y?_B:NT4 4O[5M
M_P#GE>?^ <O_ ,31_:MO_P \KS_P#E_^)J[10!2_M2W_ .>5Y_X!R_\ Q-<S
M!X:T*$P%O[7F,*LH,L$I+!BQ.XA!G[[\]?G.<\8[.J!US2 4SJED-^=F;A/F
MP<''/.#Q0!3TD:=HM@ME9PWPA5V<!K24G+,2?X?>KW]JV_\ SRO/_ .7_P")
MJVCK(NY&5ADC(.>1P:=0!2_M6W_YY7G_ (!R_P#Q-']JV_\ SRO/_ .7_P")
MJ[10!2_M6W_YY7G_ (!R_P#Q-']JV_\ SRO/_ .7_P")J[10!2_M6W_YY7G_
M (!R_P#Q-']JV_\ SRO/_ .7_P")J[10!AV^IP?VU?'RKOF.+_ETE_V_]FK_
M /:MO_SRO/\ P#E_^)IMO_R&[[_KE#_[/5^@"E_:MO\ \\KS_P  Y?\ XFC^
MU;?_ )Y7G_@'+_\ $U=HH I?VK;_ //*\_\  .7_ .)H_M6W_P">5Y_X!R__
M !-7:* *7]JV_P#SRO/_  #E_P#B:/[5M_\ GE>?^ <O_P 35VB@##U06.KP
MQ0W U)8DD60I';2J'*D$ _)TR >,=*S8M"T2.:WF9-4EF@N/M*R26\I)<DDY
M^3')(SC'W1743W5O:F,7$\47F,$3S'"[F]!GJ?:HX-3L+D@07UM*3C'ERJV<
MD@=#Z@C\#0 S^U;?_GE>?^ <O_Q-']JV_P#SRO/_  #E_P#B:NT4 4O[5M_^
M>5Y_X!R__$T?VK;_ //*\_\  .7_ .)J[10!2_M6W_YY7G_@'+_\31_:MO\
M\\KS_P  Y?\ XFKM% %+^U;?_GE>?^ <O_Q-1S:I;^1)^ZO/NG_ESE]/]VM&
MF3?ZB3_=/\J *.1[_E12T4 :%(_W&^E+2,,J0/2@"OIW_(+M/^N*?^@BK-9=
MI>O!900O8WF^.-5;$>>0,>M3?VE_TXWG_?K_ .O0!>HJC_:7_3C>?]^O_KT?
MVE_TXWG_ 'Z_^O0!>HJC_:7_ $XWG_?K_P"O1_:7_3C>?]^O_KT 9E[XSTG3
M-1N;*^>6&2%PH*Q-(&!16S\H./O8Y]*3_A.- +.JW4KLN[*I;2$G! XPO.20
M!CKVIEWI>DWUW+=7&CWCS2XWMM89X"]F] *I6?AG1K6TDA;3-1D>7.^8EE?!
M<, "&^7! QC'ZF@"_)X\\-131Q/J:!Y 2H\MN@SST]OU'J*IW/C+P;)/;7UW
M/&+B%V2%Y[5Q(AQS@%<CIC/KQUJ0^']!\^69="NTDER)"@9=P,:Q[3ANFU5X
M]L]:)=!T.60R-HM[O(921N&0V20?FZ$L3CZ>E #KGQS8II&HZA;6\TL=D\2'
MS08%<N0.K#C&<'/0BA?''AK4(Y+5YFE<IB6V^SNY&=HVD ')RP7'<\5/'8:9
M$LJKI%YMFE29U*D@NC;E;&>N?SP*B?1](>2>3^R;\/.S,Q4N-K%U<E<-\IWJ
M&XQS0 D_Q \.PQW)CNWN)(/,#1PPNQ+(,E>F 3T&>IIUSXT\-$FWO+G:RR#?
M'+ _R,JB3+#'&.#GU%1_V%HFUE.BWI5BYVG<0-YRV/FX!/-9LW@W1WU*"ZBL
M=1BC4R>?%M+^<'&""2V1GG..N?7F@#:O?&6G6MCI5_'NGL=0E*"=>!& K'<0
M>>J[<>IJM8?$+0KJ&W%Q<?9;N58B]NP+&,R$!02!CJ1],BK%UI^EWVGP6-WI
M-[/;PC"+(&)Z8Y.[)_&JLGAW099%D;1+W*R+* "X&\=#C=],^N!0!OZ5J]EK
M5H;JQE:2(,4):-D(/!Z, >A!^AJ]6-I_V72X##9Z9>1QL0Q&PGD*%[GT4?E5
MO^TO^G&\_P"_7_UZ +U%4?[2_P"G&\_[]?\ UZ/[2_Z<;S_OU_\ 7H O57M/
MNS?]=F_G4/\ :7_3C>?]^O\ Z]0V]\T8DW6-Y\TC,/W78GZT :E%4?[2_P"G
M&\_[]?\ UZ/[2_Z<;S_OU_\ 7H O451_M+_IQO/^_7_UZ/[2_P"G&\_[]?\
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M_P#KT 7J*H_VE_TXWG_?K_Z]']I?].-Y_P!^O_KT 7J*H_VE_P!.-Y_WZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &O F4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **IZKJ=IHNE76IWTGEVMK&997P3A1[#K6%?\ Q"\.:9'827-U,(KZ
MV%W%)';R.JPG'SN5!VCYAR>E '4T5BOXKTA))8S<,3'>PV#%4)'G2A2@![@A
MUYZ<U7\/^.-!\37;VNFW,IG6/S0DT#Q&2/.W>FX#<N>,C- '145BP^*M)N$M
M3'.Y-U>R6$:^6V[SH]^]2,< >6W)X_.MG(QG(P: %HJA<ZO;6NLV&E2+(;B]
M25XBH^4",*6R<\??&*GO;R*QL+B\ER8H(FE;;R2%&3C\J +%%8D_B>S@T6SU
M8V]V]M=0F=?+BW&-?*,OS\X7A<=>I [U;TG6['6H3)9S;F1(VDC(PT>]%D4,
M/7:P/XT :%%96B^(M+\0+?-IMSYHLKI[2<E2NV1<9'/4<]>E:F0,\CCK0 M%
M)D9QGDT9!QR.>E "T4F1QR.>E5[_ %&TTNS>[O;A(+="H:1^@W,%'YD@4 6:
M*QM2\3Z;I6KV6EW#3M=WG*)# \FQ2P4,Y4'8NX@9/%;&1ZCKB@!:*S],UFVU
M9[];<2*;*[:TD\P 9=0I..>1\PK0H **YS1?&^D:]J]SIEFM\+FV!,WGV<D2
MITX+,  3D$#N*VHM1M)KZYLH[A&N;54::,=4#YVD_7:?RH LT5FC6[/^VKO2
MV+K-:VJ7<CL $".7 YSU^1L_A4>@>(]/\2V37FG_ &CR P4-/ \6\$ JR[@,
MJ0001UH UJ*3(R1D<=: 0>A![T +1535-2M=&TJZU*]<QVMK&TLK!2Q"@9/
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MF&XFNXO+$TDK+M1,\L %)STZ5WW]H:Y_T H__ U?_B:/[0US_H!1_P#@:O\
M\30!YUJV@ZO;^*/$ABT66^TZ"&YU&T0A@EQ/<11QM'Q@G&V4X!S\_O6#_P (
MGJ5[H,RMH]^%M;74YM/C2WDM]DIEA:'9'N)7^,JI)Q@^E>Q_VAKG_0"C_P#
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M*0?ED DY (/K7L;6^J'6()DOX1IRPE9;8V^9'DYPP?=P.G&.W6JW]H:Y_P!
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M)[*."%9XU9&<*#YCDKR6+;=H)( 0 ]37HU% %#6^=!U$?].TG_H)J;[!:_\
M/%:BUO\ Y .H?]>TG_H)J]0!7^P6O_/%:/L%K_SQ6K%% %?[!:_\\5H^P6O_
M #Q6K%% %?[!:_\ /%:/L%K_ ,\5JQ10!7^P6O\ SQ6C[!:_\\5JQ10!7^P6
MO_/%:/L%K_SQ6K%% %?[!:_\\5H^P6O_ #Q6K%% %?[!:_\ /%:/L%K_ ,\5
MJQ10!7^P6O\ SQ6C[!:_\\5JQ10!7^P6O_/%:/L%K_SQ6K%% %?[!:_\\5H^
MP6O_ #Q6K%% %?[!:_\ /%:/L%K_ ,\5JQ10!7^P6O\ SQ6C[!:_\\5JQ10!
M7^P6O_/%:/L%K_SQ6K%% %?[!:_\\5H^P6O_ #Q6K%% %?[!:_\ /%:/L%K_
M ,\5JQ10!7^P6O\ SQ6C[!:_\\5JQ10!7^P6O_/%:/L%K_SQ6K%% %?[!:_\
M\5H^P6O_ #Q6K%% %?[!:_\ /%:/L%K_ ,\5JQ10!7^P6O\ SQ6C[!:_\\5J
MQ10!7^P6O_/%:/L%K_SQ6K%% %?[!:_\\5H^P6O_ #Q6K%% %?[!:_\ /%:/
ML%K_ ,\5I7N0E[';>5(3(C.' &T8QG/.>XJ>@"O]@M?^>*T?8+7_ )XK5BB@
M"O\ 8+7_ )XK1]@M?^>*U8HH K_8+7_GBM'V"U_YXK5BB@"O]@M?^>*U2O+6
M"&^TQHXPK?:2,C_KE)6K5#4/^/O3/^OH_P#HJ2@"_1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4=;_Y .H?]>TG_H)J]5'6
M_P#D ZA_U[2?^@FKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"_O_UJLT4 5O-NO^?5?^_O_P!:CS;K_GU7_O[_ /6JS10!6\VZ_P"?5?\
MO[_]:CS;K_GU7_O[_P#6JS10!6\VZ_Y]5_[^_P#UJ/-NO^?5?^_O_P!:K-%
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MFIOL%K_SP3\J +-%5OL%K_SP3\J/L%K_ ,\$_*@"S15;[!:_\\$_*C[!:_\
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M)^5 %FBJWV"U_P">"?E1]@M?^>"?E0!9HJJUE9HI9HHP!U)[5E2ZGHXD,5K
MU[,.J6J%\?4]!^)IJ+>Q+DEN;]->1(T+NZJHZEC@"N?%GJEZ?EM+33HCW?\
M?2?D,*/UJ>#PO8*=]V9;U^N;ALKGV7[OZ57*ENQ<S?PHDD\16A8QV237T@XQ
M;)N4?5ONC\Z9C7KX\FWTZ(^G[Z3^BC]:T$TZSC0(EM&JCHJK@?E2_8+7_G@G
MY4<R6R%RM[LHQ>'++>);LRWTH_CNGW@?1?NC\JU5144*BA5'0 8 J#[!:_\
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MS2K5 !1110 4444 %%%% !5#4/\ C[TS_KZ/_HJ2K]4-0_X^],_Z^C_Z*DH
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M_P#UJ +-%5O-N_\ GV3_ +^__6H\V[_Y]D_[^_\ UJ +-%5O-N_^?9/^_O\
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M_P#UJ/-N_P#GV3_O[_\ 6H L457\V[_Y]D_[^_\ UJ/-N_\ GV3_ +^__6H
M23_D)V__ %QD_FE6:HM%(]TERUE&9D4JK^;R >HZ5-YMW_S[)_W]_P#K4 6*
M*K^;=_\ /LG_ ']_^M1YMW_S[)_W]_\ K4 6**K^;=_\^R?]_?\ ZU'FW?\
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MQ8XR:9I/Q%TW6KF.WLK6Y:29H1$K;07WC+DC.1L ).?3C- '1ZW_ ,@'4/\
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M_P"OH_\ HJ2K]4-0_P"/O3/^OH_^BI* +]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5P?@6UMX=:U.1]!U.PORT@>6<L;;:9"<0@L=H;(<C _0
M5WE>2>!;62T^(%\NGW/AV<+YR:A]EO97N7!E+*\@*;2X)"]>,M]* /6Z***
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MYG_OL_XU9HH K?8+;_GF?^^S_C1]@MO^>9_[[/\ C5FB@"M]@MO^>9_[[/\
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M!FZ?-<C3;4"T)'DISY@]!5GS[G_GT/\ W\%&G?\ (,M/^N*?R%6: *WGW/\
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M>?<_\^A_[^"CS[G_ )]#_P!_!5FB@"MY]S_SZ'_OX*//N?\ GT/_ '\%6:*
M*WGW/_/H?^_@H\^Y_P"?0_\ ?P59HH K>?<_\^A_[^"CS[G_ )]#_P!_!5FB
M@"MY]S_SZ'_OX*//N?\ GT/_ '\%6:* *WGW/_/H?^_@H\^Y_P"?0_\ ?P59
MHH K>?<_\^A_[^"CS[G_ )]#_P!_!5FB@"MY]S_SZ'_OX*//N?\ GT/_ '\%
M6:* *WGW/_/H?^_@H\^Y_P"?0_\ ?P59HH K>?<_\^A_[^"CS[G_ )]#_P!_
M!5FB@"MY]S_SZ'_OX*//N?\ GT/_ '\%6:* *WGW/_/H?^_@H\^Y_P"?0_\
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M_P \_P#QX_XT?8+;_GG_ ./'_&@"S15;[!;?\\__ !X_XT?8+;_GG_X\?\:
M+-%5OL%M_P \_P#QX_XT?8+;_GG_ ./'_&@"S5#4/^/O3/\ KZ/_ **DJ;[!
M;?\ //\ \>/^-4[NUAAOM,>-,-]I(SDG_EE)0!JT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %'6_P#D ZA_U[2?^@FKU4=;
M_P"0#J'_ %[2?^@FKU !1110 4444 %%%% !1VHH[4 5M._Y!EI_UQ3^0JS5
M;3O^09:?]<4_D*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %4-0_X^],_Z^C_Z*DJ_5#4/^/O3/^OH_P#HJ2@"_1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45S/CZ)IO"<R+?6UIB
M6)F>YO&M4=5<,4,J\KN (R/6O/XM;EL;^PU*22[;2KZ.RN'M/M#-)"-F8HV9
MC@G*LW'+A!G[U 'K&M_\@'4/^O:3_P!!-7JH:W_R =1_Z]I/_034WG7/_/I_
MY$% %FBJWG7/_/I_Y$%'G7/_ #Z?^1!0!9HJMYUS_P ^G_D04>=<_P#/I_Y$
M% %FBJWG7/\ SZ?^1!1YUS_SZ?\ D04 6:.U5O.N?^?3_P B"CSKG_GT_P#(
M@H -._Y!EI_UQ3^0JS6=I\UR--M<6N1Y*?\ +0>@JQYUS_SZ?^1!0!9HJMYU
MS_SZ?^1!1YUS_P ^G_D04 6:*K>=<_\ /I_Y$%'G7/\ SZ?^1!0!9HJMYUS_
M ,^G_D04>=<_\^G_ )$% %FBJWG7/_/I_P"1!1YUS_SZ?^1!0!9HJMYUS_SZ
M?^1!1YUS_P ^G_D04 6:*K>=<_\ /I_Y$%'G7/\ SZ?^1!0!9HJMYUS_ ,^G
M_D04>=<_\^G_ )$% %FBJWG7/_/I_P"1!1YUS_SZ?^1!0!9HJMYUS_SZ?^1!
M1YUS_P ^G_D04 6:*K>=<_\ /I_Y$%'G7/\ SZ?^1!0!9HJMYUS_ ,^G_D04
M>=<_\^G_ )$% %FBJWG7/_/I_P"1!1YUS_SZ?^1!0!9HJMYUS_SZ?^1!1YUS
M_P ^G_D04 6:*K>=<_\ /I_Y$%'G7/\ SZ?^1!0!9HJMYUS_ ,^G_D04>=<_
M\^G_ )$% %FBJWG7/_/I_P"1!1YUS_SZ?^1!0!9HJMYUS_SZ?^1!1YUS_P ^
MG_D04 6:*K>=<_\ /I_Y$%'G7/\ SZ?^1!0!9HJMYUS_ ,^G_D04>=<_\^G_
M )$% %FBJWG7/_/I_P"1!1YUS_SZ?^1!0!9HJMYUS_SZ?^1!1YUS_P ^G_D0
M4 6:H:A_Q]Z9_P!?1_\ 14E3>=<_\^G_ )$%4[R29K[3!)!L7[2>=X/_ "RD
MH U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (KBV
M@NX3#<P1S1-C*2(&4X]C2-:6S$EK>$DLKDE!RR]#]1@8-344 4=;_P"0#J'_
M %[2?^@FKU4=;_Y .H?]>TG_ *":O4 %%%% !1110 4444 %(<[3MQG'&:6B
M@""RADM[*"&5U=XT"ED7 .!CH2:GHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *H:A_P ?>F?]?1_]%25?JAJ'_'WIG_7T?_14
ME %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK+
MU_6DT+31<FVENII)4@@MX2 TLCMA5!8@#ZD\ &L+2?B+IVM7,=O96ERTLQA$
M2L5!;>-SDC.5V $G/7'&: .CUO\ Y .H?]>TG_H)J]5'6O\ D!:A_P!>TG_H
M)J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !5#4/^/O3/^OH_P#HJ2K]4-0_X^],_P"OH_\
MHJ2@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B
M^)]'NM8TV!;">&&]M;J*[MVG0M&71LX8 @X(R./6N5;X;W*VVGQV^HQ0RV*0
M1),B,K,J@^8Y*D'<6VE020 @'<UZ)10!0UP!M U%2,@VL@(_X":J_P#"*:)_
MSXK_ -_&_P :MZW_ ,@'4/\ KVD_]!-7J ,;_A%-$_Y\5_[^-_C1_P (IHG_
M #XK_P!_&_QK9HH QO\ A%-$_P"?%?\ OXW^-'_"*:)_SXK_ -_&_P :V:*
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M\C@CNH[>-9D@&(U<* 0H[+GI5Z@#&_X131/^?%?^_C?XT?\ "*:)_P ^*_\
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M_/BO_?QO\:A?0]-T[4M,GM+41R?:"NX,QX\J3U-;]4-0_P"/O3/^OH_^BI*
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MKI\L 25;<@1M&$9G <#<X&') )%;-Q)XBT:QU-(9=9\J[DN)46!"BVLGVN8
MJ5C9@K#!(P2=PY .: /3IHM8MU5I]?L8E9E12]EM!8G  S)U). *D^Q:]_T&
M;7_P /\ \<KSH7WB^ZNQ',EW(MM)97*^; -LK3M VW&.!&5F!_N[JKZ3=^*[
M\0HVKZW;P".2:2YGM#N6X6W5G0KLR8UE/  YP5!- 'IOV+7O^@S:_P#@ ?\
MXY5:%]1N9W@@\2Z;+,F=\:6H9EP<'($F1S5;PO=ZU=>&-$F$(RQ87C7\S^:4
M#$!T^0%MV 1N"\$9YKDM8L#I&N^(;VSM+G3H)]0M4N;[3;/,ZP&#<Y0A23F4
M)NP#U.: .^^Q:]_T&;7_ , #_P#'*K&345MWN&\2Z:($<QM(;0!58':5)\S&
M0>,>M>7W%[XETS3-3E=M>77+J:WG81HPB1_L:D<+&V<NK*5&!E0"0.NUKMHP
M\#22RVTINX==N[JVMWT][F.X?S)ML<D8!^1PQ ;H"5.: ._^QZ]_T&;7_P
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MHH R/L6O?]!FU_\   __ !RC[%KW_09M?_  _P#QRM>B@#(^Q:]_T&;7_P
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MH *HQ?\ (>NO^O6'_P!"EJ]5&+_D/77_ %ZP_P#H4M %ZBBB@ HHHH ****
M"J6JZM8:)I\E_J5RMO:QX#2,"<9.!P.35VL/Q<ES+X9O(;2'4)995V :<\:3
MJ#W4N0OU]B: &/XW\-)//"=9M?,@@6YD4,3B-MNUACKG<O3^\/6M:TU"TOFF
M6UG67R6"N5Y )4,!GH?E8'\:\Q@T+6+F2.UUGPW<%-.T2.ULOL<T:1&;;&SX
M8-N4[T1!Q@!&.>:ZCP+IFL:+%J&G:B@^RPR#[-)M4>83DLPP<D'Y?O<@Y'0"
M@#KZ*** "BBB@ HHHH *H:A_Q]Z9_P!?1_\ 14E7ZH:A_P ?>F?]?1_]%24
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M_".Q?]!+5O\ P-?_ !K8HH Q_P#A'8O^@EJW_@:_^-'_  CL7_02U;_P-?\
MQK8HH Q_^$=B_P"@EJW_ (&O_C4EMH4%O=17!NKZ=HB619[EG4$@C."?0G\Z
*U** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (P F$# 2(  A$! Q$!_\0
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M@"C_ &Q:?W;O_P  Y?\ XFC^V+3^[=_^ <O_ ,35[/L:,^QH H_VQ:?W;O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH S=?_P"1?O\ _KBW\JT?E]JSM?\ ^1?O_P#KBW\JT<B@ ^7VH^7VHRM&
M5H /E]J/E]J,K1E: #Y?:CY?:C*T96@ ^7VH^7VHRM&5H /E]J/E]J,K1E:
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M_P ^T_\ Z%'6A@^OZ5GS9_X2"RY_Y=I__0HZ -&BBB@ HHHH **** "BBB@
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M_P"><?\ WR*/)@_YYQ_]\BGY%&10 SR8/^><?_?(H\F#_GG'_P!\BGY%&10
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M7I]>;^,H+6+Q]IMTPM%;R$>1MJK(-LG#,YA?(QD 94\''L >@V5I%86-O9P
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MZ=1110 4444 %%%% &;K_P#R+]__ -<6_E6CCZUG:_\ \B_?_P#7%OY5HX%
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M_OC\JHR2(_B&SV$'%M/_ .A1UI9]C6?,<^(++_KVG_\ 0HZ -&BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O.?'BLGC#1)673TB8")9[Q
M"H1R_'S[2">F$R.?J"/1J\[\9 -XZTGR[_3K:Z2%&B%W(B8!EPQPZ-YF1P%4
MJ0>>X( /1**** "BBB@ HHHH S=?_P"1?O\ _KBW\JT<GTK.U_\ Y%^__P"N
M+?RK1Y]J #)]*,GTHY]J.?:@ R?2C)]*.?:CGVH ,GTHR?2CGVHY]J #)]*,
MGTHY]J.?:@ R?2C)]*.?:CGVH ,GTHR?2CGVHY]J #)]*,GTHY]J.?:@ R?2
MC)]*.?:CGVH ,GTJ*YNH;.W>XN)%BBC&YG8X %17^H6^FVK7%RX5 < #DL3T
M '<GTK,MM/N=6N$O]6CV1(=UO9$Y">C/ZM[=!]>:39E.;3Y8ZO\ K<C6"X\2
M.);N-X-)!S';-PUQ_M/Z+Z+W[^E= JA%"JH"@8 ':EY]!1S[4)#A#EU>K#)]
M*,GTHY]J.?:F:!D^E&3Z4<^U'/M0 R(G:>/XC_.GY/I4<395L$'#$=?>I,GV
M_.D@#)]*,GTI&<(I9F4 =R:I3:UIEO\ Z[4;./\ WYU'\S5686+V3Z49/I6(
M_B_P_&VW^V+-FZXCE#G],TP>,-(<9A-W/_UQLIFS^2T^278?*S>R?2C)]*P?
M^$GW$"'1-9ESW^R[!_X^11_;>L/_ *GPS=X]9KB%/Y,:.20<K-[)]*,^U8(O
MO$TJC9HMC"3_ ,]KXG'_ 'S&:,>+'89?1H5[_++(?YK1R>:#E-[)]*,GTK!_
ML[Q+)GS-?M8O:&P_^*<U5GLKL,(IO$^HS3 \QVL,*G\<(<?B:I0OU&H^9U&?
M:HIKF*W7=,ZH/<]:YN+PQ=7#AY]5U6-,YVF]8L?KMP!^M:$_A72;H(+JV:<I
MT,DSG^M/E@MW]P[16[)IM4=A^Z6.!#_RUN6V#\%ZG\<51DU+05;.H:Y9S./X
M)+A H_X"#_/-6(_"?A^+!71;$D=VA5C^HJ]#IEC;_P"HL;:+_<C _D*.:*V"
MZZ&9_P )CX=1=L>H1R < 0(TG_H(-:MA<I=V$,\6XQNN5W*5./H<$58"X'"@
M4R GR4^E0VK:$NW0DR?2C)]*.?:CGVJ1!D^E&3Z4<^U'/M0 9/I1D^E'/M1S
M[4 &3Z5GS?\ (P67'_+M/_Z%'6AS[5GS9_X2"R_Z]I__ $*.@#1HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS7Q\+F;Q=ID-G?M!<^2C
MQ!LA(SYH^<?O4#$_=(PQQV&>?2JXS7/#6KZGXLM]4A%DD, 2-6\\AVC#!B"I
MB89SG&"/K0!V$(E$$8G*&;:-Y0$*6QS@'.!FGT44 %%%% $+7=LHE+7$0\K_
M %F7'R?7TIWGPY(\U,@@$;AP3T'XUP&K>!-2O_$MYJT?]F>5(\)%I-DI<!'+
M8DP@V@YSC#Y8 YP,4RQ^'6H:3-I]QI]];+-;BW68RAG68HN'DP<X/)"CL"3D
M$\ '::__ ,B_?_\ 7%OY5H\^H_*L[Q!_R+]__P!<&_E5WR7_ .?B7_QW_"@"
M3GU'Y4<^H_*H_)?_ )^)?_'?\*/)?_GXE_\ '?\ "@"3GU'Y4<^H_*H_)?\
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M]!5GR6'_ "WD_)?\*=I=PYJ*VBWZO_)&$=0\3W/_ ![Z-:VJ]FN[K)'_  %
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MY%&1_D5%Y[?\\)?R'^-'GM_SPE_(?XT 2Y'^11D?Y%1>>W_/"7\A_C1Y[?\
M/"7\A_C0!+D?Y%9\QSX@LO\ KVG_ /0HZM^>W_/"7\A_C5)Y"_B"SS&ZXMI_
MO8_O1T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ,,,1+9C0[A@Y4<TNQ2<[1UST[^M.HH S=?\ ^1?O_P#KBW\J
MT<GTK.U__D7[_P#ZXM_*M'GVH ,GT_6C)]/UHY]J.?:@ R?3]:,GT_6CGVHY
M]J #)]/UHR?3]:.?:CGVH .?3]:8K@NX!!((R >E/Y]JS;VZLM&66ZD3$L[
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MYW5<GIJ='L[?$[$EQK-I#(8D9IYQ_P LH!O8?7'3\:BSJ][T$=A$>YQ))_\
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M[+!_<'YFJFO_ /(OW_\ UQ;^5:.5]J (?LMO_<'YFC[+;_W!^9J;*^U&5]J
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MH[/L?RHS['\J,GTHR?2I*#/L?RHS['\J,GTHR?2@ S['\J,^Q_*C)]*,GTH
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M;H-S'!'+8AD@$2PKO;$:QC"JO/"\GCOGF@"WX@('AZ_)( $#9)^E3_VCI_\
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MH3CYY")A^[']T\U(_P 0)FNX(8M#@B22[CB\VXN %\II98BW"_*=T7 /]X4
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M:NUE/!!<ZEIL<D[;(U96Y.TMS\W'"GDUSLWPOL'EE<ZE."[;DS&F=WF+(=[
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MB?);^,>E:/VNV_Y^(O\ OL5DZ[IFGIH-\RV-J"(6P1"OI]*T?[*T[_GPM?\
MORO^% $OVNV_Y^(O^^Q1]KMO^?B+_OL5%_96G?\ /A:_]^5_PH_LK3O^?"U_
M[\K_ (4 2_:[;_GXB_[[%'VNV_Y^(O\ OL5%_96G?\^%K_WY7_"C^RM._P"?
M"U_[\K_A0!+]KMO^?B+_ +[%'VNV_P"?B+_OL5%_96G?\^%K_P!^5_PH_LK3
MO^?"U_[\K_A0 2MI\Y0S-;2%#E2Y4[3[9Z4*^GH24:V4EB^05'S'J?J?6D.E
MZ:!DV%J!_P!<5_PJ/[%I&"?LMC@ '/EIT/0_C0!8CGLXHUCCE@1%X"JP 'X4
M[[7;?\_$7_?8J+^RM._Y\+7_ +\K_A1_96G?\^%K_P!^5_PH E^UVW_/Q%_W
MV*/M=M_S\1?]]BHO[*T[_GPM?^_*_P"%']E:=_SX6O\ WY7_  H E^UVW_/Q
M%_WV*/M=M_S\1?\ ?8J+^RM._P"?"U_[\K_A1_96G?\ /A:_]^5_PH E^UVW
M_/Q%_P!]BL[6;JW-O;8N(O\ C\@_C'_/05<_LK3O^?"U_P"_*_X5G:SIE@MO
M;;;&U&;N ?ZE?[X]J -;[7;?\_$7_?8H^UVW_/Q%_P!]BHO[*T[_ )\+7_OR
MO^%']E:=_P ^%K_WY7_"@"7[7;?\_$7_ 'V*/M=M_P _$7_?8J+^RM._Y\+7
M_ORO^%']E:=_SX6O_?E?\* )?M=M_P _$7_?8H^UVW_/Q%_WV*B_LK3O^?"U
M_P"_*_X4?V5IW_/A:_\ ?E?\* )?M=M_S\1?]]BH9/[-FE$DOV1Y%& S;20/
MK^)I?[*T[_GPM?\ ORO^%-.F:8&"FQM QZ#RER?TH 5?[-2(1+]D6,*4"C:
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MU'RO,(VD]4SP$4<$<<=#BM^'1DM[&6RB\/6BVLKB1X?M1V9!## V\ $ X'%
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MI9M.@ '4F[_^QH TJ*R)-5O(9XH);2T2:;/EQM>@,^.N!MYJ;[5JO_0,A_\
M K_[&@ U_P#Y%^__ .N+?RK1KGM<N=3.A7P;3H0ODMDBZ]O]VM#[5JO_ $#8
M?_ K_P"QH T:*SOM6J_] R'_ ,"O_L:/M6J_] R'_P "O_L: -&BL[[5JO\
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MM0@$%TBE702&3H3@EB3DD8)Y/)K4H H_V19?\\Y/^_S_ .-']D67_/.3_O\
M/_C5ZB@"C_9%E_SSD_[_ #_XT?V19?\ /.3_ +_/_C5ZB@"C_9%E_P \Y/\
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M5?H H_V19?\ /.3_ +_/_C1_9%E_SSD_[_/_ (U>HH H_P!D67_/.3_O\_\
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M!2^WR?\ 0.O/R3_XJC[?)_T#KS\D_P#BJNT4 4OM\G_0.O/R3_XJC[?)_P!
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M\D_^*H^WR?\ 0.O/R3_XJKM% %+[?)_T#KS\D_\ BJ/M\G_0.O/R3_XJKM%
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M#_\ B*/[/F_Z"=Y_Y#_^(H O451_L^;_ *"=Y_Y#_P#B*/[/F_Z"=Y_Y#_\
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MFEE0?974('D9]H 7  W8'L* .BHK._MVP_OS?^ \G_Q-']NV']^;_P !Y/\
MXF@#1HK._MVP_OS?^ \G_P 31_;MA_?F_P# >3_XF@#1HK._MVP_OS?^ \G_
M ,31_;MA_?F_\!Y/_B: #7_^1?O_ /KBW\JT:Y[7=:L7T*^422Y,+=;>3T_W
M:T/[<L/[\W_@/)_\30!HT5G?V[8?WYO_  'D_P#B:/[=L/[\W_@/)_\ $T :
M-%9W]NV']^;_ ,!Y/_B:/[=L/[\W_@/)_P#$T :-%9W]NV']^;_P'D_^)H_M
MVP_OS?\ @/)_\30!!XG>_B\/W$FFS-%<*R'<L;.Q7>-P4*K$$KD [3C.<<5Q
M5MJ/CBVM[.>^CN[E7CB:Y@A@ DCRQVJ#MP6('S<<;OX>".\_MVP_OS?^ \G_
M ,31_;MA_?F_\!Y/_B: -&BL[^W;#^_-_P" \G_Q-']NV']^;_P'D_\ B: -
M&BL[^W;#^_-_X#R?_$T?V[8?WYO_  'D_P#B: -&BL[^W;#^_-_X#R?_ !-'
M]NV']^;_ ,!Y/_B: -&LW6O^/>U_Z_(/_1@I?[=L/[\W_@/)_P#$UG:QK5B\
M%L \O%W">;>3^^/]F@#HJ*SO[=L/[\W_ (#R?_$T?V[8?WYO_ >3_P")H T:
M*SO[=L/[\W_@/)_\31_;MA_?F_\  >3_ .)H T:*SO[=L/[\W_@/)_\ $T?V
M[8?WYO\ P'D_^)H T:Y#Q%?ZG#XKTZ"SDU6.T$$DMTT-GYL++M8*BD(3YI;!
MY( "C@[JWO[=L/[\W_@/)_\ $T?V[8?WYO\ P'D_^)H \_@O_&G]D6]Y%/?R
MEA.9+2>QV311[OEW,4 :1590,#!(. P!KTC3IGN--M9I8989'B5FBF^^A(Z-
M[U7_ +=L/[\W_@/)_P#$T?V[8?WYO_ >3_XF@#1HK._MVP_OS?\ @/)_\31_
M;MA_?F_\!Y/_ (F@#1HK._MVP_OS?^ \G_Q-']NV']^;_P !Y/\ XF@#1HK.
M_MVP_OS?^ \G_P 31_;MA_?F_P# >3_XF@!U]_R$M,_ZZO\ ^BVJ_6!>:U8'
M4-.(DEXE?/\ H\G_ #S;_9J]_;MA_?F_\!Y/_B: -&BL[^W;#^_-_P" \G_Q
M-']NV']^;_P'D_\ B: -&BL[^W;#^_-_X#R?_$T?V[8?WYO_  'D_P#B: -&
MBL[^W;#^_-_X#R?_ !-']NV']^;_ ,!Y/_B: .3\1WOB./Q)<PZ5->+9_8F9
MV^S,T<;AHR-I\L\E=X&W><G)4!:S(M1\<VUI:W5S'>7*-"IGM8K<":,>8=N&
MV\NRCGC@$Y"\5W_]NV']^;_P'D_^)H_MVP_OS?\ @/)_\30!H*2R D%21G!Z
MBEK._MVP_OS?^ \G_P 31_;MA_?F_P# >3_XF@#1HK._MVP_OS?^ \G_ ,31
M_;MA_?F_\!Y/_B: -&BL[^W;#^_-_P" \G_Q-']NV']^;_P'D_\ B: -&L^?
M_D8++_KVG_\ 0HZ3^W;#^_-_X#R?_$U62_M[WQ%:"!G)6VF)W1LO\4?J!0!M
M4444 4=:_P"0#J/_ %[2?^@FE4W^T;5@QCC+'_"DUK_D ZC_ ->TG_H)JY'_
M *I/]T5G.'-U:]!IV&PF8I^^"!L_P'(J2J[W82]2U\B<ED+^:$)C&.Q;L?:O
M/;;XGWQTR"=]!6=_LXEE>.Y$:[OLYG8!2"<!%8=>N!WR+BK*PCI/&W]O3Z5#
M8^'1,EY<RX:YC95\A%!;.6! R0J].A-8-SXB\:M87$T>C7,5T8X?)MQ:!PI*
M NS/OY^?<NT#@ 'OFI8OB8+FYFM[72#+()DAB472\EI_)'F<?N^?F .<C/I3
M&^*<,:7$TFCS>1"VUF24,R,3(B*Z@?([/&%V]@ZFF!5O-6\>MJSW$6F2JD,#
M 0+%^[^;R/GSN_>, 9<+CC;CG/-B;4_B"Z%X;>V7$0P/L3'>WD-)GEP1EU5,
M$<%SZ"K'_"QIWN)[:+0)3/'=+:!7N57]YE@0W&5'RD@X((Y]JAM_B@9Y;2%M
M!G2:Y:-E7[0N/+=(W7YB -^)/N?[)YH O:-?^)CK=O!?6<T%E*\\C-Y1ER?,
M;:I8M^[4+M(X.<XXQ60#X]TVRNM0C=YS<7;Q+;3(9FAC$LI$NT '!7REVC/'
MS=:N6_Q%NKJ_TZ!='CMTN[F%#)-=# BD$P5AA>&W0D;3Z@9R>%OO&NL:=J^M
MR/IB3Z/ILOE/(BE&#%(BGS%CG)D;=\HVJN<GI0!#?2^.KB\BNT0A+:>X:.SB
MC*)-LA)CWMO!*LYQCCH,TX:MX\D@D:*S7;'&[1/+9[7G/F*J[DW_ "8!<XSR
M%'3-3'XCN$W-HPB4?9U:2:\18T>7<1N8 @* A^;U*C'/#)/B7(;FY@MM"DE:
M*>2!=]RJ;BBRLQ(P2O$1(X.0PY[4 0W.L>/;2SNP; 74VTBWDAM,;6661!N4
MN<AD6-N.F_TY#WUGQX(GF;345)2P\M+7<]LH>(;P-_[PE7D(7C[GYLE^*(M(
M;J>XTZ+8L\:P1+<8E>)X4EW%=I .&XYP<$ \<N?XI 1RR1Z))(@NFMHB+E1O
M*AR<Y "GY,#)P2>O!H VO#^H^([OQ!?PZK:+#81K_HY,+*S_ '=K;LD<@ME>
MH(Q]>IKA/$/C;4]'\22Z?#813026T4=J=K;_ +9*7\M7P<;#L;)[8ZU6L/B<
MTEJOVO30)([&.XFF$NR/>R(V I!;82^ W/(.?6@#T2BN(T/XA_VUJ%C ND20
MP73K$9C."4E,;R8VXY&(V&[/<<>G;T %%%% !1110 4444 9VO\ _( O_P#K
MBW\JT:SM?_Y%^_\ ^N+?RK1H **** "BBB@ HHHH KWM[;Z=9R75TY2&/[Q5
M"QZXX !)_"LZW\6:#=[/LVI0S;UC9 F3N$F-N..2=PX[9YQ5K6=/FU72+FQ@
MOY[%YEV_:(,;T&><9Z$C(SU&>.:YZ;X?VLJ6K)>-:SVL4<,,MI$L155R#T]5
MP!Z8]SD ["BBB@ HHHH **** "LW6O\ CWM?^OR#_P!&"M*LW6O^/>U_Z_(/
M_1@H TJ*** "BBB@ HHHH *IRZK8PZI#IDERBWL\;2QPG[S(O4_3FKE8.M^&
MAK>J6MU+?2Q0PP30-!&H&]91M?YNJG &".F* %B\9^')D5XM7MW1ED<,"<$(
M2&[>JM]<'&:VT8.BN,X89&00?R-<9_PK;3A8?9!>7)"2S312L%,D;NP*X;&=
MJ\_+W)R><5UMC;&SL+>V::2<Q1JAEE.6? QDGU- %BBBB@ HHHH **** *%[
M_P A+3/^NK_^BVJ_5"^_Y"6F?]=7_P#1;5?H **** "BBB@ HHHH R[KQ'H]
MC<W5M<W\4<]K$LTT9R2B,=JG ]3@ #DY%00^+M N&"PZG%(Y56"*"6.Y@H&,
M9SD@8ZC/(JMJOA/^U=7NKZ6^^2>S%H+=X%=% ;>&]20W/7^59I^&M@ME;0P7
MUS!-;1A8KF,*)=Q8L[%AR2=Q _N]NIH [:BD4;5"Y)P,9/4TM !1110 4444
M %9\_P#R,%E_U[3_ /H4=:%9\_\ R,%E_P!>T_\ Z%'0!H4444 4-;_Y .HX
MZ_99?_0338X=4\M?]/M>@_Y=#_\ %T_6O^0%J/\ U[2?^@FJP\-:-( [Z?"6
M;DDCJ335NHG?H6/(U3_G_M?_  %/_P <IOV74L?\?EG_ . 9_P#BZLV=C;:?
M!Y-I"L4>2VU>F34T<B2QK)&ZNC#(93D$?6DQF7;Z9=VB,EM/8Q*[M(P2S(RS
M$L3]_J22?QK-U'75TN[GM;C4H#-%#]IG6+39)!&F"0SE6(7.PXSC.*ZBL#4?
M"EO?ZA>W:WMW;"_MA;7D413;.H#!2=RD@@.>01GC- "1ZBCJ\PUW201L\PM"
M 5)^Z&_><'T!I3>HTJQ'7=',F\JJ&(9W*.0!YG4#\JRI/AMILCW3M?Z@9)]F
M)"Z%X@C%EV-MRI!8X/4"I4^'.CB:]DEFN91=PW,)C)4+$L^W?L 7Y3\N<CJ2
M2>M &BE^DJVY37M'=;AML!6,$2L#T7]YR0?2BWU%;R;[/;>(-(GE?/[N.,,S
M8'/ DYX(K*_X5OI1N1<2WEV\TD@>X/[M?/(='48"@+@QK]S;D YS4ND>#- T
MO5K=[.XS>60B.S<FX!(6B&X 9Y5R3ZG% #[3Q!:7CW=O'K>GH+3Y9O.LFC10
M'9.K. 1N5EX[BI+?6K>XN;Z-=<TM)K1]MP)+?81@*=W,G*X=1NZ<XK/D^%^C
M237,QN;L2S3F<$; %8R-)R OS\NP&_) .!BIS\.=)4$V]Q=6TA9B'A**0"L2
M[?N_=Q"O'N?P +USJ*V]L+AM7TV1"Z(OEVV\LS8V@ 2<\-GZ'/2JME:Z5I9N
M19:AH-N6E6*?9"!^\R=J',G!R6PON<"JZ?#/0T: K-=_Z/;Q0*N]<9C=6$A&
MW[^%"Y_N\58L?A[I-CJ%O>"6XF>VD#PK+L*HH\W"\+S@S.<G+=.>* -S[/J>
M<_;;3/\ UZ'_ .+IIL]0)R;NS)V[?^/,]/3[_2KS7$*R-&TT8=4WLI89"^I'
MI[TZ.1)8UDC=71AE64Y!'J#0!1%KJ0Z7MH/^W0__ !=+Y&J_\_\ :_\ @(?_
M (Y5^B@"AY&J_P#/_:_^ A_^.4>1JO\ S_VO_@(?_CE7Z* *'D:K_P _]K_X
M"'_XY1Y&J_\ /_:_^ A_^.5?HH H>1JO_/\ VO\ X"'_ ..4>1JO_/\ VO\
MX"'_ ..5?HH P-=AU,:#?;KZV*^2V0+4CM_OUH>1JO\ S_VO_@*?_CE-U_\
MY%^__P"N+?RK1H H>1JO_/\ VO\ X"'_ ..4>1JO_/\ VO\ X"'_ ..5?HH
MH>1JO_/_ &O_ ("'_P".4>1JO_/_ &O_ ("'_P".5?HH H>1JO\ S_VO_@(?
M_CE'D:K_ ,_]K_X"'_XY5^B@"AY&J_\ /_:_^ A_^.4>1JO_ #_VO_@(?_CE
M0>)M471O#M[J#7:6HA3/FO"9<'(  0$;B<X R.2*XU?&^N6L=E+J,=B8)X()
M)I;+,HA+?>'7!+$.H&>V><8(!W/D:K_S_P!K_P" A_\ CE'D:K_S_P!K_P"
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M?RH T?(U7_G_ +7_ ,!#_P#'*/(U7_G_ +7_ ,!#_P#'*Y4>+]2M_%2Z=>)
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MQ:?%;CQ;"ABMQ"GDWLD:+BW*#"JX'^MVO^%>H^1#_P \D_[Y%'D0_P#/)/\
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M +_+_C5CR(?^>2?]\BCR(?\ GDG_ 'R* *_]K:;_ -!"U_[_ "_XT?VMIO\
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M/^^10!6_M33!TO[3_O\ +_C2_P!K:;_T$+7_ +_+_C5CR(?^>2?]\BCR(?\
MGDG_ 'R* *_]K:;_ -!"U_[_ "_XT?VMIO\ T$+7_O\ +_C5CR(?^>2?]\BC
MR(?^>2?]\B@"O_:VF_\ 00M?^_R_XT?VMIO_ $$+7_O\O^-6/(A_YY)_WR*/
M(A_YY)_WR* *_P#:VF_]!"U_[_+_ (T?VMIO_00M?^_R_P"-6/(A_P">2?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &+ F(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[5,DC2,?JS$DGW)H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\* +/G1?\]$_[Z%'G1?\]$_[Z%5O[)T[_H'VO_?E?\*/[)T[_H'VO_?E?\*
M+/G1?\]$_P"^A1YT7_/1/^^A5;^R=._Z!]K_ -^5_P */[)T[_H'VO\ WY7_
M  H L^=%_P ]$_[Z%'G1?\]$_P"^A5;^R=._Z!]K_P!^5_PH_LG3O^@?:_\
M?E?\* +/G1?\]$_[Z%'G1?\ /1/^^A5;^R=._P"@?:_]^5_PH_LG3O\ H'VO
M_?E?\* +/G1?\]$_[Z%'G1?\]$_[Z%5O[)T[_H'VO_?E?\*/[)T[_H'VO_?E
M?\* +/G1?\]$_P"^A1YT7_/1/^^A5;^R=._Z!]K_ -^5_P */[)T[_H'VO\
MWY7_  H L^=%_P ]$_[Z%'G1?\]$_P"^A5;^R=._Z!]K_P!^5_PH_LG3O^@?
M:_\ ?E?\* +/G1?\]$_[Z%'G1?\ /1/^^A5;^R=._P"@?:_]^5_PH_LG3O\
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MJ+RI?^?AO^^1_A1Y4O\ S\-_WR/\* ):*B\J7_GX;_OD?X4>5+_S\-_WR/\
M"@"6BHO*E_Y^&_[Y'^%'E2_\_#?]\C_"@"6BHO*E_P"?AO\ OD?X4>5+_P _
M#?\ ?(_PH EHJ+RI?^?AO^^1_A1Y4O\ S\-_WR/\* ):*B\J7_GX;_OD?X4>
M5+_S\-_WR/\ "@"6BHO*E_Y^&_[Y'^%'E2_\_#?]\C_"@"6BHO*E_P"?AO\
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MVYQN.2Q+=\<GC % &W117GOCO4I+#Q3X>-KJ;Q3&[@66TAORLDD;28.+?&)
M>0S$_*!D"@#T*BO"+34-4U:QN<>(+N5Q9QW-_$\[GR;PRR1B%-O*-RNV,<$H
MN1SFO1_ NKSZ@^K6]ZC_ -H0S[KE_-#J&)9-@'\&WR\8[C#?Q4 =7-_K(/\
MKI_[*U2U!<%@T!5=Q\SIG'\)I?,G_P"> _[[_P#K4 345#YD_P#SP'_??_UJ
M/,G_ .> _P"^_P#ZU $U%0^9/_SP'_??_P!:CS)_^> _[[_^M0!-14/F3_\
M/ ?]]_\ UJ/,G_YX#_OO_P"M0!-14/F3_P#/ ?\ ??\ ]:CS)_\ G@/^^_\
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M^_\ ZU $U%0^9/\ \\!_WW_]:CS)_P#G@/\ OO\ ^M0!-14/F3_\\!_WW_\
M6H\R?_G@/^^__K4 345#YD__ #P'_??_ -:CS)_^> _[[_\ K4 345#YD_\
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M#_OO_P"M5:S+'4K\LNTYCXSG^&@"_1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >3^/=0U'2_$]U'=^-].TNPOK-4@M7L)+B5 "=SA5X!R>'[X Q
M\N:]/TX*-+M MP]PODIB:3[T@VCYC[GK7GWCB1K?QK9R6&OW^EW\M@T<AM=-
M2X7RU,DB[V?@9VN%'7(->@:;.MUI=I<+,9UEA1Q*5VEP5!W8[9ZXH M4PQ1M
M*LC1J9%R%8CD9]#3Z* (Q!$"2(D!9MY^4<MZ_6G+&B%BJ*I8Y8@8R?4TZB@"
M*;_60?\ 73_V5JEJ*;_60?\ 73_V5JEH **** "BBB@ HHHH **** "BBB@
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M2RX&"2><D>M %FL#4_"EOJ?B.RUPZAJ-O=6D?E1K!*HC*EMS J5/WL $C!(
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ML_\ T&KU4;7_ )"E_P#]L_\ T&@"]1110 4444 %%%% !1110 4444 %%%%
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MLU-10!#]G'_/27_OLT?9Q_STE_[[-344 0_9Q_STE_[[-'V<?\])?^^S4U%
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MV]-^!NQ[9S0!8HHHH **:\B1KN=U5<@98X'/ I0REBH8$KU /2@".;_60?\
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M:/\ 2?6+\C4U% $/^D^L7Y&C_2?6+\C4U% $/^D^L7Y&C_2?6+\C4U% $/\
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M]:FHH A_TGUB_6C_ $GUB_6IJ* (?])]8OUH_P!)]8OUJ:B@"'_2?6+]:/\
M2?6+]:FHH A_TGUB_6C_ $GUB_6IJ* (?])]8OUH_P!)]8OUJ:B@"'_2?6+]
M:/\ 2?6+]:FHH A_TGUB_6C_ $GUB_6IJ* (?])]8OUH_P!)]8OUJ:B@"'_2
M?6+]:/\ 2?6+]:FHH A_TGUB_6C_ $GUB_6IJ* (?])]8OUH_P!)]8OUJ:B@
M"'_2?6+]:/\ 2?6+]:FHH A_TGUB_6C_ $GUB_6IJ* (?])]8OUH_P!)]8OU
MJ:B@"'_2?6+]:/\ 2?6+]:FHH A_TGUB_6JUEO\ [2O]^W.8_N_[M7ZHVO\
MR%+_ /[9_P#H- %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \D
M^(MC:ZEXO@N7LM)UB&"S\AK>[UH6GD2;R20 <Y(P#GT'I7J>GJ%TVU58UC A
M0!$?>J\#@-W'OWK)N_!'A6_NY;N[\.Z7/<2L6DEDM49G)[DD<FMR*-(8DBB1
M4C10JJHP% Z "@!U%%% !1110!%-_K(/^NG_ +*:EJ*;_60?]=/_ &4U+0 4
M444 %%%% !1110 52U+_ %,'_7S%_P"ABFZTTZZ)>M;78M)EB8I.5#;"!UP>
M/SKRJ_\ %NM2:9HEPNJD21:5IE\80J'[=--.L;AN,\ =%Q@G\* /9**\PT37
MM6T_Q%!I>M7ES/$EVR>;%(LBR2L(X]K-Q\BO(#M )!D4'[AKT#5-9LM'M_-N
MY@N?NH.68^@%.,7)V2)G.,(\TG9%XD 9)P!7-WWB62YN6L-!A%W=#AY?^647
MU/>JPMM7\4G=>%].TL\B!3^]E'^T>P]O_P!==+8V%KIMLMO:0K%$O91_/UK?
MEA2^+5]NB]3DYZN(^#W8]^K].WJS(TOPRD%S]OU.8WVH'GS'^ZGLH[5T%%%9
M3J2F[R.BE1A25H(****@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J-
MK_R%+_\ [9_^@U>JC:_\A2__ .V?_H- %ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N=UO4]3L?$_AVVMVM_L%]<20SJR$R$B&208.<
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M^[+_ -^V_P */M"?W9?^_;?X5+10!%]H3^[+_P!^V_PH^T)_=E_[]M_A4M%
M$7VA/[LO_?MO\*/M"?W9?^_;?X5+10!%]H3^[+_W[;_"C[0G]V7_ +]M_A4M
M% $7VA/[LO\ W[;_  JK9L'U*_(!',?4$?P^]7ZHVO\ R%+_ /[9_P#H- %Z
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BF
M_P!9!_UT_P#96J6HIO\ 60?]=/\ V5JEH **** "BBB@ HHHH *I:E_J8/\
MKYB_]#%7:I:E_J8/^OF+_P!#% %VBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ JC:_P#(4O\ _MG_ .@U>JC:_P#(4O\ _MG_
M .@T 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M+/Q)T]M)FU*/3;\P1W'D(6,0\T@.6V_.<8$;'#8)X '-=+I6JQ:O%-/;QO\
M9DE,<<K=)L<%E]LY&>^#VQ7)P^ ;AKC5[FXN--CFU!(H"MG8^4@1'+&0J6.9
MB&(#=L"MCPOX7/ARYU)EN%>WN''DPJI C0%B,Y)R<,%R,<(M &]-_K(/^NG_
M +*U2U!<(KM K#(\S_V4TOV6#_GF* )J*A^RP?\ /,4?98/^>8H FHJ'[+!_
MSS%'V6#_ )YB@":BH?LL'_/,4?98/^>8H FJEJ7^I@_Z^(O_ $,5/]E@_P">
M8JGJ5M"(8,1C_CXB_P#0Q0!I45#]E@_YYC\Z/LL'_/,?G0!-14/V6#_GF/SH
M^RP?\\Q^= $U%0_98/\ GF/SH^RP?\\Q^= $U%0_98/^>8_.C[+!_P \Q^=
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M_0: +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!Z4
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M_A1_:T?_ #ZWW_@*_P#A0!?HJA_:T?\ SZWW_@*_^%']K1_\^M]_X"O_ (4
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MK?\ :T?_ #ZWW_@*_P#A0!?HJA_:T?\ SZWW_@*_^%']K1_\^M]_X"O_ (4
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M )=G_OGVH VZ*H?VM'_SZWW_ ("O_A1_:T?_ #ZWW_@*_P#A0!?HJA_:T?\
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M4O\ _MG_ .@TG]K1_P#/K??^ K_X5'ILXN+^_=8Y4&4&)4*'[OH: -.BBB@
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M0V&D66F37,MI#Y;W)0RG<3N*(L:]>F%51^%/OM,M-1>T:ZBWFTG%S#\Q&V0
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M3Q##I6N74[*ET5:2,(X>1@B!"R@80/(#Z@R(#]UJ]+H **** "BBB@ HHHH
MIZM_R"+S_KBW\JN53U;_ )!%Y_UQ;^57* "BBB@ HHHH **** "BBO*[KQ?K
M&F66OS'65N;(W4=EI^IRVJA(IL,9CA!\R)C )!RP(R: /5**\BC\6>(GM-+O
M_MLDUOJ>FP@- J%D8B-7<1X&'\PNHR=I+H.@->J:?>0ZAIMK>6[,T$\2R1LP
MP2I&1GWH LT444 %%%% !1110 52TG_D')_OO_Z&:NU2TG_D')_OO_Z&: +M
M%%% !1110 4444 %%%<)KFI^(X_&4MGH%\EYY=A-//8R0H([=O+_ '&9.#N>
M0'@G[H)P,9(!W=%>/VOBCQ<T,DTDMU(NG:@D,D<\<,$TS.D3>6ZKD$?-(HV\
MC<I/0UZ#X/U;^V- 2=YYIKA7(G:6,)\S /\ *!_#M==O?&,\YH WZ*** "BB
MB@ HHHH *HVO_(4O_P#MG_Z#5ZJ-K_R%+_\ [9_^@T 7J*** "J6D?\ ((M?
M^N8J[658S75K90P/IMTS1J%)5HL'Z?/0!JUYSXBUG5['QI>6VG7ODM/_ &9;
M)YR&6.+S9)P[!,@9PH_(5W/VZ?\ Z!=W_P!]1?\ Q=(;N4G)TFZ)]<Q?_%T
M>50^/_$L.FI-?:CIZ&>.UE%Q]D(2W5KIH'+#=\W"[^HP<CI4UAXZ\47.FZQ?
MK/:3Q:98>;'LM#B[W331K/UR$VQA]HZ\X.*]#O[>'4XH8KK1;MTBFCG0!XUP
MZ,&4\/V(SCI5P7<J_=TFZ'&.#%T_[[H \PB\=^(OM4-I#?6FH07MT=/L-1AM
M=J32AHF,F,D;0CRC@X)BIMAX]\5:C+?()=/MV:_@M8D95>2U+W/E$/&&W?=.
M?FVG(XX->H"ZE 4#2;H!>@!BX_\ 'Z/M4N2?[)NLD@DYBY_\?H \GN/B#XLL
M-/#S7%E.\\?$RVPB6VV71@:1BS;<$ 'D@*3Z5IVGC#Q1<7%B\EWIZ1*-.6XC
MBB\U9C<S21%E<-@ !5;C//&<5Z+]JDP1_9%UR,=8NG_?='VJ7_H$W7;O%VZ?
MQT >8?VGJUS\);9[C5+K4-0;68K6;R9?LTW_ !\A3"7!RI([G& P]*D_X2#Q
M;X;U3PYX>N9K4R/&CS/=SJQF#SLOE"1B"[)'M&5!).">*]+^URXQ_9-UUSUB
MZ^OWZ4WDQ()TJZ)'0DQ<?^/T ><Z5XRUZ9]$_M#5;*W34$FN4)M,?:"DJQK:
MH=WWB,MGKSP,"J6A^.?%NN6EK']KTVVFO=0A@$BQK*UMOBF=T:,-P5,:XW$-
MUR*]2^URX _LFZPO(YBX_P#'Z!=2CII-T.=W6+KZ_?H \F3QSK<45WJESK*1
M/<:1I\\%I]G78CR2,CR*68!5!'S$G WC/W1F73/B-XAU/5-'@6:U5GL%NIK=
M(5_TG"RDA26R&+(@"J#PQ.>,5ZI]IDQC^R+G&,=8NGI]^L6?P[I5QXACUR7P
M_>-?HRN&\Y0FY00K%/,VE@"0#C(H Q_ /BS7]>\/:A?7<-GJ%Q%Y;00VLT:L
M2RY:-OF(0@]-W/J,U#\0M3U2SN?#=];R7-H]LD]_=6D<N1(L2HSQMCAOE+CZ
MUW*WDRYVZ5=#)R<&+K_WW0;R9NNE71^IB_\ BZ /&U\8>(]+M]2O8KS#ZE?0
M3*][(/+LHI8'E1!O8*F0$7D]<]R*O7_Q,U^#5+Z!'M0T.DR3M#Y8(CG6W27<
MIW;F0EB 2 ".!R":]5-U(00=(N2#U!,7/_C]!NI"23I-T21@DF+_ .+H Y_P
M]J.IWEU<6FJW$-S/8:J8%FBA\H.IMA(/ER<8WD=>PKKZRIY[F2:V=-*N@(Y2
M[_-$,C8R_P!_W%6/MT__ $"[O_OJ+_XN@"[15+[=/_T"[O\ [ZB_^+H^W3_]
M N[_ .^HO_BZ +M%4OMT_P#T"[O_ +ZB_P#BZ/MT_P#T"[O_ +ZB_P#BZ +M
M%4OMT_\ T"[O_OJ+_P"+H^W3_P#0+N_^^HO_ (N@"6_L+34[&6ROK>.XMIAM
MDBD&58>XK-A\(>';?[#Y6BV*_8&+6F(1^Y).25].>?K5W[=/_P! N[_[ZB_^
M+H^W3_\ 0+N_^^HO_BZ &?V'I7F6TAT^W+VLCRPL8QF-W.68>Y/)]^:T*I?;
MI_\ H%W?_?47_P 71]NG_P"@7=_]]1?_ != %VBJ7VZ?_H%W?_?47_Q='VZ?
M_H%W?_?47_Q= %VBJ7VZ?_H%W?\ WU%_\71]NG_Z!=W_ -]1?_%T 7:*I?;I
M_P#H%W?_ 'U%_P#%T?;I_P#H%W?_ 'U%_P#%T +JW_((O/\ KBW\JN5E7\]U
M<Z?<01Z7=;Y(RJY:(#)'^_5C[=/_ - N[_[ZB_\ BZ +M%4OMT__ $"[O_OJ
M+_XNC[=/_P! N[_[ZB_^+H NT52^W3_] N[_ .^HO_BZ/MT__0+N_P#OJ+_X
MN@"[15+[=/\ ] N[_P"^HO\ XNC[=/\ ] N[_P"^HO\ XN@"[61I?A?0M$:=
MM,TJUM#<+ME\F,+O'/!_,U:^W3_] N[_ .^HO_BZ/MT__0+N_P#OJ+_XN@")
MO#^D/:-:MIML8&@2V,?EC'E)]Q/H,\>E7XHHX(4AA18XHU"HBC 4#@ #TJK]
MNG_Z!=W_ -]1?_%T?;I_^@7=_P#?47_Q= %VBJ7VZ?\ Z!=W_P!]1?\ Q='V
MZ?\ Z!=W_P!]1?\ Q= %VBJ7VZ?_ *!=W_WU%_\ %T?;I_\ H%W?_?47_P 7
M0!=HJE]NG_Z!=W_WU%_\71]NG_Z!=W_WU%_\70!=JEI/_(.3_??_ -#-'VZ?
M_H%W?_?47_Q=5K">ZMK18I-+NMP9CPT1ZL3_ '_>@#6HJE]NG_Z!=W_WU%_\
M71]NG_Z!=W_WU%_\70!=HJE]NG_Z!=W_ -]1?_%T?;I_^@7=_P#?47_Q= %V
MBJ7VZ?\ Z!=W_P!]1?\ Q='VZ?\ Z!=W_P!]1?\ Q= %VL>;PIH%QJ\FK3:1
M9OJ$@*O<-&"[ KLP3W^7CZ5;^W3_ /0+N_\ OJ+_ .+H^W3_ /0+N_\ OJ+_
M .+H BLO#^D:;!;066FVUO%;.TD*1Q@!'8$%A[D$C/O5C3]-LM*MOLUA:Q6T
M&XMLB4*,GJ:9]NG_ .@7=_\ ?47_ ,71]NG_ .@7=_\ ?47_ ,70!=HJE]NG
M_P"@7=_]]1?_ !='VZ?_ *!=W_WU%_\ %T 7:*I?;I_^@7=_]]1?_%T?;I_^
M@7=_]]1?_%T 7:*I?;I_^@7=_P#?47_Q='VZ?_H%W?\ WU%_\70!=JC:_P#(
M4O\ _MG_ .@TOVZ?_H%W?_?47_Q=)8K,UW=SRV[P+(5VJY4DX'7Y2: +U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (] FH# 2(  A$! Q$!_\0
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MX2X*701 [[<-\IPVT#)%>P&]TD];BS/R;/O+]WT^GM0MYI"H$6>S"!=H4,N
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M3%_SR3_OD4^B@!GDQ?\ /)/^^11Y,7_/)/\ OD4^B@!GDQ?\\D_[Y%'DQ?\
M/)/^^13Z* &>3%_SR3_OD4>3%_SR3_OD4^B@!GDQ?\\D_P"^11Y,7_/)/^^1
M3Z* &>3%_P \D_[Y%'DQ?\\D_P"^13Z* &>3%_SR3_OD4>3%_P \D_[Y%/HH
M 9Y,7_/)/^^11Y,7_/)/^^13Z* &>3%_SR3_ +Y%5+B-$U"R*HH^9^@_V35Z
MJ=U_Q_V/^\__ *": +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5'4_NVG_ %\Q_P ZO51U/[MI_P!?,?\
M.@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4;,M]OU %
MW91*NT,Q(7Y%/'IR35ZJ-G_R$-1_ZZI_Z+6@"]1110 4444 %%%% !5.Z_X_
M['_>?_T$U<JG=?\ '_8_[S_^@F@"Y1110 4444 %%%% !1110 4444 %%%%
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M* (OM$/]\4?:(?[XJ6B@"+[1#_?%'VB'^^*EHH B^T0_WQ5*SN(AJ&H_./\
M6I_Z+6M*J-G_ ,A#4?\ KJG_ *+6@"S]HA_OBC[1#_?%2T4 1?:(?[XH^T0_
MWQ4M% $7VB'^^*/M$/\ ?%2T4 1?:(?[XJK/*DFH605@2&?_ -!-7ZIW7_'_
M &/^\_\ Z": +E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !5'4_NVG_7S'_.KU4=3^[:?]?,?\Z +U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1R_
M>B_W_P"AJ2HY?O1?[_\ 0U)0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %4;/\ Y"&H_P#75/\ T6M7JHV?_(0U'_KJG_HM: +U%%% !1110 4444 %
M4[K_ (_['_>?_P!!-7*IW7_'_8_[S_\ H)H N4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 451UA[A-'NWM))([A8R
M4:*$3.#_ +*$C<?0>M><:=XO\23P:)<W%V4CN8WMO^/%=DMYYDJ)%*<YA;Y8
M\X!&XD9% 'JM4=3^[:?]?,?\ZY'PAXJOM1UG^R]7N1'=P1O'Y1B ,\@8DDE<
MJ-JC&T'D[_[M=;JAVI:DYXN8^@SWH OT5%YZ_P!V3_OVW^%'GK_=D_[]M_A0
M!+147GK_ '9/^_;?X4>>O]V3_OVW^% $M%1>>O\ =D_[]M_A1YZ_W9/^_;?X
M4 2T5%YZ_P!V3_OVW^%'GK_=D_[]M_A0!+147GK_ '9/^_;?X4>>O]V3_OVW
M^% $M%1>>O\ =D_[]M_A1YZ_W9/^_;?X4 2T5%YZ_P!V3_OVW^%'GK_=D_[]
MM_A0!+147GK_ '9/^_;?X4>>O]V3_OVW^% $M%1>>O\ =D_[]M_A1YZ_W9/^
M_;?X4 2T5%YZ_P!V3_OVW^%'GK_=D_[]M_A0!+147GK_ '9/^_;?X4>>O]V3
M_OVW^% $M%1>>O\ =D_[]M_A1YZ_W9/^_;?X4 ++]Z+_ '_Z&I*K23KNB^63
M[_\ SS/H?:I//7^[)_W[;_"@"6BHO/7^[)_W[;_"CSU_NR?]^V_PH EHJ+SU
M_NR?]^V_PH\]?[LG_?MO\* ):*B\]?[LG_?MO\*//7^[)_W[;_"@"6BHO/7^
M[)_W[;_"CSU_NR?]^V_PH EHJ+SU_NR?]^V_PH^T+_=D_P"_;?X4 2T5";F,
M<D./JA_PJN^L6,;;6G /I@_X5G.M3A\4DBE&4MD7J*S3JRM_J+6XF]PF!^M1
MF\U*7[EFL(]9,D_D!6'URF_AN_1,KV4NNAK51LO^0AJ/_75/_1:U7\J]E_UM
M[(H_NQ0$?J11IC""XOHB9GVRK\S(23E%//%73JU)RU@TO.WY"<4EN:U%1>>O
M]V3_ +]M_A1YZ_W9/^_;?X5T$$M%1>>O]V3_ +]M_A1YZ_W9/^_;?X4 2T5%
MYZ_W9/\ OVW^%'GK_=D_[]M_A0!+5.Z_X_['_>?_ -!-3^>O]V3_ +]M_A56
M>0/J%D ''S/]Y2/X3ZT 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH K:A86VJ6,ME>(7@E&'4.5/7/!4@CD=C63;>
M"?#MI<6,\&FHCV(Q;_O'*H<L=VTG!;+,=Q!/)YK?HH RK3PUH]C>6]W;V*)<
M6\/D1/N)*IDGN>3\S<GGD\\FI]3^[:?]?,?\ZO51U/[MI_U\Q_SH O4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'+
M]Z+_ '_Z&I*CE^]%_O\ ]#4E !137D1%RS*H]2:IR:O8QG'VA6/HGS']*RG7
MI4_CDE\RE"4MD7J*S?[4>0_Z/8W$GNPVC]:"^JRGY8H(!_M,6/Z5C]<@_@3?
MHG_P"O92ZZ&E36=5&68 >YK/^P7<O^OU"3Z1*%IRZ-9@YD5Y6]9'+4>UKR^&
MG;U?^5PY8+>7W#Y-5L8N&N$)]%Y/Z5'_ &J7.(+.XE]]NT?F:N16T$(Q'$B#
M_97%2XH]GB9?%-+T7^87@ME<S3+JLI^2"&$>KON/Z4?8KV7_ %VH,!Z1(%_6
MM*BCZHG\<F_G_E8/:-;)(SET:U)S+YDQ]9')JU%:6\ Q%#&GT6IZ*TAAJ,-8
MQ1+J2>[#%%%%;V)"LZPB2/4M49007F0MEB?^6:^O2M&J-G_R$-1_ZZI_Z+6@
M"]1110 4444 %%%% !5.Z_X_['_>?_T$U<JG=?\ '_8_[S_^@F@"Y1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 51U/[MI_U\Q_SJ]5'4_NVG_7S'_.@"]1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%4;RYD:06=J?W[C+-VC7U^OI656
MJJ<;O_ARHQ<G8CN;J:>Z6WL]H*-\\C#(4X/'N:/[/N9/]?J$I]HP$%6(K:.U
MBABC' ?DGJ3@\FK58+#>T]ZLVV^EW9>13J6TB9Z:-9#EXS*WK(Q;^=7(X(81
MB.)$'L,5)16T,/2A\,4B7.4MV&****V)"BBB@ HHHH **** "BBB@ HHHH *
MHV?_ "$-1_ZZI_Z+6KU4+%U;4=3"LI(E3(!Z?NUH OT444 %%%% !1110 53
MNO\ C_L?]Y__ $$U<JG=?\?]C_O/_P"@F@"Y1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %'61,='NA;R3QS&,[&MR@
MDSZ*7^4$] 3QS7D>G^+?$M[;V9BUIA>6K6]KY$L:8GEFN)H6\WCYB@C7E,#(
M)Y!KV*]L;74K.6SO;>.XMI1MDBE4,K#W!JE%X9T.&:REBTBR22Q0I:LL*@PJ
M>H4XXZG\S0!R'@SQ+?7.NKI6L7<S3Q1211<!DF8.Q9F<  D!2HP /D<]Q7:Z
MH<):G!/^DQ\#ZTMOHNF6MQ!<06%O'-!#]GBD6,!DCSG:#V%&I_=M/^OF/^=
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MB@ HHILDB11L[L%51DD]J3:2NP&7%Q':P-+(<*/UJK9V\DLWVVZ&)2,1Q_\
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M %%%% !1110 4444 %%%% '*_$*;2T\+^1J^J)I]I<W,,+2.Y4."X)3(((!
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M)L3_ +Y6M.VM8K./9;V<42^B8%%ZLME;\1VI1W=_P,_[?K5[_P >FG+;(?\
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M_7S'_.KU4=3^[:?]?,?\Z +U%%% !1110 4444 %%%% !1110 4444 %%%%
M!56]NQ:Q@*N^9SMC0=S_ (4^ZNH[2 R/D]@HZL>P%065M(9#=W0!N'' [1KZ
M"N:M4DY>RI[]7V7^?8N*27-+8?96AMU:25M]Q)S(_P#0>PJW116U.G&G'EB3
M*3D[L****L0445AW.HW&ISO9:00 IVS7A&5C]E]6_05$YJ)<(.1-J.K-'/\
M8=/C%Q?,/NY^6(?WG/;Z=34FFZ0MF[7,\AN+V3_63M_)1V'M4VGZ;;Z9;^7
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MA5+4_NVG_7S'_.@"UNF_YYI_WW_]:C=-_P \T_[[_P#K5)10!'NF_P">:?\
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M++>B@;GZ-G^$^U7JIW7_ !_V/^\__H)H N4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <K\1H8)O!-XMQ-#'&'B?]]"\R.5D4A#&O
M+[L8V]\U/X(2*'PXL,:Z:OERNK+IUJUO"ISGA&)(/(R>]-\?BW/@N_\ M,EI
M'$-AWW<KQ(#O&,.GS*V>A /..#TJ/X=^0?!EH;?3+O3T+.3%=NSR.=QRY9@&
M8'J"0.,<"@#J:*** "BBB@ JCJ?W;3_KYC_G5ZJ.I_=M/^OF/^= %ZBBB@ H
MHHH **** "@]#12-G8=N,XXSTH 9!_Q[Q_[H_E4E0VGF&SA\X()-HR$)(_#-
M34 %%%9US*]Y.;*W8JH_UTH_A'H/<UE6JJG'NWLNY48\S&R%M4G,2$BSC/[Q
MA_RT/H/;UK250JA5  '0"FQ1)!$L<:A448 %/J:-)QO.>LGO_DO(<I7T6P44
MA( R3@5CW'B&$S-;:;"]_<C@K#]Q#_M/T%:RDH[F;:6YL$@#-8=]XILK>86U
MH&O;MC@10\C/N>@K*OQ?WUP+2YG^T73C/V*V8K%$/65^I'MQFMO1=!M])0N
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M_:8\9^M %^BH_P!_ZQ_D:/W_ *Q_D: )**C_ '_K'^1H_?\ K'^1H DHJ/\
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M[^::,%005VF+G.X"IO".DW&B>'XK&Z@M895=V*6L\LJ#)SPTI+?G0!NT444
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG=?\?\
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M_/0?]\T;9?\ GH/^^:DHH CVR_\ /0?]\T;9?^>@_P"^:DHH CVR_P#/0?\
M?-&V7_GH/^^:DHH CVR_\]!_WS1ME_YZ#_OFI** (]LO_/0?]\T;9?\ GH/^
M^:DHH CVR_\ /0?]\T;9?^>@_P"^:DHH CVR_P#/0?\ ?-&V7_GH/^^:DHH
MCVR_\]!_WS1ME_YZ#_OFI** (]LO_/0?]\T;9?\ GH/^^:DHH CVR_\ /0?]
M\T;9?^>@_P"^:DHH CVR_P#/0?\ ?-&V7_GH/^^:DHH CVR_\]!_WS1ME_YZ
M#_OFI** (]LO_/0?]\U5G#C4++<X/S/VQ_":O53NO^/^Q_WG_P#030!<HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *HZG]VT_P"OF/\ G5ZJ.I_=M/\ KYC_ )T 7J*** "BBB@ HHHH *#T
M-%!Z&@".#_CWC_W1_*I*C@_X]X_]T?RJ2@ J"\O;;3[22ZNYEA@C&6=CP*AU
M35;31[,W-W)M7.U5499V/15'<FL>STJ[UJ[CU378]B(=UKI^<K%Z,_\ >?\
M05<8:<TMB'+HMR*.UNO%LJW.H1R6VC*=T-FW#W'HTGHOHOYUU*JJ(%10J@8
M P *6BE*?-IT'&-@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IW7_ !_V/^\_
M_H)JY5.Z_P"/^Q_WG_\ 030!<HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K-O/$&D:?JD&F7>HV\%[<(7B@=\,RC.
M2/;@_E6E7$^)M+U*]\76#6%I>^3+&L&H3>9']EDM<OOC92=^_P";@J._7@T
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M_P ]7_3_  HV-_SU?]/\* 'T4S8W_/5_T_PHV-_SU?\ 3_"@!]%,V-_SU?\
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MTO\ WU1Y'_3:7_OJI:* (O(_Z;2_]]4>1_TVE_[ZJ6B@"+R/^FTO_?5'D?\
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M_*@#=HJC_9%IZ3_^!$G_ ,51_9%IZ3_^!$G_ ,50!>HJC_9%IZ3_ /@1)_\
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M_P#/1?\ OG_Z] #Z*@GE%M \\]Q%%%&-SR2?*JCU))X%/ D(R)%Q_N__ %Z
M)**9ME_YZ+_WS_\ 7HVR_P#/1?\ OG_Z] #Z*9ME_P">B_\ ?/\ ]>C;+_ST
M7_OG_P"O0 ^BHFWHI9I4"@9)*\ ?G2CS& (E0@C((7K^M $E%,VR_P#/1?\
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MK67XH\&77B#Q/'?26I>V5;) /M)3:HED-P, CJC*/<9%=]ME_P">B_\ ?/\
M]>C;+_ST7_OG_P"O0!Y"G@?Q2KV2O!NFAM4CCN_MG^HC6*5&@QGG>60YZ>IR
MHIW_  KK4[;R##IR2>5YHCW763&TME&C/ECS^^5LCWS7KFV7_GHO_?/_ ->C
M;+_ST7_OG_Z] 'EFG^!M7TF^TG[)8 PVM[%,%DN \,:F&%9F*D[M^]'*E>^<
MC#5ZM3-LO_/1?^^?_KT;9?\ GHO_ 'S_ /7H ?13-LO_ #T7_OG_ .O1ME_Y
MZ+_WS_\ 7H ?13-LO_/1?^^?_KT;9?\ GHO_ 'S_ /7H 5_]6WT-)#_J(_\
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M;)/?WK8HH **** "HKC[J?\ 71?YU+45Q]U/^NB_SH EHHHH **** "BBB@
MJCJ.L:?I+6BW]U' UW.MO &_Y:2'HH_*KU<1XT\+:QK6N:/J&GSVKPV<\):W
MGC)* 2JSNIW#^%0",9(&!UH Z+3_ !)I&JF 6-ZDYG\SRPBMSLQN/3@#<O)Z
M[ACK6K7G>@>%]9T3Q5#=65NMMI<Y=9X6E60Q1KN"*226)/RM\IP.0> *]$H
M**** "BBB@ HHHH :/OM^%.IH^^WX4Z@ HHHH **** "J][>VNFV,U[>SQP6
MT"%Y)9#A5 [DU8K.UV.>70;Z*VM!=SO"RQP%E7>2,#EN!Z_A0!4?QAX?BN+2
M"35(%DN[<7,(.1NC*E@V<8&0K$ X)P<=*MZ?KVF:JT2V-VLS20F=0%(.S<5R
M<CCY@1@\\'T->=0^"=4O9?#J7FF7%LEO;6R:F#=Q/#*($=54*/F+'=P00,-S
MR*V?"7AW7-"UW>Z"/3KJ$RSH95D,;Y.V/<?G8J#US@DL>IH [VBBB@ HHHH
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MF08QZCRI"1Z+]*B?XF^&5NFA'VUU#8\Y+-S$0"H9@V,;5WH2>VX4 =EYL?\
M?7\ZAGD0JGSK_K%[^]<S-\1?#L4MS$#<RR03"$)#;,[3,69/W8'WAO1ESZCT
MYI^B^,++Q+J5S:65G<""".WG2Z>,A)5D 8 9'!'I['TH ZGS8_[Z_G1YL?\
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M_='Y4;5_NC\J $\V/^^OYT>;'_?7\Z7:O]T?E1M7^Z/RH 3S8_[Z_G1YL?\
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MW5P8Y&B2$,(T"%-A4!VR"ISG)[59O?AUI=];20R75XF]WD+1LJX9K=8#@!<
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M ':K%AX4TK3+^"\MHI%F@@\A<RL01DDL1T+G)RW4Y- &U1110 4444 %%%%
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M)YO_ $SD_*DN'\N(OM9MO.U1DG'85D?\)$?^@1J?_?BHE4C'<J,)2V-CS?\
MIG)^5'F_],Y/RKS_ ,1>)-7L-:ANFDO+/2YK.1+5%BC(-T$E;;,""PR%4J1Q
MP<]:Y>/XAZ\VBWEI=ZE'9ZM#:V=L9FA!59Y7=O.P!R#"%;&,9[52=U=":L[,
M]H\W_IG)^5'F_P#3.3\J\LLO&6OZQX@TFYT^6YDLFL;.ZN[>*V5XE1A+YY9L
M;@X* *H/)&,5;U'QO=V7B&;46NI8]!MI+7SH98/+98YHI>6W ,I\Q8^OK3$>
MD>;_ -,Y/RH\W_IG)^5<!J=_XCC\+^%WBUAX]>O9(<VHMT87#.59P_&52--^
M2,=!STIOA3QO+=ZG>?VJ=3+W,K&UA6W62%8A.\2E?+!<<KAC)WYX% 'H/F_]
M,Y/RJ&6*">>">6TWRP,6B=D!,9(*D@]N"1^->8Z5\0?$%M9//>PVUY%]EM1$
M06$C3S3R1@LJ*?E^0Y !/RC );B_-\2-;\^**#PU&KNL:,EU=&)XY7A>7:5*
M9V@1-SUY7CK@ [)]#T:2^GO7T>W:ZGV^;*8%W/M(9<GO@JI_ >E1W'AO0+MK
MMKC0K65KQE>X9K=2967[I8]R/6I-.\06]_!I+^3<))J5JMS&!$S(@*AL,X&T
M'GN1GM7%V^MZ]I&K:K;_ -H2:Q.=3&GV<%X8X(D'V87#,S(F<XW*/P^M ';/
MHND2(R/I$#*X<,# N#N4(WYJ #[ "LC5? V@:E:/%%ID=E,QC_?P6\>["%2J
MD,"&7Y%!4C!P*YI/B7JHTW5-6-E8FU!@>R@>9_-8/;"9D.Q&R<9.>@YR<#-7
M1J^OZCX;U^YTB6=[A=43RHU*&5+<Q0NZ1;_EW[6?&>] '1Z/X6T;18[$P:?Y
MEU90^1%=RH&FV\\;OQ/ X .!Q6Q/'!=(J7%J955UD4.@(#*05/U! (^E<+9_
M$*XN=.:YT^UCOK-/LMI#<W,WDRSW,PCVED"X5/WHR1W!P,5$?B;?^3<2#18<
M6J1QSD7#-BXDN'@55"H2R;HV;(&<8&,T =@^@Z+);-;/HMLT#HT;1F!=I5GW
MD8]W^;Z\U&/#7A\2"0:#:;Q#]G#?9USY>TKM^F"1CTHTWQ$;C2M+N;_3[RTN
M;]O+\C[/(_EODCYCM^5>,@L!P:Y"^\?:OH][K4:V,>HQVMW</AYA#Y5O$EN2
MJX4[B3*<9_.@#T&"*"U,I@M/*,S^9(40#>V ,GU. !^%3>;_ -,Y/RKSO_A9
M>H17*PSZ) I@E,=]LNR?+_TGR/W8V_/R5/..X]*$^)6IBTM+F;0[=%EA6\E4
M7A)6W:58D*_+RY9B=O   YR: /1/-_Z9R?E1YO\ TSD_*O.)/BG=- @M-":>
MZW"!X5=V(G5)'EB&U"20$4#CJ_. *<_Q+U1;MC_PCT2V8D?+O>8D$<=PL+DI
MM^]EUP,]FYZ4 >B^;_TSD_*CS?\ IG)^5>>P_$C4[X'[!X>WB>[^SV<D\KQ1
MR#]Z#N8IC</*R0NX88#.16IX*\4:GXFO]2FN+>WAT]8K:6V57)D7S(5<JW&#
MUZT ==YO_3.3\JBGERJ?NY/OKV]ZLU%<?=3_ *Z+_.@!?-_Z9R?E1YO_ $SD
M_*I** (_-_Z9R?E1YO\ TSD_*I** (_-_P"F<GY4>;_TSD_*I** (_-_Z9R?
ME1YO_3.3\JDHH C\W_IG)^5'F_\ 3.3\JDHH C\W_IG)^5'F_P#3.3\JDHH
MC\W_ *9R?E1YO_3.3\JDHH C\W_IG)^5'F_],Y/RJ2B@"$2_,?W<GY4[S?\
MIG)^5.'WV_"G4 1^;_TSD_*CS?\ IG)^5244 1^;_P!,Y/RH\W_IG)^5244
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M9R?E1YO_ $SD_*I** (_-_Z9R?E2!]TBC8PX/45+33]]?QH =1110 Q_X?\
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MZFC[[?A3J "BBB@ HHHH *QO%=W96/A;4;K4;VXLK2*+=+/;2;)0,CA6[$G
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M 'T?\*,R_P!U/^^C_A3Z* &9E_NI_P!]'_"C,O\ =3_OH_X4^B@!F9?[J?\
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@_P"%/HH 9F7^ZG_?1_PH <N"P4 >AI]% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U 5L# 2(  A$! Q$!_\0
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M<E)5J4*F(PK<*JE=^W2J?O&]?:.;?E\^> _^#='Q)XX\!^"_&L'[4GA_2_\
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M4X8A*>[=3^W%1C/;253D4FU;F<VUO=?=/_!!W]I=_C=^Q3IGP\UK5OMOB_\
M9TU@_#^Z-X2=0F\#RK_:G@+4Y1R0#H4NH^&HV&23X=ES@9W<A_P<"?M&2?"_
M]DK1/@IX=NP?%_[27BW_ (1N>WM%0ZA_PA'@Q1X@\0SP8!*F3Q"W@GPL[<,?
M^$C8?Q.*^"?V-9I/^"<W_!9WXM?LQWXET+X2_M$WM]I/@>R+N-)B_MX_\)S\
M%BK -\\$;>(_A?"& !G"!RH!82?$0_\ #QS_ (+G:/X'T^--5^#_ .RA<M::
ML1$ITS[%\*=475_&33"/!F_X2/XQZO!X1:1F+&WMERV%&/17"F5X7Q:?'3C-
M\&QX;CXIKX8N?/'GCAUM'G?$C]DH.5^:4>9M>\<CXLS;$^#:X%32XQ_UC_XA
MBX]5&+_B-?%R_P!@1UDE:VRUL\'_ (-LK/4=-^-_[5FE:I;7.GW^E^!/"]E?
MV-SC-G?CQGXC#H>G)&1CG/'K7]?CX!!Z@!B?ICFOY4_^"#1$W[:'[?LW7.H:
MDOUS\3O$)X_PQWYS7]5K$8SV .X]L!ADGVP#GM@$U\#X^XJ./\4,SQD7[M7#
M9!./1.,\AH<ENCNJBMKKLK['Z-]';#/ ^%^!PD[)TN(N)E-MK_EUGE53;>ED
MG3DVW91CN]+G\^W_  7]_:ONOA7^S7H/[/'@W4;A?''[26IMIVL6-IM;4K/X
M9Z*\<FM;5!)A/B?7QHGAA 0%GMKC7CNS""?S4_X)G7/Q(_X)E_\ !1S3OV4?
MC??1Z;H'[27@;P%9W+<-I:^+-9T4ZYX%=0VX!XO$VLZ[\,LY(\[!P H Y>3]
MH#X,?MH_\%EU^,WQS^*7@CP3^S3\"=9SX#OO''B'1=+TSQ'I_P *-:QX(TO1
M_P"WA&KMXM^)&_XHMM"E_!N5)7((][_X+F_$S]E[XX>&_@M^T%^S[^T1\)_$
M?QL^#_B<^')M*\%>.]"U/Q1>^%M?_P")[HNKZ089G:1_"/B;03)&1&J);Z_X
MAC)9T85^PY!D\<AR?A?PIQ625*D>.^&*M?BGB7ZO6J4Z7$?$,'7X84YQI>RI
M+A[V5-3C.2E&I-N\6[GX?Q!G2S_.>)O%JAG=-5.!^*:5#ACAE\14J<JG#G#]
M3V?$4X4N>[>?.3E&,%+GBE%\Z1_6UG=*1C CD7''&'3@_B1G/Y>M?EO_ ,%H
MT$7_  3._:?P>?[*\"$'IC_BY_@8C'7T]OZ5]%_L+_M+:/\ M9_LL?"'XXV4
MUG_:WB/PU%:>-K.U"[--\<Z%NT3QGH_( 0VWB."X157AHQ%R6R!\X_\ !:5]
MW_!-#]ITX(SHW@0_^9.\"GWZ[NGXY[5_-_"N68K)O$7AS*\8N2ME/%^%H8A7
M>E6CGL*5U=)N+49U(2LN:$X/=M+^G^+\RP><^%_$N;X5\^6YWPGB*\+-/W*V
M2\[C>-US1<XTY6V<7>SV_E<_X)=?M^^/OV ?B9X87XC6GB.?]E;XXWTDFOPB
MRU8Z=ICG5)/#1^)W@E7PL@\)^(-(_P"$<\;!LA_"2QR,'>+P:#_>3H'B+0O%
MF@Z9XG\-:GIVM^']=TO3M:T75M*N4O=.U+2M5C$VD:GI\JDQ-'-$R.K*NUD)
MR#MR?YF/V+/V%O /[=__  1\\"?#OQ(;/1/'GA7Q+\5M9^$GC_[)\_A/Q/-X
MBO41]HC9W\/^*9$6/QA"CH9O.GPKR0HM>5?\$GOVY_'G[&GQIU?_ ()T_MGK
M=>$M,LO& \-_#74O$]\NSX<>/M90[?!?]KR.(G^'?BUY!<>!O$Q,<37&LP,6
M1/$\7E?MWB;P[E/B'C.*\YX7M2XSX'Q-2CQ/PU#WI<1\/TK1CQ+0CROFKTUR
M>UI1BY\L&K3?*Y?@7A+Q#FOAO@>%\GXEDY\&<:T?:\-<2R;Y>',_K1DI</5W
M+2%.;3E&<VHN4VXRY>=+1_8;)/\ P<!?M6D]3KO[1)/U.L^'C7]:S]1]&_E7
M\E/[#3!O^#@']JQ@00VN_M$L".00=8\/$$'N"*_K6;J/HW\J_/\ QK_Y'W!*
MZKPLX0375-85Z/LUV=GY'Z?X$N_#O%[OS*7B=Q>U+^9/.YOF3V:ENFFT[Z-E
MI>@^@_E2/]QO]UOY&E7H/H/Y4C_<;_=;^1K\>6Z]5^:/W*7PR_PR_P#29'\=
MO[('_*PS\:_^RH?M,_\ IEURO[#E_B_W3_2OX\?V0/\ E89^-9['XH?M,X/8
M_P#$EUO_ !'YBO[#E[^ZG%?L'C<FLTX+NFK^%W"+5TU?_8WJKI7^5S\$\ 6G
MEGB%9I_\;2XJV:?_ "^79L0]?P7^0K\N/^"S7_*,_P#:C_[ /@O_ -69X(K]
M1SS@CD8'(Y'3U_ _D:_+C_@LU_RC/_:C_P"P#X+_ /5F>"*^#X$:?'/"5FG_
M ,91P[LU_P!!F&/TCQ#_ .2'XN_[)?B+_P!1:QX/_P &_G_*/?0O^RH?$/\
M]':;7[?IP<^[?UK\0/\ @W\_Y1[Z'_V5#XA_^CM-K]OT'/.1DL/3N:]+Q67_
M !L+B_1Z<58MO1W2YX:^7J>9X0_\FQX%_P"R9H+Y^_I_P/P%! P?K_(?X_\
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M%OO$_P 0]>MLI8ZWX\\0O!/KTEA!)O,>D6XCBT6T214D6WTN,O&LC/C\.?\
M@K7-$O\ P6&_X)R R$%;SX"!0>20/VD=7YS_ +VX#G(QVK^JS";2W3?U8=2%
M. /S ]>V.E><>(_AK\.O%FOZ)XN\3>!/!_B'Q)X=\C_A'M>USPEH^J^(]$>.
M0ZBHT75M6A>ZT4B7,NRWDA*2C+L7VX^(X>XYQ>6\4YMQ;F\7G&)SNCQ)3K\O
M+37/Q)A:N&E-?%&U"59RIK7W84X)Z:_?<2>'F%S3A3*.$<JJ+*<JR.MPY4IR
M2;O#AZM3JP32>LJLH7FWO*<NVO\ .M_P<-? O6]&TG]G_P#;=^'MQ<:!XO\
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M6>&43[_+6%5C)>,-7Q=^T3^W?\4/#O[77B[]E;X:>._V+?V?]3^''P[^&WQ
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MVSX;R^)_X5G)X7;X;M\0U_9XDA:V'CL?#=FL8X1\9_\ A'XO&['QG'IJZ?\
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M (W7Y@2=REJ^H_L,?M ,\<;;5,BQB0A2RJ3\Q."QHHH ^,_&_P"SSIO[.O\
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210!^]%%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W G # 2(  A$! Q$!_\0
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M>C2:K8"P^(FK:=X/^'.C2>+/$\6E0V$7BG5-<O-,MUL$L+D@'[(^*?C;\&/
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M_LK^V9\#?CK+\-?V!Y/@=\.)_C?XG_9*_:;^#OQ,\6^$]2^)>F>'=<\2>#/
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M6[OXD2WFHM\)M+O4T*P\-:[KFF6.J-^@FH:%^T'H?[%7BOX4?LY_LXVOP/\
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M;1O%(T7QGK]S):06.NMINH31Z<UA+&3J=K<.E[:JZ%[;YL57^&G[4/P9\?\
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M (:I^*O_ ,NOS]NF3Q1_9/!'_1;YI_X@V9?_ #_#Z_Q;_P!$S@/_ !),)_\
M.L_77S_;]/\ Z]4'LM.DOTU5K&T.J1VCV$>I_9;<ZA'8RS1W$EE'>LAN4M)+
MB**=[991 \T:2LA=0P_)G_ARW^RU_P!%#_:[_P#$J?BK_P#+OZ?Y')_PY;_9
M:_Z*%^UW_P")4_%7_P"7?U_R>#^R>"/^BWS3_P 0;,O_ )_A]?XM_P"B9P'_
M (DF$_\ G6?KKY_M_G\Z//\ ;]/_ *]?D3_PY;_9;_Z*%^UU_P")5?%7_P"7
M?T_R.3_ARW^RU_T4+]KO_P 2I^*O_P N_3]<#U(/[)X(_P"BWS3_ ,0;,O\
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M  )J;S_;]/\ Z]?D5_PY;_9:_P"BA?M=_P#B5/Q5_P#EW]?\G@_X<M_LM?\
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M. _\23"?_.L_77S_ &_3_P"O1YWM^G_UZ_(K_ARW^RU_T4+]KO\ \2I^*O\
M\N_K_D\'_#EO]EK_ **%^UW_ .)4_%7W_P"HW]/U].3^R>"/^BWS3_Q!LR_^
M?X?7^+?^B9P/_B283_YUGZZ^?[?I_P#7H\_V_3_Z]?D5_P .6_V6O^BA?M=_
M^)4_%7_Y=T?\.6_V6O\ HH7[7?\ XE3\5?3_ +#?K^G/M1_9/!'_ $6^:?\
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ME%M*L+Z\UJ*PEU67SD6STYKA;R^<E+.&=U8+!\3/^"6W[!7P7\)7_C[XN?M
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M ,(>%-)\*/HT?BOQ1J7C"WU.UNO!Q\.Z)J4?BC3V?4-)>XM+>ZE@_.'XY?\
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MSN-^@:LO@36=9ETG5+"WTZ/5)[/1[',MS;+;MH^!M9_;W\7^(?#>D>-[/6?
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M>O3:?X<GU/1?AAH.CZO>7\&D7.@^(K*^\*>*M4OHQJOB*'7;7Q)+>&\E9+
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M'^,KK2+#Q/!I'_#0/B/5=0N-2\.07%S8^"D\-:II=['=ZG:7NK7IBN;XRI"
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@!, ]0#VYY_G00"<D GU(&:**
M# '0#\J7 SG SZ]_SHHH :$10 JJ !@ *  /0 #@>PXI=J]<#/'.!VSC\LG'
MU/K110 8'/ YZ\#GZ_3^M! (((X/4444 &!Z#C..!QGJ/\]>]&!DG YZ\#GM
MS]!Q]#110 8'/ &<9X'..Q_#CZ=*7'^?;T^E%% "8'H/R%+110 F!Z#G@\=0
M.@I< = /_P!73\J** $P.N!^7ISGZY[T8'H/7H.OK110 N!Z#KG\?7ZTF >H
M!_"BB@ VCJ0#CID#@>WI_G-&!Z#MV].GY=J** # YX'/7CKCIGUQ1M'H/3.!
M110 $ ]AZ=!Q2X'3''I110 F!QP..G X^GI1@=P#G&<CKCIGZ444 +C_ #Q_
MGWI,#K@9]<#/UHHH 7 /49I,#T'Y?3_#-%% !@9S@9^G^?0>_%+@>@HHH 3
:ZXYQC/J/\]?_ *PHP/0?D/\ /<_G110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ex8-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "$ 7T# 2(  A$! Q$!_\0
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MBBB@ HHHH **** "BBB@ HHHH **** /FO\ X+!_\HT/B[_V"$_]*(:^0?\
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M\G^+_P!BI?\ _HRWK]S*\?(O]V^9\SPA_N'_ &\_T"BBBO9/J HHHH ****
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M=117MGU84444 ?/?_!57_E']\2/^O.V_]+(*^A7^]7SU_P %5?\ E']\2/\
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MQ;J?_!2CQYX&NM?,W@S0_ VC:]9:9]BA5HKN[N[^&4F8+YC+MM4*J3P6;D\
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M\%4K.\U+]G[PM!8:7K.KW$?Q$\*WSP:9I\U[+';VVLVMQ/*R1*Q"1Q1N[,>
M%]<"OH?Q+JD5AX7O[Q_-\F*UDE/EQ-(Y7:3PB@L3[ 9/I6AG%&: /@+_ ()I
MV'@GX-?LU_ NVF^&7BV+XP6NEP:1<(_AC4;633I9UQ<O=3/$(8XU0%G9FZJ
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M2:U\.+_2Y8_@=\.M=F^(/@V[)S#/-J7FE-+5>RV%RU_,O/ GLP!\E?:.:,T
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MMOAR3QE^S?X9TM-#U7Q#'/\ $'PQ/=V=AITU\QM(=6MYKF1TB4L(TA1V9CP
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M7OVD]1\.W_Q1E:;3GM]"&DV_AR*:$J'N;ZW7RUE93EU,TB9P 50-UQFL2?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ex99-6_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-6_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W /P# 2(  A$! Q$!_\0
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MQKD^&JU)_5LLR_A7,YT,)1YKTH+$XO(L16KU'3LZM6LIN4W+E:@X./VKI?\
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M)3PV'S7/<KIX-9%D^ H44\+E]3'8K+,+AZ4\35:J*A-SJ1Q.)BU_0+7\?O\
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M89J\KR[%9A1P='!5\]Q>9U:U;#0E2A3P]7-XTZ?O2E5C!N$6H.4^>_X+%_\
M!.6X_:H\"2_&SX3VDJ?'CX;:'>P)HNEZ5937?Q1\)K#F3P[-<M);S+KWA^.;
M4-2\)W9:YF\^>[T>.%FO;.2V_GZ_9@_:P^)OB_4/V*_V2/%;2W5K\&/VO_AE
MXB\(7E_J-X=6T#3!XA.DZUX.U2YFB21K#2]6N9TTF.]::ZMH]3M]$A@:6XLH
MK'^\:.,7$"RR*%=E8E1M;:>5(# L&&!@-W')"Y*C\&_VG/\ @DGJ'B/]N+X+
M_M6_L_R>'?#VDK\6/!'Q ^-?A34[V]TZ*35_#'B!-9U/QEX?>WCN@MQX@TV.
M>PU'0K2.V@FUJ<ZHJQG4M2NH/J. N.\ LGJ<+<5NBJ>"PV;8_AG,L;*2EE^8
M1RS,J/\ 9<'%SC"GBJ->I'"7BN:O5]C.493A;XSQ8\*LW>>T.-N!*>*6*SC&
MY-@N-<DP%.*6;8!YKDE2>94Z$Y03G1>6X2MCZ:ITJKGAYXZ%JDL5.K^MO[30
MG;]F?X]1P6GV^Y?X+?$Q8K$M<I]KD_X0W6R+7?9W%K>(9S^Z#VMU;W"%MT-Q
M#(%E7^2;_@A5\+?AA\8_VF_C!IWQ*\ >%/B+X>M?A+K-]I&F^,/#6A>(M)M[
MF/Q[X0ACU%;'5I=:LS?6ZWEW:V5W91!O)>Z3[;<I.(8?ZL/VL=/^-6O_  8\
M6^!O@MX,\)^+]?\ '?A3Q/X.U$^+?%LOA*WT6Q\0^'M3TPZG9%=)U=-5NUGN
M4A6RN9]-@@687KWER+9[.?\ G[_8G_X)S_\ !2/]ACXD^)/B+\-M)^ _B_4/
M$W@_6/"MYI7C;QWK,'A]+>]UK0]>M[X6OAVUAO+C6TN]'>S2.:46$-O>/<I>
M[UF@NL?#_%4<-P'QS@7GF"RK-,X67PRFCB,U_LW%2G0H-5JD*D*?M,-3E=TG
M5E5BIN4H.-KFGBUEF)Q_BIX89M_JKGO$&1\.U,REQ%/"<,XW.L%2P^*K<]&,
M:4:$Z&,K)6E*E!5?9M:WDFC]K_@_^SI\"OV!O$7[1/Q<TK6=%^''PI^+FJ_#
MW4IO"L6FQ:5X:\$:UI%K=: ;?2&MIIY+E/$VK:U$+'3H;.V-E*;?3+.&2U6T
MCM_T!1UD&Y>F<<\<\?XU^"'[0GP#_P""H/[77_"G_!?Q3T']G;P)\.?"?Q6\
M%?$+QI:^ ?$7BBXN/$"^'-:AG:WU.+Q(=26>STRUAO[_ $NQL6Q=7^IZ:+SY
MM,::#]Z[="B$$Y.XD_B%X'L/_K=LU\+Q-1JQEEV+QV=83.,XQM*I#,'@L9AL
MPAA*&7X?+\#ED<1BJ-.DZF(K8>C4<JDE4<XT(*<^:TG^O<#9AA:\\ZRW)N&,
MVX<X:RROAI90\VRC'9'+'XO-98[,\XE@\NS!JOA\'A,55IT:=.-*E0A.K/V"
M]F^6/\X__!Q@)[OX$? ;3K<P*]W\7-1BVS&2,NR>&9I(93,FJ::J6%M<&UN-
M3>=9+.WLHY+VYNK&*SE=_P"6?X&:$+KXP_"K3K+396NKSQKX026WL4CELM3:
M6;3[*[TF;$LTU[>7J27&F2:<87COK:[O+%HK]B/MG]5G_!PIHEYX@^#W[/&C
MZ59:K>ZSJ7Q@O].TR+0XX[C4;B_OM 2"RTVVMI8;E)[G4KW[/9VJ_8[ATN)H
MV\VS0RWEO\[_ +.7[._P]_X)B> [7XQ?M!67A7XC?MG>-M"&H?"SX?PM:WMO
M\+X[FWN)&NM2U&^\JXMM<U&6[ U22U#0F;0KG3O"S&VM-?UI/Z*\/,WHX#PX
MRC 4*,LQSC-\RSO"95E-%J-?%8EXENK.<Y1E3PN!P5.K'%8_'XAPH8?#TI-2
MJUW3H2_C/QRRB>/\6^)<SQN+PV2\,Y#@.'L;Q'Q+CN;ZKE.$IX'#5H4(4X/V
M^/S',?85,'EF58.-7$8S%XB$)?5Z'M\1'^CCQ-XK_9Z^'=Y:+XR\0?"+P7J[
MQVM_;+XBU?P7X=U%_.E6&WNX!J=S8WDBM-"$2ZB5E!A.)!L(&6WQX_9CUV0&
M3XM_!/56B)0,_CWP/J+1%3',5)&KW BV_:(9<%D)-Q Z@^<A/\>?C[XI^,?B
MGXIUGQ?XR\33^(-<\0-J5U/?2:Y')?2W4CQ:?;'2IK+4FT-+.TAN;FP@M+57
ML=/LML1LY$V"'EX=<U..\@U:\B(U",6%U?&74Y+N6TOXH[812VUQ9W-Y$MS<
M6LFE*FZ":S @BB9D>]O =L+]'#"XC#4)XWC/'+'.E3E7>%PU+ZE2KSC&I4I4
M*M?$QQ<H4Y6@JDU3E.45+EY'%+Y+,_IY^QS#&8/*?#C(JN32K2A@ZN8XK$PQ
M6(P5!2A0Q&887!9<L']8JJ7NX6@ZRH<];FJVC-5/[*_^%J_LJW,C*GQ"^!-U
M+/&-P7Q9X!=YHQDY;=J0\Q 8SGES^[. =G$[?$C]EIAYDGC;X$J(P8?,;Q/X
M!;8LISY7-]N42^:2(R%!\YB 1*=_\;6J:I=6L9N;]9<7Z1_:9+'5+VYFCF,U
MU:VT;94E+B:Z,DMA*(9KBVLVOHS!-!<:8D66=?N19P1SVKI-'!=-$JWHO([.
M2WL!?K%9VQMKR_>_NY-/MYKDVT; M/%:3V5M<WWV5.Z/T9\L:C[7C;.H<MO9
MM8>A*+=M7#_A3NDM+7C%V:T6QXM;Z=V8TW>/A%PI4C4NE-5L535:*=HMQGD\
MI5(M--14G9.U]3]G_P#@JOXM_9M\6:;\*;/X;ZYX(UOQ79W_ (KDOYOAK?\
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M\%VECJ#>'-/?RQ9S>(]5U+4M(T+19+\R!;*UOM5@N[G#R1P/&A:OD=9;:/\
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
